<SEC-DOCUMENT>0001104659-22-080312.txt : 20220718
<SEC-HEADER>0001104659-22-080312.hdr.sgml : 20220718
<ACCEPTANCE-DATETIME>20220718061006
ACCESSION NUMBER:		0001104659-22-080312
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220715
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220718
DATE AS OF CHANGE:		20220718

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NortonLifeLock Inc.
		CENTRAL INDEX KEY:			0000849399
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-PREPACKAGED SOFTWARE [7372]
		IRS NUMBER:				770181864
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0401

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17781
		FILM NUMBER:		221088090

	BUSINESS ADDRESS:	
		STREET 1:		60 E RIO SALADO PARKWAY
		STREET 2:		SUITE 1000
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281
		BUSINESS PHONE:		650-527-2900

	MAIL ADDRESS:	
		STREET 1:		60 E RIO SALADO PARKWAY
		STREET 2:		SUITE 1000
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SYMANTEC CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2221114d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:nlok="http://symantec.com/20220715">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_nlok_symantec.com_20220715 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220715_20220715 -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0000849399 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityCentralIndexKey">0000849399</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="nlok-20220715.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-07-15to2022-07-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000849399</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-15</xbrli:startDate>
        <xbrli:endDate>2022-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><b>UNITED STATES</b></p>

<p style="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><b>FORM <span id="xdx_906_edei--DocumentType_c20220715__20220715_zT6paI1c85g7"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Pursuant to Section
13 or 15(d)</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><b>of the Securities Exchange
Act of 1934</b></p>

<p style="font: 13.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white">Date of Report (Date
of earliest event reported):<b> <span id="xdx_905_edei--DocumentPeriodEndDate_c20220715__20220715_zW8NpqdA5FHk"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July 15,
2022</ix:nonNumeric></span></b></p>

<p style="font: 13.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span id="xdx_908_edei--EntityRegistrantName_c20220715__20220715_zHC9a48KFOPl"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityRegistrantName">NortonLifeLock Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white">(Exact Name of Registrant as Specified in its Charter)</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 45%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
  <tr style="vertical-align: top">
    <td style="padding: 1.5pt 1pt; width: 30%">
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20220715__20220715_z6PNvYqpe8o1"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b><span style="font-family: Times New Roman, Times, Serif; font-size: 5pt">&#160;</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 5pt; text-align: center">(State or other Jurisdiction <br />
of
    Incorporation)&#160;</p></td>
    <td style="padding: 1.5pt 1pt; width: 40%">
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span id="xdx_904_edei--EntityFileNumber_c20220715__20220715_zvncny7adFpb"><b><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityFileNumber">000-17781</ix:nonNumeric></b></span>&#160;</p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">(Commission File Number)&#160;</p></td>
    <td style="padding: 1.5pt 1pt; width: 30%">
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20220715__20220715_zUMwU7wpuOj5"><b><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityTaxIdentificationNumber">77-0181864</ix:nonNumeric></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 5pt">&#160;</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">(IRS Employer <br />
Identification No.)</p></td></tr>
  </table>

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 45%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: center"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20220715__20220715_zJRnxtic02b2"><b><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityAddressAddressLine1">60
E. Rio Salado Parkway</ix:nonNumeric></b></span><b>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20220715__20220715_z5jdPUIacWj2"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityAddressAddressLine2">Suite
1000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: center"><span id="xdx_904_edei--EntityAddressCityOrTown_c20220715__20220715_zkMOuzABxDC1"><b><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityAddressCityOrTown">Tempe</ix:nonNumeric></b></span><b>,&#160;&#160;&#160;
<span id="xdx_905_edei--EntityAddressStateOrProvince_c20220715__20220715_zqYRHmnYjvNi"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityAddressStateOrProvince">AZ</ix:nonNumeric></span></b><b> &#160;&#160;&#160; <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20220715__20220715_zE6VMvvTEe02"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityAddressPostalZipCode">85281</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: center">(Address of principal executive
offices) (Zip Code)</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: left"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: center">Registrant's telephone number,
including area code: <b>(<span id="xdx_900_edei--CityAreaCode_c20220715__20220715_zoLZzjTeWygg"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:CityAreaCode">650</ix:nonNumeric></span>) <span id="xdx_90B_edei--LocalPhoneNumber_c20220715__20220715_zFFJwZCjkc22"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:LocalPhoneNumber">527-8000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: center"><span style="font-size: 6pt"></span>&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: left">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: left">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-bottom: 3pt; width: 4%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_909_edei--WrittenCommunications_c20220715__20220715_zXmN1o8v5v4c"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="padding-bottom: 3pt; width: 96%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 3pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90C_edei--SolicitingMaterial_c20220715__20220715_z0wQR9rF1xuh"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="padding-bottom: 3pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 3pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_909_edei--PreCommencementTenderOffer_c20220715__20220715_zEIGQc6C7581"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="padding-bottom: 3pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 3pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20220715__20220715_zm4N5Hxkvy7a"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="padding-bottom: 3pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: left">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: left">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: left">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; width: 32%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; width: 32%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; width: 32%; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Name
                                            of each exchange on which</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>registered</b></span></p></td></tr>
  <tr>
    <td style="padding: 1.5pt 1pt 5pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_907_edei--Security12bTitle_c20220715__20220715_ztLv3oP0UqC7"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:Security12bTitle">Common Stock, par value $0.01 per share</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="padding: 1.5pt 1pt 5pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_901_edei--TradingSymbol_c20220715__20220715_zu0oyNlCJ3J7"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:TradingSymbol">NLOK</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="padding: 1.5pt 1pt 5pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_909_edei--SecurityExchangeName_c20220715__20220715_zgmLanqtCPQi"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></b></span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: left">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">Emerging growth company&#160;&#160;&#160;&#160;<span style="font-family: Wingdings"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20220715__20220715_zFubrsqG3ua4"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: left">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: left"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1pt; text-align: left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 1in"><b>Item&#160;1.01.</b></td><td style="text-align: justify"><b>Entry into a Material Definitive Agreement.</b></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On July 15, 2022, NortonLifeLock Inc. (the &#8220;Company&#8221;)
and Avast plc (&#8220;Avast&#8221;), in connection with the previously-announced merger of the Company with Avast (the &#8220;Merger&#8221;),
entered into the Amendment and Restatement Agreement, dated as of July 15, 2022 (the &#8220;Amendment Agreement&#8221;), pursuant to which
the existing Co-operation Agreement dated August 10, 2022 was amended and restated as set forth in the Schedule to the Amendment Agreement
to revise the maximum number of Avast shares which may be granted under Avast&#8217;s 2018 Long Term Incentive Plan.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The foregoing summary of the Amendment Agreement
does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amendment Agreement, a copy
of which is attached as Exhibit 2.01 to this Current Report on Form 8-K, and which is incorporated herein by reference.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>Forward-Looking Statements </b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K contains certain
forward-looking statements. These forward-looking statements can be identified by the fact that they do not relate only to historical
or current facts. Forward-looking statements often use words such as &#8220;anticipate&#8221;, &#8220;target&#8221;, &#8220;expect&#8221;,
&#8220;estimate&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;goal&#8221;, &#8220;believe&#8221;, &#8220;aim&#8221;, &#8220;will&#8221;,
&#8220;may&#8221;, &#8220;would&#8221;, &#8220;could&#8221; or &#8220;should&#8221; or other words of similar meaning or the negative
thereof. There are many factors which could cause actual results to differ materially from those expressed or implied in forward-looking
statements. Such factors include, but are not limited to, the possibility that the Merger will not be completed on a timely basis or at
all, whether due to the failure to satisfy the conditions of the Merger (including approvals or clearances from regulatory and other agencies
and bodies) or otherwise. Additional information concerning these and other risk factors is contained in the Risk Factors sections of
the Company&#8217;s most recent reports on Form 10-K and Form 10-Q, the contents of which are not incorporated by reference into, nor
do they form part of, this Current Report on Form 8-K.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">By their nature, these forward-looking statements
involve known and unknown risks, as well as uncertainties because they relate to events and depend on circumstances that will occur in
the future. No assurance can be given that such expectations will prove to have been correct and persons reading this Current Report on
Form 8-K are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this
Current Report on Form 8-K. All subsequent oral or written forward-looking statements attributable to the Company, Avast or any persons
acting on their behalf are expressly qualified in their entirety by the cautionary statement above. The Company does not assume any obligation
to update the forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required
by applicable law, regulation or stock exchange rules.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 9.01</b></td><td style="text-align: justify"><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">(d) Exhibits</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 11%; text-align: justify; font-size: 10pt">Exhibit Number</td>
    <td style="padding: 0.25pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 88%; text-align: justify; font-size: 10pt">Exhibit Title or Description</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; text-align: justify; font-size: 10pt"><a href="tm2221114d1_ex2-01.htm" style="-sec-extract: exhibit">2.01</a></td>
    <td style="padding: 0.25pt; text-align: left; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify; font-size: 10pt"><a href="tm2221114d1_ex2-01.htm" style="-sec-extract: exhibit">Amendment and Restatement Agreement, dated as of July 15, 2022, by and between NortonLifeLock Inc., Nitro Bidco Limited and Avast plc</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; text-align: justify; font-size: 10pt">104</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify; font-size: 10pt">The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.</td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b></b>&#160;</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SIGNATURE</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.2in; background-color: white">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>NortonLifeLock
    Inc.</b></span></td></tr>
  <tr>
    <td style="width: 50%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; width: 48%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Date: July 15, 2022</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">By:</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/
    Bryan  Ko</span></td></tr>
  <tr>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Bryan
     Ko</span></td></tr>
  <tr>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; vertical-align: bottom"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Chief Legal Officer and Corporate Secretary</p></td></tr>
  </table>
<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div>
    <!-- Field: /Page -->

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVEKwjAQRE/QOyz5Fm0iIvRPi4pYRYqIv8FuJdhmyyateiRvaWwRl4VlmXkzQozEhtamQobLMs/ghHVTaY+QY4mM9orBkW53CYSb4804z9r6/v2BKQUGAzMbS3UNQm/tjMMigXg2kfOJUiBVEk9hsRfRV0/JlqZA642uQNsCjkwNG/SaX0PCST/JUv3qq87IzpBNQI7jQX6DiqWCA3X6QXx3kGWpiEb9RGLD1DbfmtZ5qmFVYR263ID+N/oADv9JOQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>tm2221114d1_ex2-01.htm
<DESCRIPTION>EXHIBIT 2.01
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>Exhibit 2.01</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><IMG SRC="tm2221114d1_ex2-01img01.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Dated 15 July 2022</B></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Amendment and Restatement Agreement</B></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">between</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>NortonLifeLock Inc. </B></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Nitro Bidco Limited</B></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Avast plc</B></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">White
 &amp; Case LLP<BR>
 5 Old Broad Street <BR>
London EC2N 1DW&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt">Table
of Contents</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>Page</B></FONT></P>


<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 90%; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interpretation</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 10%; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">1</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment
    and Restatement of the Co-operation Agreement</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">1</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further
    Assurance</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
    Agreement</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severance
    and Validity</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Variations
    and Waivers</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
    Rights under Contracts (Rights of Third Parties) Act 1999</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing
    Law and Jurisdiction</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">3</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Agent
    for Service of Process</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">3</FONT></TD></TR>
  <TR STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -1in; padding-top: 6pt; padding-bottom: 0in; padding-left: 1in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Schedule&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
    Amended and Restated Co-operation Agreement</B></FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">4</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->)</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>This
Amendment and Restatement Agreement</B></FONT> is made on 15 July 2022</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Between:</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>(1)</B></FONT></TD><TD STYLE="text-align: justify"><B>NortonLifeLock Inc.,</B> a Delaware corporation with a place of business at 60 E. Rio Salado Parkway,
Suite 1000, Tempe, AZ 85281 (&#8220;<B>NortonLifeLock</B>&#8221;);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>(2)</B></FONT></TD><TD STYLE="text-align: justify"><B>Nitro Bidco Limited,</B> a company incorporated in England with registered company number 13514724
and whose registered office is at 10 Norwich Street, London EC4A 1BD (&#8220;<B>Bidco</B>&#8221;); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>(3)</B></FONT></TD><TD STYLE="text-align: justify"><B>Avast plc,</B> a company incorporated in England with registered company number 07118170 and whose
registered office is at 110 High Holborn, London, England, WC1V 6JS (&#8220;<B>Avast</B>&#8221; or the&nbsp;&#8220;<B>Company</B>&#8221;),</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">together referred to as the &#8220;Parties&#8221;
and each as a &#8220;Party&#8221; to this agreement (the &#8220;<B>Amendment and Restatement Agreement</B>&#8221;).</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Whereas:</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(A)</FONT></TD><TD STYLE="text-align: justify">On 10 August 2021, the boards of Avast and NortonLifeLock announced that they had reached agreement on
the terms of a recommended merger of Avast with NortonLifeLock, in the form of a recommended offer by Bidco, a wholly-owned subsidiary
of NortonLifeLock, for the entire issued and to be issued ordinary share capital of the Company (the &#8220;<B>Merger</B>&#8221;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(B)</FONT></TD><TD STYLE="text-align: justify">The Parties have agreed to co-operate with each other and take certain steps to effect the implementation
and conduct of the Merger and entered into a co-operation agreement dated 10&nbsp;August 2021 to record their respective rights, commitments
and obligations relating to such matters (the &#8220;<B>Co-operation Agreement</B>&#8221;).&#9;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(C)</FONT></TD><TD STYLE="text-align: justify">The Parties wish to amend and restate the Co-operation Agreement in the form set out in the &#8206;Schedule
(<I>The Amended and Restated Co-operation Agreement</I>) to this Amendment and Restatement&nbsp;Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>It is agreed:</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>1.</B></FONT></TD><TD>Interpretation</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">1.1</FONT></TD><TD STYLE="text-align: justify">In this Agreement:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Effective
Date</B>&#8221; means the date of this Amendment and Restatement Agreement; and</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt">&#8220;</FONT><FONT STYLE="font-size: 10pt"><B>Proceedings</B>&#8221;
means any proceedings, suit or action arising out of or in connection with this Amendment and Restatement Agreement or the transactions
contemplated hereby, whether contractual or non-contractual.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>2.</B></FONT></TD><TD>Amendment and Restatement of the Co-operation Agreement</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">2.1</FONT></TD><TD STYLE="text-align: justify">With effect from the Effective Date, the Parties agree that the Co-operation Agreement shall be amended
and restated in the form set out in the <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>&#8206;</B></FONT>Schedule
(<I>The Amended and Restated Co-operation Agreement) </I>to this document so that the Parties&#8217; rights and obligations under it shall
be read and construed for all purposes in accordance with the amended and restated terms and conditions as set out in the <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>&#8206;</B></FONT>Schedule.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">2.2</FONT></TD><TD STYLE="text-align: justify">The amendment and restatement of the Co-operation Agreement pursuant to this Amendment and Restatement
Agreement shall constitute a variation of the Co-operation Agreement in accordance with Clause&nbsp;<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>&#8206;</B></FONT>17.3
(<I>Variations</I>) of the Co-operation Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">2.3</FONT></TD><TD STYLE="text-align: justify">Save as amended and restated in accordance with Clause&nbsp;<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>&#8206;</B></FONT>2.1
above, the Co-operation Agreement shall continue in full force and effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>3.</B></FONT></TD><TD>Further Assurance</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Each of the Parties shall from time to
time and at their own cost do, execute and deliver or procure to be done, executed and delivered all such further acts, documents and
things required by law or as may be necessary or desirable to give full effect to this Amendment and Restatement Agreement and the rights,
powers and remedies conferred under this Amendment and Restatement Agreement.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>4.</B></FONT></TD><TD>Entire Agreement</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.1</FONT></TD><TD STYLE="text-align: justify">This Amendment and Restatement Agreement, together with any other documents referred to in this Amendment
and Restatement Agreement and all documents entered into pursuant to this Amendment and Restatement Agreement, constitutes the whole agreement
between the Parties and supersedes any previous arrangements or agreements between them relating to the subject matter of this Amendment
and Restatement Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.2</FONT></TD><TD STYLE="text-align: justify">The Parties confirm that they have not entered into this Amendment and Restatement Agreement on the basis
of any representation, warranty, undertaking or any other statement whatsoever not expressly incorporated into this Amendment and Restatement
Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.3</FONT></TD><TD STYLE="text-align: justify">The Parties agree, to the extent permitted by law, that the only right or remedy in relation to breach
of this Amendment and Restatement Agreement shall be for contractual damages.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.4</FONT></TD><TD STYLE="text-align: justify">Nothing in this Clause&nbsp;<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>&#8206;</B></FONT>4
shall operate to limit or exclude any liability for fraud.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>5.</B></FONT></TD><TD>Severance and Validity</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If any provision of this Amendment and
Restatement Agreement is or becomes illegal, invalid or unenforceable in any respect under the law of any jurisdiction, such provision
shall be deemed to be severed from this Amendment and Restatement Agreement. The remaining provisions will remain in full force in that
jurisdiction and all provisions will continue in full force in any other jurisdiction.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>6.</B></FONT></TD><TD>Variations and Waivers</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 11pt">No variation
or waiver of this Amendment and Restatement Agreement shall be effective unless in writing and signed by or on behalf of the Parties.
</FONT><FONT STYLE="font-size: 10pt">No single or partial exercise of, or failure or delay in exercising, any right or remedy provided
by law or under this Amendment and Restatement Agreement shall constitute a waiver, or preclude any other nor restrict any further exercise,
of that or any other right or remedy.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>7.</B></FONT></TD><TD>No Rights under Contracts (Rights of Third Parties) Act 1999</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A person who is not a Party to this Amendment
and Restatement Agreement or the Co-operation Agreement shall have no right under the Contracts (Rights of Third Parties) Act 1999 to
enforce any of their terms.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>8.</B></FONT></TD><TD>Counterparts</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This Amendment and Restatement Agreement
may be executed in counterparts and shall be effective when each Party has executed and delivered a counterpart. Each counterpart shall</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">constitute an original of this Amendment
and Restatement Agreement, but all the counterparts shall together constitute one and the same instrument.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>9.</B></FONT></TD><TD>Governing Law and Jurisdiction</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">9.1</FONT></TD><TD STYLE="text-align: justify">This Amendment and Restatement Agreement, including any non-contractual obligations arising out of or
in connection with this Amendment and Restatement Agreement, is governed by and shall be construed in accordance with English law; provided
that notwithstanding the foregoing, any matters concerning or implicating the NortonLifeLock directors&#8217; fiduciary duties shall be
governed by and construed in accordance with the applicable fiduciary duty laws of the State of Delaware.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">9.2</FONT></TD><TD STYLE="text-align: justify">The Parties agree that the courts of England shall have exclusive jurisdiction to hear and determine any
Proceedings arising out of or in connection with this Amendment and Restatement Agreement and, for such purposes, irrevocably submit to
the jurisdiction of such&nbsp;courts.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>10.</B></FONT></TD><TD>Agent for Service of Process</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">10.1</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock will maintain an agent for service of process and any other documents in Proceedings in
England or any other Proceedings in connection with this Amendment and Restatement Agreement. Such agent will be Macfarlanes LLP, currently
of 20 Cursitor Street, London EC4A 1LT, and any claim form, judgment or other notice of legal process will be sufficiently served on NortonLifeLock
if delivered to such agent at its address for the time being, and marked for the attention of Harry Coghill and Tom Rose.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">10.2</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock will be entitled to appoint an agent for service in England in the place of Macfarlanes
LLP by written notice to Avast, whereupon Macfarlanes LLP will cease to be NortonLifeLock&#8217;s agent for service, and any claim form,
judgment or other notice of legal process will be sufficiently served on NortonLifeLock if delivered to such replacement agent at its
address for the time being (but shall no longer be effective if served upon Macfarlanes LLP after the appointment, and notification to
Avast of the appointment, of such new agent for&nbsp;service).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>This
Agreement </B></FONT>has been entered into by the Parties on the date first above written.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>Schedule</B></FONT></P>

<P STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Amended and Restated Co-operation Agreement</P>

<P STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Dated 15 July 2022</B></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Amended and Restated</B></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Co&#45;operation Agreement</B></P>

<P STYLE="font: bold 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">between</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>NortonLifeLock Inc.</B></P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Nitro Bidco Limited</B></P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Avast plc</B></P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>Page</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 95%; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interpretation</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 5%; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">1</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effectiveness
    and the Terms of the Transaction</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">9</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
    Conditions and Other Clearances</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">9</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scheme
    Document and other Avast documents</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">12</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Solicitation
    Applicable to NortonLifeLock; Preparation of the Proxy Statement and NortonLifeLock Stockholder Approval</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">13</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NortonLifeLock
    Prospectus</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">17</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Implementation
    of the Scheme</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">18</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NortonLifeLock
    Conduct of Business</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">19</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Switching
    to an Offer</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">20</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
    Share Plans</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">22</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors&#8217;
    and Officers&#8217; Insurance and POSI</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">22</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Break
    Payments</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">23</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Guarantee</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">26</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Announcements</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">27</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">27</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warranties
    and Undertakings</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">28</FONT></TD></TR>
  <TR STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -0.5in; padding-top: 6pt; padding-bottom: 0in; padding-left: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General</FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">29</FONT></TD></TR>
  <TR STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -1in; padding-top: 6pt; padding-bottom: 0in; padding-left: 1in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Schedule&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
    Announcement</B></FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">34</FONT></TD></TR>
  <TR STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -1in; padding-top: 6pt; padding-bottom: 0in; padding-left: 1in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Schedule&nbsp;2&nbsp;&nbsp;&nbsp;&#8239;&nbsp;
    Avast Share Plans</B></FONT></TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 6pt; padding-bottom: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">119</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>This
Agreement</B></FONT> <FONT STYLE="font-weight: normal">is originally dated 10 August 2021 and amended and restated as of 15 July 2022</FONT></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Between:</B></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>(1)</B></FONT></TD><TD STYLE="text-align: justify"><B>NortonLifeLock Inc.</B> a Delaware corporation with a place of business at 60 E. Rio Salado Parkway,
Suite 1000, Tempe, AZ 85281 (&#8220;<B>NortonLifeLock</B>&#8221;);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>(2)</B></FONT></TD><TD STYLE="text-align: justify"><B>Nitro Bidco Limited</B>, a company incorporated in England with registered company number 13514724
and whose registered office is at 10 Norwich Street, London EC4A 1BD (&#8220;<B>Bidco</B>&#8221;); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>(3)</B></FONT></TD><TD STYLE="text-align: justify"><B>Avast plc</B>, a company incorporated in England with registered company number 07118170 and whose
registered office is at 110 High Holborn, London, England, WC1V 6JS (&#8220;<B>Avast</B>&#8221;),</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">together referred to as the &#8220;<B>parties</B>&#8221;
and each as a &#8220;<B>party</B>&#8221; to this agreement (the&nbsp;&#8220;<B>Agreement</B>&#8221;).</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Whereas:</B></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(A)</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock, Bidco and Avast propose to release the Announcement immediately following the execution
of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(B)</FONT></TD><TD STYLE="text-align: justify">The parties intend that the Transaction will be effected by means of a scheme of arrangement of Avast
pursuant to Part 26 of the Companies Act (the &#8220;<B>Scheme</B>&#8221;), but each of NortonLifeLock and Bidco reserves the right, as
set out in (and subject to the terms and conditions of) the Announcement and this Agreement, to elect to implement the Transaction by
way of a takeover offer as defined in Chapter 3 of Part 28 of the Companies Act (an &#8220;<B>Offer</B>&#8221;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(C)</FONT></TD><TD STYLE="text-align: justify">The parties have agreed to co&#45;operate with each other and take certain steps to effect the implementation
and conduct of the Transaction and wish to enter into this Agreement to record their respective rights, commitments and obligations relating
to such matters.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>It is agreed:</B></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt"></FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify">Interpretation</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">1.1</FONT></TD><TD STYLE="text-align: justify">In this Agreement:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Acceptance
Condition</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;9.2(a);</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Acceptance
Condition Invocation Notice</B>&#8221; means a notice in which NortonLifeLock and/or Bidco gives notice of its intention to invoke the
Acceptance Condition so as to cause the Offer to lapse in accordance with Rule 31.6 of the Takeover Code;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Affiliate</B>&#8221;
means in relation to a party, any person that directly or indirectly, through one or more intermediaries, controls, is controlled by,
or is under common control with, the party, and for these purposes a party shall be deemed to control a person if such party possesses,
directly or indirectly, the power to direct or cause the direction of the management and policies of the person, whether through the ownership
of voting securities, by contract or otherwise;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Agreed Switch</B>&#8221;
has the meaning given to it in Clause&nbsp;&#8206;9.1(a);</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Announcement</B>&#8221;
means the announcement pursuant to Rule&nbsp;2.7 of the Takeover Code in relation to the Transaction, in the form appended to this Agreement
at &#8206;Schedule&nbsp;1 (<I>Announcement</I>);</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Avast Board</B>&#8221;
means the board of directors of Avast from time to time;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Avast Board
Recommendation</B>&#8221; means the unanimous recommendation of the Avast Board to the Avast Shareholders to vote in favour of the Resolutions
(or, following an Agreed Switch, accept the Offer);</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Avast Board
Recommendation Change</B>&#8221; means: (i) if Avast makes any announcement prior to the publication of the Scheme Document that: (a)
the Avast Directors no longer intend to make the Avast Board Recommendation or intend to adversely modify or qualify such recommendation;
(b) it shall not convene the Court Meeting or the Avast General Meeting (or shall convene such meetings and adjourn them without specifying
a date for re-convening); or (c) it intends not to publish the Scheme Document; (ii) any failure to include the Avast Board Recommendation
in the Scheme Document; (iii) any withdrawal of the Avast Board Recommendation; (iv) any adverse modification or qualification of the
Avast Board Recommendation; (v) if, after the Scheme has been approved by Avast Shareholders at the Court Meeting and/or the Avast General
Meeting, the Avast Directors announce that they shall not implement the Scheme (other than in connection with an announcement of an Offer
by NortonLifeLock and/or Bidco where the Avast Board Recommendation continues to apply to such Offer); and/or (vi) any third party announces
a firm intention under the Takeover Code to make an offer or revised offer for Avast (whether or not subject to the satisfaction or waiver
of any pre-conditions or conditions) which is recommended by all or a majority of the Avast&nbsp;Directors;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Avast Directors</B>&#8221;
means the directors of Avast from time to time;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Avast General
Meeting</B>&#8221; means the general meeting of Avast (including any adjournment thereof) to be convened and held in connection with the
Transaction, notice of which will be set out in the Scheme Document, to consider, and if thought fit, approve the Resolutions;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Avast Group</B>&#8221;
means Avast and its subsidiaries and subsidiary undertakings from time to time and, &#8220;<B>member of the Avast Group</B>&#8221; will
be construed accordingly;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Avast Remuneration
Committee</B>&#8221; means the remuneration committee of the Avast Board as constituted from time to time prior to the Effective Date;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Avast Share
Plans</B>&#8221; means the LTIP, the SMP and the Share Option Plan;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Avast Shareholder</B>&#8221;
means a registered holder of an Avast Share from time to time;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Avast Shares</B>&#8221;
means the ordinary shares of &pound;0.10 each in the capital of Avast from time to&nbsp;time;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Bidco Directors</B>&#8221;
means the directors of Bidco from time to time;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Break Payment
Events</B>&#8221; means each of (i) a NortonLifeLock Board Recommendation Change; (ii) the NortonLifeLock Stockholders Meeting having
not occurred prior to the Long Stop Date in breach of NortonLifeLock&#8217;s obligations under this Agreement; (iii) a Regulatory Condition
Satisfaction Failure Event; and (iv) a NortonLifeLock Stockholder Approval Failure&nbsp;Event;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Break Payments</B>&#8221;
means, collectively, (i) the NortonLifeLock Board Recommendation Change Break Payment; (ii) the Regulatory Condition Break Payment; and
(iii) the NortonLifeLock Stockholder Approval Failure Break Payment;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Business
Day</B>&#8221; means a day, other than a Saturday, Sunday or public or bank holiday, on which banks in London and New York City are open
for ordinary banking business;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Clean Team
and Joint Defence Agreement</B>&#8221; means the clean team and joint defence agreement between NortonLifeLock and Avast dated 24 June
2021 entered into in connection with the Transaction, including any subsequent agreement in writing to be bound by the terms</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">of the Clean Team and Joint Defence Agreement
executed by Additional Counsel (as defined in the Clean Team and Joint Defence Agreement);</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Combined
Company</B>&#8221; has the meaning given to it in the Announcement;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Companies
Act</B>&#8221; means the Companies&nbsp;Act&nbsp;2006, as amended from time to time;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Conditions</B>&#8221;
means the conditions to the implementation of the Transaction which are set out in Part A of Appendix 1 to the Announcement and to be
set out in the Scheme Document;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Confidentiality
Agreement</B>&#8221; means the confidentiality agreement entered into between NortonLifeLock and Avast in connection with the Transaction
on 23 June 2021;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Court</B>&#8221;
means the High Court of Justice in England and Wales;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Court Meeting</B>&#8221;
means the meeting of the holders of Avast Shares to be convened by order of the Court pursuant to section 896 of the Companies Act, notice
of which will be set out in the Scheme Document, for the purpose of considering, and if thought fit, approving (with or without modification)
the Scheme, including any adjournment thereof;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Court Order</B>&#8221;
means the order of the Court sanctioning the Scheme under section 899 of the Companies Act;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Court Sanction
Hearing</B>&#8221; means the hearing of the Court to sanction the Scheme, including any adjournment thereof;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Effective
Date</B>&#8221; means the date on which either: (i)&nbsp;the Scheme becomes effective pursuant to its terms; or (ii)&nbsp;if NortonLifeLock
and/or Bidco elects, with the consent of the Panel (and subject to the terms of this Agreement), to implement the Transaction by means
of an Offer, the Offer becomes or is declared unconditional in all respects in accordance with the requirements of the Takeover Code;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Excess
NortonLifeLock Dividend</B>&#8221; has the meaning given to it in Clause&nbsp;</FONT>&#8206;8.2;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Excess
NortonLifeLock Dividend Notice</B>&#8221; has the meaning given to it in Clause&nbsp;</FONT>&#8206;8.2;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Exchange
Act</B>&#8221; means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>FCA</B>&#8221;
means the Financial Conduct Authority;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>FCA Handbook</B>&#8221;
means the FCA&#8217;s Handbook of rules and guidance as amended from time to time;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Guarantee</B>&#8221;
has the meaning given to it in Clause&nbsp;&#8206;13.1;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Indemnified
Executives</B>&#8221; means such executives of Avast who, as at the date of the original Agreement, have a right to be indemnified or
are insured in a substantially equivalent manner to the directors and officers of any member of the Avast Group;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Law</B>&#8221;
means any applicable statues, common law, rules, ordinances, regulations, codes, orders, judgments, injunctions, writs, decrees, directives,
governmental guidelines or interpretation having force of law or bylaws, in each case, of a Regulatory Authority;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Long Stop
Date</B>&#8221; means 11.59&nbsp;p.m. on 31 December 2022 (or such later time and/or date as may be agreed in writing between the parties
(with the Panel&#8217;s consent and as the Court may approve (if such consent or approval is required));</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>LTIP</B>&#8221;
means the Avast 2018 Long Term Incentive Plan, as amended from time to time;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Split-Segment; Name: A01 -->
<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Match
Period</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;5.7(a);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>material
official authorisation or regulatory clearance</B>&#8221; means an official authorisation or regulatory clearance where the Panel is
satisfied that the failure to obtain the authorisation or clearance could give rise to circumstances which are of material significance
to NortonLifeLock and/or Bidco in the context of the Offer;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Maximum
Premium</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;11.3(b);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NASDAQ</B>&#8221;
means the NASDAQ Stock Market;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>New
NortonLifeLock Shares</B>&#8221; means the NortonLifeLock Shares proposed to be issued to Avast Shareholders in accordance with the terms
of the Transaction;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Alternative Proposal</B>&#8221; shall mean any proposal or offer from any person or group relating to any: (i) direct or indirect acquisition,
purchase, lease, exchange, transfer or licence, in a single transaction or a series of related transactions, including by means of the
acquisition of capital stock of any member of the NortonLifeLock Group, of assets or properties that constitute 20 per cent. or more
of the assets and properties (based on fair market value) of the NortonLifeLock Group, taken as a whole; (ii) direct or indirect acquisition
or purchase, in a single transaction or a series of related transactions, of beneficial ownership, or the right to acquire beneficial
ownership, of 20 per cent. or more of the voting power of all outstanding equity securities of NortonLifeLock; or (iii) issuance or sale
or other disposition (including by way of merger, consolidation, share exchange, business combination, reorganisation, recapitalisation
or other similar transaction) in a single transaction or a series of related transactions of 20 per cent. or more of the voting power
of all outstanding equity securities of NortonLifeLock, in each case, other than the Transaction;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Board</B>&#8221; means the board of directors of NortonLifeLock from time to time;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Board Recommendation</B>&#8221; means a unanimous recommendation by the NortonLifeLock Board to NortonLifeLock Stockholders to vote in
favour of the NortonLifeLock Stockholder Matters;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Board Recommendation Change</B>&#8221; means if NortonLifeLock: (i) withdraws, withholds or qualifies (or amends or modifies in any manner
adverse to Avast), or proposes publicly to withdraw, withhold or qualify (or amend or modify in any manner adverse to Avast), the NortonLifeLock
Board Recommendation; (ii) approves, recommends, adopts or proposes publicly to approve, recommend or adopt, any NortonLifeLock Alternative
Proposal or any NortonLifeLock Takeover Proposal; or (iii) fails to include the NortonLifeLock Board Recommendation in the definitive
Proxy Statement;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Board Recommendation Change Break Payment</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;12.1(a);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Convertible Notes</B>&#8221; means NortonLifeLock&#8217;s 2.00% Convertible Senior Notes Due 2022 issued under an indenture dated 4 February
2020 entered into between NortonLifeLock and Wells Fargo Bank, National Association;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Directors</B>&#8221; means the directors of NortonLifeLock from time to time;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Documents</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;5.3(b);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Group</B>&#8221; means NortonLifeLock and its subsidiaries and subsidiary undertakings from time to time and &#8220;<B>member of the
NortonLifeLock Group</B>&#8221; will be construed accordingly;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Intervening Event</B>&#8221; means any effect, change, event, fact, condition, development or occurrence that is material to the NortonLifeLock
Group, taken as a whole,</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">that:
(i) first becomes known after the date of the original Agreement and prior to receipt of the NortonLifeLock Stockholder Approval; and
(ii) was not known by or reasonably foreseeable to the NortonLifeLock Board as of the date of the original Agreement; provided, however,
that in no event shall any of the following effects, changes, events, facts, conditions, developments or occurrences be taken into account
in determining whether a NortonLifeLock Intervening Event has occurred: (A) the receipt, existence or terms of a NortonLifeLock Alternative
Proposal, or an inquiry, proposal or offer that could reasonably be expected to lead to a NortonLifeLock Alternative Proposal, or any
matter relating thereto or direct or indirect consequence thereof; or (B) the fact that, in and of itself, any member of the NortonLifeLock
Group exceeds any internal or published projections, forecasts, estimates or predictions in respect of revenues, earnings or other financial
or operating metrics, or changes or prospective changes in the market price or trading volume of the NortonLifeLock Shares (it being
understood that the underlying facts giving rise or contributing to such events may be taken into account in determining whether there
has been a NortonLifeLock Intervening Event if such facts are not otherwise excluded under this definition);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Prospectus</B>&#8221; means the prospectus required to be published by NortonLifeLock in respect of the New NortonLifeLock Shares, including
any supplementary prospectus;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Shares</B>&#8221; means the shares of common stock, par value $0.01 per share, of NortonLifeLock;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Stockholder Approval</B>&#8221; means the approval of the NortonLifeLock Stockholder Matters by the requisite vote of NortonLifeLock
Stockholders;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Stockholder Approval Failure Break Payment</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;12.1(c);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Stockholder Approval Failure Event</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;12.1(c);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Stockholder Matters</B>&#8221; means the proposals to be voted on by NortonLifeLock Stockholders at the NortonLifeLock Stockholders Meeting
to approve the issuance of the New NortonLifeLock Shares and such other matters (if any) that are required to be approved by NortonLifeLock&#8217;s
Stockholders to consummate the Transaction;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Stockholders</B>&#8221; means the holders of NortonLifeLock Shares from time to time;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Stockholders Meeting</B>&#8221; means the meeting of NortonLifeLock Stockholders (including any adjournment or postponement thereof)
to be convened and held to consider, and if thought fit, approve the NortonLifeLock Stockholder Matters;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>NortonLifeLock
Takeover Proposal</B>&#8221; means any bona fide written proposal made by a person or group after the date of the original Agreement
to enter into a NortonLifeLock Alternative Proposal, with all references to 20 per cent. in the definition of NortonLifeLock Alternative
Proposal being treated as references to 50 per cent. for these purposes, that: (i) did not result from a breach of Clause&nbsp;&#8206;5.1;
(ii) is on terms that the NortonLifeLock Board determines in good faith (after consultation with its outside financial advisors and outside
legal counsel) to be more favourable from a financial point of view to the NortonLifeLock Stockholders than the Transaction, taking into
account all relevant factors; and (iii) is reasonably likely to be capable of being completed in accordance with its terms, taking into
account all financial, regulatory, legal and other aspects of such proposal;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Offer</B>&#8221;
has the meaning given to it in Recital&nbsp;&#8206;(B) and reference to &#8220;<B>Offer</B>&#8221; also includes any increased, renewed
or revised offer;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Offer
Document</B>&#8221; means, if NortonLifeLock and/or Bidco elects to implement the Transaction by means of an Offer, the document setting
out (amongst other things) details of the Transaction and the full terms and conditions of the Offer, to be sent to (among others) the
Avast Shareholders, including any revised or supplementary offer document;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Panel</B>&#8221;
means the UK Panel on Takeovers and Mergers;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Proceedings</B>&#8221;
means any proceedings, suit or action arising out of or in connection with this Agreement or the transactions contemplated hereby, whether
contractual or non&#45;contractual;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Proxy
Approval</B>&#8221; means the first Business Day after NortonLifeLock receives written confirmation from the SEC that it has no further
comments on the Proxy Statement or, if the SEC has not informed NortonLifeLock that it will review the Proxy Statement, the first Business
Day after the tenth day after the Proxy Statement is filed;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Proxy
Statement</B>&#8221; means, collectively, the preliminary proxy statement and the definitive proxy statement of NortonLifeLock to be
filed with the SEC and mailed to the NortonLifeLock Stockholders in connection with the NortonLifeLock Stockholders Meeting (including
any amendments or supplements thereto);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Qualifying
NortonLifeLock Takeover Proposal</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;5.2;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Recoverable
VAT Amount</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;12.6;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Regulatory
Approvals</B>&#8221; means all consents, authorisations, approvals, clearances, permissions, waivers and/or filings that are required
in order to satisfy any of the Regulatory Conditions and also the expiry of all waiting periods that may need to have expired, from or
under any of the laws, regulations or practices applied by any Regulatory Authority in respect of the Transaction, to satisfy any of
the Regulatory Conditions and any reference to Regulatory Approvals having been &#8220;<B>satisfied</B>&#8221; or &#8220;<B>obtained</B>&#8221;
shall be construed as meaning that the foregoing have been obtained or deemed to have been obtained or, in the case of waiting periods,
expired in accordance with the Regulatory Condition;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Regulatory
Authority</B>&#8221; means, any central bank, ministry, governmental, supranational (including the European Union), statutory, regulatory
(including the SEC and NASDAQ) or investigative body, authority or tribunal (including any national or supranational antirust, competition
or merger control authority, any sectoral ministry or regulator and foreign investment or national security review body), national, state,
municipal or local government (including any subdivision, court, tribunal, administrative agency or commission or other authority thereof),
including the Panel;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Regulatory
Conditions</B>&#8221; means the Conditions set out in Conditions 3.5, 3.6, 3.7, 3.8, 3.9, 3.10, 3.11, 3.12, 3.13.1, 3.13.2, 3.13.3, 3.13.4
and 3.13.5 (inclusive) of Part A of Appendix 1 to the Announcement;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Regulatory
Condition Break Payment</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;12.1(b);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Regulatory
Condition Satisfaction Failure Event</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;12.1(b);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Regulatory
Newswire</B>&#8221; means, with respect to any announcement referred to in this Agreement: (i) a &#8220;regulatory information service&#8221;,
as defined in the FCA Handbook, if the announcement is to be published between 7.00&nbsp;a.m. and 6.30&nbsp;p.m. (UK) time on any day
on which the London Stock Exchange plc is open for the transaction of business; or (ii) if the announcement is to be published other
than during the times described in (i), two newswire services operating in the UK, provided that an announcement published pursuant to
(ii) shall be submitted for publication in the UK as soon as the regulatory information service described</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 14; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">in
(i) re-opens (in each case (a) as required by Rule 30.1(b) of the Takeover Code and (b) except where the consent of the Panel is provided
with respect to an alternative means of publication);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Relevant
Third Parties</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;17.7(a);</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Resolutions</B>&#8221;
means such resolutions to be proposed at the Avast General Meeting and the Court Meeting as are necessary to approve, implement and effect
the Scheme and Transaction and changes to Avast&#8217;s articles of association;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Rule
15 Letter</B>&#8221; means the communication to be prepared by Avast and NortonLifeLock to each of the participants in the Avast Share
Plans in satisfaction of NortonLifeLock&#8217;s and Bidco&#8217;s obligations under Rule 15 of the Takeover Code;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Scheme</B>&#8221;
has the meaning given to it in Recital&nbsp;&#8206;(B), and reference to Scheme also includes any modified, renewed or revised scheme;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Scheme
Conditions</B>&#8221; means the Conditions relating to the Scheme becoming effective in accordance with its terms, set out in Conditions&nbsp;2.1
to 2.6 (inclusive) of Part A of Appendix&nbsp;1 to the Announcement;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Scheme
Document</B>&#8221; means the circular to be sent to (amongst others) Avast Shareholders setting out (amongst other things) the details
of the Transaction, the full terms and conditions of the Scheme and the explanatory statement required pursuant to Part 26 of the Companies
Act and incorporating the notices convening the Court Meeting and the Avast General Meeting, including any revised or supplementary circular;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>SEC</B>&#8221;
means the US Securities and Exchange Commission;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Securities
Act</B>&#8221; means the United States Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Sensitive
Information</B>&#8221; has the meaning given to it in Clause&nbsp;&#8206;3.10;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Share
Option Plan</B>&#8221; means the Avast employee share option plan (formerly known as the Avast Holding 2014 Share Option Plan), as amended
from time to time;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Shareholder
Approval Conditions</B>&#8221; means Conditions 2.1, 2.3 and 3.1 of Part A of Appendix&nbsp;1 to the Announcement or, following an Agreed
Switch, any equivalent condition;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>SMP</B>&#8221;
means the Avast Share Matching Plan, as amended from time to time;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Takeover
Code</B>&#8221; means the UK City Code on Takeovers and Mergers issued from time to time by or on behalf of the Panel;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Tax</B>&#8221;
or &#8220;<B>Taxation</B>&#8221; means and includes all forms of taxation and statutory and governmental, state, provincial, local governmental
or municipal charges, duties, contributions and levies, withholdings and deductions wherever and whenever imposed and all related penalties
and&nbsp;interest;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Tax
Authority</B>&#8221; means any governmental or other authority competent to impose Taxation including any person, authority or body responsible
for collection of Tax; and</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&#8220;<B>Transaction</B>&#8221;
means the proposed combination of the NortonLifeLock Group with the Avast Group, which is proposed to be effected by Bidco (or another
member of the NortonLifeLock Group) acquiring the entire issued and to be issued share capital of Avast.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Except
                                            where expressly provided to the contrary or the context otherwise requires, words and expressions
                                            defined in the Announcement have the same meanings when used in this&nbsp;Agreement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 15; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">The
                                            Schedules form part of this Agreement and will have the same force and effect as if set out
                                            in the body of this Agreement and any reference to this Agreement will include the Schedules.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">In
                                            this Agreement, except where the context otherwise requires:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">references
                                            to &#8220;<B>this Agreement</B>&#8221; or to &#8220;<B>any other agreement or document referred
                                            to in this Agreement</B>&#8221; is a reference to this Agreement or such other document or
                                            agreement as amended, varied, supplemented, replaced or novated (in each case, other than
                                            in breach of the provisions of this Agreement or such other agreement or document) from time
                                            to time;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">the
                                            expression &#8220;<B>group</B>&#8221;, in relation to a party, means the party together with
                                            its subsidiaries and subsidiary undertakings from time to time;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">the
                                            expressions &#8220;<B>body corporate</B>&#8221;, &#8220;<B>holding company</B>&#8221;, &#8220;<B>subsidiary</B>&#8221;
                                            and &#8220;<B>subsidiary undertaking</B>&#8221; shall have the meaning given in the Companies
                                            Act;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">the
                                            expression &#8220;<B>acting in concert</B>&#8221; has the meaning given to it in the Takeover
                                            Code;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">any
                                            reference in this Agreement to &#8220;<B>Clauses</B>&#8221; and &#8220;<B>Schedules</B>&#8221;
                                            are, unless otherwise stated, to clauses and schedules of and to this Agreement and references
                                            to &#8220;<B>paragraphs</B>&#8221; are to paragraphs&nbsp;of the relevant Schedule;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">the
                                            expression &#8220;<B>offer</B>&#8221; shall have the meaning given in the Takeover Code;
                                            the expression &#8220;<B>takeover offer</B>&#8221; shall have the meaning given in section
                                            974 of the Companies Act;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">references
                                            to a &#8220;<B>company</B>&#8221; shall include any company, corporation or other body corporate,
                                            wherever and however incorporated or established;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">references
                                            to &#8220;<B>include</B>&#8221;, &#8220;<B>including</B>&#8221; or &#8220;<B>in particular</B>&#8221;
                                            are to be construed without&nbsp;limitation;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">references
                                            to &#8220;<B>other</B>&#8221; and &#8220;<B>otherwise</B>&#8221; shall not be limited by
                                            any foregoing words where a wider construction is possible;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(j)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">references
                                            to a &#8220;<B>person</B>&#8221; include any individual, corporation, partnership, limited
                                            liability company, unincorporated body, firm, partnership, association, joint venture, trust,
                                            organisation, government, committee, department, authority or other body, or any agency or
                                            political subdivision thereof or any other entity, whether or not having separate legal personality
                                            and that person&#8217;s personal representatives, successors or permitted assigns;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(k)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">a
                                            reference to &#8220;<B>writing</B>&#8221; or &#8220;<B>written</B>&#8221; means any method
                                            of reproducing words in a legible form and shall include e&#45;mail but shall exclude writing
                                            in a transitory form;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(l)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">headings
                                            and the table of contents are for convenience only and shall not affect the interpretation
                                            of this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(m)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">unless
                                            the context otherwise requires, words in the singular include the plural (and vice versa)
                                            and references to any gender includes references to all other genders;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(n)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">references
                                            in this Agreement to any statute or statutory provision or to any secondary legislation made
                                            thereunder shall be construed as a reference to such primary or secondary legislation as
                                            the same may have been, or may from time to time be, amended, varied, supplemented, replaced
                                            or re&#45;enacted, provided, that as between the parties, no such amendment, variation, supplement,
                                            replacement or re&#45;enactment shall apply for the purposes of this Agreement to the extent
                                            that it would impose any new or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 16; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">extended
                                            obligation, liability or restriction on, or otherwise adversely affect the rights of, any
                                            party;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(o)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)
                                            the rule known as the <I>ejusdem generis </I>rule shall not apply and accordingly general
                                            words introduced by the word &#8220;other&#8221; shall not be given a restrictive meaning
                                            by reason of the fact that they are preceded by words indicating a particular class of acts,
                                            matters or things; and (ii) general words shall not be given a restrictive meaning by reason
                                            of the fact that they are followed by particular examples intended to be embraced by the
                                            general words;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(p)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">references
                                            to times are to London time (unless otherwise expressly stated); and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(q)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">if
                                            a period of time is specified as from a given day, or from the day of an act or event, it
                                            shall be calculated exclusive of that day.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Effectiveness
                                            and the Terms of the Transaction</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">The
                                            obligations of the parties under this Agreement (other than Clause&nbsp;<I>&#8206;</I>1,
                                            this Clause&nbsp;<I>&#8206;</I>2.1 and Clauses&nbsp;<I>&#8206;</I>15 to <I>&#8206;</I>17
                                            (inclusive)) shall be conditional on the release of the Announcement via a Regulatory Newswire
                                            at or before 11.59&nbsp;p.m. on the date of the original Agreement, or such later time and
                                            date as the parties may agree (and, where required by the Takeover Code, approved by the
                                            Panel). Clause&nbsp;<I>&#8206;</I>1, this Clause&nbsp;<I>&#8206;</I>2.1 and Clauses&nbsp;<I>&#8206;</I>15
                                            to <I>&#8206;</I>17 (inclusive) shall take effect on and from the execution of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">The
                                            terms of the Transaction shall be as set out in the Announcement, together with such other
                                            terms as may otherwise be agreed by the parties in writing (save in the case solely of an
                                            increase in the consideration to be paid to Avast Shareholders under the terms of the Transaction,
                                            which will be at the absolute discretion of NortonLifeLock and Bidco) and, where required
                                            by the Takeover Code, approved by the Panel. The terms of the Transaction at the date of
                                            posting of the Scheme Document shall be as set out in the Scheme Document and any form of
                                            election. Should NortonLifeLock and/or Bidco elect to implement the Transaction by way of
                                            an Offer in accordance with Clause&nbsp;<I>&#8206;</I>9, the terms of the Transaction shall
                                            be set out in the announcement made in accordance with Rule 2.7 of the Takeover Code of the
                                            switch to an Offer, and in the Offer Document and any form of acceptance and form of election.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">2.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Each
                                            of NortonLifeLock and Bidco shall use all reasonable endeavours to take, or cause to be taken,
                                            all appropriate action, and do, or cause to be done, and assist and cooperate with Avast
                                            in doing, all things necessary, proper or advisable to consummate and make effective, as
                                            soon as reasonably practicable and in any event prior to the Long Stop Date, the transactions
                                            contemplated hereby, including the satisfaction of the condition specified in Clause&nbsp;<I>&#8206;</I>2.1.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>3.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Regulatory
                                            Conditions and Other Clearances</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Notwithstanding
                                            anything to the contrary in this Agreement but taking due account of its legal obligations
                                            with respect to the Regulatory Approvals, NortonLifeLock will have the right to: (a)&nbsp;determine
                                            the strategy to be pursued for: (i) obtaining the Regulatory Approvals; and (ii)&nbsp;satisfying
                                            the Regulatory Conditions; (b) lead all meetings and communications (including any negotiations)
                                            with any Regulatory Authority in connection with obtaining the Regulatory Approvals; and
                                            (c) control the defence and settlement of any litigation, action, suit, investigation of
                                            proceeding brought by or before any Regulatory Authority in connection with the Regulatory
                                            Approvals. NortonLifeLock shall consult with Avast in good faith and in a reasonable manner
                                            and shall take into account the views and comments of Avast and its professional advisers,
                                            in connection with the foregoing, on the basis set out in this Clause&nbsp;<I>&#8206;</I>3.
                                            For the avoidance of doubt, the matters described in this Clause&nbsp;<I>&#8206;</I>3.1 shall
                                            not impose any</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 17; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">obligations on Avast or
                                                                                                                                               NortonLifeLock other than those expressly set out in this Clause&nbsp;<I>&#8206;</I>3 and Clause&nbsp;<I>&#8206;</I>12.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Each
                                            of the parties undertakes to the other parties to cooperate with each other and their respective
                                            professional advisers, and NortonLifeLock and Bidco each undertake to use all reasonable
                                            endeavours, to obtain any Regulatory Approvals which are required to implement the Transaction
                                            in substantially the form contemplated by the Announcement (provided, that Avast&#8217;s
                                            obligations under this Clause&nbsp;<I>&#8206;</I>3.2 shall be limited to actions that are
                                            permitted under Rule 21.2(b)(iii) of the Takeover Code).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            and Bidco shall have primary responsibility for obtaining all Regulatory Approvals in respect
                                            of the Transaction, save in respect of any Regulatory Approvals (if any) that Avast is required
                                            to obtain solely on its own account, in respect of which Avast shall procure that the content
                                            of all relevant filings submitted by Avast shall (i) be consistent with the strategy determined
                                            by NortonLifeLock in accordance with Clause&nbsp;<I>&#8206;</I>3.1 and (ii) incorporate the
                                            views and comments of NortonLifeLock and its professional advisers in connection with the
                                            foregoing and consistent with Clause&nbsp;<I>&#8206;</I>3.1.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Where
                                            NortonLifeLock and/or Bidco is (or are) responsible for obtaining any Regulatory Approvals
                                            under any Law (or as soon as it is agreed by the parties, acting reasonably and in good faith,
                                            that a Regulatory Approval has become applicable), NortonLifeLock and Bidco&nbsp;shall:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">as
                                            promptly as reasonably practicable, but in no event later than the thirtieth Business Day
                                            following the date of the original Agreement or as otherwise agreed between the parties acting
                                            reasonably and in good faith, take all actions necessary to file or cause to be filed the
                                            filings required of it or any of its Affiliates under any such Law in connection with this
                                            Agreement and the transactions contemplated hereby provided, that if it is customary in connection
                                            with any Regulatory Approval to make a draft filing in advance of such filing, such 30 Business
                                            Day period shall apply to the first draft filing, with the filing to be filed as soon as
                                            reasonably practicable after the draft filing has been filed;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">use
                                            all reasonable endeavours to obtain the Regulatory Approvals prior to the Long Stop Date;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">as
                                            promptly as reasonably practicable, comply with (or seek to reduce the scope of) any formal
                                            or informal request for additional information or documentary material received by it or
                                            any of its Affiliates from any Regulatory Authority; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">subject
                                            to Clauses&nbsp;&#8206;3.1, &#8206;3.10 and &#8206;3.12, consult and cooperate with Avast,
                                            and incorporate reasonable comments from Avast, in connection with any analyses, appearances,
                                            presentations, memoranda, briefs, arguments, opinions and proposals made or submitted by
                                            or on behalf of any party in connection with proceedings under or relating to any Law. For
                                            the avoidance of doubt, but subject to Clause&nbsp;&#8206;3.1, NortonLifeLock and/or Bidco
                                            will not make any filings in connection with any Regulatory Approvals without the prior written
                                            consent of Avast, such consent not to be unreasonably withheld or delayed.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Where
                                            Avast is responsible for obtaining any Regulatory Approvals under any Law (or as soon as
                                            it is agreed by the parties, acting reasonably and in good faith, that a Regulatory Approval
                                            has become applicable), Avast shall:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">as
                                            promptly as reasonably practicable, but in no event later than the thirtieth Business Day
                                            following the date of the original Agreement or as otherwise agreed between the parties acting
                                            reasonably and in good faith, take all actions necessary to file or cause to be filed the
                                            filings required of it or any of its Affiliates under any such Law in</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 18; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">connection
                                            with this Agreement and the transactions contemplated hereby (including determining the content
                                            of such filings, provided that Avast shall procure that the content of all relevant filings
                                            submitted by Avast shall (i) be consistent with the strategy determined by NortonLifeLock
                                            in accordance with Clause&nbsp;&#8206;3.1 and (ii) incorporate the views and comments of
                                            NortonLifeLock and its professional advisers in connection with the foregoing and consistent
                                            with Clause&nbsp;&#8206;3.1); provided, that if it is customary in connection with any Regulatory
                                            Approval to make a draft filing in advance of such filing, such 30 Business Day period shall
                                            apply to the first draft filing, with the filing to be filed as soon as reasonably practicable
                                            after the draft filing has been filed; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">subject
                                            to Clauses&nbsp;&#8206;3.1, &#8206;3.10 and &#8206;3.12, consult and cooperate with NortonLifeLock
                                            and incorporate reasonable comments from NortonLifeLock, in connection with any analyses,
                                            appearances, presentations, memoranda, briefs, arguments, opinions and proposals made or
                                            submitted by or on behalf of any party in connection with proceedings under or relating to
                                            any Law.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Each
                                            of NortonLifeLock, Bidco and Avast will, in each case save as stipulated or required by the
                                            relevant Regulatory Authority, promptly notify each other of any written communication made
                                            to or received by either NortonLifeLock, Bidco and/or Avast, as the case may be, from any
                                            Regulatory Authority regarding the Transaction, and, subject to Clauses&nbsp;<I>&#8206;</I>3.1,
                                            <I>&#8206;</I>3.10 and <I>&#8206;</I>3.12, to any stipulation or requirement of a Regulatory
                                            Authority, and to the impact of any Law, if practicable, permit the other party to review
                                            in advance any proposed written communication to any such Regulatory Authority and incorporate
                                            the other party&#8217;s reasonable comments, not agree to participate in any substantive
                                            meeting or discussion with any such Regulatory Authority in respect of any filing, investigation
                                            or inquiry concerning this Agreement or the Transaction unless (to the extent permitted by
                                            Law), it consults (acting reasonably and in good faith) with the other party in advance and,
                                            to the extent permitted by such Regulatory Authority, gives the other party the opportunity
                                            to attend, and furnish the other party with copies of all material correspondence, filings
                                            and written communications between them and their Affiliates and their respective representatives
                                            on one hand and any such Regulatory Authority or its respective staff on the other hand,
                                            with respect to this Agreement and the Transaction.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Each
                                            of NortonLifeLock, Bidco and Avast undertakes, to the extent not prohibited by Law, to keep
                                            each other reasonably informed of its progress in respect of obtaining each Regulatory Approval
                                            and any developments which are material to the obtaining of each Regulatory Approval (in
                                            each case, save in respect of any Regulatory Approvals (if any) that the other party is required
                                            to obtain on its own account).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            and/or Bidco shall be responsible for paying any filing, administrative or other similar
                                            fees levied by any Regulatory Authority in respect of the Regulatory Approvals, unless such
                                            fees are payable by Avast as specified by Law.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            shall not, and shall cause other members of the NortonLifeLock Group not to, acquire or agree
                                            to acquire, by merging with or into or consolidating with, or by purchasing a substantial
                                            portion of the assets of or equity in, or by any other manner, any business or any corporation,
                                            partnership, association or other business organisation or division thereof, or otherwise
                                            acquire or agree to acquire any assets or enter into any licensing arrangement or other arrangement
                                            or collaboration with a third party, if the entering into of a definitive agreement relating
                                            to, or the consummation of such acquisition, merger, consolidation, arrangement, licensing
                                            arrangement or collaboration could reasonably be expected to impose any material delay in
                                            the obtaining of, or materially increase the risk of not obtaining, any consents of any Regulatory
                                            Authority necessary to obtain any Regulatory Approvals, or the expiration or termination
                                            of any applicable waiting period.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.10</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">If
                                            a provision of this Agreement obliges NortonLifeLock, Bidco or Avast (the &#8220;<B>disclosing
                                            party</B>&#8221;) to disclose any information to the other:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 19; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">that
                                            is personally identifiable information of a shareholder, director, officer or employee of
                                            the disclosing party or any member of its group, unless that information can reasonably be
                                            anonymised (in which case the disclosing party will provide the relevant information on an
                                            anonymous basis);</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">which
                                            the disclosing party reasonably considers to be commercially or competitively&nbsp;sensitive;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">which
                                            the disclosing party is prohibited from disclosing by Law or the terms of an existing contract;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">where
                                            such disclosure would result in the loss of privilege that subsists in relation to such information
                                            (including legal professional privilege)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.11</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(together
                                            &#8220;<B>Sensitive Information</B>&#8221;), the disclosing party will, to the extent permitted
                                            by Law, disclose the relevant information to the other party on an outside counsel or retained
                                            expert only basis pursuant to the Clean Team and Joint Defence Agreement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.12</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">No
                                            party will be required to disclose information to another party under this Clause&nbsp;<I>&#8206;</I>3
                                            if and to the extent such disclosure would reasonably be expected to have a material adverse
                                            effect on the disclosing party&#8217;s legitimate business interests, and such information
                                            may be provided by the disclosing party directly to the Regulatory Authority and, in such
                                            circumstances, the disclosing party will provide, or procure the provision to the other party
                                            or parties of a non-confidential version of such information.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.13</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock,
                                            Bidco and Avast each acknowledge and agree that, for the purposes of this Clause&nbsp;<I>&#8206;</I>3,
                                            all reasonable endeavours shall require NortonLifeLock and Bidco to take, or agree to take,
                                            all actions necessary to obtain the Regulatory Approvals and to satisfy the Regulatory Conditions
                                            required to implement the Transaction in substantially the form contemplated by the Announcement
                                            (including accepting any relevant remedies or required disposals), in each case except to
                                            the extent that such actions would, individually or in the aggregate, be of material significance
                                            to NortonLifeLock and Bidco in the context of the Transaction (as such material significance
                                            standard is or would fall to be determined by the Panel under the Takeover Code), in which
                                            case NortonLifeLock and Bidco shall not be required to take, or agree to take, such&nbsp;actions.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>4.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Scheme
                                            Document and other Avast documents</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Subject
                                            to Clauses&nbsp;<I>&#8206;</I>3.10 and <I>&#8206;</I>3.12, NortonLifeLock undertakes to (and
                                            undertakes to procure that each member of the NortonLifeLock Group will):</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">promptly
                                            provide to Avast (and/or its legal advisers), for the purposes of inclusion in the Scheme
                                            Document or any other document required to be produced by Avast in connection with the Transaction
                                            (including any supplementary circular), all such information about the Transaction, NortonLifeLock,
                                            the NortonLifeLock Directors, Bidco, the Bidco Directors, and the other members of the NortonLifeLock
                                            Group, as may be necessary or reasonably required (and which is or are requested on reasonable
                                            notice by Avast and/or its legal advisers) in order to satisfy the disclosure requirements
                                            of the Takeover Code, Companies Act and any other Law in connection with the preparation
                                            of the relevant document or documents;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">promptly
                                            provide Avast with all such other assistance and access as may be necessary or reasonably
                                            required (and which is or are requested on reasonable notice by Avast and/or its legal advisers)
                                            in connection with the preparation of the Scheme Document or any other document required
                                            by the Takeover Code or other Law to be produced by Avast in connection with the Transaction
                                            (including any supplementary circular),</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 20; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">including
                                            access to, and ensuring the provision of reasonable assistance by, NortonLifeLock&#8217;s
                                            relevant professional advisers; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">procure
                                            that the NortonLifeLock Directors and Bidco Directors (and any other person connected with
                                            NortonLifeLock and/or the NortonLifeLock Group), in each case to the extent required by the
                                            Panel to do so, accept responsibility for all information (including any expressions of opinion)
                                            in the Scheme Document relating to themselves (and their close relatives (as defined in the
                                            Takeover Code), related trusts and persons connected with them), the NortonLifeLock Group,
                                            NortonLifeLock concert parties, the Transaction, the financing of the Transaction, any statement
                                            of intention or belief in relation to the Transaction or NortonLifeLock&#8217;s and/or Bidco&#8217;s
                                            future plans for the Avast Group, its management and employees, any statements of opinion,
                                            belief, intention or expectation of the NortonLifeLock Directors and/or Bidco Directors in
                                            relation to the Transaction or the Combined Company following the Effective Date and any
                                            other information in the Scheme Document for which NortonLifeLock, Bidco and/or its or their
                                            respective directors is or are required to accept responsibility under the Takeover Code.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">If
                                            any supplementary circular is required to be published by Avast in connection with the Scheme,
                                            NortonLifeLock shall, as soon as reasonably practicable, provide such co-operation and information
                                            (including such information as is necessary or reasonably required for such supplementary
                                            circular or document to comply with any Law) as Avast may reasonably request in order to
                                            prepare and publish such document.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock,
                                            Bidco and Avast each agrees to correct any information provided by it for use in the Scheme
                                            Document or any other document to be prepared in connection with the Transaction to the extent
                                            that such information has become false or misleading, and to notify the other party or parties
                                            as promptly as reasonably practicable after that party becomes aware that such information
                                            has become false or misleading.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Each
                                            of the parties agrees that the posting of the Scheme Document is anticipated to occur at
                                            or around the same time as the publication of the Proxy Statement and the NortonLifeLock
                                            Prospectus, or otherwise in accordance with the timetable agreed in writing between the parties.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Non-Solicitation
                                            Applicable to NortonLifeLock; Preparation of the Proxy Statement and NortonLifeLock Stockholder
                                            Approval</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">5.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            agrees that neither it, nor any member of the NortonLifeLock Group, shall, and that it shall
                                            use all reasonable endeavours to cause its and their respective Affiliates and representatives
                                            not to, directly or indirectly from the date of the original Agreement until the earlier
                                            of the termination of this Agreement and the Effective Date, enter into, continue or participate
                                            in any discussions or negotiations regarding, or furnish any information with respect to,
                                            or otherwise cooperate in any way that could otherwise be reasonably expected to lead to,
                                            a NortonLifeLock Alternative Proposal, except to notify such person of the existence of NortonLifeLock&#8217;s
                                            obligations under this Clause&nbsp;<I>&#8206;</I>5.1. Upon the execution and delivery of
                                            this Agreement, NortonLifeLock shall, shall cause the members of the NortonLifeLock Group
                                            to, and shall use all reasonable endeavours to cause its and their respective Affiliates
                                            and representatives to, immediately cease and cause to be terminated all existing discussions
                                            or negotiations with any person with respect to any NortonLifeLock Alternative Proposal or
                                            any enquiry or proposal that may reasonably be expected to lead to a NortonLifeLock Alternative
                                            Proposal.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">5.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Notwithstanding
                                            anything to the contrary contained in Clause&nbsp;<I>&#8206;</I>5.1 or any other provision
                                            of this Agreement, if at any time after the execution of this Agreement and prior to obtaining
                                            the NortonLifeLock Stockholder Approval, any member of the NortonLifeLock Group or any of
                                            their respective representatives receives a bona fide, unsolicited NortonLifeLock Alternative</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 21; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Proposal,
                                            which NortonLifeLock Alternative Proposal did not result from a breach by NortonLifeLock
                                            or a member of the NortonLifeLock Group of Clause&nbsp;<I>&#8206;</I>5.1, then in response
                                            to such NortonLifeLock Alternative Proposal: (i) NortonLifeLock and its representatives may
                                            contact the person or group that made such NortonLifeLock Alternative Proposal to clarify
                                            the terms and conditions thereof or to request that such NortonLifeLock Alternative Proposal
                                            made orally be made in writing; and (ii) if the NortonLifeLock Board determines in good faith
                                            (after consultation with its outside legal counsel and financial advisers) that such NortonLifeLock
                                            Alternative Proposal constitutes or would reasonably be expected to lead to a NortonLifeLock
                                            Takeover Proposal from the person or group submitting such NortonLifeLock Alternative Proposal
                                            and that the failure to take such action would reasonably be expected to be inconsistent
                                            with the NortonLifeLock Directors&#8217; fiduciary duties under Law (a&nbsp;&#8220;<B>Qualifying
                                            NortonLifeLock Takeover Proposal</B>&#8221;), NortonLifeLock may (A) enter into an confidentiality
                                            agreement with such person or group making the Qualifying NortonLifeLock Takeover Proposal
                                            and thereafter furnish information (including non-public information) with respect to the
                                            NortonLifeLock Group to such person or group and its representatives pursuant to such confidentiality
                                            agreement so long as, prior to or substantially concurrently with the time such information
                                            is provided or made available to such person or group or any of its representatives, NortonLifeLock
                                            also provides Avast any information furnished to such person or group or any of its representatives
                                            which was not previously furnished to Avast; and (B) engage in or otherwise participate in
                                            discussions or negotiations with such person or group and its representatives regarding such
                                            Qualifying NortonLifeLock Takeover Proposal.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">5.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            undertakes to Avast to:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">subject
                                            to Avast complying with its obligations under Clause&nbsp;&#8206;5.4, as promptly as reasonably
                                            practicable after the date of the original Agreement, and in any event no later than 25 Business
                                            Days following the date of the original Agreement, prepare and cause to be filed with the
                                            SEC a preliminary Proxy Statement;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">provide
                                            Avast and its legal counsel with reasonable opportunity to review and comment on: (i) drafts
                                            of the Proxy Statement and any other document to be sent by NortonLifeLock to the NortonLifeLock
                                            Stockholders in connection with the NortonLifeLock Stockholder Approval (the &#8220;<B>NortonLifeLock
                                            Documents</B>&#8221;) before filing any such draft with the SEC or transmitting it to NortonLifeLock
                                            Stockholders, as applicable; and (ii) any response to comments received from the SEC. NortonLifeLock
                                            shall in good faith consider all comments reasonably and promptly proposed by Avast or its
                                            legal counsel in relation to the NortonLifeLock Documents;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">as
                                            promptly as reasonably practicable, notify Avast and provide copies of any material communications
                                            sent to or received from the SEC in relation to the Proxy Statement;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">as
                                            soon as reasonably practicable, respond to any comments received from the SEC concerning
                                            the Proxy Statement and use its best endeavours to resolve such comments with the SEC as
                                            promptly as reasonably practicable;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">use
                                            its best endeavours to obtain the Proxy Approval as soon as reasonably practicable after
                                            the date of the original Agreement;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">other
                                            than in the circumstances specified in Clause&nbsp;&#8206;5.7, through the NortonLifeLock
                                            Board, make the NortonLifeLock Board Recommendation to the NortonLifeLock Shareholders and
                                            include the NortonLifeLock Board Recommendation in the Proxy&nbsp;Statement;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">other
                                            than in the circumstances specified in Clause&nbsp;&#8206;5.7, not make a NortonLifeLock
                                            Board Recommendation Change;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 22; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">transmit
                                            the Proxy Statement to NortonLifeLock Stockholders and establish a record date for, call
                                            and give notice of the NortonLifeLock Stockholders Meeting as promptly as reasonably practicable
                                            after receipt of the Proxy Approval;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">in
                                            accordance with Law, NortonLifeLock&#8217;s certificate of incorporation, bylaws and the
                                            rules of NASDAQ, convene and hold the NortonLifeLock Stockholders Meeting as promptly as
                                            reasonably practicable and, to the extent reasonably practicable, on the same day as the
                                            Avast General Meeting and Court Meeting; provided, however, that NortonLifeLock may, without
                                            the prior written consent of Avast, adjourn or postpone the NortonLifeLock Stockholders Meeting:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">if
                                            as of the time for which the NortonLifeLock Stockholders Meeting is originally scheduled
                                            (as set forth in the definitive Proxy Statement) there are insufficient NortonLifeLock Shares
                                            represented (either in person or by proxy) to constitute a quorum necessary to conduct the
                                            business of the NortonLifeLock Stockholders Meeting;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">after
                                            consultation with Avast, if the failure to adjourn or postpone the NortonLifeLock Stockholders
                                            Meeting would reasonably be expected to be a violation of applicable Law for the distribution
                                            of any required supplement or amendment to the Proxy Statement;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">after
                                            consultation with Avast, not more than twice, each time not to exceed 10 Business Days, to
                                            solicit additional proxies if necessary to obtain the NortonLifeLock Stockholder Approval;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">if
                                            necessary, due to an adjournment of the Avast General Meeting and Court Meeting to ensure
                                            that the NortonLifeLock Stockholders Meeting is held on the same day as the Avast General
                                            Meeting and Court Meeting,</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(v)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">it
                                            being acknowledged and agreed that NortonLifeLock shall not be able to invoke the Shareholder
                                            Approval Condition at Condition 3.1 where the applicable meetings have not been held by the
                                            applicable long stop date set out in the Scheme Document solely as a result of the NortonLifeLock
                                            Stockholders Meeting not yet having been held;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(j)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">unless
                                            NortonLifeLock has effected a NortonLifeLock Board Recommendation Change in accordance with
                                            Clause&nbsp;&#8206;5.7, use all reasonable endeavours to obtain the NortonLifeLock Stockholder
                                            Approval, including using all reasonable endeavours to solicit from NortonLifeLock Stockholders
                                            proxies in favour of the NortonLifeLock Stockholder Approval;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(k)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">use
                                            all reasonable endeavours to cause all New NortonLifeLock Shares to be issued to Avast Shareholders
                                            pursuant to the Scheme or Offer (as the case may be) to be approved for listing on NASDAQ,
                                            subject only to official notice of issuance, prior to the Effective Date;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(l)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">for
                                            so long as the Transaction is being implemented by way of the Scheme, use all reasonable
                                            endeavours to cause all New NortonLifeLock Shares issued to Avast Shareholders upon the Scheme
                                            becoming effective to be issued in reliance on an exemption from the registration requirements
                                            of the Securities Act; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(m)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">procure
                                            that the New NortonLifeLock Shares to be issued to Avast Shareholders pursuant to the Scheme
                                            or the Offer (as the case may be) shall be issued and credited as fully paid and rank <I>pari
                                            passu</I> with all other NortonLifeLock Shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 23; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">5.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Subject
                                            to Clauses&nbsp;<I>&#8206;</I>3.10 and <I>&#8206;</I>3.12, Avast undertakes to (and undertakes
                                            to procure that each member of the Avast Group will):</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">promptly
                                            provide to NortonLifeLock (and/or its legal advisers), for the purposes of inclusion in the
                                            Proxy Statement or any other document required to be produced by NortonLifeLock in connection
                                            with the Transaction (including any amendment or supplement thereto), all such information
                                            about the Transaction, Avast, the Avast Directors and the other members of the Avast Group
                                            as may be necessary or reasonably required (and which is or are requested on reasonable notice
                                            by NortonLifeLock and/or its legal advisers) in order to satisfy the disclosure requirements
                                            of the Exchange Act, NASDAQ and any other Law in connection with the preparation of the relevant
                                            document or documents;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">promptly
                                            provide NortonLifeLock with all such other assistance and access as may be necessary or reasonably
                                            required (and requested on reasonable notice by NortonLifeLock and/or its legal advisers)
                                            in connection with the preparation of the Proxy Statement or any other document required
                                            by the Securities Act, the Exchange Act, or other Law to be produced by NortonLifeLock in
                                            connection with the Transaction (including any amendment or supplement thereto), including
                                            access to, and ensuring the provision of reasonable assistance by, Avast&#8217;s relevant
                                            professional advisers; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">co-operate
                                            with, and provide reasonable assistance to, NortonLifeLock in relation to the preparation
                                            of the Proxy Statement and the resolution of comments received from the SEC in respect of
                                            it.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">5.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">If
                                            any amendment or supplement is required by Law to be published by NortonLifeLock in connection
                                            with the Proxy Statement, Avast shall, as soon as reasonably practicable, provide such co-operation
                                            and information (including such information as is necessary or reasonably required for such
                                            supplement or document to comply with any Law) as NortonLifeLock may reasonably request in
                                            order to prepare and publish such document.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">5.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Avast
                                            and NortonLifeLock each agree to correct any information provided by them for use in the
                                            Proxy Statement or any other document to be prepared in connection with the Transaction to
                                            the extent that such information has become false or misleading as promptly as reasonably
                                            practicable after that party becomes aware that such information has become false or&nbsp;misleading.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">5.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Notwithstanding
                                            any other provision of this Agreement, at any time prior to the NortonLifeLock Stockholder
                                            Approval, solely in response to either (x) a bona fide, unsolicited NortonLifeLock Alternative
                                            Proposal that has been made and not withdrawn or (y) a NortonLifeLock Intervening Event that
                                            is continuing, the NortonLifeLock Board may make or announce a NortonLifeLock Board Recommendation
                                            Change if it determines, acting in good faith: (i)&nbsp;with respect to such a NortonLifeLock
                                            Alternative Proposal, after consultation with its financial advisors and outside legal counsel,
                                            such NortonLifeLock Alternative Proposal constitutes a NortonLifeLock Takeover Proposal;
                                            and (ii) with respect to such a NortonLifeLock Alternative Proposal or such a NortonLifeLock
                                            Intervening Event, after consultation with its outside legal counsel, that failure to take
                                            such action would reasonably be expected to be inconsistent with the NortonLifeLock Directors&#8217;
                                            fiduciary duties under Law; <U>provided</U>, <U>however</U>, that NortonLifeLock and the
                                            NortonLifeLock Board shall not be entitled to make a NortonLifeLock Board Recommendation
                                            Change as contemplated by this Clause&nbsp;<I>&#8206;</I>5.7 unless:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            has given Avast at least five Business Days&#8217; prior written notice of its intention
                                            to take such action (the five business days following such written notice being the&nbsp;&#8220;<B>Match
                                            Period</B>&#8221;);</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 24; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            has sought to negotiate in good faith (and has caused its representatives to seek to negotiate)
                                            with Avast during the Match Period, if and to the extent Avast wishes to negotiate, to enable
                                            Avast to propose and/or the parties to agree revisions to the terms of this Agreement and
                                            (subject to the parties&#8217; obligations under Law and any requirement, consent or direction
                                            of the Panel or any other Regulatory Authority) to the terms of the Transaction; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">following
                                            the end of the Match Period, the NortonLifeLock Board shall have considered in good faith
                                            any revised terms proposed by Avast and/or agreed in accordance with Clause&nbsp;&#8206;5.7(b),
                                            and shall have determined: (x) solely with respect to a NortonLifeLock Alternative Proposal,
                                            after consultation with its financial advisors and outside legal counsel, that such NortonLifeLock
                                            Alternative Proposal would continue to constitute a NortonLifeLock Takeover Proposal if the
                                            revisions proposed by Avast were to be given effect; and (y) with respect to a NortonLifeLock
                                            Alternative Proposal or a NortonLifeLock Intervening Event, after consultation with its outside
                                            legal counsel, that the failure to make a NortonLifeLock Board Recommendation Change would
                                            reasonably be expected to be inconsistent with the NortonLifeLock Directors&#8217; fiduciary
                                            duties under Law (it being understood and agreed that, if applicable, any amendment to the
                                            financial terms or any other material term of any NortonLifeLock Takeover Proposal to which
                                            any Match Period relates shall require a new notice and a new Match Period, provided, that
                                            such Match Period shall be a two Business Day period for the purposes of Clause&nbsp;&#8206;5.7&#8206;(a)
                                            and thereafter the remainder of this Clause&nbsp;&#8206;5.7 rather than five Business Days).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">5.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Nothing
                                            contained in this Agreement shall prohibit or restrict NortonLifeLock or the NortonLifeLock
                                            Directors from taking and disclosing to the NortonLifeLock Stockholders a position or making
                                            a statement contemplated by Rule 14d-9, Rule 14e-2(a) or Item 1012(a) of Regulation M-A promulgated
                                            under the Exchange Act (provided, however, that any such disclosure which constitutes a NortonLifeLock
                                            Board Recommendation Change shall be subject to the terms of Clause&nbsp;<I>&#8206;</I>5.3(g)
                                            and Clause&nbsp;<I>&#8206;</I>5.7).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">5.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            shall promptly (and in any event within 48 hours of the occurrence or receipt thereof) notify,
                                            orally and in writing, Avast in the event that any NortonLifeLock Alternative Proposal is
                                            received by NortonLifeLock or any member of the NortonLifeLock Group, and shall disclose
                                            to Avast the material terms and conditions of any such NortonLifeLock Alternative Proposal
                                            and the identity of the Person or group making such NortonLifeLock Alternative Proposal (and
                                            shall include with such notice unredacted copies of any written materials received from or
                                            on behalf of such Person relating to such NortonLifeLock Alternative Proposal, and NortonLifeLock
                                            shall promptly, and, in any event within 48 hours of the occurrence or receipt thereof, keep
                                            Avast informed of any material oral or written communications regarding, and any material
                                            developments with respect to the status and terms of, any such NortonLifeLock Alternative
                                            Proposal and shall provide to Avast unredacted copies of all written materials related thereto.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>6.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            Prospectus</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            undertakes to Avast to:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">use
                                            all reasonable endeavours to prepare and submit a draft of the NortonLifeLock Prospectus
                                            for review and comment by the FCA as promptly as reasonably practicable after the date of
                                            the original Agreement and in any event within 30 Business Days after the date of the original
                                            Agreement;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">provide,
                                            or procure the provision of, to Avast (or its advisers) draft copies of the NortonLifeLock
                                            Prospectus and material communications sent to the FCA by or on behalf of NortonLifeLock
                                            in relation to the NortonLifeLock Prospectus, at such time</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 25; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">as
                                            will allow Avast a reasonable opportunity to provide comments on the NortonLifeLock Prospectus
                                            and such communications before they are submitted or&nbsp;sent;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">incorporate
                                            reasonable comments from Avast or its legal counsel in relation to the NortonLifeLock Prospectus,
                                            including any written responses to comments on drafts thereof received from the FCA;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">promptly
                                            provide Avast or its legal advisers with copies of any material communications sent to or
                                            received from the FCA in relation to the NortonLifeLock&nbsp;Prospectus;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">promptly
                                            respond to any comments received from the FCA concerning the NortonLifeLock Prospectus and
                                            shall use all reasonable endeavours to resolve such comments with the FCA as promptly as
                                            possible;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">keep
                                            Avast or its legal advisers informed promptly of developments which are material in relation
                                            to the NortonLifeLock Prospectus and the approval of the NortonLifeLock Prospectus by the
                                            FCA;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">use
                                            all reasonable endeavours to obtain the approval of the NortonLifeLock Prospectus by the
                                            FCA as soon as reasonably practicable after the date of the original Agreement; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">use
                                            all reasonable endeavours to cause the NortonLifeLock Prospectus to be dispatched and published
                                            (subject to approval from the FCA to do the same) on the date that each of the Scheme Document
                                            and the Proxy Statement are published and dispatched.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">6.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Avast
                                            undertakes to provide, and to procure that those of the Avast Directors who will be appointed
                                            as directors of the Combined Company with effect from the Effective Date provide, NortonLifeLock
                                            with all such information about itself, the Avast Group and its directors (including information
                                            regarding such Avast Directors, and including all requisite financial information and reports)
                                            as may be reasonably requested and which is required for the purpose of inclusion in the
                                            NortonLifeLock Prospectus, and to provide all other assistance which may reasonably be required
                                            in connection with the preparation of the NortonLifeLock Prospectus to the standard that
                                            is required for NortonLifeLock to meet its legal and regulatory obligations in relation to
                                            the preparation of the NortonLifeLock Prospectus.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">6.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Avast
                                            and NortonLifeLock each agree to correct any information provided for use in the NortonLifeLock
                                            Prospectus to the extent that such information has become false or misleading as promptly
                                            as reasonably practicable after that party becomes aware that such information has become
                                            false or misleading.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>7.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Implementation
                                            of the Scheme</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">7.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            and Bidco each undertakes to Avast:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">save
                                            in respect of NortonLifeLock and Bidco&#8217;s obligations with respect to obtaining the
                                            Regulatory Approvals, which shall be determined in accordance with Clause&nbsp;&#8206;3,
                                            to co-operate with Avast and its advisers and to take or cause to be taken all such steps
                                            as are permissible by the Takeover Code and Law and are within its power that are necessary
                                            or reasonably requested by Avast to implement the Transaction in accordance with, and subject
                                            to the terms and conditions set out in, this Agreement, the Announcement and the Scheme Document
                                            (or, following an Agreed Switch, the Offer&nbsp;Document);</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 26; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">that
                                            neither NortonLifeLock nor Bidco will object to the Court Sanction Hearing being convened
                                            as soon as reasonably practicable after the satisfaction or waiver of the Regulatory Conditions
                                            and the Shareholder Approval Conditions;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">that
                                            before the Court Sanction Hearing, NortonLifeLock and/or Bidco shall deliver a notice in
                                            writing to Avast confirming either:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">the
                                            satisfaction or waiver of all Conditions (other than the Scheme Condition capable of being
                                            satisfied only upon or following the sanction of the Scheme by the Court), as contemplated
                                            by Section 3(g)(i) of Appendix 7 to the Takeover Code; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock&#8217;s
                                            and/or Bidco&#8217;s intention to invoke a Condition (if permitted by the Panel as contemplated
                                            in Section 3 of Appendix 7 to the Takeover Code), in which case NortonLifeLock and/or Bidco
                                            shall promptly provide Avast with details of the event which has occurred, or circumstances
                                            which have arisen, which NortonLifeLock and/or Bidco reasonably considers to be sufficiently
                                            material for the Panel to permit NortonLifeLock and/or Bidco to invoke the Condition (and,
                                            if such matter is capable of remedy by Avast, shall provide Avast with reasonable opportunity
                                            to remedy such matter); and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">to
                                            the extent that all the Conditions (other than the Scheme Condition capable of being satisfied
                                            only upon or following the sanction of the Scheme by the Court) have been satisfied or, where
                                            permissible, waived on or before the date of the Court Sanction Hearing, NortonLifeLock and/or
                                            Bidco shall, as contemplated by Section 3(g)(ii) of Appendix 7 to the Takeover Code, instruct
                                            counsel to appear on NortonLifeLock&#8217;s and/or Bidco&#8217;s behalf at the Court Sanction
                                            Hearing and to undertake to the Court to be bound by the terms of the Scheme in so far as
                                            it relates to&nbsp;NortonLifeLock and/or&nbsp;Bidco.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">7.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">If
                                            NortonLifeLock and/or Bidco becomes aware, after the publication of the Scheme Document,
                                            of any fact, matter or circumstance that is (in NortonLifeLock&#8217;s reasonable opinion
                                            likely to (i)&nbsp;significantly change the Scheme timetable or (ii) applying the test set
                                            out in Rule&nbsp;13.5 of the Takeover&nbsp;Code, permit NortonLifeLock and/or Bidco to invoke
                                            any of the Conditions, NortonLifeLock shall (subject to Law) inform Avast of the same as
                                            soon as reasonably practicable, providing reasonable details of such fact, matter or circumstance.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>8.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">NortonLifeLock
                                            Conduct of Business</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">8.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Except:
                                            (i) with the prior written consent of Avast (not to be unreasonably withheld, conditioned
                                            or delayed); (ii) as required by Law; or (iii) as expressly contemplated by this Agreement
                                            or the Announcement, NortonLifeLock shall not (and shall procure that no member of the NortonLifeLock
                                            Group shall) before the Effective Date:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">split,
                                            combine, consolidate, sub-divide, reclassify, redeem, cancel or repurchase any NortonLifeLock
                                            Shares or any shares of capital stock, voting securities or equity interests of NortonLifeLock
                                            or any securities convertible into, or rights to acquire, shares of capital stock, voting
                                            securities or equity interests of NortonLifeLock or which otherwise refer to the value of
                                            shares of capital stock of NortonLifeLock, other than:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">the
                                            repurchase, redemption or acquisition of NortonLifeLock Shares in connection with the acceptance
                                            of shares as payment for the exercise price of equity awards or as payment for Taxes incurred
                                            in connection with the exercise, vesting and/or settlement of equity awards or the forfeiture
                                            of equity awards; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 27; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: A02 -->
<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">any redemption, cancellation or repurchase of any NortonLifeLock Convertible Notes;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">other than the Agreed NortonLifeLock Dividends and (to the extent otherwise restricted by this Clause&nbsp;&#8206;8.1(b))
any dividends or distributions payable pursuant to the terms of the NortonLifeLock Convertible Notes, authorise, declare or pay any dividends
on or make any distribution in cash or otherwise with respect to NortonLifeLock Shares or any securities referred to in Clause&nbsp;&#8206;8.1(a)
above, except dividends or distributions with a record date after the Effective Date so that, after the Transaction is completed, the
New NortonLifeLock Shares will rank <I>pari passu</I> with all other NortonLifeLock Shares with respect to participation in such dividend
or other&nbsp;distribution;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">amend its organisational documents in a manner likely to have a material adverse effect for Avast Shareholders
who are due to receive NortonLifeLock Stock pursuant to the&nbsp;Transaction;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify">solely with respect to NortonLifeLock, adopt a plan of complete or partial liquidation or dissolution;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify">sell, lease, license, transfer, exchange, swap or otherwise dispose of, or subject to any lien, any of
its material assets (including shares in the capital of its or their material subsidiaries and including material intellectual property)
on any basis, other than (i) for transactions conducted with a third party on a bona fide arm&#8217;s length basis; (ii) for transactions
solely between members of the NortonLifeLock Group; (iii) in the case of any licensing arrangements, in the ordinary course of business;
or (iv) liens securing NortonLifeLock Group&#8217;s obligations under any of its financing agreements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(f)</FONT></TD><TD STYLE="text-align: justify">delist the NortonLifeLock Shares from NASDAQ; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(g)</FONT></TD><TD STYLE="text-align: justify">agree, resolve, commit or announce its intention to do any of the foregoing (as applicable), whether conditionally
or unconditionally.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">8.2</FONT></TD><TD STYLE="text-align: justify">If NortonLifeLock determines to make, pay or declare any dividend or distribution (excluding, for clarity,
any dividend or distribution on the NortonLifeLock Convertible Notes) other than, or in excess of, the Agreed NortonLifeLock Dividends
(each of, without duplication, (i) such dividend other than an Agreed NortonLifeLock Dividend and (ii) the amount of any NortonLifeLock
quarterly dividend in excess of 12.5 cents per NortonLifeLock Share, an &#8220;<B>Excess NortonLifeLock Dividend</B>&#8221;):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock shall give Avast not less than five Business Days&#8217; prior notice in writing of its
intention to pay an Excess NortonLifeLock Dividend (an &#8220;<B>Excess NortonLifeLock Dividend Notice</B>&#8221;), which notice shall
include the proposed amount of, and proposed payment date for, the Excess NortonLifeLock Dividend; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock and Bidco shall increase the cash consideration per Avast Share payable under each of the
Majority Cash Option and the Majority Stock Option by an amount equal to: (i) the amount of the relevant Excess NortonLifeLock Dividend
(expressed on a per NortonLifeLock Share basis) multiplied by (ii) in the case of the Majority Cash Option, 0.0302, and, in the case of
the Majority Stock Option, 0.1937.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>9.</B></FONT></TD><TD STYLE="text-align: justify">Switching to an Offer</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">9.1</FONT></TD><TD STYLE="text-align: justify">The parties currently intend that the Transaction will be implemented by way of the Scheme. Notwithstanding
the foregoing, and subject to the consent of the Panel, NortonLifeLock and/or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 28; Options: NewSection; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Bidco may elect to implement the Transaction
by way of an Offer rather than the Scheme (prior to any termination of this Agreement), if:</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">Avast provides its prior written consent (an &#8220;<B>Agreed Switch</B>&#8221;) in which case Clause&nbsp;&#8206;9.2
shall apply;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">without prejudice to any relevant party&#8217;s right to terminate this Agreement pursuant to Clause&nbsp;&#8206;15.1(c)
in such circumstances, an Avast Board Recommendation Change&nbsp;occurs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">without prejudice to Clause&nbsp;&#8206;9.1(b), any of the circumstances set out in Note&nbsp;2 on Section&nbsp;8
of Appendix&nbsp;7 of the Takeover&nbsp;Code applies with respect to the Transaction;&nbsp;or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify">a third party announces a firm intention to make an offer for the entire issued and to be issued share
capital of Avast, provided, that NortonLifeLock and/or Bidco shall consult with Avast prior to electing to implement the Acquisition by
way of an Offer in such&nbsp;circumstances.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">9.2</FONT></TD><TD STYLE="text-align: justify">In the event of an Agreed Switch, unless otherwise agreed in writing between Avast and NortonLifeLock
or required by the Panel:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">the acceptance condition to the Offer (the &#8220;<B>Acceptance Condition</B>&#8221;) shall be set at
75&nbsp;per&nbsp;cent. of the Avast Shares to which the Offer relates, or such other lesser percentage as may be agreed in writing between
Avast and NortonLifeLock after, to the extent necessary, consultation with the Panel, being in any case more than 50&nbsp;per&nbsp;cent.
of the Avast Shares to which the Offer relates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock shall not take any action (including, if applicable, NortonLifeLock and/or Bidco serving
any Acceptance Condition Invocation Notice) which would cause the Offer not to proceed, to lapse or to be withdrawn, in each case by reason
of the non&#45;fulfilment of the Acceptance Condition before the 60<SUP>th</SUP> day after publication of the Offer Document and NortonLifeLock
shall ensure that the Offer remains open until at least such time;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock shall ensure that the only conditions to the Offer shall be the Conditions, subject to
replacing the Scheme Conditions with the Acceptance&nbsp;Condition;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify">where a material official authorisation or regulatory clearance remains outstanding, NortonLifeLock and
Avast shall ensure that appropriate steps are taken to suspend the offer timetable by 5:00&nbsp;p.m. on the second day prior to Day 39
(including, if applicable, making a joint request to the Panel pursuant to Rule 31.4(a)(i) of the Takeover Code in respect of such a suspension);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify">if and to the extent that the Long Stop Date ceases to apply, NortonLifeLock shall, in accordance with
the Takeover Code, agree with Avast a new long stop date by which the Offer must become unconditional;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(f)</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock shall keep Avast informed, on a regular and confidential basis and in any event by the
next Business Day following a request from Avast, of the number of Avast Shareholders that have validly returned their acceptance or withdrawal
forms or incorrectly completed their acceptance or withdrawal forms;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(g)</FONT></TD><TD STYLE="text-align: justify">the parties agree that all provisions of this Agreement relating to the Scheme and its implementation
shall apply to the Offer or its implementation <I>mutatis mutandis</I>; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 29; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(h)</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock shall:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">prepare the Offer Document and shall consult with Avast in relation to it;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">submit drafts and revised drafts of the Offer Document to Avast for review and comment and shall take
into account any reasonable comments from Avast;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify">seek to obtain Avast&#8217;s approval for any information relating to Avast in the Offer Document before
it is posted or published and afford Avast sufficient time to consider such information in order to give its approval (without prejudice
to Avast&#8217;s ability to make an Avast Board Recommendation Change, such approval not to be unreasonably withheld, conditioned or delayed);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(iv)</FONT></TD><TD STYLE="text-align: justify">make all necessary filings (if any) with the SEC with respect to such Offer and comply with all applicable
rules and regulations under the Securities Act and the Exchange Act including Regulation 14E and the rules promulgated thereunder; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(v)</FONT></TD><TD STYLE="text-align: justify">if a registration statement on Form S-4 is filed with the SEC in connection with the Offer, (A) cause
such registration statement to become effective as promptly as practicable following its filing; (B) resolve any comments from the SEC
as promptly as practicable following receipt; and (C) keep such registration statement effective as long as is necessary to consummate
the&nbsp;Offer.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>10.</B></FONT></TD><TD STYLE="text-align: justify">Employee Share Plans</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">10.1</FONT></TD><TD STYLE="text-align: justify">The provisions of <I>&#8206;</I>Schedule&nbsp;2 (<I>Avast Share Plans</I>) with respect to certain employee-related
matters will be implemented in accordance with that Schedule.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>11.</B></FONT></TD><TD STYLE="text-align: justify">Directors&#8217; and Officers&#8217; Insurance and POSI</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">11.1</FONT></TD><TD STYLE="text-align: justify">If and to the extent such obligations are permitted by Law, for six years after the Effective Date, NortonLifeLock
shall procure that the members of the Avast Group indemnify their respective directors, officers and Indemnified Executives, and to advance
their costs and expenses, in each case to the extent provided in the respective governing documents and indemnification or similar agreements
to which Avast or any other member of the Avast Group is a party or bound and with respect to matters existing or occurring before the
Effective Date. Promptly following the Effective Date, NortonLifeLock shall enter into indemnification or similar agreements with the
Avast Directors appointed to the NortonLifeLock Board on terms and conditions substantially similar to indemnification or similar agreements
between NortonLifeLock and the other NortonLifeLock Directors.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">11.2</FONT></TD><TD STYLE="text-align: justify">With effect from the Effective Date, NortonLifeLock shall procure the provision of directors&#8217; and
officers&#8217; liability insurance cover for both current and former directors, officers and Indemnified Executives of the Avast Group,
including directors, officers and Indemnified Executives who retire or whose employment is terminated as a result of the Transaction,
for acts and omissions up to and including the Effective Date, in the form of run-off cover for a period of six years following the Effective
Date. Such insurance cover shall be with reputable insurers and provide cover, in terms of amount and breadth, substantially equivalent
to that provided under the Avast Group&#8217;s directors&#8217; and officers&#8217; liability insurance as at the date of the original
Agreement; provided, however, that in no event shall NortonLifeLock be required to spend or commit to spend for such policies an amount
in aggregate in excess of the Maximum Premium, and if the cost of such policies exceeds such amount, NortonLifeLock shall obtain a policy
with the greatest coverage available for an aggregate cost not exceeding the Maximum&nbsp;Premium.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 30; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">11.3</FONT></TD><TD STYLE="text-align: justify">If NortonLifeLock fails to put in place run&#45;off insurance cover as described in Clause&nbsp;<I>&#8206;</I>11.2
by the earlier of: (i)&nbsp;30 November&nbsp;2021; or (ii)&nbsp;the date falling 14&nbsp;days after posting of the Scheme Document; and/or
if Avast reasonably considers that the terms of the run&#45;off cover which NortonLifeLock intends to put in place with effect from the
Effective Date are less favourable (in the aggregate) to those provided under the Avast Group&#8217;s directors&#8217; and officers&#8217;
liability insurance as at the date of the original Agreement and it informs NortonLifeLock of the same:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock shall be released from its obligation to procure the provision of directors' and officers&#8217;
insurance in accordance with this Clause&nbsp;&#8206;11.3; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">Avast shall be entitled to purchase its own comparable run&#45;off cover, provided, that the aggregate
premium payable in respect of such run&#45;off cover for the full six year period referred to above shall not exceed an aggregate amount
of $4,000,000 (such amount, the&nbsp;&#8220;<B>Maximum Premium</B>&#8221;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">11.4</FONT></TD><TD STYLE="text-align: justify">Prior to publication of the NortonLifeLock Prospectus, NortonLifeLock shall use its reasonable endeavours
to obtain public offering of securities insurance cover for financial loss or liability arising from any prospectus claim made against
any director, prospective director, officer and/or employee of the Combined Company named in the NortonLifeLock Prospectus. Such insurance
cover shall be with reputable insurers and shall include cover for any reputational recovery costs, public relations and crisis management
expenses.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>12.</B></FONT></TD><TD STYLE="text-align: justify">Break Payments</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">12.1</FONT></TD><TD STYLE="text-align: justify">Subject to Clauses&nbsp;<I>&#8206;</I>12.2 and <I>&#8206;</I>12.7, NortonLifeLock undertakes that if,
on or prior to the Long Stop Date:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">either (i) a NortonLifeLock Board Recommendation Change has occurred; or (ii) the NortonLifeLock Stockholders
Meeting has not occurred prior to the Long Stop Date in breach of NortonLifeLock&#8217;s obligations under this Agreement, NortonLifeLock
shall pay to Avast an amount equal to $300,000,000 (the&nbsp;&#8220;<B>NortonLifeLock Board Recommendation Change Break Payment</B>&#8221;),
in cash, in US dollars;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">either (i) Bidco and/or NortonLifeLock invokes (and is permitted by the Panel to invoke) any Regulatory
Condition so as to cause the Transaction to lapse, to be withdrawn, or not to proceed; or (ii) a Regulatory Condition has not been satisfied
or waived by Bidco and/or NortonLifeLock as at the Long Stop Date (each a&nbsp;&#8220;<B>Regulatory Condition Satisfaction Failure Event</B>&#8221;),
NortonLifeLock shall pay to Avast an amount equal to $200,000,000 (the&nbsp;&#8220;<B>Regulatory Condition Break Payment</B>&#8221;),
in cash, in US dollars; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">the NortonLifeLock Stockholders do not approve the NortonLifeLock Stockholder Matters at the NortonLifeLock
Stockholders Meeting and there has been no NortonLifeLock Board Recommendation Change (the&nbsp;&#8220;<B>NortonLifeLock Stockholder Approval
Failure Event</B>&#8221;), NortonLifeLock shall pay to Avast an amount equal to $100,000,000 (the&nbsp;&#8220;<B>NortonLifeLock Stockholder
Approval Failure Break Payment</B>&#8221;), in cash, in US dollars,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify">in each case by way of compensation for any loss suffered by Avast in connection with the preparation
and negotiation of the Transaction.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">12.2</FONT></TD><TD STYLE="text-align: justify">Notwithstanding Clause&nbsp;<I>&#8206;</I>12.1, no Break Payment shall be payable by NortonLifeLock pursuant
to this Agreement if:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">prior to the time the relevant Break Payment Event occurs, an Avast Board Recommendation Change has occurred
(irrespective of whether or not this Agreement has been terminated pursuant to Clause&nbsp;&#8206;15.1(c)(i));</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 31; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">prior to the time the relevant Break Payment Event occurs, this Agreement has been terminated in accordance
with Clauses&nbsp;&#8206;15.1(a) or &#8206;15.1(b);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">prior to the relevant Break Payment Event occurring, this Agreement has been terminated pursuant to:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">the occurrence of one or more events set out in:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(A)</FONT></TD><TD STYLE="text-align: justify">Clause&nbsp;&#8206;15.1(c)(iii);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(B)</FONT></TD><TD STYLE="text-align: justify">Clause&nbsp;&#8206;15.1(d);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(C)</FONT></TD><TD STYLE="text-align: justify">Clause&nbsp;&#8206;15.1(f); or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(D)</FONT></TD><TD STYLE="text-align: justify">Clause&nbsp;&#8206;15.1(g), except where the Scheme is not sanctioned at the Court Sanction Hearing in
circumstances where Bidco, in each case with the Panel&#8217;s permission, does not intend to invoke or has not invoked a Condition as
contemplated by Clause&nbsp;7.1(c)(ii), and the non-sanction of the Scheme has occurred as a result of Bidco failing to deliver the notice
contemplated by Clause&nbsp;7.1(c)(i) by the time and date specified in Clause&nbsp;7.1(c); or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">the occurrence of one or more events set out in Clauses&nbsp;&#8206;15.1(i) or &#8206;15.1(j), except
where such termination arises as a result of a Break Payment Event (and not as a result of any other Condition that does not give rise
to a Break Payment Event); or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify">an automatic termination event or a right to terminate this Agreement has arisen, in each case, on the
Long Stop Date in the case of a Break Payment Event that is triggered on the Long Stop Date (an &#8220;<B>Applicable Termination Right</B>&#8221;),
pursuant to:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">the occurrence of one or more events set out in:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(A)</FONT></TD><TD STYLE="text-align: justify">Clause&nbsp;&#8206;15.1(c)(iii);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(B)</FONT></TD><TD STYLE="text-align: justify">Clause&nbsp;&#8206;15.1(c)(iv) (other than, with respect to the Regulatory Condition Break Payment or
a NortonLifeLock Board Recommendation Change Break Payment, if termination or the Applicable Termination Right pursuant to Clause&nbsp;&#8206;15.1(c)(iv)
applies due to a Break Fee Payment Event occurring (and not due to any other Condition that does not give rise to a Break Payment Event));</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(C)</FONT></TD><TD STYLE="text-align: justify">Clause&nbsp;&#8206;15.1(f); or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(D)</FONT></TD><TD STYLE="text-align: justify">Clause&nbsp;&#8206;15.1(g), except where the Scheme is not sanctioned at the Court Sanction Hearing in
circumstances where Bidco, in each case with the Panel&#8217;s permission, does not intend to invoke or has not invoked a Condition as
contemplated by Clause&nbsp;&#8206;7.1&#8206;(c)&#8206;(ii), and the non-sanction of the Scheme has occurred as a result of Bidco failing
to deliver the notice contemplated by Clause&nbsp;&#8206;7.1&#8206;(c)&#8206;(i) by the time and date specified in Clause&nbsp;&#8206;7.1&#8206;(c);
or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">the occurrence of one or more events set out in Clauses&nbsp;&#8206;15.1(i) or &#8206;15.1(j), except
where such termination arises as a result of a Break Payment Event (and not as a result of any other Condition that does not give rise
to a Break Payment Event); or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 32; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify">the relevant Break Payment Event is a Regulatory Condition Satisfaction Failure Event, in circumstances
either where:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">Avast has materially obstructed NortonLifeLock and Bidco from being able to obtain a Regulatory Approval
(and such action(s) or non-actions(s) are a material and contributory cause of such failure to obtain such Regulatory Approval) in sufficient
time to avoid a Regulatory Condition not having been satisfied as at the Long Stop Date; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">Avast has undertaken, or entered into any agreement to undertake, or announced, after the date of the
original Agreement, an acquisition of any material interest in shares, businesses or assets or any licensing arrangement or other arrangement
or collaboration with a third party, and such action was a material and contributory cause of the Regulatory Condition Satisfaction Failure
Event.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">12.3</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock shall pay any Break Payment by electronic bank transfer to a bank account designated by
Avast within seven days of the occurrence of the relevant Break Payment Event. For the avoidance of doubt (i) in no event shall NortonLifeLock
be required to pay more than one Break Payment; and (ii) if, on the Long Stop Date, the circumstances set out in Clauses&nbsp;<I>&#8206;</I>12.1(a)
and <I>&#8206;</I>12.1(b) have both occurred such that both the NortonLifeLock Board Recommendation Change Break Payment and Regulatory
Condition Break Payment are payable, then NortonLifeLock shall only be obligated (subject to the terms of this Agreement) to make the
NortonLifeLock Board Recommendation Change Break Payment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">12.4</FONT></TD><TD STYLE="text-align: justify">The parties acknowledge and agree that, at the date of the original Agreement, it is not possible to ascertain
the amount of the overall loss that Avast would incur as a result of a Break Payment Event and that the Break Payments represent a genuine
pre-estimate by the parties of the amount of the overall loss that Avast would incur as a result of such Break Payment Event having&nbsp;occurred.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">12.5</FONT></TD><TD STYLE="text-align: justify">The parties to this Agreement intend and shall use reasonable endeavours to procure that the Break Payments
are not treated for VAT purposes as consideration for a taxable supply. Each of the parties to this Agreement shall keep the other party
fully informed of any correspondence with HMRC or any other Tax Authority with regard to the VAT treatment of the Break Payments, and
will take into account the reasonable comments of the other party in any submissions to or correspondence with HMRC or any other Tax Authority
relating to the VAT treatment of the Break Payments.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">12.6</FONT></TD><TD STYLE="text-align: justify">Subject
                                            to the remainder of this Clause&nbsp;12.6, the Break Payments are inclusive of any applicable
                                            VAT or any other similar taxes. If, however, a Break Payment is treated by HMRC or any other
                                            Tax Authority, in whole or in part, as consideration for a taxable supply, and Avast or another
                                            member of the Avast Group is liable for VAT on that taxable supply, then to the extent that
                                            NortonLifeLock (or another member of the NortonLifeLock Group) is entitled to recover VAT
                                            due on that taxable supply from HMRC or any other Tax Authority by repayment or credit (the
                                            amount of such entitlement to repayment or credit being the &#8220;<B>Recoverable VAT Amount</B>&#8221;),
                                            and subject to the receipt of a valid VAT invoice, NortonLifeLock shall pay to Avast the
                                            Recoverable VAT Amount in addition to the Break Payment. To the extent HMRC or the other
                                            Tax Authority determines that NortonLifeLock (or another member of the NortonLifeLock Group)
                                            is not entitled to recover that VAT, Avast shall refund the Recoverable VAT Amount if already
                                            received by it to NortonLifeLock.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">12.7</FONT></TD><TD STYLE="text-align: justify">If a Break Payment is treated by HMRC or any other Tax Authority, in whole or in part, as consideration
for a taxable supply, and NortonLifeLock (or another member of the NortonLifeLock Group) is liable for VAT on that taxable supply, the
amount of that Break Payment shall be reduced by an amount equal to that VAT to the extent NortonLifeLock (or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 33; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">any other member of the NortonLifeLock
Group liable for that VAT) is not entitled to recover that VAT by repayment or credit.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">12.8</FONT></TD><TD STYLE="text-align: justify">In the event that a Break Payment is due and payable in accordance with Clause&nbsp;<I>&#8206;</I>12.1,
except with respect to fraud, Avast&#8217;s right to receive such Break Payment shall be the sole and exclusive remedy of Avast, any member
of the Avast Group and any of their respective Affiliates against NortonLifeLock, any member of the NortonLifeLock Group, Bidco and any
of their respective Affiliates for any and all losses and damages suffered in connection with this Agreement and the transactions contemplated
by this Agreement. In no event shall NortonLifeLock be required to pay a Break Payment more than once.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">12.9</FONT></TD><TD STYLE="text-align: justify">In the event that a Break Payment Event has occurred as contemplated by Clause&nbsp;<I>&#8206;</I>12.1
prior to the payment of the Break Payment pursuant to Clause&nbsp;<I>&#8206;</I>12.1 of this Agreement, Avast shall provide to NortonLifeLock
a properly completed and executed U.S. Internal Revenue Service Form W-8BEN-E (or applicable successor form) certifying that Avast is
a publicly-traded NFFE (within the meaning of such Form W-8BEN-E) and any other documentation reasonably requested by NortonLifeLock as
Avast may provide in accordance with Law to allow NortonLifeLock to establish that the withholding of Tax is not required with respect
to the Break Payment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>13.</B></FONT></TD><TD STYLE="text-align: justify">Guarantee</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">13.1</FONT></TD><TD STYLE="text-align: justify">In consideration of Avast entering into this Agreement, NortonLifeLock irrevocably and unconditionally
guarantees to Avast as principal obligor the due and punctual performance and observance by Bidco of all of its obligations under this
Agreement (the &#8220;<B>Guarantee</B>&#8221;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">13.2</FONT></TD><TD STYLE="text-align: justify">The Guarantee is to be a continuing security which shall remain in full force and effect until the obligations
of Bidco under this Agreement have been fulfilled or shall have expired in accordance with the terms of this Agreement, or this Agreement
has been terminated (without prejudice to the rights of any party that may have arisen prior to termination (including the payment of
any Break Payment pursuant to Clause&nbsp;<I>&#8206;</I>12, if applicable)), and the Guarantee is to be in addition, and without prejudice
to, and shall not merge with, any other right, remedy, guarantee or security which Avast may now or hereafter hold in respect of all or
any of the obligations of Bidco under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">13.3</FONT></TD><TD STYLE="text-align: justify">The liability of NortonLifeLock under the Guarantee shall not be affected, impaired or discharged by:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">any amendment, variation or modification to, or replacement of, this Agreement (save that, for the avoidance
of doubt, following such amendment, variation, modification or replacement, this Guarantee shall only apply in respect of NortonLifeLock&#8217;s
obligations of Bidco as so amended, varied, modified or replaced);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">the taking, variation, compromise, release, refusal or neglect to perfect or enforce any rights, remedies
or securities against Bidco or any other person (except to the extent that such taking, variation, compromise, release, refusal or neglect
to perfect or enforce affects the obligations guaranteed hereunder); or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">Bidco becoming insolvent, going into receivership or liquidation or having an administrator appointed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">13.4</FONT></TD><TD STYLE="text-align: justify">The Guarantee shall constitute the primary obligations of NortonLifeLock and Avast shall not be obliged
to make any demand on Bidco or any other person before enforcing its rights against NortonLifeLock under the Guarantee.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">13.5</FONT></TD><TD STYLE="text-align: justify">No delay or omission of Avast in exercising any right, power or privilege under the Guarantee shall impair
such right, power or privilege or be construed as a waiver of such right, power or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 34; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">privilege nor shall any single or partial
exercise of any such right, power or privilege preclude any further exercise thereof or the exercise of any other right, power or&nbsp;privilege.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">13.6</FONT></TD><TD STYLE="text-align: justify">This Guarantee shall continue in full force and effect notwithstanding:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">that any purported obligation of Bidco to Avast becomes wholly or partly void, invalid or unenforceable
for any reason whether or not known to Avast or NortonLifeLock; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">any incapacity or any change in the constitution of, or any amalgamation or reconstruction of, NortonLifeLock
or Bidco or any other circumstance that might otherwise constitute a legal or equitable discharge of Bidco under this Agreement (other
than payment and/or satisfaction of the obligation guaranteed hereunder).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">13.7</FONT></TD><TD STYLE="text-align: justify">If at any time any one or more of the provisions of the Guarantee is or becomes invalid, illegal or unenforceable
in any respect under any Law, the validity, legality or enforceability of the remaining provisions hereof shall not be in any way affected
if impaired thereby.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>14.</B></FONT></TD><TD STYLE="text-align: justify">Announcements</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Other than in connection with a NortonLifeLock
Board Recommendation Change, NortonLifeLock will, insofar as it is reasonably practicable to do so, allow Avast and its advisers a reasonable
opportunity to provide comments on any announcement or communication that it makes to the market in connection with the Transaction (other
than any communication which does not contain any information which is not already in the public domain or any communication which directs
such persons to information which is already in the public domain), and consider Avast&#8217;s reasonable comments on such announcement
or&nbsp;communication.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>15.</B></FONT></TD><TD STYLE="text-align: justify">Termination</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">15.1</FONT></TD><TD STYLE="text-align: justify">Subject to Clause&nbsp;<I>&#8206;</I>15.2 and without prejudice to the rights of any party that may have
arisen prior to termination (including the payment of any Break Payment pursuant to Clause&nbsp;<I>&#8206;</I>12, if applicable) and,
except where expressly stated to the contrary, the provisions of this Agreement shall terminate with immediate effect, and all rights
and obligations of the parties under this Agreement shall cease forthwith:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">if agreed in writing by the parties prior to the Effective Date;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">if the Announcement is not released via a Regulatory Newswire at or before the time and date specified
in Clause&nbsp;&#8206;2.1 (unless, before that time, the parties have agreed another later time and date in accordance with Clause&nbsp;&#8206;2.1,
in which case that later time and date shall apply for the purpose of this Clause&nbsp;&#8206;15.1(b));</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">upon service of written notice either by (A) Avast to NortonLifeLock and Bidco, or (B)&nbsp;NortonLifeLock
to Avast:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">if an Avast Board Recommendation Change occurs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">if a Break Payment Event occurs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify">if Bidco and/or NortonLifeLock invokes (and is permitted by the Panel to invoke) a Condition (other than
a Regulatory Condition or in respect of the NortonLifeLock Stockholder Approval not having being obtained at the NortonLifeLock Stockholders
Meeting) so as to cause the Transaction to lapse, to be withdrawn, or not to proceed; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 35; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(iv)</FONT></TD><TD STYLE="text-align: justify">unless otherwise agreed in writing by the parties, if the Effective Date has not occurred on or prior
to the Long Stop Date;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify">if, prior to the Long Stop Date, a third party announces a firm intention to make an offer or revised
offer for Avast which completes, becomes effective or is declared or becomes unconditional in all respects;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify">the NortonLifeLock Stockholder Approval is not obtained at the NortonLifeLock Stockholders Meeting;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(f)</FONT></TD><TD STYLE="text-align: justify">if the Scheme is not approved by the requisite majority of Avast Shareholders at the Court Meeting and/or
the relevant resolutions relating to the Scheme are not approved by the requisite majority of Avast Shareholders at the Avast General
Meeting, other than in circumstances where NortonLifeLock has elected, pursuant to an Agreed Switch, to implement the Transaction by means
of an Offer; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(g)</FONT></TD><TD STYLE="text-align: justify">if the Scheme is not sanctioned at the Court Sanction Hearing;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(h)</FONT></TD><TD STYLE="text-align: justify">upon service of written notice by Avast to NortonLifeLock if NortonLifeLock makes an announcement before
the publication of the Proxy Statement that:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">it will not convene the NortonLifeLock Stockholders Meeting; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">it does not intend to post the Proxy Statement or to convene the NortonLifeLock Stockholders Meeting;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">on the earliest to occur of:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">the date on which the Scheme lapses, terminates or is withdrawn (unless NortonLifeLock has elected to
implement the Transaction by way of an Offer pursuant to an Agreed Switch before such lapse, termination or withdrawal); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">the Effective Date; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(j)</FONT></TD><TD STYLE="text-align: justify">in the event of an Agreed Switch, on the earliest to occur of:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">the date on which the Offer lapses, terminates or is withdrawn; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">the Effective Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">15.2</FONT></TD><TD STYLE="text-align: justify">This Clause&nbsp;<I>&#8206;</I>15, Clauses&nbsp;<I>&#8206;</I>1, <I>&#8206;</I>11 (where this Agreement
terminates on the Effective Date), <I>&#8206;</I>12, <I>&#8206;</I>16 and <I>&#8206;</I>17 (other than Clause&nbsp;<I>&#8206;</I>17.9)
shall survive termination of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>16.</B></FONT></TD><TD STYLE="text-align: justify">Warranties and Undertakings</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">16.1</FONT></TD><TD STYLE="text-align: justify">Each of the parties warrants to the other on the date of the original Agreement that:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">it has the requisite power and authority to enter into and perform its obligations under this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">this Agreement constitutes its binding obligations in accordance with its terms;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">the execution and delivery of, and performance of its obligations under, this Agreement will not:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">result in a breach of any provision of its constitutional documents;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">result in a breach of, or constitute a default under, any instrument to which it is a party or by which
it is bound; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 36; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify">result in a breach of any order, judgment or decree of any court or governmental agency to which it is
a party or by which it is bound.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">16.2</FONT></TD><TD STYLE="text-align: justify">No party shall have any claim for breach of warranty after the Effective Date (without prejudice to any
liability for fraudulent misrepresentation or fraudulent misstatement).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>17.</B></FONT></TD><TD STYLE="text-align: justify">General</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.1</B></FONT></TD><TD STYLE="text-align: justify"><B>Entire Agreement</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">Save for the Confidentiality Agreement and the Clean Team and Joint Defence Agreement (each of which remain
in force), and any other agreements the parties agree in writing are deemed to be included in this Clause&nbsp;&#8206;17.1, this Agreement
constitutes the whole and only agreement between the parties relating to the subject matter of this Agreement, and supersedes any previous
agreement whether written or oral between the parties in relation to such matters.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">Except in the case of fraud, each party acknowledges that it is entering into this Agreement in reliance
upon only this Agreement and that it is not relying upon any pre-contractual statement that is not set out in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">Except in the case of fraud, no party will have any right of action (including those in tort or arising
under statute) against the other party arising out of or in connection with any pre-contractual statement except to the extent that it
is repeated in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify">For the purposes of this Clause&nbsp;&#8206;17.1, &#8220;<B>pre-contractual statement</B>&#8221; means
any draft, agreement, undertaking, representation, warranty, promise, assurance or arrangement of any nature whatsoever, whether or not
in writing, relating to the subject matter of this Agreement made or given by any person at any time before the date of the original&nbsp;Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.2</B></FONT></TD><TD STYLE="text-align: justify"><B>Notices</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">Any notice or other communication given or made under or in connection with the matters contemplated by
this Agreement shall be in writing and shall be delivered by hand or by courier or recorded delivery or sent by air mail (if posted to
or from a place outside the United Kingdom) or by email to the email address specified below and as detailed below (unless a party notifies
the other parties in writing of a change to the address or email address or details below and such notification is received by the other
party before the notice is dispatched), and provided that any notice sent other than by email must also be accompanied by a copy sent
by email:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>In the case of Avast to:</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1.5in">Name:</TD><TD STYLE="text-align: justify">Avast plc</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1.5in">Address:</TD><TD STYLE="text-align: justify">110 High Holborn, London, England, WC1V 6JS</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 1.5in">For the attention of:</TD>
  <TD STYLE="text-align: justify">[***]</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1.5in">Email:</TD><TD STYLE="text-align: justify">[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">With a copy (which shall not constitute
notice) to:</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">White &amp; Case LLP, marked for the attention
of Dominic Ross (dominic.ross@whitecase.com) and Allan Taylor (ataylor@whitecase.com);</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>In the case of NortonLifeLock:</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 1in">&nbsp;</TD>
                                                                                                                                                                         <TD STYLE="width: 1.5in">Name:</TD><TD STYLE="text-align: justify">NortonLifeLock Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1.5in">Address:</TD><TD STYLE="text-align: justify">60 E. Rio Salado Parkway, Suite 1000, Tempe, AZ, USA</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 1.5in">For the attention of:</TD>
  <TD STYLE="text-align: justify">[***]</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1.5in">Email:</TD><TD STYLE="text-align: justify">[***]</TD></TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">With a copy (which shall not constitute
notice) to:</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">Kirkland &amp; Ellis LLP, marked for the
attention of Daniel Wolf (daniel.wolf@kirkland.com), Edward J. Lee (edward.lee@kirkland.com) and Carlo Zenkner (carlo.zenkner@kirkland.com);
and</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">Macfarlanes LLP, marked for the attention
of Harry Coghill (harry.coghill@macfarlanes.com) and Tom Rose (tom.rose@macfarlanes.com); and</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>In the case of Bidco:</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 1in"></TD>
                                                                                                                                                                         <TD STYLE="width: 1.5in">Name:</TD><TD STYLE="text-align: justify">NortonLifeLock Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1.5in">Address:</TD><TD STYLE="text-align: justify">60 E. Rio Salado Parkway, Suite 1000, Tempe, AZ, USA</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 1.5in">For the attention of:</TD>
  <TD STYLE="text-align: justify">[***]</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1.5in">Email:</TD><TD STYLE="text-align: justify">[***]</TD></TR></TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">With a copy to:</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">Kirkland &amp; Ellis LLP, marked for the
attention of Daniel Wolf (daniel.wolf@kirkland.com), Edward J. Lee (edward.lee@kirkland.com) and Carlo Zenkner (carlo.zenkner@kirkland.com);
and</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">Macfarlanes LLP, marked for the attention
of Harry Coghill (harry.coghill@macfarlanes.com) and Tom Rose (tom.rose@macfarlanes.com).</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">A notice given under Clause&nbsp;&#8206;17.2(a) shall be effective on receipt and shall be deemed&nbsp;received:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">if delivered by hand, by courier, by recorded delivery or by air mail, upon delivery at the address of
the relevant party; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">if sent by electronic mail when actually received by the intended recipient in readable form,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify">and provided that the first such receipt shall be deemed effective for the purposes of this Agreement
where a notice is sent in accordance with Clause&nbsp;&#8206;17.2(a) via more than one method.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.3</B></FONT></TD><TD STYLE="text-align: justify"><B>Variations</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">Subject
to Clause&nbsp;</FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt">&#8206;</FONT>17.7(c), no variation of
this Agreement will be valid unless it is in writing (which, for this purpose, does not include email) and signed by or on behalf of each
of the&nbsp;parties.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.4</B></FONT></TD><TD STYLE="text-align: justify"><B>Remedies and Waivers</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">No delay or omission by any party to this Agreement in exercising any right, power or remedy provided
by Law or under this Agreement will:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">affect that right, power or remedy; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">operate as a waiver of it.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 38; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Split-Segment; Name: A04 -->
<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">The single or partial exercise of any right, power or remedy provided by Law or under this Agreement will
not preclude any other or further exercise of it or the exercise of any other right, power or remedy.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">The rights, powers and remedies provided in this Agreement are cumulative and not exclusive of any rights,
powers and remedies provided by Law. Nothing in this Agreement shall exclude any party from making any claim for losses and damages suffered
in connection with the fraud of another party.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify">Without prejudice to any other rights and remedies which another party may have, each party acknowledges
and agrees that damages alone may not be an adequate remedy for any breach by another party of the provisions of this Agreement and any
other party will be entitled to seek the remedies of injunction, specific performance and other equitable remedies, for any threatened
or actual breach of any such provision of this Agreement by a party and no proof of special damages will be necessary for the enforcement
by any party of its rights under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.5</B></FONT></TD><TD STYLE="text-align: justify"><B>Partnership</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">No provision of this Agreement creates
a partnership between any of the parties or makes a party the agent of another party for any purpose. No party has any authority or power
to bind, to contract in the name of, or to create a liability for, another party in any way or for any&nbsp;purpose.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.6</B></FONT></TD><TD STYLE="text-align: justify"><B>Assignment</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">No party may assign (whether absolutely
or by way of security and whether in whole or in part), transfer, or delegate to a third party of, or otherwise dispose of (in any manner
whatsoever) the benefit of this Agreement (or any part of it) or sub-contract in any manner whatsoever its performance under this Agreement
without the prior written consent of each other party.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.7</B></FONT></TD><TD STYLE="text-align: justify"><B>Third Party Rights</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">Clause&nbsp;&#8206;11 is intended to confer benefits on and be enforceable by the third parties referred
to therein (the &#8220;<B>Relevant Third Parties</B>&#8221;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">Subject to Clause&nbsp;&#8206;17.7(a), the parties do not intend that any term of this Agreement should
be enforceable, by virtue of the Contracts (Rights of Third Parties)&nbsp;Act&nbsp;1999, by any person who is not a party to this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">The parties may vary or amend this Agreement without the consent of any of the Relevant Third Parties,
except that any variation or amendment of Clauses&nbsp;&#8206;11.1, &#8206;11.2 or &#8206;11.4 shall require the consent of each Relevant
Third Party affected by the variation or&nbsp;amendment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.8</B></FONT></TD><TD STYLE="text-align: justify"><B>Severance</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If any provision of this Agreement is
or becomes illegal, invalid or unenforceable in any respect under the Law of any jurisdiction, such provision shall be deemed to be severed
from this Agreement and the parties shall replace it with a provision which has an effect as close as possible to the deficient provision.
The remaining provisions will remain in full force in that jurisdiction and all provisions will continue in full force in any other jurisdiction.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.9</B></FONT></TD><TD STYLE="text-align: justify"><B>Further Assurance</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Each party will, at its own cost, use
reasonable endeavours to, or procure that any relevant third party will, do and/or execute and/or perform all such further deeds, documents,
assurances, acts and things as may be reasonably required to give effect to this Agreement and to implement the&nbsp;Transaction.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 39; Options: NewSection; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.10</B></FONT></TD><TD STYLE="text-align: justify"><B>Counterparts</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This Agreement may be executed in counterparts
and shall be effective when each party has executed a counterpart. Each counterpart shall constitute an original of this Agreement. Delivery
of an executed signature page of a counterpart by electronic transmission shall take effect as delivery of an executed counterpart of
this Agreement.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.11</B></FONT></TD><TD STYLE="text-align: justify"><B>Fees and Expenses</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Each party shall pay its own costs and
expenses in relation to the negotiation, preparation, execution and carrying into effect of this Agreement and any matter contemplated
by it.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.12</B></FONT></TD><TD STYLE="text-align: justify"><B>Takeover Code and Relevant Law</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">The parties agree that, if the Panel determines that any provision of this Agreement that requires Avast
to take or not to take action, whether as a direct obligation or as a condition to any other person&#8217;s obligation (however expressed),
is not permitted by Rule&nbsp;21.2 of the Takeover&nbsp;Code, Avast shall not be required to take or not take the relevant action contemplated
by this Agreement, and shall instead be entitled and required to take such action as may be directed by the Panel (such that, for the
purposes of the taking or not taking of that relevant action, such provision shall be superseded by the direction of the Panel).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">Nothing in this Agreement shall be taken to restrict Avast, NortonLifeLock, any member of the Avast Board,
any NortonLifeLock Director or Bidco Director, or any member of the Avast Group or NortonLifeLock Group from complying with all relevant
legislation, orders of court or regulations including the Takeover Code, the FCA&#8217;s Listing Rules or the rules and regulations of
any applicable regulatory body.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>17.13</B></FONT></TD><TD STYLE="text-align: justify"><B>Governing Law and Jurisdiction</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">This Agreement, including any non&#45;contractual obligations arising out of or in connection with this
Agreement, is governed by and shall be construed in accordance with English law; provided, that notwithstanding the foregoing, any matters
concerning or implicating the NortonLifeLock Directors&#8217; fiduciary duties shall be governed by and construed in accordance with the
applicable fiduciary duty laws of the State of&nbsp;Delaware.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">The parties agree that the courts of England shall have exclusive jurisdiction to hear and determine any
Proceedings arising out of or in connection with this Agreement and, for such purposes, irrevocably submit to the jurisdiction of such
courts.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock will maintain an agent for service of process and any other documents in proceedings in
England or any other proceedings in connection with this Agreement. Such agent will be Macfarlanes LLP, currently of 20 Cursitor Street,
London EC4A 1LT, and any claim form, judgment or other notice of legal process will be sufficiently served on NortonLifeLock if delivered
to such agent at its address for the time being, and marked for the attention of Harry Coghill and Tom Rose. NortonLifeLock will be entitled
to appoint an agent for service in England in the place of Macfarlanes LLP by written notice to Avast, whereupon Macfarlanes LLP will
cease to be NortonLifeLock&#8217;s agent for service, and any claim form, judgment or other notice of legal process will be sufficiently
served on NortonLifeLock if delivered to such replacement agent at its address for the time being (but shall no longer be effective if
served upon Macfarlanes LLP after the appointment, and notification to Avast of the appointment, of such new agent for service).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>In
Witness Whereof</B></FONT> this Agreement has been executed on the date first above written.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>Signed</B></FONT>
    by John Schwarz</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><BR>
    as authorised signatory for and on behalf of <BR>
<B>Avast plc</B></P></TD>
    <TD STYLE="width: 7%; padding-top: 7px; padding-right: 5.4pt; padding-left: 7px; font-size: 11pt"><IMG SRC="tm2221114d1_ex2-01img02.jpg" ALT=""></TD>
    <TD STYLE="width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">/s/ John Schwarz</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Authorised Signatory</P></TD></TR>
  </TABLE>
<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>Signed</B></FONT>
    by Vincent Pilette</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><BR>
    as authorised signatory for and on behalf of <B><BR>
NortonLifeLock Inc.</B></P></TD>
    <TD STYLE="width: 7%; padding-top: 6px; padding-right: 5.4pt; padding-left: 7px; font-size: 11pt"><IMG SRC="tm2221114d1_ex2-01img02.jpg" ALT=""></TD>
    <TD STYLE="width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">/s/ Vincent Pilette</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Authorised Signatory</P></TD></TR>
  </TABLE>
<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>Signed</B></FONT>
    by Bryan Ko</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><BR>
    as authorised signatory for and on behalf of <B><BR>
Nitro Bidco Limited</B></P></TD>
    <TD STYLE="width: 7%; padding-top: 7px; padding-right: 5.4pt; padding-left: 7px; font-size: 11pt"><IMG SRC="tm2221114d1_ex2-01img02.jpg" ALT=""></TD>
    <TD STYLE="width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">/s/ Bryan Ko</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Authorised Signatory</P></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature</I> <I>page to the co-operation
agreement</I>]</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>Schedule
1</B></FONT><B><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"></FONT></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 13pt">The
Announcement</FONT></FONT></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 13pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,
IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT
LAWS OR REGULATIONS OF SUCH JURISDICTION</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>FOR IMMEDIATE RELEASE</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><B>10 August 2021</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>RECOMMENDED MERGER</B></P>

<P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>of</B></P>

<P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>AVAST PLC</B></P>

<P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>with</B></P>

<P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>NORTONLIFELOCK INC.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>to be effected by means of a Scheme of Arrangement<BR>
under Part 26 of the Companies Act 2006</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Summary</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Further to the announcements made by NortonLifeLock Inc. (&ldquo;<B>NortonLifeLock</B>&rdquo;) and Avast
plc (&ldquo;<B>Avast</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;) on 14 July 2021, the boards of NortonLifeLock and Avast are pleased
to announce that they have reached agreement on the terms of a recommended merger of Avast with NortonLifeLock, in the form of a recommended
offer by Nitro Bidco Limited (&ldquo;<B>Bidco</B>&rdquo;), a wholly-owned subsidiary of NortonLifeLock, for the entire issued and to be
issued ordinary share capital of the Company (the &ldquo;<B>Merger</B>&rdquo;). It is intended that the Merger will be effected by means
of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act (the &ldquo;<B>Scheme</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The boards of NortonLifeLock and Avast believe the Merger has compelling strategic logic and represents
an attractive opportunity to create a new, industry leading consumer Cyber Safety business, leveraging the established brands, technical
expertise and innovation of both groups to deliver substantial benefits to consumers, shareholders and other stakeholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Under the terms of the Merger, Avast Shareholders will be entitled to receive:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 0.5in; text-align: justify; width: 50%"><B>for each Avast Share held:</B></TD>
  <TD STYLE="text-align: justify; width: 50%"><B>USD 7.61 in cash</B></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><B>and</B></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><B>0.0302 of a New NortonLifeLock Share</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 6.9in; text-align: justify; text-indent: -3.4in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">in respect of their entire holding of
Avast Shares (the &ldquo;<B>Majority Cash Option</B>&rdquo;). Based on NortonLifeLock&rsquo;s closing share price of USD 27.20 on 13 July
2021 (being the last Business Day on which NortonLifeLock Shares traded on NASDAQ before the commencement of the Offer Period in relation
to the Merger) and the Announcement Exchange Rate, the Majority Cash Option values each Avast Share at 608.4 pence per share (USD 8.43
per share).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Majority Cash Option comprises approximately 90% by value in cash and approximately 10% by value in
New NortonLifeLock Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Majority Cash Option represents a premium of approximately:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">20.7% to the Closing Price of 504.2 pence per Avast Share on 14 July 2021, being the last Business Day
on which Avast Shares traded on the London Stock Exchange prior to the commencement of the Offer Period in relation to the Merger (the
 &ldquo;<B>Unaffected Date</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">28.0% to the volume weighted average price of 475.1 pence per Avast Share for the three months up to the
Unaffected Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">As an alternative to the Majority Cash Option, Bidco will make available to Avast Shareholders the option
to elect for a different mix of cash and share consideration, pursuant to which Avast Shareholders (other than those resident in a Restricted
Jurisdiction) may elect to receive:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 0.5in; text-align: justify; width: 50%"><B>for each Avast Share held:</B></TD>
  <TD STYLE="text-align: justify; width: 50%"><B>0.1937 of a New NortonLifeLock Share</B></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><B>and</B></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><B>USD 2.37 in cash</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">in respect of their entire holding of
Avast Shares (the &ldquo;<B>Majority Stock Option</B>&rdquo;). Based on NortonLifeLock&rsquo;s closing share price of USD 27.20 on 13
July 2021 (being the last Business Day on which NortonLifeLock Shares traded on NASDAQ before the commencement of the Offer Period in
relation to the Merger) and the Announcement Exchange Rate, the Majority Stock Option values each Avast Share at 551.1 pence per share
(USD 7.64 per share).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Majority Stock Option comprises approximately 31% by value in cash and approximately 69% by value
in New NortonLifeLock Shares. The Majority Stock Option enables Avast Shareholders to participate more fully in the upside and long-term
value creation opportunity resulting from the Merger.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Each of the Avast Directors who holds Avast Shares has irrevocably undertaken to elect for the Majority
Stock Option, as well as to vote or procure votes in favour of the Scheme (or, in the event that the Merger is implemented by way of a
Takeover Offer, accept or procure acceptance of the Takeover Offer), in respect of their entire beneficial holdings of Avast Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Depending on the elections of other Avast Shareholders, and on the same basis as set out above, the Merger
values the entire issued and to be issued ordinary share capital of Avast between approximately &pound;6.2 billion (USD 8.6 billion) (if
all Avast Shareholders, other than the Avast Directors who hold Avast Shares, receive the Majority Cash Option) and &pound;5.8 billion
(USD 8.1 billion) (if all Avast Shareholders elect for the Majority Stock Option). The enterprise value attributed to Avast is between
approximately &pound;6.6 billion (USD 9.2 billion) (if all Avast Shareholders, other than the Avast Directors who hold Avast Shares, receive
the Majority Cash Option) and &pound;6.2 billion (USD 8.6 billion) (if all Avast Shareholders elect for the Majority Stock Option).</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Avast Shareholders who do not positively elect to receive the Majority Stock Option will receive the Majority
Cash Option.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In addition to the consideration payable in connection with the Merger, Avast Shareholders will be entitled
to receive certain agreed ordinary course Avast dividends prior to the completion of the Merger, on the basis set out further below.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Bidco will procure that a facility will be made available under which Avast Shareholders will be able
to elect (subject to the terms and conditions of the facility) to receive cash consideration in GBP rather than USD at the prevailing
market exchange rate (after deduction of any transaction or dealing costs associated with the conversion) under the Majority Cash Option
or the Majority Stock Option (as described further below).</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Upon completion of the Merger, and subject to the elections made by Avast Shareholders, Avast Shareholders
will own between approximately 14% (if all Avast Shareholders, other than the Avast Directors who hold Avast Shares, receive the Majority
Cash Option) and approximately 26% (if all Avast Shareholders elect for the Majority Stock Option) of the Combined Company on a fully
diluted basis.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">To the extent that Avast Shareholders elect for the Majority Stock Option, NortonLifeLock intends, subject
to market conditions and other capital requirements, to implement an incremental share buyback programme over time following completion
of the Merger (the &ldquo;<B>Post-Merger Buyback</B>&rdquo;) with a view to establishing a net leverage ratio for the Combined Company
in the region of approximately 3.5x net debt to pro forma EBITDA. If all Avast Shareholders elect for the Majority Stock Option, NortonLifeLock
expects that the amount of the Post-Merger Buyback, if implemented, would be up to approximately USD 3 billion. However, this amount would
be reduced by the amount of any incremental cash consideration payable to Avast Shareholders who receive the Majority Cash Option.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 43; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Agreed Avast Dividends</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In addition to the consideration payable in connection with the Merger, the Avast Board will be entitled
to declare and pay an interim dividend in respect of the six month period ended 30 June 2021 of 4.8 cents per Avast Share (the &ldquo;<B>Interim
Avast Dividend</B>&rdquo;). It is expected that the Interim Avast Dividend will be announced by Avast in August 2021 and paid in October
2021.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In addition to the consideration payable in connection with the Merger and the Interim Avast Dividend,
if the Merger has not become Effective before 1 March 2022, the Avast Board reserves the right to declare and pay either a further interim
dividend or recommend and pay a final dividend in respect of the year ending 31 December 2021 of 11.2 cents per Avast Share (the &ldquo;<B>Second
Avast Dividend</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In addition to the consideration payable in connection with the Merger and the Interim Avast Dividend
and the Second Avast Dividend, if the Merger has not become Effective before 11 August 2022, the Avast Board reserves the right to declare
and pay an interim dividend in respect of the six month period ended 30 June 2022 of 4.8 cents per Avast Share (the &ldquo;<B>Third Avast
Dividend</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Bidco has agreed that Avast Shareholders will be entitled to receive the Interim Avast Dividend, the Second
Avast Dividend and the Third Avast Dividend (together, the &ldquo;<B>Agreed Avast Dividends</B>&rdquo;), if and to the extent declared
and paid in accordance with the terms set out in this Announcement, in each case without any reduction to the consideration payable by
Bidco under the terms of the Merger.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">If any dividend and/or other distribution and/or other return of capital or value (a &ldquo;<B>Return
of Value</B>&rdquo;) is announced, declared, made, payable or paid in respect of the Avast Shares on or after the date of this Announcement
and prior to the Effective Date, other than, or in excess of, the Agreed Avast Dividends, Bidco reserves the right to reduce the aggregate
consideration payable in respect of the Avast Shares by the aggregate amount of such Return of Value.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Summary Strategic and Financial Rationale for
the Merger</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The boards of NortonLifeLock and Avast believe that the Merger has compelling strategic and financial
rationale, with the potential to deliver substantial benefits to consumers, shareholders and other stakeholders. In particular, the Merger
will:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">accelerate the transformation of consumer Cyber Safety, with the Combined Company having over 500 million
users;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">combine Avast&rsquo;s strength in privacy and NortonLifeLock&rsquo;s strength in identity to create a
broad and complementary product portfolio beyond core security and towards adjacent trust-based solutions;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">provide greater geographic diversification and access to a larger global user base, as well as facilitating
expansion into the SOHO and VSB segments, and the building of stronger B2B2C and OEM partnerships;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">unlock significant value creation through approximately USD 280 million of annual gross cost synergies,
providing additional upside potential from new reinvestment capacity for innovation and growth; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">bring together two strong and highly experienced consumer-focused management teams with a common culture
of excellence and innovation.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 44; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Merger will also enhance the financial profile of the Combined Company through increased scale, long-term
growth, cost synergies with reinvestment capacity and strong cash flow generation supported by a resilient balance sheet, and is expected
to drive double-digit non-GAAP EPS accretion within the first full year following completion of the Merger and double-digit revenue growth
in the long-term.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>The Combined Company</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">With effect from the Effective Date, it is intended that Avast&rsquo;s CEO, Ondrej Vlcek, will join NortonLifeLock
as President and become a member of the NortonLifeLock Board. In addition, Pavel Baudi&scaron;, a founder of Avast and current member
of the Avast Board, is expected to join the NortonLifeLock Board as an independent director.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On completion of the Merger, the Combined Company will be dual headquartered in Prague, Czech Republic,
and Tempe, Arizona, USA, and will have a significant presence in the Czech Republic. The Combined Company will be listed on NASDAQ.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock intends to undertake a review process, in collaboration with Avast&rsquo;s CEO, to determine
the post-Merger name of the Combined Company to ensure that it best reflects its strategic vision of expanding its Cyber Safety platform
with trust-based solutions and its broad global prospects.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Recommendation and irrevocable undertakings</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Avast Directors, who have been so advised by UBS and J.P. Morgan Cazenove as to the financial terms
of the Majority Cash Option and the Majority Stock Option, unanimously consider the terms of the Majority Cash Option and the Majority
Stock Option to be fair and reasonable. In providing their financial advice to the Avast Directors, UBS and J.P. Morgan Cazenove have
taken into account the commercial assessments of the Avast Directors. UBS is providing independent financial advice to the Avast Directors
for the purposes of Rule 3 of the Code.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Accordingly, the Avast Directors intend to recommend unanimously that Avast Shareholders vote or procure
votes in favour of the resolutions relating to the Scheme at the Meetings, as each of the Avast Directors who owns Avast Shares has irrevocably
undertaken to do in respect of their entire beneficial holdings of Avast Shares. In addition, the Vl&ccaron;ek Family Foundation has irrevocably
undertaken to vote in favour of the resolutions relating to the Scheme at the Meetings in respect of its entire beneficial holding of
Avast Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Avast Directors&rsquo; (and the Vl&ccaron;ek Family Foundation&rsquo;s) irrevocable commitments are
in respect of, in aggregate, 381,057,227 Avast Shares, representing approximately 36.93% of the existing issued ordinary share capital
of Avast on the Latest Practicable Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Timetable and Conditions</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Merger is subject to the Conditions and certain further terms set out in Appendix 1 to this Announcement,
and to the full terms and conditions which will be set out in the Scheme Document. These Conditions include (amongst others):</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the receipt or waiver of any applicable antitrust approvals or clearances in the United States, the United
Kingdom, Germany and Spain (and/or, upon referral, approval from the European Commission), Australia and New Zealand;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a written notification from CFIUS that it has completed action under section 721 of the DPA or, if CFIUS
has sent a report to the President of the United States, that the President has announced a decision not to take action or has not taken
action after fifteen days from the end of the investigation period;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the receipt or waiver of applicable foreign investment approvals in Germany, the Czech Republic, Romania
and, if in force and applicable, any such approvals required in the United Kingdom and the Netherlands;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 45; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">approval of Avast Shareholders at the Court Meeting and the General Meeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the FCA having approved the NortonLifeLock Prospectus and it having been made available to the public
in accordance with the UK Prospectus Regulation Rules;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the issuance of the New NortonLifeLock Shares in connection with the Merger having been approved by NortonLifeLock
Shareholders at the NortonLifeLock Shareholders&rsquo; Meeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">confirmation having been received by NortonLifeLock that the New NortonLifeLock Shares have been approved
for listing, subject to official notice of issuance, on NASDAQ;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the sanction of the Scheme by the Court; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the delivery of a copy of the Scheme Court Order to the Registrar of Companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Further details of the Merger will be contained in the Scheme Document, which is intended to be posted
to Avast Shareholders (other than those resident in Restricted Jurisdictions), along with the Forms of Proxy and the Form of Election,
in late Q3 or early Q4 of 2021. For the purposes of paragraph 3(a) of Appendix 7 of the Code, the Panel has consented to this arrangement.
It is also expected that, at or around the same time as the Scheme Document is posted to Avast Shareholders (other than those resident
in Restricted Jurisdictions), the NortonLifeLock Prospectus will be published and the NortonLifeLock Proxy Statement will be mailed.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Subject to the satisfaction or waiver (as applicable) of all relevant conditions, including the Conditions,
and certain terms set out in Appendix 1 to this Announcement and to be set out in the Scheme Document, the Scheme is expected to become
Effective in mid-2022. An expected timetable of principal events will be included in the Scheme Document.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Commenting on the Merger, Vincent Pilette, Chief
Executive Officer of NortonLifeLock, said:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&ldquo;<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; background-color: white">This
transaction is a huge step forward for consumer Cyber Safety and will ultimately enable us to achieve our vision to protect and empower
people to live their digital lives safely. With this combination, we can strengthen our Cyber Safety platform and make it available to
more than 500 million users. We will also have the ability to further accelerate innovation to transform Cyber Safety.</FONT><I>&rdquo;</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Commenting on the Merger, Ondrej Vlcek, Chief Executive
Officer of Avast, said:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&ldquo;The Avast Board believes the proposed merger
of Avast and NortonLifeLock creates a united Cyber Safety business of compelling strategic scale, unlocking value for shareholders today
with considerable potential upside. With NortonLifeLock, Avast will be even better positioned to pursue its ambitions and evolve its product
portfolio to meet the demand of today&rsquo;s consumers. It is clear that both NortonLifeLock and Avast have a shared vision of protecting
the consumer&rsquo;s digital life and together will be better able to deliver value for all stakeholders.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Avast&rsquo;s long-standing mission has been to
enable a digital world that provides safety and privacy for all. Our proposed merger with NortonLifeLock is a major step forward along
this path, creating a world-leading consumer Cyber Safety business which combines Avast&rsquo;s strength in privacy and NortonLifeLock&rsquo;s
strength in identity protection. United, our highly complementary product portfolios will have far-reaching benefits, significantly enhancing
our ability to drive innovation through R&amp;D, and accelerating the transformation of our Cyber Safety platform for our more than half
a billion combined users.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">At a time when global cyber threats are growing,
yet cyber safety penetration remains very low, together with NortonLifeLock, we will be able to accelerate our shared vision of providing
holistic cyber protection for consumers around the globe. Our talented teams will have better opportunities to innovate and develop enhanced
solutions and services, with improved capabilities from access to superior data insights. Through our well-established brands, greater
geographic diversification and access to a larger global user base, the combined businesses will be poised to access the significant growth
opportunity that exists worldwide.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 46; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>This summary should be read in conjunction with,
and is subject to, the full text of this Announcement, including its Appendices. The Merger will be subject to the Conditions set out
in Appendix 1 to this Announcement, and to the full terms and conditions which will be set out in the Scheme Document. Appendix 2 to this
Announcement contains the bases and sources of certain information used in the summary and in the full text of this Announcement. Appendix
3 to this Announcement contains details of the irrevocable undertakings received in relation to the Merger that are referred to in this
Announcement. Appendix 4 to this Announcement contains details and bases of belief of the anticipated quantified financial benefits of
the Merger and copies of the related reports from NortonLifeLock&rsquo;s reporting accountants, Deloitte, and its financial adviser, Evercore.
Appendix 5 to this Announcement contains the NortonLifeLock Profit Forecast, and the assumptions, basis of preparation and the NortonLifeLock
Directors&rsquo; confirmation relating thereto. Appendix 6 to this Announcement contains the Avast Profit Forecast, and the assumptions,
basis of preparation and the Avast Directors&rsquo; confirmation relating thereto. Appendix 7 to this Announcement contains definitions
of certain terms used in this Announcement. For the purposes of Rule 28 of the Code, the Quantified Financial Benefits Statement contained
in this Announcement is the responsibility of NortonLifeLock and the NortonLifeLock Directors. Each of Deloitte and Evercore has given
and not withdrawn its consent to the publication of its respective report in this Announcement in the form and context in which it is
included.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Investor Call</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">A joint investor conference call regarding the Merger
will take place on 10 August 2021 at 2 p.m. PT time / 5 p.m. ET time.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Webcast:
                                            <U>Investor.NortonLifeLock.com</U></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Phone
                                            Dial-In: <U>Investor.NortonLifeLock.com</U> to register in advance for call details</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Live webcasts of the conference call, including
the presentations, will be published on the investor relations sections of NortonLifeLock&rsquo;s and Avast&rsquo;s respective websites.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Enquiries</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; width: 60%; padding-top: 2; padding-bottom: 10; text-align: left"><B>NortonLifeLock</B></TD>
    <TD STYLE="padding-left: 5; width: 40%; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Mary Lai, Head of Investor Relations</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">IR@NortonLifeLock.com</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Spring Harris, Head of Global Corporate Communications and PR</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Press@NortonLifeLock.com </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left"><B>Evercore (Financial adviser to NortonLifeLock and Bidco)</B></TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Naveen Nataraj</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">+1 (0)212 857 3100</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Edward Banks</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">+44 (0)20 7653 6000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Anil Rachwani</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Swag Ganguly</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Wladimir Wallaert</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left"><B>Sard Verbinnen (Communications adviser to NortonLifeLock)</B></TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Charles Chichester</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">+44 (0)20 7467 1050</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">John Christiansen</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">+1 (0)415 618 8750</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Jared Levy</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">+1 (0)212 687 8080</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 47; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: justify; width: 60%"><B>Avast</B></TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left; width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Peter Russell, Director of Investor Relations</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">IR@avast.com</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Stephanie Kane, VP PR and Corporate Communications</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left"><B>UBS (Financial adviser and Corporate Broker to Avast)</B></TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Tel: +44 207 567 8000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Christian Lesueur</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Rahul Luthra</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Jonathan Rowley</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Aadhar Patel</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Meera Sheth</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left"><B>J.P. Morgan Cazenove (Financial adviser and Corporate Broker to Avast)</B></TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Tel: +44 207 742 4000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Bill Hutchings</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">James Robinson</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">James Summer</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Jonty Edwards</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left"><B>Finsbury Glover Hering (Communications adviser to Avast)</B></TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Avast-LON@fgh.com</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Dorothy Burwell</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Tel: +44 7733 294 930</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Nidaa Lone</TD>
    <TD STYLE="padding-left: 5; padding-top: 2; padding-bottom: 10; text-align: left">Tel: +44 7841 400 607</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Kirkland &amp; Ellis LLP and Macfarlanes LLP are
retained as (respectively) US and UK legal advisers to NortonLifeLock. White &amp; Case LLP is retained as legal adviser to Avast.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Important notices relating to financial advisors</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Evercore Partners International LLP (&ldquo;<B>Evercore</B>&rdquo;),
which is authorised and regulated by the FCA in the United Kingdom, is acting exclusively as financial adviser to NortonLifeLock and Bidco
and no one else in connection with the Merger and will not be responsible to anyone other than NortonLifeLock or Bidco for providing the
protections afforded to clients of Evercore nor for providing advice in connection with the matters referred to herein. Neither Evercore
nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or
indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Evercore in connection with any
matter referred to herein or otherwise. Apart from the responsibilities and liabilities, if any, which may be imposed on Evercore by FSMA,
or the regulatory regime established thereunder, or under the regulatory regime of any jurisdiction where exclusion of liability under
the relevant regulatory regime would be illegal, void or unenforceable, neither Evercore nor any of its affiliates accepts any responsibility
or liability whatsoever for the contents of this Announcement, and no representation, express or implied, is made by it, or purported
to be made on its behalf, in relation to any matter referred to herein, including its accuracy, completeness or verification, or any other
statement made or purported to be made by it, or on its behalf, in connection with NortonLifeLock, Bidco or the matters described in this
Announcement. To the fullest extent permitted by applicable law, Evercore and its affiliates accordingly disclaim all and any responsibility
or liability whether arising in tort, contract or otherwise (save as referred to above) which it or they might otherwise have in respect
of this Announcement or any statement contained herein.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>UBS AG London Branch (&ldquo;<B>UBS</B>&rdquo;)
is authorised and regulated by the Financial Market Supervisory Authority in Switzerland. It is authorised by the PRA and subject to regulation
by the FCA and limited regulation by the PRA in the United Kingdom. UBS provided financial and corporate broking advice to Avast and no
one else in connection with the process or contents of this Announcement. In connection with such matters, UBS will not regard any other
person as its client, nor will it be responsible to any other person for providing the protections afforded to its clients or for providing
advice in relation to the process, contents of this Announcement or any other matter referred to herein.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 48; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>J.P. Morgan Securities plc, which conducts its
UK investment banking business as J.P. Morgan Cazenove, (&ldquo;<B>J.P. Morgan Cazenove</B>&rdquo;) and which is authorised in the United
Kingdom by the PRA and regulated in the United Kingdom by the PRA and the FCA, is acting exclusively as financial adviser to Avast and
no one else in connection with the Merger and will not regard any other person as its client in relation to the Merger and shall not be
responsible to anyone other than Avast for providing the protections afforded to clients of J.P. Morgan Cazenove or its affiliates, nor
for providing advice in connection with the Merger or any matter or arrangement referred to herein.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>No offer or solicitation</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>This Announcement is for information purposes
only and is not intended to and does not constitute, or form any part of, an offer to sell or the solicitation of an offer to subscribe
for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction
pursuant to the Merger or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention
of applicable law or regulation. In particular, this announcement is not an offer of securities for sale in the United States. No offer
of securities shall be made in the United States absent registration under the U.S. Securities Act or pursuant to an exemption from, or
in a transaction not subject to, such registration requirements. Any securities issued as part of the Merger are anticipated to be issued
in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The Merger will be implemented solely in accordance
with the Scheme Document (or, in the event that the Merger is to be implemented by means of a Takeover Offer, the offer document), which
will contain the full terms and conditions of the Merger, including details of how to vote in respect of the Scheme. Any voting decision
or response in relation to the Merger should be made solely on the basis of the information contained in the Scheme Document, the Forms
of Proxy, the Form of Election and the NortonLifeLock Prospectus.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>This Announcement does not constitute a prospectus
or a prospectus exempted document.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>This Announcement has been prepared for the
purpose of complying with English law and the Code and the information disclosed may not be the same as that which would have been disclosed
if this Announcement had been prepared in accordance with the laws of jurisdictions other than England and Wales.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Important additional information will be
filed with the SEC</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>This Announcement may be deemed to be solicitation
material in respect of the Merger, including the issuance of NortonLifeLock Shares. In connection with the proposed issuance of NortonLifeLock
Shares, NortonLifeLock is expected to file the NortonLifeLock Proxy Statement with the SEC. To the extent NortonLifeLock effects the Merger
as a Scheme under English law, the issuance of NortonLifeLock Shares would not be expected to require registration under the U.S. Securities
Act pursuant to an exemption provided by Section 3(a)(10) of the U.S. Securities Act. If, in the future, Bidco exercises its right to
implement the Merger by way of a Takeover Offer or otherwise in a manner that is not exempt from the registration requirements of the
U.S. Securities Act, it will file a registration statement on Form S-4 with the SEC that will contain a prospectus with respect to the
issuance of New NortonLifeLock Shares. BEFORE MAKING ANY VOTING DECISION, NORTONLIFELOCK&rsquo;S SHAREHOLDERS ARE URGED TO READ THESE
MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION
WITH THE MERGER OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT (IF ANY) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE MERGER AND THE PARTIES TO THE MERGER. NortonLifeLock&rsquo;s shareholders and
investors will be able to obtain, without charge, a copy of the NortonLifeLock Proxy Statement (or, if applicable, the registration statement
on Form S-4), including the Scheme Document (or, if applicable the offer document), and other relevant documents filed with the SEC (when
available) from the SEC&rsquo;s website at http://www.sec.gov. NortonLifeLock&rsquo;s shareholders and investors will also be able to
obtain, without charge, a copy of the NortonLifeLock Proxy Statement, including the Scheme Document (or, if applicable the offer document),
and other relevant documents (when available) by directing a written request to NortonLifeLock (Attention: Investor Relations), or from
NortonLifeLock&rsquo;s website at https://investor.nortonlifelock.com/.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Participants in the solicitation</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>NortonLifeLock, Bidco and certain of their directors
and executive officers and employees may be considered participants in the solicitation of proxies from the stockholders of NortonLifeLock
in respect of the Merger, including the proposed issuance of NortonLifeLock Shares. Information regarding the persons who may, under the
rules of the SEC, be deemed participants in the solicitation of the stockholders of NortonLifeLock in connection with the Merger, including
a description of their direct or indirect interests, by security holdings or otherwise, will be set out in the NortonLifeLock Proxy Statement
when it is filed with the SEC. Information regarding NortonLifeLock&rsquo;s directors and executive officers is contained in NortonLifeLock&rsquo;s
Annual Report on Form 10-K for the fiscal year ended 2 April 2021 and its Proxy Statement on Schedule 14A, dated 28 July 2021, which are
filed with the SEC.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Overseas shareholders</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The release, publication or distribution of
this Announcement in jurisdictions other than the United Kingdom may be restricted by law and therefore any persons who are subject to
the laws of any jurisdiction other than the United Kingdom (including Restricted Jurisdictions) should inform themselves about, and observe,
any applicable legal or regulatory requirements. In particular, the ability of persons who are not resident in the United Kingdom or who
are subject to the laws of another jurisdiction to vote their Avast Shares in respect of the Scheme at the Meetings, or to execute and
deliver the Forms of Proxy (appointing another to vote at the Meetings on their behalf) or the Form of Election, may be affected by the
laws of the relevant jurisdictions in which they are located or to which they are subject. Any failure to comply with applicable legal
or regulatory requirements of any jurisdiction may constitute a violation of securities laws in that jurisdiction.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Copies of this Announcement and any formal documentation
relating to the Merger are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or
into or from any Restricted Jurisdiction, including any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction,
and persons receiving such documents (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send
them in or into or from any Restricted Jurisdiction. Doing so may render invalid any related purported vote in respect of acceptance of
the Merger.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>If the Merger is implemented by way of a Takeover
Offer (unless otherwise permitted by applicable law and regulation), the Takeover Offer may not be made, directly or indirectly, in or
into or by use of the mails or any other means or instrumentality (including facsimile, e-mail or other electronic transmission, telex
or telephone) of interstate or foreign commerce of, or any facility of a national, state or other securities exchange of, any Restricted
Jurisdiction and the Merger will not be capable of acceptance by any such use, means, instrumentality or facilities or from within any
Restricted Jurisdiction.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Further details in relation to Avast Shareholders
in overseas jurisdictions will be contained in the Scheme Document.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Notice to U.S. investors in Avast</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The Merger relates to the shares of an English
company and is being made by means of a scheme of arrangement under Part 26 of the Companies Act. A scheme of arrangement is not subject
to the tender offer rules or the proxy solicitation rules under the U.S. Exchange Act and other requirements of U.S. law. Accordingly,
the Merger is subject to the disclosure requirements and practices applicable to a scheme of arrangement involving a target company in
England listed on the London Stock Exchange, which differ from the disclosure requirements of U.S. tender offer and proxy solicitation
rules. If, in the future, Bidco exercises its right to implement the Merger by way of a Takeover Offer and determines to extend the Takeover
Offer into the U.S., the Merger will be made in compliance with applicable U.S. laws and regulations.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 50; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The New NortonLifeLock Shares to be issued
pursuant to the Merger have not been registered under the U.S. Securities Act, and may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of the U.S. Securities Act. The New NortonLifeLock Shares
to be issued pursuant to the Merger will be issued pursuant to the exemption from registration provided by Section 3(a)(10) under the
U.S. Securities Act. If, in the future, Bidco exercises its right to implement the Merger by way of a Takeover Offer or otherwise in
a manner that is not exempt from the registration requirements of the U.S. Securities Act, it will file a registration statement with
the SEC that will contain a prospectus with respect to the issuance of New NortonLifeLock Shares. In this event, Avast Shareholders are
urged to read these documents and any other relevant documents filed with the SEC, as well as any amendments or supplements to those
documents, because they will contain important information, and such documents will be available free of charge at the SEC&rsquo;s website
at <U>www.sec.gov</U> or by directing a request to NortonLifeLock&rsquo;s Investor Relations team identified above.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>New NortonLifeLock Shares issued to persons
other than &quot;affiliates&quot; of NortonLifeLock (defined as certain control persons, within the meaning of Rule 144 under the U.S.
Securities Act) will be freely transferable under US law after the Merger. Persons (whether or not US persons) who are or will be &quot;affiliates&quot;
of NortonLifeLock within 90 days prior to, or of the Combined Company after, the Effective Date will be subject to certain transfer restrictions
relating to the New NortonLifeLock Shares under US law.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Neither the SEC nor any U.S. state securities
commission has approved or disapproved of the New NortonLifeLock Shares to be issued in connection with the Merger, or determined if this
Announcement is accurate or complete. Any representation to the contrary is a criminal offence in the United States.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Financial information relating to Avast included
in this Announcement and to be included in the Scheme Document has been or will have been prepared in accordance with accounting standards
applicable in the United Kingdom and may not be comparable to financial information of U.S. companies or companies whose financial statements
are prepared in accordance with U.S. GAAP. U.S. GAAP differs in certain significant respects from accounting standards applicable in the
United Kingdom.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Avast is incorporated under the laws of England
and Wales. In addition, some of its officers and directors reside outside the United States, and some or all of its assets are or may
be located in jurisdictions outside the United States. Therefore, investors may have difficulty effecting service of process within the
United States upon those persons or recovering against Avast or its officers or directors on judgments of United States federal, state
or district courts, including judgments based upon the civil liability provisions of the U.S. federal securities laws. It may not be possible
to sue Avast or its officers or directors in a non-U.S. court for violations of the U.S. securities laws.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Forward-looking statements</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>This Announcement contains certain forward-looking
statements with respect to the NortonLifeLock Group and the Avast Group. These forward-looking statements can be identified by the fact
that they do not relate only to historical or current facts. Forward-looking statements often use words such as &ldquo;anticipate&rdquo;,
 &ldquo;target&rdquo;, &ldquo;expect&rdquo;, &ldquo;estimate&rdquo;, &ldquo;intend&rdquo;, &ldquo;plan&rdquo;, &ldquo;goal&rdquo;, &ldquo;believe&rdquo;,
 &ldquo;aim&rdquo;, &ldquo;will&rdquo;, &ldquo;may&rdquo;, &ldquo;would&rdquo;, &ldquo;could&rdquo; or &ldquo;should&rdquo; or other words
of similar meaning or the negative thereof. Forward-looking statements include statements relating to the following: (i) future capital
expenditures, expenses, revenues, economic performance, financial conditions, dividend policy, losses and future prospects, (ii) business
and management strategies and the expansion and growth of the operations of the NortonLifeLock Group or the Avast Group, and (iii) the
effects of government regulation on the business of the NortonLifeLock Group or the Avast Group. There are many factors which could cause
actual results to differ materially from those expressed or implied in forward-looking statements. Such factors include the possibility
that the Merger will not be completed on a timely basis or at all, whether due to the failure to satisfy the conditions of the Merger
(including approvals or clearances from regulatory and other agencies and bodies) or otherwise, general business and economic conditions
globally, industry trends, competition, changes in government and other regulation, changes in political and economic stability, disruptions
in business operations due to reorganisation activities, interest rate and currency fluctuations, the inability of the Combined Company
to realise successfully any anticipated synergy benefits when (and if) the Merger is implemented, the inability of the Combined Company
to integrate successfully the operations of the NortonLifeLock Group and the Avast Group when (and if) the Merger is implemented and the
Combined Company incurring and/or experiencing unanticipated costs and/or delays or difficulties relating to the Merger when (and if)
it is implemented. Additional information concerning these and other risk factors is contained in the Risk Factors sections of NortonLifeLock&rsquo;s
most recent reports on Form 10-K and Form 10-Q, the contents of which are not incorporated by reference into, nor do they form part of,
this Announcement.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 51; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>These forward-looking statements are based
on numerous assumptions regarding the present and future business strategies of such persons and the environment in which each will operate
in the future. By their nature, these forward-looking statements involve known and unknown risks, as well as uncertainties because they
relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking
statements in this Announcement may cause the actual results, performance or achievements of any such person, or industry results and
developments, to be materially different from any results, performance or achievements expressed or implied by such forward-looking statements.
No assurance can be given that such expectations will prove to have been correct and persons reading this Announcement are therefore
cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement. All subsequent
oral or written forward-looking statements attributable to the NortonLifeLock Group or the Avast Group or any persons acting on their
behalf are expressly qualified in their entirety by the cautionary statement above. None of NortonLifeLock, Bidco or Avast undertake
any obligation to update publicly or revise forward-looking statements, whether as a result of new information, future events or otherwise,
except to the extent required by applicable law, regulation or stock exchange rules.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>No profit forecasts or estimates</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The NortonLifeLock Profit Forecast is a profit
forecast for the purposes of Rule 28 of the Code. The NortonLifeLock Profit Forecast, the assumptions and basis of preparation on which
the NortonLifeLock Profit Forecast is based and the NortonLifeLock Directors&rsquo; confirmation, as required by Rule 28.1 of the Code,
are set out in Appendix 5 to this Announcement.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The Avast Profit Forecast is a profit forecast
for the purposes of Rule 28 of the Code. The Avast Profit Forecast, the assumptions and basis of preparation on which the Avast Profit
Forecast is based and the Avast Directors&rsquo; confirmation, as required by Rule 28.1 of the Code, are set out in Appendix 6 to this
Announcement.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Other than in respect of the NortonLifeLock
Profit Forecast and the Avast Profit Forecast, no statement in this Announcement is intended as, or is to be construed as, a profit forecast
or estimate for any period and no statement in this Announcement should be interpreted to mean that earnings or earnings per ordinary
share, for NortonLifeLock or Avast, respectively for the current or future financial years would necessarily match or exceed the historical
published earnings or earnings per ordinary share for NortonLifeLock or Avast, respectively.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>For the purposes of Rule 28 of the Code: (i)
the NortonLifeLock Profit Forecast contained in this Announcement is the responsibility of NortonLifeLock and the NortonLifeLock Directors;
and (ii) the Avast Profit Forecast contained in this Announcement is the responsibility of Avast and the Avast Directors.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Use of Non-GAAP financial information</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>NortonLifeLock uses the non-GAAP measures of
operating margin, which are adjusted from results based on U.S. GAAP and exclude certain expenses, gains and losses. NortonLifeLock also
provides the non-GAAP metric of free cash flow, which is defined as cash flows from operating activities less purchases of property and
equipment. These non-GAAP financial measures are provided to enhance the user&rsquo;s understanding of NortonLifeLock&rsquo;s past financial
performance and its prospects for the future. NortonLifeLock&rsquo;s management team uses these non-GAAP financial measures in assessing
NortonLifeLock&rsquo;s performance, as well as in planning and forecasting future periods. These non-GAAP financial measures are not computed
according to U.S. GAAP and the methods used by NortonLifeLock to compute them may differ from the methods used by other companies. Non-GAAP
financial measures are supplemental, should not be considered a substitute for financial information presented in accordance with U.S.
GAAP and should be read only in conjunction with NortonLifeLock&rsquo;s consolidated financial statements prepared in accordance with
U.S. GAAP. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>NortonLifeLock is unable to provide a reconciliation
of these forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures because certain information is
dependent on future events, some of which are outside the control of NortonLifeLock. Moreover, estimating such U.S. GAAP financial measures
with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without
unreasonable effort.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Quantified Financial Benefits Statement</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Statements of estimated cost savings and synergies
relate to future actions and circumstances which, by their nature, involve risks, uncertainties and contingencies. As a result, the cost
savings and synergies referred to in the Quantified Financial Benefits Statement may not be achieved, may be achieved later or sooner
than estimated, or those achieved could be materially different from those estimated. No statement in the Quantified Financial Benefits
Statement, or this Announcement generally, should be construed as a profit forecast (other than the NortonLifeLock Profit Forecast and
the Avast Profit Forecast) or interpreted to mean that the Combined Company&rsquo;s earnings in the first full year following the Effective
Date of the Scheme, or in any subsequent period, would necessarily match or be greater than or be less than those of Avast and/or NortonLifeLock
for the relevant preceding financial period or any other period. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>For the purposes of Rule 28 of the Code, the
Quantified Financial Benefits Statement contained in this Announcement is the responsibility of NortonLifeLock and the NortonLifeLock
Directors.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Publication on website</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>A copy of this Announcement and the documents
required to be published pursuant to Rule 26.1 and Rule 26.2 of the Code will be made available (subject to certain restrictions relating
to persons resident in Restricted Jurisdictions) on NortonLifeLock&rsquo;s website (at https://investor.nortonlifelock.com/) and on Avast&rsquo;s
website (at https://investors.avast.com/) by no later than 12 noon London time on the business day following the date of this Announcement.
Neither the contents of these websites nor the content of any other website accessible from hyperlinks on such websites is incorporated
into, or forms part of, this Announcement.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Requesting hard copy documents</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>In accordance with Rule 30.3 of the Code, a
person so entitled may request a copy of this Announcement (and any information incorporated into it by reference to another source) in
hard copy form free of charge. A person may also request that all future documents, announcements and information sent to that person
in relation to the Merger should be in hard copy form. For persons who have received a copy of this Announcement in electronic form or
via a website notification, a hard copy of this Announcement will not be sent unless so requested from either Avast by contacting Avast&rsquo;s
registrars, Equiniti, at Aspect House, Spencer Road, Worthing, Lancing BN99 6DA or, between 8.30 a.m. and 5.30 p.m. Monday to Friday (except
UK public holidays), on 0371 384 2030 from within the UK or +44 121 415 7047 if calling from outside the UK (calls are charged at the
standard geographic rate and will vary by provider; calls from outside the UK will be charged at the applicable international rate), or
NortonLifeLock by contacting Investor Relations at IR@NortonLifeLock.com, as appropriate.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Information relating to Avast Shareholders</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Please be aware that addresses, electronic addresses
and certain other information provided by Avast Shareholders, persons with information rights and other relevant persons for the receipt
of communications from Avast may be provided to Bidco during the Offer Period as required under Section 4 of Appendix 4 of the Code to
comply with Rule 2.11(c) of the Code.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 53; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Dealing and opening position disclosure requirements
of the Code</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Under Rule 8.3(a) of the Code, any person who
is interested in one per cent or more of any class of relevant securities of an offeree company or of any securities exchange offeror
(being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash)
must make an Opening Position Disclosure following the commencement of the Offer Period and, if later, following the announcement in which
any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person&rsquo;s interests
and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities
exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London
time) on the 10<SUP>th</SUP> Business Day (as defined in the Code) following the commencement of the Offer Period and, if appropriate,
by no later than 3.30 p.m. (London time) on the 10<SUP>th</SUP> Business Day (as defined in the Code) following the announcement in which
any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of
a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Under Rule 8.3(b) of the Code, any person who
is, or becomes, interested in one per cent or more of any class of relevant securities of the offeree company or of any securities exchange
offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange
offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person&rsquo;s interests and short positions in,
and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save
to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies
must be made by no later than 3.30 p.m. (London time) on the Business Day (as defined in the Code) following the date of the relevant
dealing.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>If two or more persons act together pursuant
to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company
or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Opening Position Disclosures must also be made
by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any
persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Details of the offeree and offeror companies
in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure
Table on the Panel&rsquo;s website at <U>www.thetakeoverpanel.org.uk,</U> including details of the number of relevant securities in issue,
when the Offer Period commenced and when any offeror was first identified. You should contact the Panel&rsquo;s Market Surveillance Unit
on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Rounding</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Certain figures included in this Announcement
have been subjected to rounding adjustments. Accordingly, figures shown for the same category presented in different tables may vary slightly
and figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that precede them.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,
IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT
LAWS OR REGULATIONS OF SUCH JURISDICTION</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>FOR IMMEDIATE RELEASE</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><B>10 August 2021</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>RECOMMENDED MERGER</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>of</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>AVAST PLC</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>with</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>NORTONLIFELOCK INC.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>to be effected by means of a Scheme of Arrangement<BR>
under Part 26 of the Companies Act 2006</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45pt">1</TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Introduction</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Further to the announcements made by NortonLifeLock
Inc. (&ldquo;<B>NortonLifeLock</B>&rdquo;) and Avast plc (&ldquo;<B>Avast</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;) on 14 July 2021,
the boards of NortonLifeLock and Avast are pleased to announce that they have reached agreement on the terms of a recommended merger of
Avast with NortonLifeLock, in the form of a recommended offer by Nitro Bidco Limited (&ldquo;<B>Bidco</B>&rdquo;), a wholly-owned subsidiary
of NortonLifeLock, for the entire issued and to be issued ordinary share capital of the Company (the &ldquo;<B>Merger</B>&rdquo;). It
is intended that the Merger will be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act (the
 &ldquo;<B>Scheme</B>&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45pt"><FONT STYLE="font-weight: normal">2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>The Merger</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><B><I>Merger consideration &ndash;
Majority Cash Option</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Under the terms of the Merger, Avast Shareholders
will be entitled to receive:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 45pt; width: 35%"><B>for each Avast Share held:</B></TD>
  <TD STYLE="text-align: justify"><B>USD 7.61 in cash</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -2.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%">&nbsp;</TD>
  <TD STYLE="text-align: justify"><B>and</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 3.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 35%">&nbsp;</TD>
  <TD STYLE="text-align: justify"><B>0.0302 of a New NortonLifeLock Share</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 3.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">in respect of their entire holding of
Avast Shares (the &ldquo;<B>Majority Cash Option</B>&rdquo;). Based on NortonLifeLock&rsquo;s closing share price of USD 27.20 on 13 July
2021 (being the last Business Day on which NortonLifeLock Shares traded on NASDAQ before the commencement of the Offer Period in relation
to the Merger) and the Announcement Exchange Rate, the Majority Cash Option values each Avast Share at 608.4 pence per share (USD 8.43
per share). The Majority Cash Option comprises approximately 90% by value in cash and approximately 10% by value in New NortonLifeLock
Shares and delivers significant cash proceeds to Avast Shareholders who desire immediate liquidity.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 55; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Majority Cash Option represents a
premium of approximately:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">20.7% to the Closing Price of 504.2 pence per Avast Share on the Unaffected Date; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">28.0% to the volume weighted average price of 475.1 pence per Avast Share for the three months up to the
Unaffected Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">As an alternative to the Majority Cash
Option, Avast Shareholders may elect to receive the Majority Stock Option in respect of their entire holding of Avast Shares, as described
below.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><B><I>Alternative Merger consideration
 &ndash; Majority Stock Option</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">As an alternative to the Majority Cash
Option, Bidco will make available to Avast Shareholders the option to elect for a different mix of cash and share consideration, pursuant
to which Avast Shareholders (other than those resident in a Restricted Jurisdiction) may elect to receive:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 65pt; width: 40%"><B>for each Avast Share held:</B></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><B>0.1937 of a New NortonLifeLock Share</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -2.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 40%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><B>and</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 40%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><B>USD 2.37 in cash</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">in respect of their entire holding of
Avast Shares (the &ldquo;<B>Majority Stock Option</B>&rdquo;). Based on NortonLifeLock&rsquo;s closing share price of USD 27.20 on 13
July 2021 (being the last Business Day on which NortonLifeLock Shares traded on NASDAQ before the commencement of the Offer Period in
relation to the Merger) and the Announcement Exchange Rate, the Majority Stock Option values each Avast Share at 551.1 pence per share
(USD 7.64 per share).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Majority Stock Option comprises approximately
31% by value in cash and approximately 69% by value in New NortonLifeLock Shares. The Majority Stock Option enables Avast Shareholders
to participate more fully in the upside and long-term value creation opportunity resulting from the Merger. See paragraph 14 (<I>Electing
to receive the Majority Stock Option</I>) for further information.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">In addition to the consideration payable
in connection with the Merger, Avast Shareholders will be entitled to receive certain agreed ordinary course Avast dividends prior to
the completion of the Merger, on the basis set out below.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Avast Shareholders who do not positively
elect to receive the Majority Stock Option will receive the Majority Cash Option.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">As explained in paragraphs 4 (<I>Recommendation</I>)
and 6 (<I>Irrevocable undertakings</I>) below, each of the Avast Directors who holds Avast Shares has irrevocably undertaken to elect
for the Majority Stock Option, as well as to vote or procure votes in favour of the Scheme (or, in the event that the Merger is implemented
by way of a Takeover Offer, accept or procure acceptance of the Takeover Offer), in respect of their entire beneficial holdings of Avast
Shares, on the terms summarised in Appendix 3 to this Announcement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><B><I>Aggregate transaction value</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">The aggregate transaction value and
the percentage of the Combined Company held by Avast Shareholders immediately following completion of the Merger depend on the elections
made by Avast Shareholders for the Majority Stock Option, with the range of possible outcomes being bound by the two following bookends:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">If all Avast Shareholders, other than the Avast Directors who hold Avast Shares, receive the Majority
Cash Option, Avast&rsquo;s entire issued and to be issued ordinary share capital would be valued, on the same basis as set out above,
at approximately &pound;6.2 billion (USD 8.6 billion), comprised of approximately &pound;4.4 billion (USD 6.1 billion) in cash and approximately
 &pound;1.8 billion (USD 2.5 billion) in New NortonLifeLock Shares, with an enterprise value attributed to Avast of approximately &pound;6.6
billion (USD 9.2 billion). NortonLifeLock Shareholders and Avast Shareholders would own approximately 86% and 14% of the Combined Company
(on a fully diluted basis), respectively, and no Post-Merger Buyback would be expected in this scenario; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 56; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">If all Avast Shareholders elect to receive the Majority Stock Option, Avast&rsquo;s entire issued and
to be issued ordinary share capital would be valued, on the same basis as set out above, at approximately &pound;5.8 billion (USD 8.1
billion), comprised of approximately &pound;1.8 billion (USD 2.5 billion) in cash and approximately &pound;4.0 billion (USD 5.6 billion)
in New NortonLifeLock Shares, with an enterprise value attributed to Avast of approximately &pound;6.2 billion (USD 8.6 billion). NortonLifeLock
Shareholders and Avast Shareholders would own approximately 74% and 26% of the Combined Company (on a fully diluted basis), respectively.
If all Avast Shareholders elect for the Majority Stock Option, NortonLifeLock expects that the amount of the Post-Merger Buyback, if implemented,
would be up to approximately USD 3 billion.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><B><I>GBP currency facility</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Prior to completion of the Merger, Bidco
will procure that a facility will be made available under which Avast Shareholders will be able to elect (subject to the terms and conditions
of the facility) to receive cash consideration in GBP rather than USD (after deduction of any transaction or dealing costs associated
with the conversion) under the Majority Cash Option or the Majority Stock Option (as applicable) at the prevailing market exchange rate
(which may be determined over a period of more than one day) on the latest practicable date for fixing such rate prior to the relevant
payment date. Further details of this facility will be set out in the Scheme Document.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: 2.15pt"><B><I>Agreed Avast
Dividends</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: 2.15pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">In addition to the consideration payable
in connection with the Merger, the Avast Board will be entitled to declare and pay an interim dividend in respect of the six month period
ended 30 June 2021 of 4.8 cents per Avast Share (the &ldquo;<B>Interim Avast Dividend</B>&rdquo;). It is expected that the Interim Avast
Dividend will be announced by Avast in August 2021 and paid in October 2021.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">In addition to the consideration payable
in connection with the Merger and the Interim Avast Dividend, if the Merger has not become Effective before 1 March 2022, the Avast Board
reserves the right to declare and pay either a further interim dividend or recommend and pay a final dividend in respect of the year ending
31 December 2021 of 11.2 cents per Avast Share (the &ldquo;<B>Second Avast Dividend</B>&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">In addition to the consideration payable
in connection with the Merger and the Interim Avast Dividend and the Second Avast Dividend, if the Merger has not become Effective before
11 August 2022, the Avast Board reserves the right to declare and pay an interim dividend in respect of the six month period ended 30
June 2022 of 4.8 cents per Avast Share (the &ldquo;<B>Third Avast Dividend</B>&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Bidco has agreed that Avast Shareholders
will be entitled to receive the Interim Avast Dividend, the Second Avast Dividend and the Third Avast Dividend (together, the &ldquo;<B>Agreed
Avast Dividends</B>&rdquo;), if and to the extent declared and paid in accordance with the terms set out in this Announcement, in each
case without any reduction to the consideration payable by Bidco under the terms of the Merger.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Avast Shareholders on the register of
members as at close of business on the relevant record date will be entitled to receive the relevant Agreed Avast Dividend(s). Avast Shareholders
may also elect to receive the Agreed Avast Dividends in Pounds Sterling in accordance with Avast&rsquo;s dividend currency election facility.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">If any dividend and/or other distribution
and/or other return of capital or value (a &ldquo;<B>Return of Value</B>&rdquo;) is announced, declared, made, payable or paid in respect
of the Avast Shares on or after the date of this Announcement and prior to the Effective Date, other than, or in excess of, the Agreed
Avast Dividends, Bidco reserves the right to reduce the aggregate consideration payable in respect of the Avast Shares by the aggregate
amount of such Return of Value.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 57; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: 2.15pt"><B><I>Agreed NortonLifeLock
Dividends</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: 2.15pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">NortonLifeLock intends to continue to
declare and pay quarterly dividends of 12.5 cents per NortonLifeLock Share to NortonLifeLock Shareholders in the period up to the Effective
Date (the &ldquo;<B>Agreed NortonLifeLock Dividends</B>&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">If any Return of Value is announced, declared,
made, payable or paid in respect of the NortonLifeLock Shares on or after the date of this Announcement and prior to the Effective Date
and which has a record date prior to the Effective Date, other than, or in excess of, the Agreed NortonLifeLock Dividends (an &ldquo;<B>Excess
NortonLifeLock Dividend</B>&rdquo;), Bidco will be required to revise the terms of the consideration payable under the terms of the Merger
to put Avast Shareholders in the same economic position as they would have been if any such Excess NortonLifeLock Dividend had not been
paid. This will be achieved by increasing the cash consideration per Avast Share payable under each of the Majority Cash Option and the
Majority Stock Option by an amount equal to (i) the amount of the relevant Excess NortonLifeLock Dividend (expressed on a per NortonLifeLock
Share basis) multiplied by (ii) in the case of the Majority Cash Option, 0.0302, and, in the case of the Majority Stock Option, 0.1937.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><B><I>Implementation of the Merger</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Merger will be put to Avast Shareholders
at the Court Meeting and at the General Meeting. In order to become Effective, the Scheme must be approved by a majority in number of
the Scheme Shareholders present and voting at the Court Meeting, either in person or by proxy, representing at least 75% in value of the
Scheme Shares voted. In addition, a special resolution implementing the Scheme must be passed by Avast Shareholders representing at least
75% of votes cast at the General Meeting.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Merger is subject to the Conditions
and certain further terms set out in Appendix 1 to this Announcement, and to the full terms and conditions which will be set out in the
Scheme Document.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Further details of the Merger will be
contained in the Scheme Document, which is intended to be posted to Avast Shareholders (other than those resident in Restricted Jurisdictions),
along with the Forms of Proxy and the Form of Election, in late Q3 or early Q4 of 2021. For the purposes of paragraph 3(a) of Appendix
7 of the Code, the Panel has consented to this arrangement. It is also expected that, at or around the same time as the Scheme Document
is posted to Avast Shareholders (other than those resident in Restricted Jurisdictions), the NortonLifeLock Prospectus will be published
and the NortonLifeLock Proxy Statement will be mailed.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Subject to the satisfaction or waiver
(as applicable) of all relevant conditions, including the Conditions, and certain terms set out in Appendix 1 to this Announcement and
to be set out in the Scheme Document, the Scheme is expected to become Effective in mid-2022. An expected timetable of principal events
will be included in the Scheme Document.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Avast Shares will be acquired by Bidco
(and/or its nominee) with full title guarantee, fully paid and free from all liens, equitable interests, charges, encumbrances, rights
of pre-emption and any other third party rights or interests whatsoever and together with all rights existing at the date of this Announcement
or thereafter attaching thereto, including the right to receive and retain, in full, all dividends and other distributions (if any), declared,
made or paid or any other return of capital (whether by way of reduction of share capital or share premium account or otherwise) made
on or after the date of this Announcement in respect of the Avast Shares, other than the Agreed Avast Dividends.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The New NortonLifeLock Shares will be
fully paid and non-assessable and will rank pari passu in all respects with the existing NortonLifeLock Shares, save that they will not
participate in any dividend payable by NortonLifeLock with reference to a record date prior to the Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 58; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Background to and reasons for the Merger</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">On 10 May 2021, NortonLifeLock presented
its &ldquo;transforming for growth&rdquo; strategy to enable NortonLifeLock to achieve its long-term vision through improved customer
experience, enhancing the scale of its Cyber Safety platform and accelerating innovation of trust-based solutions. NortonLifeLock&rsquo;s
strategy is underpinned by the following ambitions: (i) make customers happy and double its net promoter score to over 70; (ii) popularise
Cyber Safety by doubling the number of customers to approximately 100 million; and (iii) expand NortonLifeLock&rsquo;s trust-based digital
solutions to drive double digit revenue growth and double non-GAAP EPS to approximately USD 3.00 within three to five years, with business
growth and productivity, reinvestment strategies, its share buyback programme, as well as mergers and acquisitions, as levers and accelerators.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The boards of NortonLifeLock and Avast
recognise the unique opportunity for the businesses to combine their complementary strengths and accelerate such strategy by creating
a new, global player able to lead the transformation of consumer Cyber Safety by leveraging the established brands, go-to-market reach,
technical expertise and innovation of NortonLifeLock and Avast.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Merger will combine NortonLifeLock&rsquo;s
vision to protect and empower people to live their digital lives safely with Avast&rsquo;s vision to empower digital citizens to have
safer online experiences, creating a common determination to empower digital freedom for everyone.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The global Cyber Safety segment was estimated
at USD 13 billion in 2020 &ndash; however, the NortonLifeLock Board believes that the market is still significantly under-penetrated,
with less than 5% penetration of an estimated 5 billion internet users globally, as the segment has expanded from securing personal devices
to protecting consumers to enable them to live their digital lives safely. The NortonLifeLock Board believes that this presents a large
and growing TAM opportunity with the core addressable space (security, identity and privacy) expected to grow at a 5% to 10% CAGR in the
coming years to reach more than USD 16 billion by 2023, with an additional USD 10 billion in trust-based adjacent segments (equivalent
to a 10% to 15% CAGR between 2020 and 2023).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">A key problem to address is cyber criminality,
which currently encompasses a broader variety of activities and an expanded reach supported by a dark economy re-sell market. Threats
continue to increase every day and attacks have become extremely sophisticated, more broadly targeted, more complex and faster, with identity
records and confidential personal information being sold in underground markets. People&rsquo;s dependence on technology has continuously
increased, fuelled by an increasingly digital and connected world, making cyber criminality today a USD 6 trillion problem which touches
our modern society in many ways.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Merger will create a comprehensive
suite of complementary consumer Cyber Safety solutions, delivering giga-scale endpoint visibility, next-generation insights, autonomous
defence and personalised protection.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The boards of NortonLifeLock and Avast
believe that the Merger has a compelling strategic and financial rationale, with the potential to deliver substantial benefits to consumers,
shareholders and other stakeholders.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B>Accelerate the transformation of consumer
Cyber Safety, with the Combined Company having over 500 million users </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Merger will create a leading global
consumer Cyber Safety business with combined revenues of approximately USD 3.5 billion (based on the latest reported full year results
for each of NortonLifeLock and Avast), an enlarged base of over 500 million users and approximately 40 million direct customers, and a
common vision to empower digital freedom for everyone. The Combined Company will benefit from: (i) enhanced scale; (ii) a broadened suite
of established consumer Cyber Safety brands; (iii) leading Cyber Safety solutions; (iv) global consumer reach; and (v) expansion, through
both free and paid solutions, to new customer audiences, regions and products.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 59; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">In addition to a broader range of consumer
Cyber Safety solutions, the Combined Company will benefit from a more diverse channel mix, including consumer direct, indirect, and partners.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company will be well positioned
to capitalise on the continued growth and to lead digital disruption in the Cyber Safety segment, combining two businesses with complementary
technology-oriented cultures and a shared, consumer-centric, long-term vision. The Combined Company will benefit from NortonLifeLock&rsquo;s
and Avast&rsquo;s history of customer-centric innovation and will continue to focus on, and invest in, R&amp;D to create industry leading
Cyber Safety products to protect consumers and benefit all stakeholders.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company will extend and
expand Cyber Safety available to everyone through freemium offerings. Positive experiences with these products will expand the Combined
Company&rsquo;s user base and increase opportunities for paid product sales.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Furthermore, the Combined Company will
benefit from a diverse and talented workforce, facilitating the delivery of innovative Cyber Safety solutions on a global scale.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B>Combine Avast&rsquo;s strength in
privacy and NortonLifeLock&rsquo;s strength in identity, to create a broad and complementary product portfolio beyond core security and
towards adjacent trust-based solutions</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company will benefit from
the complementary nature of NortonLifeLock&rsquo;s and Avast&rsquo;s solutions, in particular NortonLifeLock&rsquo;s strength in identity
and Avast&rsquo;s strength in privacy. This will unlock opportunities to cross-sell a richer Cyber Safety offering to the Combined Company&rsquo;s
users and direct customers while continuing to maintain core Cyber Safety functionality to free users.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company will bring a differentiated
approach to the Cyber Safety segment supported by greater scale in threat visibility, a geographically distributed cloud data platform
and advanced AI-based automation. The Combined Company will be able to deliver: (i) giga-scale endpoint visibility, by gaining enhanced
visibility on threat and behavioural trajectories across more than 500 million endpoints and networks; (ii) next-generation insight, supported
by AI-based enrichment and best-in-class analytics of multi-factor, large-scale behaviour data in real time; (iii) autonomous defence,
with automation of the detection pipeline by leveraging modern, featureless and explainable AI; and (iv) personalised protection, with
AI-powered creation of a safe environment that matches the security, privacy and identity needs of individual users.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company will be able to
offer a market-leading suite of consumer Cyber Safety solutions to millions of individuals and families globally across identity, security
and privacy, including restoration and insurance, identity protection, performance and utility, device security, connected home, family
safety and privacy and access, complemented by adjacent trust-based solutions.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock&rsquo;s and Avast&rsquo;s
positions have been built over many years, resulting in brand recognition across large user bases in their respective existing segments.
This presents an attractive opportunity to continue to innovate and offer new and enhanced solutions and services, with improved capabilities
from access to superior data insights, in turn driving growth across new growth segments.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B>Provide greater geographic diversification
and access to a larger global user base, as well as facilitating expansion into the SOHO and VSB segments, and the building of stronger
B2B2C and OEM partnerships </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock and Avast currently operate
in highly complementary end markets and geographic regions. The Combined Company will benefit from enhanced revenue and geographic diversification
combining NortonLifeLock&rsquo;s and Avast&rsquo;s complementary positions in their consumer Cyber Safety segments. Based on the latest
reported full year results for each of NortonLifeLock and Avast, on an aggregated basis, approximately 65% of the Combined Company&rsquo;s
revenue was derived from the US, approximately 24% from Europe, Middle East and Africa and approximately 11% from the rest of the world.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 60; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Following completion of the Merger, the
Combined Company will have dual headquarters in Prague, Czech Republic, and Tempe, Arizona, USA, reflecting its global strength.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company will have the ability
to leverage the combined regional expertise of both businesses and flexibility to reinvest in product and marketing to target new growth
segments and regions, including expansion into the SOHO and VSB segments, OEM PC manufacturing channels and B2B2C partnerships.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">There is further potential to accelerate
international growth through investment in Avast&rsquo;s freemium business model and cross-selling of complementary NortonLifeLock identity
products, which are currently sold primarily in the US, to Avast&rsquo;s international user and direct customer base and cross-selling
Avast&rsquo;s privacy offerings to NortonLifeLock&rsquo;s full customer base.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B>Unlock significant value creation
through approximately USD 280 million of annual gross cost synergies, providing additional upside potential from new reinvestment capacity
for innovation and growth</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Given the complementary nature of both
NortonLifeLock and Avast, the NortonLifeLock Directors believe that the Merger will generate synergies that could not be achieved independently
of the Merger and will lead to significant long-term value creation for all shareholders.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>Significant recurring cost synergies
opportunity</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock anticipates that the Merger
will result in recurring annual pre-tax gross cost synergies for the Combined Company to reach a run-rate of approximately USD 280 million,
representing between approximately 15% and 20% of combined adjusted cost of sales and operating spend, based on the latest full year reported
results for each of NortonLifeLock and Avast. The synergies are expected to be fully realised by the end of the second year following
completion of the Merger.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock intends to approach integration
with the aim of retaining and motivating the best talent and structure across the Combined Company to create a best-in-class organisation.
The expected sources of the identified cost synergies are as follows:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Organisation: approximately 50% of the total annual run-rate pre-tax gross cost synergies are expected
to be generated through the adoption of shared best practice across existing functions and the reduction of duplicate roles across all
geographies, and from a broad range of job categories, including management, shared services, product and commercial functions;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Systems &amp; Infrastructure operating costs: approximately 25% of the total annual run-rate pre-tax gross
cost synergies are expected to be realised through migration onto a common data and security platform, integration of systems, and shared
technology and analytics infrastructure; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Contracts &amp; Shared Services: approximately 25% of the total annual run-rate pre-tax gross cost synergies
are expected to be generated primarily from site rationalisation, procurement and vendor consolidation, and spend de-duplication.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock expects to realise approximately
60% of the run-rate cost savings by the end of the first full year following completion of the Merger and 100% by the end of the second
full year following completion of the Merger, excluding any potential synergy reinvestment and associated benefits. On a reported basis,
the synergies assume the Combined Company expects to benefit from approximately USD 75 million of cost savings in the first full year
following completion of the Merger, approximately USD 245 million of cost savings in the second full year following completion of the
Merger, and the full USD 280 million of the cost savings in the third full year following completion of the Merger, excluding any potential
synergy reinvestment and associated benefits.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 61; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>


<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>One-off costs </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">In order to realise these synergies,
NortonLifeLock is expected to incur one-off restructuring and integration costs of approximately one year&rsquo;s run-rate pre-tax cost
savings, or USD 280 million, with approximately USD 180 million estimated to be incurred in the first full year following completion of
the Merger and approximately USD 100 million estimated to be incurred in the second full year following completion of the Merger. Aside
from integration costs, no material dis-benefits are expected to arise in connection with the Merger. The expected synergies will accrue
as a direct result of the Merger and would not be achieved on a standalone basis.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The paragraphs above relating to expected
cost synergies constitute a &ldquo;Quantified Financial Benefits Statement&rdquo; for the purposes of Rule 28 of the Code.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Given the strong strategic, cultural
and operational fit of the two companies, NortonLifeLock believes that the quantified cost synergies are readily achievable.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock expects to achieve the
quantified cost synergies while maintaining appropriate investment levels in sales and technology to meet the Combined Company&rsquo;s
growth targets and other objectives.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The estimated cost synergies referred
to above reflect both the beneficial elements and the relevant costs.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>Revenue opportunities </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">In addition to the quantified cost synergies
set out in this paragraph 3, NortonLifeLock believes that there will be significant revenue opportunities that the Combined Company could
pursue, which have not yet been quantified, but which solidify the foundation for driving double digit revenue growth in the long-term.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Following the completion of the Merger,
the Combined Company intends to bring additional value propositions to a larger user base by leveraging its broader global reach and cross-selling
enhanced products and solutions across core security and privacy and identity. This proposition will be supported by targeted sales and
marketing investment in the geographies where its industry-leading brands, Norton, Avira, LifeLock and Avast, are most established to
deliver localised experiences, promote customer service differentiation and drive enhanced customer experience and retention.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">By leveraging the sales and marketing
expertise of both organisations, the Combined Company will operate new and diversified sales channels through the scaling of its freemium
offering, SOHO and VSB targeting and expanded B2B2C partnerships. The Combined Company will also benefit from a strong balance sheet and
reinvestment capacity to drive innovation and expand into adjacent trust-based solutions.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>Reinvestment of synergies</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock and Avast have closely
aligned cultures of innovation, having each invested significantly over the years in technology and R&amp;D. The talent and expertise
of the Combined Company&rsquo;s team will further support investment in developing and optimising a global Cyber Safety technology platform
for the benefit of all consumers and other stakeholders. The Combined Company will have the scale, resources and expertise to innovate
beyond the current Cyber Safety platform.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company expects the anticipated
synergies from the Merger to provide new reinvestment capacity that it intends to deploy into innovation, partnerships and marketing initiatives
to develop the breadth, capability and accessibility of Cyber Safety products and solutions, thereby accelerating long-term sustainable
revenue growth for the Combined Company. The Combined Company will, in particular, evaluate investments (including product innovation
in Cyber Safety and adjacent trust-based services) and geographic expansion opportunities, further developing channels to market (including
distribution partnerships with PC manufacturers and additional B2B2C partnerships), and ensuring consumers are well informed of Cyber
Safety and the solutions that the Combined Company offers for their protection.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 62; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock and Avast have complementary
technologies and human capital that will strengthen the Combined Company&rsquo;s capabilities in core technology and identity and privacy,
which will facilitate improved product development to address the evolving threat of cybercrime and enhance the development of innovative
tools to help empower consumers in their digital lives.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock and Avast have an established
history of in-house development and innovation. The Combined Company will benefit from resource, knowledge transfer, technical expertise
and proprietary intellectual property to support its commitment to innovation, create new improved and comprehensive solutions (free and
paid) and safeguard data privacy and transparency for the ultimate benefit of customers.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Appendix 4 sets out further details on
the Quantified Financial Benefits Statement, including the bases of belief and principal assumptions, and the reports required under the
Code by Deloitte, NortonLifeLock&rsquo;s reporting accountants, and by Evercore, acting as financial adviser to NortonLifeLock. References
in this Announcement to the Quantified Financial Benefits Statement should be read in conjunction with Appendix 4.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">There are various alternative means by
which NortonLifeLock could achieve these quantified synergies and no decisions have yet been taken as to how NortonLifeLock will implement
any synergy plans. Initial synergy planning has begun in relation to the Merger, but more detailed analysis will need to be undertaken.
Any such synergy plans are subject to engagement with all appropriate stakeholders in due course.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B>The Merger is expected to be double-digit
accretive to NortonLifeLock&rsquo;s non-GAAP EPS within the first full year following completion of the Merger</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company will benefit from
a more attractive financial profile with increased scale, enhanced long-term growth potential and strong free cash flow generation supported
by a robust balance sheet position.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company will benefit from
a highly scalable, well-diversified and recurring subscription-based revenue model with aggregated revenues of approximately USD 3.5 billion,
based on the latest reported full year results for each of NortonLifeLock and Avast, delivering high single digit growth and with the
potential to deliver long-term growth in the double digits, supported by strong operating levers, reinvestment potential and cash flow
generation.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">On an aggregated basis, based on the
latest reported full year results for each of NortonLifeLock and Avast, excluding stranded costs, the Combined Company&rsquo;s adjusted
operating profit (pre-synergies) stands at approximately USD 1.8 billion, with implied operating margins (pre-synergies) at approximately
52%. Additional margin capacity from expected gross cost synergies of USD 280 million provides the Combined Company with scope for reinvestment
to support long-term growth whilst maintaining attractive margin levels and enabling operating leverage.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Merger is expected to be double-digit
accretive to NortonLifeLock&rsquo;s non-GAAP EPS from the first full year following completion of the Merger, taking into account expected
cost synergies and the Post-Merger Buyback, if implemented, but excluding one-time restructuring and integration costs.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company generates approximately
USD 1.5 billion in annual free cash flow (pre-synergies), on an aggregated basis, based on the latest reported full year results for each
of NortonLifeLock and Avast (excluding stranded costs), which is expected to grow in line with the business.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 63; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Post-integration, the Combined Company
is expected to operate with fewer than 4,000 employees.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Merger is expected to be financed
with cash and USD 5.35 billion of new permanent debt facilities, comprised of a combination of Term Loan A and Term Loan B at a blended
interest rate of approximately 2%, with other existing indebtedness of NortonLifeLock with upcoming maturities anticipated to be refinanced
prior to completion. As part of the transaction, NortonLifelock&rsquo;s revolving credit facility is also expected to be upsized to USD
1.5 billion and to be undrawn at completion of the Merger.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company is targeting a net
leverage ratio of approximately 3.5x following completion of the Merger (taking into account the potential expanded share buyback referred
to below). The Combined Company expects strong free cash flow generation to support rapid deleveraging to reach net leverage of approximately
2.0x to 3.0x, supporting NortonLifeLock&rsquo;s long-term capital allocation strategy, while maintaining flexibility to deploy capital
into R&amp;D, tuck-in acquisitions, as well as dividends and share buybacks to support growth and maximise value for shareholders. In
this context, the Combined Company anticipates:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">maintaining NortonLifeLock&rsquo;s existing dividend policy with the payment of a quarterly dividend of
USD 0.125 per NortonLifeLock Share;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increasing its current share buyback programme of approximately USD 1.8 billion by up to approximately
USD 3 billion to approximately USD 4.8 billion, to provide flexibility to implement an expanded share buyback programme over time following
completion of the Merger, depending on, amongst other things, Avast Shareholders&rsquo; elections in respect of the Majority Stock Option;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">continuing to return 100% of free cash flow (excluding mergers and acquisitions) to shareholders over
the long-term to drive sustainable shareholder value growth.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>Possible NortonLifeLock share buyback
programme</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">To the extent that Avast Shareholders
elect for the Majority Stock Option, NortonLifeLock intends, subject to market conditions and other capital requirements, to implement
the Post-Merger Buyback over time following completion of the Merger, with a view to optimising its capital structure and establishing
a net leverage ratio for the Combined Company in the region of 3.5x net debt to its pro forma EBITDA.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">If all Avast Shareholders elect for the
Majority Stock Option, NortonLifeLock expects that the amount of the Post-Merger Buyback, if implemented, would be up to approximately
USD 3 billion. However, this amount would be reduced by the amount of any incremental cash consideration payable to Avast Shareholders
who receive the Majority Cash Option. There can be no certainty that the Post-Merger Buyback will be implemented or as to its timing.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B>Brings together two strong and highly
experienced consumer-focused management teams with a common culture of excellence and innovation</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company will be led by a
highly experienced management team with significant experience in delivering consumer Cyber Safety solutions. The team has a track record
of developing solutions through innovation and by delivering growth in large, global markets with a common commitment to corporate responsibility.
Furthermore, the team has successfully executed value-enhancing mergers and acquisitions and overseen subsequent integration programmes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Both NortonLifeLock and Avast share a
history in innovation and product development with strong corporate ethos encompassing social, environmental and governance responsibility.
This important legacy will be continued through the Combined Company&rsquo;s shared vision of empowering digital freedom for everyone
through novel solutions. The Combined Company will draw on the broad expertise and harness the talent in both businesses, by offering
professional and personal growth opportunities, to promote a values and innovation-driven team and optimise consumer-centric Cyber Safety
solutions for the benefit of end consumers and other stakeholders.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 64; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Recommendation</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Avast Directors, who have been so
advised by UBS and J.P. Morgan Cazenove as to the financial terms of the Majority Cash Option and the Majority Stock Option, unanimously
consider the terms of the Majority Cash Option and the Majority Stock Option to be fair and reasonable. In providing their financial advice
to the Avast Directors, UBS and J.P. Morgan Cazenove have taken into account the commercial assessments of the Avast Directors. UBS is
providing independent financial advice to the Avast Directors for the purposes of Rule 3 of the Code.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Accordingly, the Avast Directors intend
to recommend unanimously that Avast Shareholders vote or procure votes in favour of the resolutions relating to the Scheme at the Meetings,
as each of the Avast Directors who owns Avast Shares has irrevocably undertaken to do in respect of their entire beneficial holdings of
Avast Shares. In addition, the Vl&ccaron;ek Family Foundation has irrevocably undertaken to vote in favour of the resolutions relating
to the Scheme at the Meetings in respect of its entire beneficial holding of Avast Shares.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Avast Directors&rsquo; (and the Vl&ccaron;ek
Family Foundation&rsquo;s) irrevocable commitments are in respect of, in aggregate, 381,057,227 Avast Shares, representing approximately
36.93% of the existing issued ordinary share capital of Avast on the Latest Practicable Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">In addition, each of the Avast Directors
who holds Avast Shares has irrevocably undertaken to elect for the Majority Stock Option in respect of their entire beneficial holdings
of Avast Shares, on the terms summarised in Appendix 3 to this Announcement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Background to and reasons for the recommendation</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Since its foundation in 1991, Avast has
grown into a leading global consumer cyber security company. Through its freemium distribution model and acquisitions, including AVG and
Piriform, Avast has amassed a sizeable user base, with over 435 million users. Approximately 85% of revenues are derived from the Avast
Group&rsquo;s Consumer Direct segment and the business has driven direct monetisation through up-selling and cross-selling to this user
base and by using third-party relationships to drive additional revenues. The business derives the remainder of its revenues through its
Consumer Indirect segment, which includes Avast Secure Browser and partner channels, as well as its small and medium-sized business (SMB)
segment.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The cybersecurity landscape is competitive
and is evolving at pace, along with the technology industry as a whole. Consumers increasingly expect brands to provide a seamless online
experience &ndash; for Avast, this means protecting its customers from all online risks. This is accelerating the shift towards a user-centric
model in which consumers&rsquo; entire digital lives and digital experiences are protected, and new trust-based services can be built.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">At the same time, many of the world&rsquo;s
largest technology providers have increasingly advanced into security, privacy and identity. The Avast Directors see increased competition
from major technology players and other incumbents, each of whom are scaling up and evolving their offerings into integrated solutions.
Addressing this increasing competition and new types of digital threats will require Avast to accelerate the evolution of its portfolio,
supported by higher levels of margin investment in R&amp;D, innovation, marketing and other top of the funnel initiatives over the medium
term as well as targeted mergers and acquisitions to sustain customer engagement, acquisition and retention.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 65; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Avast Directors believe that the
Merger would offer compelling strategic and operational benefits to all stakeholders including:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">bringing together leading trusted brands in consumer cyber safety and security, and creating a broad product
portfolio with geographic and product complementarity, with a focus on privacy, security and identity protection;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">creating a significant opportunity to cross-sell existing and new products and promote the value proposition
to the combined customer base, which would total over 500 million users;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">combining two highly experienced R&amp;D teams to further strengthen the Combined Company&rsquo;s technological
differentiation and provide better service to its joint customers;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">providing added scale to accelerate investment in R&amp;D and innovation initiatives to drive new product
development while capturing cost efficiencies, and greater capacity to pursue value-creating acquisitions, both of which will sustain
long-term growth;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">enhancing the ability of Avast and NortonLifeLock to respond to an increasingly competitive backdrop,
in particular from the large technology companies, by building a strong, digital trust platform for consumers that protects their digital
lives; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">bringing together two respected and highly experienced consumer-focused management teams with a common
culture of excellence and innovation.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Avast Directors also took account
of the agreement that the Combined Company will be dual headquartered in Prague, Czech Republic, and Tempe, Arizona, USA, will have a
continued significant presence in the Czech Republic, and its board of directors will include two Avast representatives, including Avast
co-founder Pavel Baudi&scaron;.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Moreover, the Avast Directors believe
that the Merger represents compelling financial value for Avast Shareholders. The Merger consideration comprises a mix of cash and NortonLifeLock
Shares and is structured such that Avast Shareholders (other than those in a Restricted Jurisdiction) have the choice to elect between
two distinct alternatives: the Majority Cash Option or the Majority Stock Option.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Any Avast Shareholder who elects for
the:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>Majority Cash Option would receive,
for each Avast Share held: USD 7.61 in cash plus 0.0302 of a New NortonLifeLock Share</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Based on NortonLifeLock&rsquo;s closing share price of USD 27.20 on 13 July 2021 (being the last Business
Day on which NortonLifeLock Shares traded on NASDAQ before the commencement of the Offer Period in relation to the Merger) and the Announcement
Exchange Rate, the Majority Cash Option values each Avast Share at 608.4 pence per share (USD 8.43 per share).</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Majority Cash Option represents a premium of approximately 28.0% to the three-month volume weighted
average price of 475.1 pence per Avast Share on the Unaffected Date and is above Avast&rsquo;s all-time high closing price of 600.0 pence
per Avast Share.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>Majority Stock Option would receive,
for each Avast Share held: USD 2.37 in cash plus 0.1937 of a New NortonLifeLock Share</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On the basis set out above, the Majority Stock Option values each Avast Share at 551.1 pence per share
(USD 7.64 per share).</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Majority Stock Option enables Avast Shareholders to benefit from a more meaningful participation in
the strategic and financial benefits of the Merger.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 66; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Following consideration of the above
factors, the Avast Directors, who have been so advised by UBS and J.P. Morgan Cazenove as to the financial terms of the Majority Cash
Option and the Majority Stock Option, unanimously consider the terms of the Majority Cash Option and the Majority Stock Option to be fair
and reasonable. In providing their financial advice to the Avast Directors, UBS and J.P. Morgan Cazenove have taken into account the commercial
assessments of the Avast Directors. UBS is providing independent financial advice to the Avast Directors for the purposes of Rule 3 of
the Code.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Accordingly, the Avast Directors intend
to recommend unanimously that Avast Shareholders vote or procure votes in favour of the resolutions relating to the Scheme at the Meetings,
as each of the Avast Directors who own Avast Shares has irrevocably undertaken to do in respect of their entire beneficial holdings of
Avast Shares. Further details of those irrevocable undertakings are set out below and in Appendix 3 to this Announcement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Irrevocable undertakings</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">As set out in paragraph 4 (<I>Recommendation</I>),
NortonLifeLock and Bidco have received irrevocable commitments to vote or procure votes in favour of the resolutions relating to the Scheme
at the Meetings (or, in the event that the Merger is implemented by way of a Takeover Offer, to accept or procure acceptance of the Takeover
Offer) from each of the Avast Directors who own Avast Shares (in relation to their beneficial holdings of such Avast Shares), and from
the Vl&ccaron;ek Family Foundation, in each case in respect of their entire holding of Avast Shares. These irrevocable commitments are
in respect of, in aggregate, 381,057,227 Avast Shares, representing approximately 36.93% of the existing issued ordinary share capital
of Avast on the Latest Practicable Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Further details of these irrevocable undertakings
are set out in Appendix 3 to this Announcement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Information on NortonLifeLock and Bidco</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><I>NortonLifeLock</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock is a leading provider
of consumer Cyber Safety solutions built around protecting and empowering people to live their digital lives safely. Founded in 1982 and
headquartered in Tempe, Arizona, NortonLifeLock serves over 80 million users in more than 150 countries, including 23 million direct customers.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock&rsquo;s service offering
is positioned across three key cyber safety pillars: Security, providing protection for PCs, Macs and mobile devices against malware,
viruses, adware, ransomware and other online threats; Identity Protection, which includes monitoring, alerts and restoration services
to protect the safety of customers; and Online Privacy, which provides enhanced security and online privacy through an encrypted data
tunnel and other privacy monitoring services.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock&rsquo;s subscription-based
Cyber Safety solutions are primarily sold direct-to-consumer through its NortonLifeLock and Avira websites, and indirectly through partner
relationships with retailers, telecom service providers, hardware original equipment manufacturers (OEMs), and employee benefit providers.
The acquisition of Avira in 2020 expanded NortonLifeLock&rsquo;s go-to-market into the freemium channel.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock is listed on NASDAQ, with
a market capitalisation of USD 15.8 billion based on its closing share price of USD 27.20 on 13 July 2021 (being the last Business Day
on which NortonLifeLock Shares traded on NASDAQ before the commencement of the Offer Period in relation to the Merger). For the year ended
2 April 2021, NortonLifeLock reported non-GAAP revenues of USD 2.6 billion, non-GAAP operating income of USD 1.3 billion, and non-GAAP
EPS of USD 1.44. For the year ended 2 April 2021, revenue from the Americas contributed 74% of the total, with Europe, the Middle East
and Africa contributing 15%, and Asia Pacific and Japan contributing 11%.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 67; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">For the fiscal quarter ended 2 July 2021,
NortonLifeLock reported non-GAAP revenues of USD 691 million, non-GAAP operating income of USD 354 million, and non-GAAP EPS of USD 0.42.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">For the fiscal quarter ending 1 October
2021, non-GAAP revenue is expected to be in the range of USD 690 million to USD 700 million, translating to 10% to 12% year-on-year growth.
Non-GAAP EPS is expected to be in the range of USD 0.41 to USD 0.43.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">For the current financial year ending
1 April 2022, NortonLifeLock anticipates non-GAAP revenue growth to be in the range of 8% to 10%+ and non-GAAP EPS to be in the range
of USD 1.65 to USD 1.75.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock is dedicated to its people,
customers and business and to society, and to work each day to create a safe and sustainable future. NortonLifeLock brings together its
people, passions and powerful technology to support social and environmental priorities and to seek to make the world a better, safer
place. NortonLifeLock&rsquo;s strong corporate responsibility ethos encompasses: (i) social responsibility, with USD 13 million in charitable
giving, a robust employee engagement programme with more than 18,000 hours logged and more than 14,000 hours in global product donations
to non-profitable organisations; (ii) environmental responsibility, by disclosing Scope 1, 2 and 3 Emissions and committing to minimise
greenhouse gases, by achieving 24% of renewable energy consumption and by delivering 90% of its products digitally; and (iii) governance
responsibility, with a commitment to gender and ethnic diversity at all levels and extensive board level oversight, with quarterly updates
on key ESG metrics.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><I>Bidco</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Bidco is a newly incorporated private
limited company, and a wholly-owned subsidiary of NortonLifeLock. Bidco has been formed at the direction of NortonLifeLock for the purposes
of implementing the Merger. Bidco has not traded since its date of incorporation, nor has it entered into any obligations other than in
connection with the Merger.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Information on Avast</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Avast is a leading global cybersecurity
provider that is dedicated to keeping people safe and private online. Avast safeguards more than 435 million users worldwide, protecting
their digital data, identity and privacy, with 1.5 billion attacks and over 200 million new files blocked each month on average in 2020.
Avast offers security software under the Avast and AVG brands, in the form of both free and paid-for products. Avast has customers in
the vast majority of countries in the world.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The majority of Avast&rsquo;s revenues
are derived from the Avast Group&rsquo;s consumer direct operations, which primarily involves up-selling paid antivirus software with
advanced features to users of its free antivirus software, and cross-selling adjacent, non-antivirus paid products such as privacy enhancement
and PC optimisation tools.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Avast Shares are admitted to the premium
listing segment of the Official List and to trading on the Main Market for listed securities of the London Stock Exchange. Avast is also
a member of the FTSE 100 index. As of the close of trading on the Unaffected Date, Avast had a market capitalisation of approximately
 &pound;5.2 billion.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">As a leading global cybersecurity provider,
Avast stands for a safe, open, and fair digital world for everyone, with a commitment to lead from the front to build a more diverse and
inclusive technology sector. Through a number of initiatives and projects, Avast commits to being: (i) socially responsible, by aiming
to maintain its annual commitment to social impact initiatives based on the 1% of profit model and by extraordinary donations such as
a USD 25 million donation for COVID relief, and by continuously encouraging employee volunteering in local communities; (ii) environmentally
responsible, by disclosing Scope 1 and 2 Emissions, and by committing to a small environmental footprint and to being carbon neutral and
Gold Standard (carbon offset); and (iii) responsible from a governance perspective, with a structured ESG reporting system and a focus
on increased female representation on its board of directors.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 68; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Avast current trading</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">For the first half of the 2021 financial
year, the Avast Group&rsquo;s revenue of USD 471.3 million was up 10.4% on an organic basis<SUP>(1)</SUP> and 8.8% at actual rates. Adjusted
EBITDA increased 11.9% to USD 270.2 million, resulting in an Adjusted EBITDA margin percentage<SUP>(2)</SUP> of 57.3%.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 95%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif">(USD m)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center">H1 2021</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center">H1 2020</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center">Change<BR>
 %</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Change %<BR>
 (excluding<BR>
 FX)<SUP>(</SUP></FONT><SUP><FONT STYLE="font-size: 10pt">3)</FONT></SUP></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 44%">Revenue</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 10%; text-align: right">471.3</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 10%; text-align: right">433.1</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 10%; text-align: right">8.8</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 10%; text-align: right">7.7</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Revenue excl. Acquisitions, Disposals and Discontinued Business<SUP>(4)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: right">470.0</TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: right">421.6</TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: right">11.5</TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: right">10.4</TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Billings of USD 482.7 million for the
six months ended 30 June 2021 were up 0.9% on an organic basis, and 2.9% at actual rates, consistent with Avast&rsquo;s expectation that
performance would be significantly weighted towards the second half. The first half of the 2021 financial year lapped a period of strong
comparatives from the effect of the pandemic lockdown in 2020. As anticipated, there was also downward pressure on billings from the strategic
transition from multi to single year subscriptions.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">In the second half of the 2021 financial
year, comparator period trends start to normalise and the impact of the transition to single year subscriptions ends. Avast anticipates
high single digit growth in the Avast Group&rsquo;s billings in the second half of the 2021 financial year. Avast&rsquo;s organic group
revenue guidance for the full 2021 financial year is maintained at the upper end of 6% to 8% growth.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">For the first half of the 2021 financial
year, the Avast Group&rsquo;s Adjusted EBITDA margin percentage was 57.3%. The Avast Group&rsquo;s Adjusted EBITDA margin percentage for
the 2021 financial year is expected to remain broadly flat versus the financial year ended 31 December 2020, in line with previous guidance
and reflecting increased user and customer acquisition costs as well as materially higher marketing spend around the flagship Avast One
product, which remains on track for launch later this year. As Avast has previously indicated, in future periods, it expects higher levels
of margin investment in R&amp;D, innovation, marketing and other top of the funnel initiatives over the medium term to sustain customer
engagement, acquisition and retention activities.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">As at 30 June 2021, net debt / LTM (&ldquo;last
twelve months&rdquo;) Adjusted EBITDA per the banking covenant was 1.0x, in line with Avast&rsquo;s expectations.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><U>Notes</U></B>:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Organic growth rate excludes the impact of foreign exchange rates, acquisitions, business disposals, and
Discontinued Business. It excludes current period billings and revenue of acquisitions until the first anniversary of their consolidation.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Adjusted EBITDA margin percentage is defined as Adjusted EBITDA divided by revenue.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Growth rate excluding currency impact is calculated by restating 2021 actual to 2020 foreign exchange
rates. Deferred revenue is translated to USD at date of invoice and is therefore excluded when calculating the impact of foreign exchange
rates on revenue.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">As Avast is exiting its toolbar-related search distribution business, which had previously been an important
contributor to AVG&rsquo;s revenues, and, separately, on 30 January 2020, the Avast Group decided to wind down the operation of its subsidiary
Jumpshot Inc. (together, including the Avast Group&rsquo;s browser clean-up business, referred to in Note 1 above as &ldquo;Discontinued
Business&rdquo;), the growth figures exclude Discontinued Business, which was negligible.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 69; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">10</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Possible NortonLifeLock share buyback programme</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">To the extent that Avast Shareholders
elect for the Majority Stock Option, NortonLifeLock intends, subject to market conditions and other capital requirements, to implement
the Post-Merger Buyback (utilising capacity under its existing share buyback authorisation and, if required, incremental capacity under
a new share buyback authorisation) over time following completion of the Merger with a view to establishing a net leverage ratio for the
Combined Company of approximately 3.5x net debt to its pro forma EBITDA.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">If all Avast Shareholders elect for the
Majority Stock Option, NortonLifeLock expects that the amount of the Post-Merger Buyback, if implemented, would be up to approximately
USD 3 billion. However, this amount would be reduced by the amount of any incremental cash consideration payable to Avast Shareholders
who receive the Majority Cash Option.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock intends to confirm the
proposed quantum of the Post-Merger Buyback, if any, following completion of the Merger and once the elections of the Avast Shareholders
for the Majority Stock Option (and, accordingly, the quantum of cash consideration payable in connection with the Merger) and the capital
requirements of the Combined Company are known.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">As noted above, the implementation of
the Post-Merger Buyback will be subject to market conditions and other capital requirements, and there can be no certainty that the Post-Merger
Buyback will be implemented or as to its timing.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">11</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Avast Share Schemes</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">The Merger will affect participants
in the Avast Share Schemes. In summary, NortonLifeLock and Avast have agreed that NortonLifeLock will make appropriate proposals to the
holders of options and awards under the Avast Share Schemes in accordance with Rule 15 of the Code. Further details of these arrangements
will be communicated to participants in the Avast Share Schemes in due course.&nbsp;Awards and options which vest and are exercised prior
to the Scheme Record Time will be satisfied by the allotment, issue or transfer of Avast Shares prior to the Scheme Record Time and those
Avast Shares will be subject to the Scheme.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">12</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financing</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The cash consideration payable to Avast
Shareholders under the terms of the Merger will be financed by debt to be provided under the Interim Facilities Agreement underwritten
by Bank of America, N.A. and Wells Fargo Bank, N.A (with Bank of America, N.A. as lead underwriter), if, and to the extent, not satisfied
through cash on hand available to Bidco (as part of the NortonLifeLock Group).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">Further information
on the financing of the Merger will be set out in the Scheme Document.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">In accordance with Rule 2.7(d) of the
Code, Evercore, in its capacity as financial adviser to NortonLifeLock and Bidco, is satisfied that sufficient resources are available
to Bidco to enable it to satisfy in full the cash consideration payable to Avast Shareholders under the terms of the Merger.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">13</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Management, employees, pensions, research and development and locations</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><I>NortonLifeLock&rsquo;s strategic
plans for Avast</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock believes that the Merger
has a compelling strategic and financial rationale, would create long-term value for both NortonLifeLock and Avast and would be consistent
with NortonLifeLock&rsquo;s long-term growth strategy, the objective of which is to protect and empower people to live their digital lives
safely.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Avast would benefit from NortonLifeLock&rsquo;s
scale, strength in identity and broad-based adoption of its Norton 360 platform. NortonLifeLock would benefit from Avast&rsquo;s strong
freemium user base, international customer base and innovative offerings in privacy. The Combined Company would be able to capitalise
on the full range of opportunities available to both NortonLifeLock and Avast.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 70; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><I>Existing employment rights</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock attaches great importance
to the skill and experience of Avast&rsquo;s management and employees and recognises their important contribution to the success that
has been achieved by Avast. As such, NortonLifeLock expects Avast&rsquo;s employees to continue to contribute to the success of the Combined
Company following completion of the Merger. NortonLifeLock intends to look at ways to optimise the structure of the Combined Company in
order to achieve the anticipated benefits of the Merger.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock&rsquo;s preliminary evaluation
work to identify potential synergies arising from the Merger suggests that there will be some duplication between the two businesses&rsquo;
management, shared services, product, commercial and other functions. NortonLifeLock has not yet received sufficiently detailed information
to formulate comprehensive plans or intentions regarding the impact of the Merger on the Avast Group, its various business units or its
employees, and intends to take a &lsquo;best of both&rsquo; approach to integration. NortonLifeLock&rsquo;s preliminary evaluation suggests
that the Combined Company is expected to fully realise pre-tax gross cost synergies of approximately USD 280 million by the end of the
second full year following completion of the Merger, a substantial portion of which would come from headcount reductions, in addition
to other initiatives in systems &amp; infrastructure and contracts &amp; shared services. Based on NortonLifeLock&rsquo;s preliminary
evaluation, the synergy plan suggests a potential headcount reduction of approximately 25% of the total Combined Company workforce, across
all geographies, and from a broad range of job categories, including management, shared services, product and commercial functions, but
before any of the Combined Company&rsquo;s expected re-investment into innovation, partnerships and marketing.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The finalisation and implementation of
any workforce reductions will be subject to comprehensive planning and appropriate engagement with stakeholders, including affected employees
and any appropriate employee representative bodies. It is anticipated that efforts will be made to mitigate headcount reductions through
redundancies, via natural attrition, the elimination of vacant roles and alternative job opportunities. Any affected individuals will
be treated in a manner consistent with NortonLifeLock&rsquo;s high standards, culture and practices. NortonLifeLock intends to approach
employee and management integration with the aim of retaining and motivating the best talent across the Combined Company to create a best-in-class
organisation.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock confirms that it has given
assurances to the Avast Directors that, upon and following completion of the Merger, it intends to fully observe the existing contractual
and statutory employment rights of all Avast management and employees and does not intend to make any material changes to the conditions
of employment of the employees or management of the Avast Group. Subject to the potential headcount reductions described above, NortonLifeLock
also does not intend to make any material changes to the balance of skills and the functions of the employees or management of the Avast
Group.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock acknowledges the importance
and value of Avast&rsquo;s employee share-based incentive arrangements. In due course, and in accordance with Rule 15 of the Code, proposals
will be sent to existing option holders and award holders, which will include proposals as to how any unvested options and awards will
be treated in connection with the Merger. In addition, NortonLifeLock confirms that it intends, following completion of the Merger, to
extend NortonLifeLock&rsquo;s share-based arrangements to Avast&rsquo;s employees on a basis consistent with arrangements for equivalent
employees of NortonLifeLock and taking into account their expected roles within the Combined Company.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><I>Composition of the board of the
Combined Company following completion of the Merger</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Following completion of the Merger, it
is intended that Avast&rsquo;s CEO, Ondrej Vlcek, will join NortonLifeLock as President and become a member of the NortonLifeLock Board.
In addition, Pavel Baudi&scaron;, a co-founder of Avast, is expected to join the NortonLifeLock Board as an independent director.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 71; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>



<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">It is intended that, upon completion
of the Merger, each of the non-executive members of the Avast Board will resign as directors of Avast.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Following completion of the Merger, it
is intended that Vincent Pilette, CEO of NortonLifeLock, will be CEO of the Combined Company, and Natalie Derse, CFO of NortonLifeLock,
will be CFO of the Combined Company.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><I>Pension schemes</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Avast does not operate or contribute
to any defined benefit pension schemes in respect of its employees. It does, however, operate certain defined contribution pension plans.
NortonLifeLock does not intend to make any changes to the eligibility rules or contribution rates that currently apply under Avast&rsquo;s
defined contribution pension plans. NortonLifeLock intends to comply with all applicable law in connection with the provision of retirement
benefits.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><I>Management incentivisation arrangements</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock has not entered into,
and has not had any discussions about proposals to enter into, any form of incentivisation arrangements with members of management of
Avast. Nor has NortonLifeLock agreed or entered into any arrangements with any of Avast&rsquo;s executive directors who are expected to
join the NortonLifeLock Board and/or management team following completion of the Merger with regard to any changes to their existing terms
of employment. NortonLifeLock does not intend to put in place any such arrangements before completion of the Merger.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><I>Locations of business, fixed assets
and headquarters</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Following completion of the Merger, Avast&rsquo;s
existing headquarters premises will continue to be utilised, and the Combined Company will have dual headquarters located in Prague, Czech
Republic, and Tempe, Arizona, USA.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company expects to maintain
a significant presence in the Czech Republic, including across R&amp;D, commercial and general and administrative functions, the level
of which will be reviewed in the first year following completion of the Merger, taking into account Avast&rsquo;s current management plans.
As part of such review, NortonLifeLock intends to evaluate the locations of business and fixed assets of Avast in order to optimise local
operations for the Combined Company, taking into consideration any existing changes planned by the current management of Avast, which
is expected to lead to rationalisation in certain sites currently operated by NortonLifeLock and/or Avast.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock intends to undertake a
review process, in collaboration with Avast&rsquo;s CEO, to determine the post-Merger name of the Combined Company to ensure that it best
reflects its strategic vision of expanding its Cyber Safety platform with trust-based solutions and its broad global prospects.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><I>Research and development</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock values the investment
that Avast has made in its technology and the infrastructure and expertise in place within the Avast Group to create, maintain and enhance
existing product offerings and intends to retain Avast&rsquo;s R&amp;D capabilities in the Czech Republic. While NortonLifeLock expects
efficiencies to arise from duplication of R&amp;D functions across the Combined Company, NortonLifeLock&rsquo;s commitment to innovation
is integral to its strategy and NortonLifeLock currently intends to reinvest part of the anticipated run-rate cost synergies into innovation,
partnerships and marketing initiatives to support and accelerate long-term sustainable growth. NortonLifeLock believes that it is important
for the long-term success of the Combined Company and for customer satisfaction to maintain a leading product offering and intends to
invest in this area following completion of the Merger in conjunction with the existing Avast infrastructure.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 72; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><I>Trading Facilities </I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Avast is currently listed on the Official
List and, as explained in paragraph 21 (<I>De-listing, cancellation of trading and re-registration</I>) below, a request will be made
to the London Stock Exchange to cancel trading in Avast Shares on the Main Market of the London Stock Exchange, and to the FCA to cancel
the listing of the Avast Shares on the Official List, in each case with effect from or shortly following the Effective Date. Avast will
be re-registered as a private company following the Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Avast is also currently listed on two
MTFs in the Czech Republic. As explained in paragraph 21 (<I>De-listing, cancellation of trading and re-registration</I>) below, requests
will be made to the PSE and RMS to cancel trading in Avast Shares on these MTFs, in each case with effect from or shortly following the
Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">It is anticipated that the unsponsored
ADR programme for the Avast Shares will be terminated on or shortly after the Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Combined Company will be listed on
NASDAQ.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B>None of the statements in this paragraph
13 are &ldquo;post-offer undertakings&rdquo; for the purposes of Rule 19.5 of the Code.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><B><I>Views of the Avast Board</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">In considering the intention to recommend
the Merger to Avast Shareholders, the Avast Board has given due consideration to the assurances that NortonLifeLock has given in relation
to management and employees within the Combined Company.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Avast Board notes that NortonLifeLock
has stated that the Combined Company is expected to fully realise pre-tax gross cost synergies of approximately USD 280 million by the
end of the second full year following completion of the Merger, a substantial portion of which could come from headcount reductions, in
addition to other initiatives. Based on this preliminary evaluation, NortonLifeLock expects a potential headcount reduction of approximately
25% of the total Combined Company workforce across all geographies, and from a broad range of job categories, including management, shared
services, product and commercial functions, but before any of the Combined Company&rsquo;s expected re-investment into innovation, partnerships
and marketing. The Avast Board is of the view that, in order for NortonLifeLock to achieve the stated synergy benefits, it will be necessary
for headcount reductions to take place.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Avast Board believes that, in implementing
the Merger, it is important that NortonLifeLock takes into account the skills and experience of the existing management and employees
of Avast and welcomes NortonLifeLock&rsquo;s intention to provide opportunities for Avast employees as well as NortonLifeLock employees.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Avast Board notes NortonLifeLock&rsquo;s
statement that, other than as a result of anticipated headcount reductions, NortonLifeLock has no intention to make any material changes
to the conditions of employment of the employees or management of the Avast Group and that the existing employment rights, including pension
rights, of existing management and employees of the Avast Group will be observed. The Avast Board considers it important that Avast employees
who remain with the Combined Company are given certainty as to the continuing terms of their employment.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The Avast Board notes NortonLifeLock&rsquo;s
statement that the Combined Company expects to maintain a significant presence in the Czech Republic, including across R&amp;D, commercial
and general and administrative functions, the level of which will be reviewed, taking into account Avast&rsquo;s current management plans.
Given the history and heritage of Avast, the Avast Board considers it important that a significant presence in the Czech Republic is maintained,
and welcomes NortonLifeLock&rsquo;s statement that the Combined Company will maintain R&amp;D, commercial and general and administrative
functions in the Czech Republic.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 73; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Given that detailed information to formulate
comprehensive plans or intentions regarding the impact of the Merger on the Avast Group is not yet available, the Avast Board is unable
to express a more detailed opinion on the impact of the Merger on Avast management, employees and offices.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">14</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Electing to receive the Majority Stock Option</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Avast Shareholders (other than those resident
in a Restricted Jurisdiction) will be entitled to elect to receive, in respect of their entire holdings of Avast Shares, the Majority
Stock Option instead of the Majority Cash Option.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Avast Shareholders will not be permitted
to elect to receive the Majority Stock Option in respect of only part of their holding of Avast Shares, so will be entitled only to receive
either the Majority Cash Option (if no election is made) or the Majority Stock Option (if they elect to do so). If an Avast Shareholder
(i) does not make an election to receive the Majority Stock Option or (ii) is resident in a Restricted Jurisdiction, they will receive
the Majority Cash Option in respect of their entire holding of Avast Shares.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Elections for the Majority Stock Option,
and entitlements to receive the Majority Cash Option or the Majority Stock Option, will not be subject to scale-back or pro rating by
reference to the elections of other Avast Shareholders, and all elections for the Majority Stock Option will (subject, among other things,
to the satisfaction of the Conditions and to the Merger becoming Effective) be satisfied in full.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Further details in relation to making
an election for the Majority Stock Option (including the action to take in order to make a valid election and the deadline for making
elections) will be contained in the Scheme Document and the Form of Election.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">15</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Tax</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Merger will be effected by Bidco (and/or
its nominee) acquiring all of the issued and to be issued ordinary shares in the share capital of Avast. NortonLifeLock will remain U.S.
domiciled for tax purposes. U.S. and U.K. tax consequences of the Merger for Avast Shareholders will be described in the Scheme Document.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">16</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Merger-related arrangements</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><B><I>Confidentiality Agreement</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">NortonLifeLock and Avast have entered
into the Confidentiality Agreement, pursuant to which each of NortonLifeLock and Avast has undertaken to keep certain information relating
directly or indirectly to the Merger and to the other party confidential and not to disclose such information to third parties, except
to certain permitted disclosees for the purposes of evaluating the Merger or if required by applicable laws or regulations. The confidentiality
obligations of each party under the Confidentiality Agreement continue for two years after the date of the Confidentiality Agreement.
The agreement also contains provisions pursuant to which each party has agreed not to solicit certain employees of the other party for
a period of 12 months from the date of the Confidentiality Agreement, subject to customary carve-outs.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><B><I>Co-operation Agreement</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">NortonLifeLock, Bidco and Avast have entered
into a Co-operation Agreement dated on the date of this Announcement, pursuant to which NortonLifeLock and Bidco have agreed to use all
reasonable endeavours (which shall include taking all steps necessary and accepting relevant remedies, except where to do so would be
of material significance to NortonLifeLock and Bidco in the context of the Merger) to implement the Merger and to secure the regulatory
clearances and authorisations necessary to satisfy the Regulatory Conditions (provided that Avast&rsquo;s obligations in connection with
such matters are limited to actions permitted under Rule 21.2(b)(iii) of the Code). The parties have also agreed to certain undertakings
to co-operate and provide one another with reasonable information, assistance and access in relation to the filings, submissions and notifications
to be made in relation to any such regulatory clearances and authorisations. Taking due account of its legal obligations with respect
to the regulatory clearances and authorisations, as well as the views and comments of Avast, NortonLifeLock will have the right to determine
the strategy for obtaining the regulatory clearances and authorisations, and for satisfying the Regulatory Conditions.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 74; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">NortonLifeLock has also agreed to certain
procedural and other commitments with respect to the preparation of the NortonLifeLock Proxy Statement (including undertaking to use its
best endeavours to obtain the clearance of the NortonLifeLock Proxy Statement from the SEC), the convening of the NortonLifeLock Shareholders&rsquo;
Meeting, the preparation of the NortonLifeLock Prospectus, and assisting with the provision of information for any documents relating
to the Merger to be prepared by Avast after the date of this Announcement, including the Scheme Document. Avast has agreed to certain
procedural and other commitments with respect to the preparation of the Scheme Document (and associated documents) and assisting with
the provision of information for documents relating to the Merger to be prepared by NortonLifeLock after the date of this Announcement,
including the NortonLifeLock Proxy Statement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">NortonLifeLock has also committed to certain
restrictions between the date of this Announcement and the Effective Date, completion of a Takeover Offer or other earlier termination
of the Co-operation Agreement, including a commitment not to solicit or engage in any discussions of alternative proposals to the Merger
(subject to certain limited exceptions) and certain commitments regarding corporate and other actions which NortonLifeLock has agreed
not to undertake while the Co-operation Agreement remains in force.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The parties have also agreed certain provisions
that will apply if NortonLifeLock and/or Bidco elects to implement the Merger by way of a Takeover Offer rather than the Scheme, which
it may (under the terms of the Co-operation Agreement) do in specified circumstances, including where Avast has provided its prior consent
(in which case certain additional provisions apply, including as to the required level of the acceptance condition for such Takeover Offer),
where the Avast Board has amended, qualified or withdrawn its recommendation of the Merger, in the circumstances set out in Note 2 on
Section 8 of Appendix 7 to the Code, and where a third party has announced a firm intention to make an offer for the entire issued and
to be issued share capital of Avast.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Co-operation Agreement contains provisions
which will apply in respect of the Avast Share Schemes, details of which will be set out in the Scheme Document, and provisions which
apply with respect to the provision of insurance to cover liabilities of Avast directors, officers and other executives. In addition,
NortonLifeLock has provided a parent company guarantee in respect of Bidco&rsquo;s obligations under the Co-operation Agreement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Co-operation Agreement will terminate
in certain circumstances, including: (i) where it is agreed in writing between NortonLifeLock, Bidco and Avast at any time prior to the
Effective Date; (ii) upon service of written notice by NortonLifeLock to Avast, or Avast to NortonLifeLock and Bidco, if (a) the Avast
Board has adversely modified or qualified, or withdrawn, its recommendation of the Merger, (b) if a break fee payment event (as described
below) occurs, (c) if Bidco and/or NortonLifeLock invokes (and is permitted by the Panel to invoke) a Condition (other than under specified
circumstances) so as to cause the Merger to lapse, to be withdrawn or not to proceed, (d) unless otherwise agreed in writing by the parties,
if the Effective Date has not occurred on or prior to the Long Stop Date; (iii) if, prior to the Long Stop Date, a third party announces
a firm intention to make an offer or revised offer for Avast which completes, becomes effective or is declared unconditional in all respects;
(iv) if the NortonLifeLock Shareholders do not approve the Merger at the NortonLifeLock Shareholders&rsquo; Meeting, (v) if the Scheme
Shareholders do not approve the Scheme at the Court Meeting and/or the relevant resolutions relating to the Scheme are not approved by
the requisite majority of Scheme Shareholders at the General Meeting, other than in circumstances where NortonLifeLock has elected, with
Avast&rsquo;s prior consent, to implement the Merger by means of a Takeover Offer; (vi) if the Scheme is not sanctioned at the Court Hearing,
(vii) upon service of written notice by Avast to NortonLifeLock if NortonLifeLock makes an announcement before the publication of the
NortonLifeLock Proxy Statement that it will not convene the NortonLifeLock Shareholders&rsquo; Meeting, or that it does not intend to
post the NortonLifeLock Proxy Statement or to convene the NortonLifeLock Shareholders&rsquo; Meeting, (viii) on the earliest to occur
of (a) the Scheme lapsing, terminating or being withdrawn (unless NortonLifeLock has elected, with Avast&rsquo;s prior consent, to implement
the Merger by means of a Takeover Offer before such lapse, termination or withdrawal) and (b) the Effective Date; and (ix) in the event
that NortonLifeLock elects, with Avast&rsquo;s prior consent, to implement the Merger by means of a Takeover Offer, the earliest to occur
of (a) the date on which that Takeover Offer lapses, terminates or is withdrawn and (b) the Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 75; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">NortonLifeLock has undertaken that if,
on or prior to the Long Stop Date, any of the following matters occurs, subject to certain qualifications, it will pay a break fee to
Avast (as described below), in each case other than in certain specified circumstances:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 44.1pt"></TD><TD STYLE="width: 14.4pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">either: (1) the NortonLifeLock Board (a) withdraws, withholds or qualifies (or amends or modifies in any
manner adverse to Avast), or proposes publicly to withdraw, withhold or qualify (or amend or modify in any manner adverse to Avast) the
recommendation by the NortonLifeLock Board of the Merger, (b)&nbsp;approves, recommends or adopts (or proposes publicly to approve, recommend
or adopt) certain material types of transaction, other than the Merger or (c) fails to include the NortonLifeLock Board&rsquo;s recommendation
of the Merger in the NortonLifeLock Proxy Statement (a&nbsp;&ldquo;<B>NortonLifeLock Board Recommendation Change Event</B>&rdquo;); or
(2) the NortonLifeLock Shareholders&rsquo; Meeting has not occurred prior to the Long Stop Date in breach of NortonLifeLock&rsquo;s obligations
under the Co-operation Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 44.1pt"></TD><TD STYLE="width: 14.4pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">either (a) Bidco and/or NortonLifeLock invokes (and is permitted by the Panel to invoke) any Regulatory
Condition so as to cause the Merger to lapse, to be withdrawn or not to proceed, or (b) a Regulatory Condition has not been satisfied
or waived by Bidco and/or NortonLifeLock as at the Long Stop Date (each a &ldquo;<B>Regulatory Condition Satisfaction Failure Event</B>&rdquo;);
or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 44.1pt"></TD><TD STYLE="width: 14.4pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock Shareholders do not approve the relevant matters at the NortonLifeLock Shareholders&rsquo;
Meeting and there has been no NortonLifeLock Board Recommendation Change Event (the &ldquo;<B>NortonLifeLock Shareholder Approval Failure
Event</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The amount of the break fee payable by
NortonLifeLock in the event of the foregoing would (subject to the conditions below) be USD 300&nbsp;million following a NortonLifeLock
Board Recommendation Change Event or in circumstances where the NortonLifeLock Shareholders&rsquo; Meeting has not occurred prior to the
Long Stop Date in breach of NortonLifeLock&rsquo;s obligations under the Co-operation Agreement, USD 200&nbsp;million following a Regulatory
Condition Satisfaction Failure Event or USD 100&nbsp;million following a NortonLifeLock Shareholder Approval Failure Event.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">No break fee would be payable by NortonLifeLock
if, at the time the relevant break fee payment event occurs: (i) the Avast Board has adversely modified or qualified, or withdrawn, its
recommendation of the Merger; (ii) at the time the relevant break fee payment event occurs, the Co-operation Agreement has been terminated
(or a right to terminate has arisen at the Long Stop Date) under certain of the other termination events described above; or (iii) with
respect to a Regulatory Condition Satisfaction Failure Event, that event occurred in circumstances where Avast has materially obstructed
NortonLifeLock and Bidco from being able to obtain a regulatory clearance or authorisation (and such action(s) or non-action(s) are a
material and contributory cause of such failure to obtain such clearance or authorisation), or Avast has undertaken, agreed to or announced
an acquisition, licensing arrangement or other arrangement or collaboration with a third party and such action was a material contributory
cause of the Regulatory Condition Satisfaction Failure Event.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 76; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><B><I>Clean Team and Joint Defence
Agreement</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">NortonLifeLock, Avast, and certain of
their respective external regulatory counsel, entered into the Clean Team and Joint Defence Agreement to ensure that the exchange and/or
disclosure of certain materials relating to the parties only takes place between their respective external regulatory counsel and external
experts, and does not diminish in any way the confidentiality of such materials and does not result in a waiver of privilege, right or
immunity that might otherwise be available.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">17</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Conditions</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Merger and, accordingly, the Scheme
will be subject to a number of conditions, which will be set out in the Scheme Document, and which are set out in Appendix 1 to this Announcement,
including the following antitrust and regulatory clearances:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the receipt or waiver of any applicable antitrust approvals or clearances in the United States, the United
Kingdom, Germany and Spain (and/or, upon referral, approval from the European Commission), Australia and New Zealand;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a written notification from CFIUS that it has completed action under section 721 of the DPA or, if CFIUS
has sent a report to the President of the United States, that the President has announced a decision not to take action or has not taken
action after fifteen days from the end of the investigation period; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the receipt or waiver of applicable foreign investment approvals in Germany, the Czech Republic, Romania
and, if in force and applicable, any such approvals required in the United Kingdom and the Netherlands.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">In addition, the Merger and, accordingly,
the Scheme will be subject to (amongst others) the following customary conditions:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Scheme becoming Effective by not later than the Long Stop Date, failing which the Scheme will lapse;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the FCA having approved the NortonLifeLock Prospectus and it having been made available to the public
in accordance with the UK Prospectus Regulation Rules;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">approval of the Scheme by a majority in number of those Scheme Shareholders present and voting at the
Court Meeting in person or by proxy, representing at least 75% in value, of the Scheme Shares voted by such Scheme Shareholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">approval of the Special Resolution by the requisite majority of Avast Shareholders at the General Meeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the issuance of the New NortonLifeLock Shares in connection with the Merger having been approved by NortonLifeLock
Shareholders at the NortonLifeLock Shareholders&rsquo; Meeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">confirmation having been received by NortonLifeLock that the New NortonLifeLock Shares have been approved
for listing, subject to official notice of issuance, on NASDAQ;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the satisfaction or (where applicable) waiver, prior to the sanction of the Scheme by the Court, of all
the other Conditions;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the sanction of the Scheme by the Court (with or without modification on terms agreed by Bidco and Avast);
and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the delivery of a copy of the Scheme Court Order to the Registrar of Companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 77; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">As summarised in paragraph 16 (<I>Merger-related
arrangements</I>), NortonLifeLock and Avast have agreed, pursuant to the Co-operation Agreement, certain mutual obligations and restrictions
with respect to seeking to facilitate the satisfaction of certain of the Conditions.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">18</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Structure of the Merger</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">It is intended that the Merger will be
implemented by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act. The Scheme is an arrangement between
Avast and the Scheme Shareholders and is subject to the approval of the Court. The procedure involves, among other things, an application
by Avast to the Court to sanction the Scheme, in consideration for which Scheme Shareholders will receive cash and New NortonLifeLock
Shares on the basis described in this Announcement, in particular paragraphs 2 (<I>The Merger</I>) and 14 (<I>Electing to receive the
Majority Stock Option</I>).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">The purpose of the Scheme is to provide
for Bidco (and/or its nominee) to become the owner of the entire issued and to be issued ordinary share capital of Avast.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Upon the Scheme becoming Effective: (i)
it will be binding on all Avast Shareholders, irrespective of whether or not they attended or voted at the Court Meeting and the General
Meeting (and, if they attended and voted, whether or not they voted in favour); and (ii) share certificates in respect of Avast Shares
will cease to be of value and should be destroyed and entitlements to Avast Shares held within the CREST system will be cancelled.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Bidco will despatch, or arrange for the
despatch of, the consideration payable under the Scheme to Scheme Shareholders by no later than 14 days after the Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Any Avast Shares issued before the Scheme
Record Time will be subject to the terms of the Scheme. The Special Resolution to be proposed at the General Meeting will, amongst other
matters, provide that the Articles be amended to incorporate provisions requiring any Avast Shares issued after the Scheme Record Time
(other than to Bidco and/or its nominee) to be automatically transferred to Bidco (and/or its nominee) on the same terms as the Merger
(other than terms as to timings and formalities). The provisions of the Articles (as amended) will avoid any person (other than Bidco
and/or its nominee) holding ordinary shares in the capital of Avast after the Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Subject to certain restrictions relating
to persons resident in a Restricted Jurisdiction, it is expected that the Scheme Document, containing further information about the Merger
and notices of the Court Meeting and General Meeting, together with the Forms of Proxy and the Form of Election, will be posted to Avast
Shareholders and (for information only) to participants in the Avast Share Schemes in late Q3 or early Q4 of 2021. For the purposes of
paragraph 3(a) of Appendix 7 of the Code, the Panel has consented to this arrangement. It is also expected that, at or around the same
time as the Scheme Document is posted to Avast Shareholders (other than those resident in Restricted Jurisdictions), the NortonLifeLock
Prospectus will be published and the NortonLifeLock Proxy Statement will be mailed.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">NortonLifeLock, Bidco and Avast urge
Avast Shareholders to read the Scheme Document (or, if applicable, the offer document), the Forms of Proxy, the Form of Election and the
NortonLifeLock Prospectus when such documents become available because they will contain important information relating to the Merger,
NortonLifeLock and Bidco. Any vote in respect of the Scheme or related matters at the Meetings should be made only on the basis of the
information contained in the Scheme Document, the Forms of Proxy, the Form of Election and the NortonLifeLock Prospectus.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Subject to the satisfaction or waiver
of all relevant conditions, including the Conditions, and certain further terms set out in Appendix 1 to this Announcement and to be set
out in the Scheme Document, and subject to the approval and availability of the Court (which is subject to change), it is expected that
the Scheme will become Effective in mid-2022.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 78; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">19</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Scheme timetable</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">A full anticipated timetable for the
Merger will be set out in the Scheme Document which will be posted as soon as practicable and at or around the same time as the publication
of the NortonLifeLock Prospectus and the mailing of the NortonLifeLock Proxy Statement. Subject to certain restrictions relating to persons
resident in Restricted Jurisdictions, the Scheme Document, the NortonLifeLock Prospectus and the NortonLifeLock Proxy Statement will also
be made available on NortonLifeLock&rsquo;s website (at https://investor.nortonlifelock.com/) and Avast&rsquo;s website (at https://investors.avast.com/).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Subject to the satisfaction or waiver
(as applicable) of all relevant conditions, including the Conditions, and certain terms set out in Appendix 1 to this Announcement and
to be set out in the Scheme Document, the Scheme is expected to become Effective in mid-2022.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">20</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Right to switch to a Takeover Offer</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Subject to obtaining the consent of the
Panel, Bidco reserves the right to elect to implement the Merger by way of a Takeover Offer as an alternative to the Scheme.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Any such Takeover Offer will be implemented
on substantially the same terms and conditions, so far as applicable, as those which would apply to the Scheme subject to appropriate
amendments to reflect the change in method of effecting the Merger. Further, if sufficient acceptances of the Takeover Offer are received
and/or sufficient Avast Shares are otherwise acquired, it is the intention of Bidco to apply the provisions of the Companies Act to compulsorily
acquire any outstanding Avast Shares to which such Takeover Offer relates.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">21</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>De-listing, cancellation of trading and re-registration</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">It is intended that dealings in Avast
Shares will be suspended on or shortly before the Effective Date at a time to be set out in the Scheme Document. It is further intended
that applications will be made to the London Stock Exchange to cancel trading in Avast Shares on the Main Market of the London Stock Exchange,
and to the FCA to cancel the listing of the Avast Shares on the Official List, in each case with effect from or shortly following the
Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">It is also intended that applications
will be made to the PSE and RMS to suspend dealings in Avast Shares on MTFs operated by the PSE and RMS on or shortly before the Effective
Date. It is further intended that applications will be made to the PSE and RMS to remove Avast Shares from trading on MTFs operated by
the PSE and RMS, in each case with effect from or shortly following the Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">On or shortly after the Effective Date,
entitlements to Avast Shares held within the CREST system will be cancelled, and share certificates in respect of Avast Shares will cease
to be valid.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">It is anticipated that the unsponsored
ADR programme for the Avast Shares will be terminated on or shortly after the Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">As soon as possible after the Effective
Date, it is intended that Avast will be re-registered as a private limited company.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The New NortonLifeLock Shares will be
listed on NASDAQ.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Avast does not hold any Avast Shares in
treasury.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 79; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">22</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Disclosure of interests in Avast</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">As at the Latest Practicable Date, save
for the disclosures in this paragraph 22 and the irrevocable undertakings referred to in paragraphs 4 (<I>Recommendation</I>) and 6 (<I>Irrevocable
undertakings</I>), none of NortonLifeLock, Bidco or any of their directors or any person acting, or deemed to be acting, in concert with
NortonLifeLock or Bidco:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">had any interest in, or right to subscribe for, or had any arrangement in relation to, Avast Shares or
any relevant securities of Avast;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">had any short position in relation to any Avast Shares or any relevant securities of Avast, whether conditional
or absolute and whether in the money or otherwise, including any short position under a derivative, any agreement to sell or any delivery
obligation or right to require another person to purchase or take delivery of, any Avast Shares or any relevant securities of Avast;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">had any dealing arrangement of the kind referred to in Note 11 on the definition of &ldquo;acting in concert&rdquo;
in the Code, in relation to the Avast Shares or in relation to any securities convertible into Avast Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">had procured an irrevocable commitment or letter of intent to accept the terms of the Merger in respect
of Avast Shares or any relevant securities of Avast; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">had borrowed or lent any Avast Shares or any relevant securities of Avast.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">For these purposes, an &ldquo;arrangement&rdquo;
includes any indemnity or option arrangement, any agreement or any understanding, formal or informal, of whatever nature, relating to
Avast Shares or relevant securities of Avast which may be an inducement to deal or refrain from dealing in such securities.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">23</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Overseas shareholders</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The availability of the Merger and the
distribution of this Announcement to persons resident in, or citizens of, or otherwise subject to, jurisdictions outside the United Kingdom
may be affected by the laws of the relevant jurisdictions. Such persons should inform themselves of, and observe, any applicable legal
or regulatory requirements of their jurisdiction. Avast Shareholders who are in any doubt regarding such matters should consult an appropriate
independent professional adviser in the relevant jurisdiction without delay.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">This Announcement is not intended and
does not constitute or form part of any offer to sell or to subscribe for, or any invitation to purchase or subscribe for, or the solicitation
of any offer to purchase or otherwise subscribe for, any securities. Avast Shareholders are advised to read carefully the Scheme Document,
the Forms of Proxy, the Form of Election and the NortonLifeLock Prospectus once these have been despatched or made available (as applicable).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">24</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Fractional entitlements</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Fractions of New NortonLifeLock Shares
will not be allotted to Avast Shareholders. Instead, Avast Shareholders shall receive, in lieu of such fractional entitlements, cash in
an amount in USD (rounded down to the nearest cent) (unless an Avast Shareholder has elected to receive cash consideration in GBP rather
than USD, in which case such Avast Shareholder shall receive, in lieu of fractional entitlements, cash in an amount in GBP (rounded down
to the nearest penny)) equal to such fractional amount multiplied by the last reported sale price of NortonLifeLock Shares on NASDAQ (as
reported in The Wall Street Journal or, if not reported therein, in another authoritative source selected by Bidco) on the last Business
Day prior to the Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 80; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">25</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>General</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Merger will be subject to the Conditions
set out in Appendix 1 to this Announcement, and to the full terms and conditions which will be set out in the Scheme Document. Appendix
2 to this Announcement contains the bases and sources of certain information used in the summary and in the full text of this Announcement.
Appendix 3 to this Announcement contains details of the irrevocable undertakings received in relation to the Merger that are referred
to in this Announcement. Appendix 4 to this Announcement contains details and bases of belief of the anticipated quantified financial
benefits of the Merger and copies of the related reports from NortonLifeLock&rsquo;s reporting accountants, Deloitte, and its financial
adviser, Evercore. Appendix 5 to this Announcement contains the NortonLifeLock Profit Forecast, and the assumptions, basis of preparation
and the NortonLifeLock Directors&rsquo; confirmation relating thereto. Appendix 6 to this Announcement contains the Avast Profit Forecast,
and the assumptions, basis of preparation and the Avast Directors&rsquo; confirmation relating thereto. Appendix 7 to this Announcement
contains definitions of certain terms used in this Announcement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Subject to certain restrictions relating
to persons resident in a Restricted Jurisdiction, it is expected that the Scheme Document, containing further information about the Merger
and notices of the Court Meeting and General Meeting, together with the Forms of Proxy and the Form of Election, will be posted to Avast
Shareholders and (for information only) to participants in the Avast Share Schemes in late Q3 or early Q4 of 2021. It is also expected
that, at or around the same time as the Scheme Document is posted to Avast Shareholders (other than those resident in Restricted Jurisdictions),
the NortonLifeLock Prospectus will be published and the NortonLifeLock Proxy Statement will be mailed.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">In deciding whether or not to vote or
procure votes in favour of the resolutions relating to the Scheme at the Meetings in respect of their Avast Shares, Avast Shareholders
should rely on the information contained, and (where applicable) follow the procedures described, in the Scheme Document, the Forms of
Proxy, the Form of Election and the NortonLifeLock Prospectus.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">The Scheme Document and the NortonLifeLock
Prospectus will not be reviewed by any federal state securities commission or regulatory authority in the U.S., nor will any commission
or authority pass upon the accuracy or adequacy of the Scheme Document or the NortonLifeLock Prospectus. Any representation to the contrary
is unlawful and may be a criminal offence.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">Each of Evercore, UBS, J.P. Morgan Cazenove
and Deloitte has given and not withdrawn its consent to the publication of this Announcement with the inclusion herein of the references
to its name in the form and context in which it appears.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">This Announcement does not constitute
an offer or an invitation to purchase or subscribe for any securities.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt"><FONT STYLE="font-weight: normal">26</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Documents on display</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Subject to certain restrictions relating
to persons resident in Restricted Jurisdictions, copies of the following documents will, by no later than 12 noon (London time) on the
Business Day following the date of this Announcement, be made available on NortonLifeLock&rsquo;s website at https://investor.nortonlifelock.com/
and on Avast&rsquo;s website at https://investors.avast.com/ until the end of the Offer Period:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">this Announcement;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Confidentiality Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Co-operation Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Clean Team and Joint Defence Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the irrevocable undertakings referred to in paragraph 6 (<I>Irrevocable undertakings</I>) and summarised
in Appendix 3 to this Announcement;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the documents relating to the financing of the Merger referred to in paragraph 12 (<I>Financing</I>);</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the consents from Evercore, UBS, J.P. Morgan Cazenove and Deloitte to being named in this Announcement;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the joint investor presentation, dated the same date as this Announcement, prepared by NortonLifeLock
and Avast in connection with the announcement of the Merger.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 81; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 5 -->
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">Neither the contents of Avast&rsquo;s
website nor the contents of NortonLifeLock&rsquo;s website, nor the content of any other website accessible from hyperlinks on either
such website, is incorporated into or forms part of, this Announcement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Enquiries</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B></B>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; padding-top: 6pt; padding-bottom: 6pt; text-align: left"><B>NortonLifeLock</B></TD>
    <TD STYLE="width: 30%; padding-top: 6pt; padding-bottom: 6pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Mary Lai, Head of Investor Relations</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">IR@NortonLifeLock.com</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Spring Harris, Head of Global Corporate Communications and PR</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Press@NortonLifeLock.com </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: left"><B>Evercore (Financial adviser to NortonLifeLock and Bidco)</B></TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Naveen Nataraj</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">+1 (0)212 857 3100</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Edward Banks</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">+44 (0)20 7653 6000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Anil Rachwani</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Swag Ganguly</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Wladimir Wallaert</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: left"><B>Sard Verbinnen (Communications adviser to NortonLifeLock)</B></TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Charles Chichester</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">+44 (0)20 7467 1050</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">John Christiansen</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">+1 (0)415 618 8750</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Jared Levy</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">+1 (0)212 687 8080</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><B>Avast</B></TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Peter Russell, Director of Investor Relations</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">IR@avast.com</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Stephanie Kane, VP PR and Corporate Communications</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: left"><B>UBS (Financial adviser and Corporate Broker to Avast)</B></TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: left">Tel: +44 207 567 8000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Christian Lesueur</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Rahul Luthra</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Jonathan Rowley</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Aadhar Patel</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Meera Sheth</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: left"><B>J.P. Morgan Cazenove (Financial adviser and Corporate Broker to Avast)</B></TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: left">Tel: +44 207 742 4000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Bill Hutchings</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">James Robinson</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">James Summer</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Jonty Edwards</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 82; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: left; width: 70%"><B>Finsbury Glover Hering (Communications adviser to Avast)</B></TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: left; width: 30%">Avast-LON@fgh.com</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Dorothy Burwell</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Tel: +44 7733 294 930</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Nidaa Lone</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: left">Tel: +44 7841 400 607</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Kirkland &amp; Ellis LLP and Macfarlanes LLP are
retained as (respectively) US and UK legal advisers to NortonLifeLock. White &amp; Case LLP is retained as legal adviser to Avast.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Important notices relating to financial advisors</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Evercore Partners International LLP (&ldquo;<B>Evercore</B>&rdquo;),
which is authorised and regulated by the FCA in the United Kingdom, is acting exclusively as financial adviser to NortonLifeLock and Bidco
and no one else in connection with the Merger and will not be responsible to anyone other than NortonLifeLock or Bidco for providing the
protections afforded to clients of Evercore nor for providing advice in connection with the matters referred to herein. Neither Evercore
nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or
indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Evercore in connection with any
matter referred to herein or otherwise. Apart from the responsibilities and liabilities, if any, which may be imposed on Evercore by FSMA,
or the regulatory regime established thereunder, or under the regulatory regime of any jurisdiction where exclusion of liability under
the relevant regulatory regime would be illegal, void or unenforceable, neither Evercore nor any of its affiliates accepts any responsibility
or liability whatsoever for the contents of this Announcement, and no representation, express or implied, is made by it, or purported
to be made on its behalf, in relation to any matter referred to herein, including its accuracy, completeness or verification, or any other
statement made or purported to be made by it, or on its behalf, in connection with NortonLifeLock, Bidco or the matters described in this
Announcement. To the fullest extent permitted by applicable law, Evercore and its affiliates accordingly disclaim all and any responsibility
or liability whether arising in tort, contract or otherwise (save as referred to above) which it or they might otherwise have in respect
of this Announcement or any statement contained herein.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>UBS AG London Branch (&ldquo;<B>UBS</B>&rdquo;)
is authorised and regulated by the Financial Market Supervisory Authority in Switzerland. It is authorised by the PRA and subject to regulation
by the FCA and limited regulation by the PRA in the United Kingdom. UBS provided financial and corporate broking advice to Avast and no
one else in connection with the process or contents of this Announcement. In connection with such matters, UBS will not regard any other
person as its client, nor will it be responsible to any other person for providing the protections afforded to its clients or for providing
advice in relation to the process, contents of this Announcement or any other matter referred to herein.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>J.P. Morgan Securities plc, which conducts its
UK investment banking business as J.P. Morgan Cazenove, (&ldquo;<B>J.P. Morgan Cazenove</B>&rdquo;) and which is authorised in the United
Kingdom by the PRA and regulated in the United Kingdom by the PRA and the FCA, is acting exclusively as financial adviser to Avast and
no one else in connection with the Merger and will not regard any other person as its client in relation to the Merger and shall not be
responsible to anyone other than Avast for providing the protections afforded to clients of J.P. Morgan Cazenove or its affiliates, nor
for providing advice in connection with the Merger or any matter or arrangement referred to herein.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>No offer or solicitation</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>This Announcement is for information purposes
only and is not intended to and does not constitute, or form any part of, an offer to sell or the solicitation of an offer to subscribe
for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction
pursuant to the Merger or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention
of applicable law or regulation. In particular, this announcement is not an offer of securities for sale in the United States. No offer
of securities shall be made in the United States absent registration under the U.S. Securities Act or pursuant to an exemption from, or
in a transaction not subject to, such registration requirements. Any securities issued as part of the Merger are anticipated to be issued
in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 83; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The Merger will be implemented solely in accordance
with the Scheme Document (or, in the event that the Merger is to be implemented by means of a Takeover Offer, the offer document), which
will contain the full terms and conditions of the Merger, including details of how to vote in respect of the Scheme. Any voting decision
or response in relation to the Merger should be made solely on the basis of the information contained in the Scheme Document, the Forms
of Proxy, the Form of Election and the NortonLifeLock Prospectus.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>This Announcement does not constitute a prospectus
or a prospectus exempted document.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>This Announcement has been prepared for the
purpose of complying with English law and the Code and the information disclosed may not be the same as that which would have been disclosed
if this Announcement had been prepared in accordance with the laws of jurisdictions other than England and Wales.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Important additional information will be
filed with the SEC</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>This Announcement may be deemed to be solicitation
material in respect of the Merger, including the issuance of NortonLifeLock Shares. In connection with the proposed issuance of NortonLifeLock
Shares, NortonLifeLock is expected to file the NortonLifeLock Proxy Statement with the SEC. To the extent NortonLifeLock effects the
Merger as a Scheme under English law, the issuance of NortonLifeLock Shares would not be expected to require registration under the U.S.
Securities Act pursuant to an exemption provided by Section 3(a)(10) of the U.S. Securities Act. If, in the future, Bidco exercises its
right to implement the Merger by way of a Takeover Offer or otherwise in a manner that is not exempt from the registration requirements
of the U.S. Securities Act, it will file a registration statement on Form S-4 with the SEC that will contain a prospectus with respect
to the issuance of New NortonLifeLock Shares. BEFORE MAKING ANY VOTING DECISION, NORTONLIFELOCK&rsquo;S SHAREHOLDERS ARE URGED TO READ
THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION
WITH THE MERGER OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT (IF ANY) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE MERGER AND THE PARTIES TO THE MERGER. NortonLifeLock&rsquo;s shareholders and
investors will be able to obtain, without charge, a copy of the NortonLifeLock Proxy Statement (or, if applicable, the registration statement
on Form S-4), including the Scheme Document (or, if applicable the offer document), and other relevant documents filed with the SEC (when
available) from the SEC&rsquo;s website at <U>http://www</U>.sec.gov. NortonLifeLock&rsquo;s shareholders and investors will also be
able to obtain, without charge, a copy of the NortonLifeLock Proxy Statement, including the Scheme Document (or, if applicable the offer
document), and other relevant documents (when available) by directing a written request to NortonLifeLock (Attention: Investor Relations),
or from NortonLifeLock&rsquo;s website at <U>https://investor</U>.nortonlifelock.com/.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Participants in the solicitation</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>NortonLifeLock, Bidco and certain of their directors
and executive officers and employees may be considered participants in the solicitation of proxies from the stockholders of NortonLifeLock
in respect of the Merger, including the proposed issuance of NortonLifeLock Shares. Information regarding the persons who may, under the
rules of the SEC, be deemed participants in the solicitation of the stockholders of NortonLifeLock in connection with the Merger, including
a description of their direct or indirect interests, by security holdings or otherwise, will be set out in the NortonLifeLock Proxy Statement
when it is filed with the SEC. Information regarding NortonLifeLock&rsquo;s directors and executive officers is contained in NortonLifeLock&rsquo;s
Annual Report on Form 10-K for the fiscal year ended 2 April 2021 and its Proxy Statement on Schedule 14A, dated 28 July 2021, which are
filed with the SEC.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Overseas shareholders</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The release, publication or distribution of
this Announcement in jurisdictions other than the United Kingdom may be restricted by law and therefore any persons who are subject to
the laws of any jurisdiction other than the United Kingdom (including Restricted Jurisdictions) should inform themselves about, and observe,
any applicable legal or regulatory requirements. In particular, the ability of persons who are not resident in the United Kingdom or who
are subject to the laws of another jurisdiction to vote their Avast Shares in respect of the Scheme at the Meetings, or to execute and
deliver the Forms of Proxy (appointing another to vote at the Meetings on their behalf) or the Form of Election, may be affected by the
laws of the relevant jurisdictions in which they are located or to which they are subject. Any failure to comply with applicable legal
or regulatory requirements of any jurisdiction may constitute a violation of securities laws in that jurisdiction.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 84; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Copies of this Announcement and any formal documentation
relating to the Merger are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or
into or from any Restricted Jurisdiction, including any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction,
and persons receiving such documents (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send
them in or into or from any Restricted Jurisdiction. Doing so may render invalid any related purported vote in respect of acceptance of
the Merger.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>If the Merger is implemented by way of a Takeover
Offer (unless otherwise permitted by applicable law and regulation), the Takeover Offer may not be made, directly or indirectly, in or
into or by use of the mails or any other means or instrumentality (including facsimile, e-mail or other electronic transmission, telex
or telephone) of interstate or foreign commerce of, or any facility of a national, state or other securities exchange of, any Restricted
Jurisdiction and the Merger will not be capable of acceptance by any such use, means, instrumentality or facilities or from within any
Restricted Jurisdiction.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Further details in relation to Avast Shareholders
in overseas jurisdictions will be contained in the Scheme Document.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Notice to U.S. investors in Avast</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The Merger relates to the shares of an English
company and is being made by means of a scheme of arrangement under Part 26 of the Companies Act. A scheme of arrangement is not subject
to the tender offer rules or the proxy solicitation rules under the U.S. Exchange Act and other requirements of U.S. law. Accordingly,
the Merger is subject to the disclosure requirements and practices applicable to a scheme of arrangement involving a target company in
England listed on the London Stock Exchange, which differ from the disclosure requirements of U.S. tender offer and proxy solicitation
rules. If, in the future, Bidco exercises its right to implement the Merger by way of a Takeover Offer and determines to extend the Takeover
Offer into the U.S., the Merger will be made in compliance with applicable U.S. laws and regulations.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The New NortonLifeLock Shares to be issued
pursuant to the Merger have not been registered under the U.S. Securities Act, and may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of the U.S. Securities Act. The New NortonLifeLock Shares
to be issued pursuant to the Merger will be issued pursuant to the exemption from registration provided by Section 3(a)(10) under the
U.S. Securities Act. If, in the future, Bidco exercises its right to implement the Merger by way of a Takeover Offer or otherwise in
a manner that is not exempt from the registration requirements of the U.S. Securities Act, it will file a registration statement with
the SEC that will contain a prospectus with respect to the issuance of New NortonLifeLock Shares. In this event, Avast Shareholders are
urged to read these documents and any other relevant documents filed with the SEC, as well as any amendments or supplements to those
documents, because they will contain important information, and such documents will be available free of charge at the SEC&rsquo;s website
at <U>www.sec.gov</U> or by directing a request to NortonLifeLock&rsquo;s Investor Relations team identified above.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>New NortonLifeLock Shares issued to persons
other than &ldquo;affiliates&rdquo; of NortonLifeLock (defined as certain control persons, within the meaning of Rule 144 under the U.S.
Securities Act) will be freely transferable under US law after the Merger. Persons (whether or not US persons) who are or will be &ldquo;affiliates&rdquo;
of NortonLifeLock within 90 days prior to, or of the Combined Company after, the Effective Date will be subject to certain transfer restrictions
relating to the New NortonLifeLock Shares under US law.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Neither the SEC nor any U.S. state securities
commission has approved or disapproved of the New NortonLifeLock Shares to be issued in connection with the Merger, or determined if this
Announcement is accurate or complete. Any representation to the contrary is a criminal offence in the United States.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 85; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Financial information relating to Avast included
in this Announcement and to be included in the Scheme Document has been or will have been prepared in accordance with accounting standards
applicable in the United Kingdom and may not be comparable to financial information of U.S. companies or companies whose financial statements
are prepared in accordance with U.S. GAAP. U.S. GAAP differs in certain significant respects from accounting standards applicable in the
United Kingdom.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Avast is incorporated under the laws of England
and Wales. In addition, some of its officers and directors reside outside the United States, and some or all of its assets are or may
be located in jurisdictions outside the United States. Therefore, investors may have difficulty effecting service of process within the
United States upon those persons or recovering against Avast or its officers or directors on judgments of United States federal, state
or district courts, including judgments based upon the civil liability provisions of the U.S. federal securities laws. It may not be possible
to sue Avast or its officers or directors in a non-U.S. court for violations of the U.S. securities laws.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Forward-looking statements</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>This Announcement contains certain forward-looking
statements with respect to the NortonLifeLock Group and the Avast Group. These forward-looking statements can be identified by the fact
that they do not relate only to historical or current facts. Forward-looking statements often use words such as &ldquo;anticipate&rdquo;,
 &ldquo;target&rdquo;, &ldquo;expect&rdquo;, &ldquo;estimate&rdquo;, &ldquo;intend&rdquo;, &ldquo;plan&rdquo;, &ldquo;goal&rdquo;, &ldquo;believe&rdquo;,
 &ldquo;aim&rdquo;, &ldquo;will&rdquo;, &ldquo;may&rdquo;, &ldquo;would&rdquo;, &ldquo;could&rdquo; or &ldquo;should&rdquo; or other words
of similar meaning or the negative thereof. Forward-looking statements include statements relating to the following: (i) future capital
expenditures, expenses, revenues, economic performance, financial conditions, dividend policy, losses and future prospects, (ii) business
and management strategies and the expansion and growth of the operations of the NortonLifeLock Group or the Avast Group, and (iii) the
effects of government regulation on the business of the NortonLifeLock Group or the Avast Group. There are many factors which could cause
actual results to differ materially from those expressed or implied in forward-looking statements. Such factors include the possibility
that the Merger will not be completed on a timely basis or at all, whether due to the failure to satisfy the conditions of the Merger
(including approvals or clearances from regulatory and other agencies and bodies) or otherwise, general business and economic conditions
globally, industry trends, competition, changes in government and other regulation, changes in political and economic stability, disruptions
in business operations due to reorganisation activities, interest rate and currency fluctuations, the inability of the Combined Company
to realise successfully any anticipated synergy benefits when (and if) the Merger is implemented, the inability of the Combined Company
to integrate successfully the operations of the NortonLifeLock Group and the Avast Group when (and if) the Merger is implemented and the
Combined Company incurring and/or experiencing unanticipated costs and/or delays or difficulties relating to the Merger when (and if)
it is implemented. Additional information concerning these and other risk factors is contained in the Risk Factors sections of NortonLifeLock&rsquo;s
most recent reports on Form 10-K and Form 10-Q, the contents of which are not incorporated by reference into, nor do they form part of,
this Announcement.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>These forward-looking statements are based on
numerous assumptions regarding the present and future business strategies of such persons and the environment in which each will operate
in the future. By their nature, these forward-looking statements involve known and unknown risks, as well as uncertainties because they
relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking
statements in this Announcement may cause the actual results, performance or achievements of any such person, or industry results and
developments, to be materially different from any results, performance or achievements expressed or implied by such forward-looking statements.
No assurance can be given that such expectations will prove to have been correct and persons reading this Announcement are therefore cautioned
not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement. All subsequent oral
or written forward-looking statements attributable to the NortonLifeLock Group or the Avast Group or any persons acting on their behalf
are expressly qualified in their entirety by the cautionary statement above. None of NortonLifeLock, Bidco or Avast undertake any obligation
to update publicly or revise forward-looking statements, whether as a result of new information, future events or otherwise, except to
the extent required by applicable law, regulation or stock exchange rules.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 86; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>No profit forecasts or estimates</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The NortonLifeLock Profit Forecast is a profit
forecast for the purposes of Rule 28 of the Code. The NortonLifeLock Profit Forecast, the assumptions and basis of preparation on which
the NortonLifeLock Profit Forecast is based and the NortonLifeLock Directors&rsquo; confirmation, as required by Rule 28.1 of the Code,
are set out in Appendix 5 to this Announcement.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The Avast Profit Forecast is a profit forecast
for the purposes of Rule 28 of the Code. The Avast Profit Forecast, the assumptions and basis of preparation on which the Avast Profit
Forecast is based and the Avast Directors&rsquo; confirmation, as required by Rule 28.1 of the Code, are set out in Appendix 6 to this
Announcement.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Other than in respect of the NortonLifeLock
Profit Forecast and the Avast Profit Forecast, no statement in this Announcement is intended as, or is to be construed as, a profit forecast
or estimate for any period and no statement in this Announcement should be interpreted to mean that earnings or earnings per ordinary
share, for NortonLifeLock or Avast, respectively for the current or future financial years would necessarily match or exceed the historical
published earnings or earnings per ordinary share for NortonLifeLock or Avast, respectively.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>For the purposes of Rule 28 of the Code: (i)
the NortonLifeLock Profit Forecast contained in this Announcement is the responsibility of NortonLifeLock and the NortonLifeLock Directors;
and (ii) the Avast Profit Forecast contained in this Announcement is the responsibility of Avast and the Avast Directors.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Use of Non-GAAP financial information</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>NortonLifeLock uses the non-GAAP measures of
operating margin, which are adjusted from results based on U.S. GAAP and exclude certain expenses, gains and losses. NortonLifeLock also
provides the non-GAAP metric of free cash flow, which is defined as cash flows from operating activities less purchases of property and
equipment. These non-GAAP financial measures are provided to enhance the user&rsquo;s understanding of NortonLifeLock&rsquo;s past financial
performance and its prospects for the future. NortonLifeLock&rsquo;s management team uses these non-GAAP financial measures in assessing
NortonLifeLock&rsquo;s performance, as well as in planning and forecasting future periods. These non-GAAP financial measures are not computed
according to U.S. GAAP and the methods used by NortonLifeLock to compute them may differ from the methods used by other companies. Non-GAAP
financial measures are supplemental, should not be considered a substitute for financial information presented in accordance with U.S.
GAAP and should be read only in conjunction with NortonLifeLock&rsquo;s consolidated financial statements prepared in accordance with
U.S. GAAP. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>NortonLifeLock is unable to provide a reconciliation
of these forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures because certain information is
dependent on future events, some of which are outside the control of NortonLifeLock. Moreover, estimating such U.S. GAAP financial measures
with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without
unreasonable effort.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Quantified Financial Benefits Statement</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Statements of estimated cost savings and synergies
relate to future actions and circumstances which, by their nature, involve risks, uncertainties and contingencies. As a result, the cost
savings and synergies referred to in the Quantified Financial Benefits Statement may not be achieved, may be achieved later or sooner
than estimated, or those achieved could be materially different from those estimated. No statement in the Quantified Financial Benefits
Statement, or this Announcement generally, should be construed as a profit forecast (other than the NortonLifeLock Profit Forecast and
the Avast Profit Forecast) or interpreted to mean that the Combined Company&rsquo;s earnings in the first full year following the Effective
Date of the Scheme, or in any subsequent period, would necessarily match or be greater than or be less than those of Avast and/or NortonLifeLock
for the relevant preceding financial period or any other period. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>For the purposes of Rule 28 of the Code, the
Quantified Financial Benefits Statement contained in this Announcement is the responsibility of NortonLifeLock and the NortonLifeLock
Directors.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 87; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Publication on website</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>A copy of this Announcement and the documents
required to be published pursuant to Rule 26.1 and Rule 26.2 of the Code will be made available (subject to certain restrictions relating
to persons resident in Restricted Jurisdictions) on NortonLifeLock&rsquo;s website (at <U>https://investor</U>.nortonlifelock.com/) and
on Avast&rsquo;s website (at <U>https://investors</U>.avast.com/) by no later than 12 noon London time on the business day following
the date of this Announcement. Neither the contents of these websites nor the content of any other website accessible from hyperlinks
on such websites is incorporated into, or forms part of, this Announcement.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Requesting hard copy documents</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>In accordance with Rule 30.3 of the Code, a
person so entitled may request a copy of this Announcement (and any information incorporated into it by reference to another source) in
hard copy form free of charge. A person may also request that all future documents, announcements and information sent to that person
in relation to the Merger should be in hard copy form. For persons who have received a copy of this Announcement in electronic form or
via a website notification, a hard copy of this Announcement will not be sent unless so requested from either Avast by contacting Avast&rsquo;s
registrars, Equiniti, at Aspect House, Spencer Road, Worthing, Lancing BN99 6DA or, between 8.30 a.m. and 5.30 p.m. Monday to Friday (except
UK public holidays), on 0371 384 2030 from within the UK or +44 121 415 7047 if calling from outside the UK (calls are charged at the
standard geographic rate and will vary by provider; calls from outside the UK will be charged at the applicable international rate), or
NortonLifeLock by contacting Investor Relations at IR@NortonLifeLock.com, as appropriate.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Information relating to Avast Shareholders</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Please be aware that addresses, electronic addresses
and certain other information provided by Avast Shareholders, persons with information rights and other relevant persons for the receipt
of communications from Avast may be provided to Bidco during the Offer Period as required under Section 4 of Appendix 4 of the Code to
comply with Rule 2.11(c) of the Code.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Dealing and opening position disclosure requirements
of the Code</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Under Rule 8.3(a) of the Code, any person who
is interested in one per cent or more of any class of relevant securities of an offeree company or of any securities exchange offeror
(being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash)
must make an Opening Position Disclosure following the commencement of the Offer Period and, if later, following the announcement in which
any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person&rsquo;s interests
and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities
exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London
time) on the 10<SUP>th</SUP> Business Day (as defined in the Code) following the commencement of the Offer Period and, if appropriate,
by no later than 3.30 p.m. (London time) on the 10<SUP>th</SUP> Business Day (as defined in the Code) following the announcement in which
any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of
a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Under Rule 8.3(b) of the Code, any person who
is, or becomes, interested in one per cent or more of any class of relevant securities of the offeree company or of any securities exchange
offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange
offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person&rsquo;s interests and short positions in,
and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save
to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies
must be made by no later than 3.30 p.m. (London time) on the Business Day (as defined in the Code) following the date of the relevant
dealing.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 88; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>If two or more persons act together pursuant
to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company
or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Opening Position Disclosures must also be made
by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any
persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Details of the offeree and offeror companies
in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure
Table on the Panel&rsquo;s website at <U>www.thetakeoverpanel.org.uk</U>, including details of the number of relevant securities in issue,
when the Offer Period commenced and when any offeror was first identified. You should contact the Panel&rsquo;s Market Surveillance Unit
on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Rounding</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Certain figures included in this Announcement
have been subjected to rounding adjustments. Accordingly, figures shown for the same category presented in different tables may vary slightly
and figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that precede them.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 89; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 6 -->
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>APPENDIX 1</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>CONDITIONS AND FURTHER TERMS OF THE MERGER</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Part A</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Conditions to the Merger</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">1</TD><TD STYLE="text-align: justify">The Merger will be conditional upon the Scheme becoming Effective, subject to the Code, by no later than
11.59&nbsp;p.m. (UK time) on the Long Stop Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Scheme approval</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">2</TD><TD STYLE="text-align: justify">The Scheme will be conditional upon:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">2.1</TD><TD STYLE="text-align: justify">its approval by a majority in number representing not less than 75% in value of the Avast Shareholders
(or the relevant class or classes thereof, if applicable) in each case present, entitled to vote and voting, either in person or by proxy,
at the Court Meeting and at any separate class meeting which may be required by the Court or at any adjournment of any such meeting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">2.2</TD><TD STYLE="text-align: justify">the Court Meeting and any separate class meeting which may be required by the Court or any adjournment
of any such meeting being held on or before the 22<SUP>nd</SUP> day after the expected date of the Court Meeting to be set out in the
Scheme Document in due course (or such later date, if any, as Bidco and Avast may agree and the Court may allow);</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">2.3</TD><TD STYLE="text-align: justify">all resolutions necessary to approve and implement the Scheme being duly passed by the requisite majority
or majorities at the General Meeting or at any adjournment of that meeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">2.4</TD><TD STYLE="text-align: justify">the General Meeting or any adjournment of that meeting being held on or before the 22<SUP>nd</SUP> day
after the expected date of the General Meeting to be set out in the Scheme Document in due course (or such later date, if any, as Bidco
and Avast may agree and the Court may allow);</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">2.5</TD><TD STYLE="text-align: justify">the Court Hearing being held on or before the 22<SUP>nd</SUP> day after the expected date of the Court
Hearing to be set out in the Scheme Document in due course (or such later date, if any, as Bidco and Avast may agree and the Court may
allow); and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">2.6</TD><TD STYLE="text-align: justify">the sanction of the Scheme by the Court with or without modification (but subject to any such modification
being acceptable to Bidco and Avast) and the delivery of a copy of the Court Order to the Registrar; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>General Conditions</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">3</TD><TD STYLE="text-align: justify">In addition, subject as stated in Part B below and to the requirements of the Panel, Bidco and Avast have
agreed that the Merger will be conditional upon the following Conditions and, accordingly, the necessary actions to make the Scheme Effective
will not be taken unless the following Conditions (as amended if appropriate) have been satisfied or, where relevant, waived:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>NortonLifeLock Shareholder approval</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.1</TD><TD STYLE="text-align: justify">the issuance of the New NortonLifeLock Shares in connection with the Merger being duly approved, as required
by the rules and regulations of The Nasdaq Stock Market, in accordance with applicable law and the certificate of incorporation and bylaws
of NortonLifeLock;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Listing on NASDAQ, effectiveness of registration</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.2</TD><TD STYLE="text-align: justify">NASDAQ having approved, and not withdrawn such approval, the listing of the New NortonLifeLock Shares
to be issued, subject to official notice of issuance;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.3</TD><TD STYLE="text-align: justify">in the event that the Merger is implemented by way of a Takeover Offer, absent an available exemption
from the registration requirements of the U.S. Securities Act, NortonLifeLock&rsquo;s registration statement having been declared effective
by the SEC and no stop order having been issued or proceedings for suspension of the effectiveness of NortonLifeLock&rsquo;s registration
statement having been initiated by the SEC and NortonLifeLock having received all necessary U.S. state securities law or blue sky authorisations;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 90; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>NortonLifeLock Prospectus </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.4</TD><TD STYLE="text-align: justify">the FCA having approved the NortonLifeLock Prospectus and it having been made available to the public
in accordance with the UK Prospectus Regulation Rules;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Antitrust approvals</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>United States</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.5</TD><TD STYLE="text-align: justify">in the United States:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.5.1</TD><TD STYLE="text-align: justify">the waiting period under the U.S. HSR Act, and any agreement between NortonLifeLock, Bidco and/or Avast,
on the one hand, and the United States Department of Justice or United States Federal Trade Commission, on the other hand, that prohibits
the consummation of the Merger, shall have terminated or expired; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.5.2</TD><TD STYLE="text-align: justify">no governmental authority of competent jurisdiction shall have issued or entered under any U.S. Antitrust
Law any order, writ, injunction, judgment or decree (whether temporary or permanent) that is then in effect and has the effect of (i)
enjoining or otherwise prohibiting the consummation of the Merger, or (ii) permitting the Merger on terms not satisfactory to Bidco;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>United Kingdom</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.6</TD><TD STYLE="text-align: justify">the CMA:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.6.1</TD><TD STYLE="text-align: justify">having decided, on terms satisfactory to Bidco, not to refer the Merger nor any matter arising from or
relating to the Merger to the chair of the CMA for the constitution of a group under Schedule 4 to the Enterprise and Regulatory Reform
Act 2013 (a &ldquo;<B>Phase 2 CMA reference</B>&rdquo;); or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.6.2</TD><TD STYLE="text-align: justify">in the event that a Phase 2 CMA reference is made, either:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.6.2.1</TD><TD STYLE="text-align: justify">concluding in a report published in accordance with section 38 of the Enterprise Act 2002 that neither
the Merger nor any matter arising from or relating to the Merger may be expected to result in a substantial lessening of competition within
any market or markets in the United Kingdom for goods or services; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.6.2.2</TD><TD STYLE="text-align: justify">allowing the Merger and any matter arising from or relating to the Merger to proceed on terms satisfactory
to Bidco;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Germany</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.7</TD><TD STYLE="text-align: justify">insofar as the Merger falls within the scope of the Act against Restraints of Competition (<I>Gesetz gegen
Wettbewerbsbeschr&auml;nkungen</I>) in Germany, the FCO authorising the Merger, on terms satisfactory to Bidco, whether expressly or implicitly
through the lapse of the applicable waiting period;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Spain</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.8</TD><TD STYLE="text-align: justify">insofar as the Merger falls within the scope of the Spanish Defence of Competition Law (<I>Ley 15/2007,
de 3 de julio, de Defensa de la Competencia</I>), the CNMC or, in its place, the Spanish Council of Ministers (<I>Consejo de Ministros</I>),
authorising the Merger, on terms satisfactory to Bidco, whether expressly or implicitly through the lapse of the applicable waiting period;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 91; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>European Union</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.9</TD><TD STYLE="text-align: justify">insofar as the Merger does not constitute a concentration with a Union dimension within the meaning of
the EU Merger Regulation, in the event that a referral request under Article 22(3) of the EU Merger Regulation is made and accepted, the
European Commission declaring, on terms satisfactory to Bidco, that the Merger is compatible with the internal market pursuant to Article
6(1)(b) (including in conjunction with Article 6(2), 8(1) or 8(2) of the EU Merger Regulation) or the European Commission being deemed
to have so declared under Article 10(6) of the EU Merger Regulation;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Australia </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.10</TD><TD STYLE="text-align: justify">the ACCC:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.10.1</TD><TD STYLE="text-align: justify"><FONT STYLE="color: #212721">not having </FONT>notified Bidco that it objects to or proposes to take any
steps to oppose the Merger under section 50 of the Australian Competition and Consumer Act 2010 (Cth); or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.10.2</TD><TD STYLE="text-align: justify">having given notice in writing stating, or stating to the effect, that it does not propose to intervene
in or seek to prevent the Merger under section 50 of the Australian Competition and Consumer Act 2010 (Cth), on terms satisfactory to
Bidco, and that notice has not been withdrawn, revoked or adversely amended;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>New Zealand</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.11</TD><TD STYLE="text-align: justify">the NZCC having, on terms satisfactory to Bidco, granted clearance for the Merger to Bidco pursuant to
section 66 of the Commerce Act 1986 (NZ) or having notified Bidco in writing that it does not intend to assess the Merger further;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Regulatory approvals</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.12</TD><TD STYLE="text-align: justify">(1) a written notification issued by CFIUS that it has concluded its review (or, if applicable, investigation)
under section 721 of the DPA and determined that (a) the Merger is not a &ldquo;covered transaction&rdquo; pursuant to the DPA or (b)
there are no unresolved national security concerns with respect to the Merger, or (2) if CFIUS has sent a report to the President of the
United States requesting the President of the United States&rsquo; decision with respect to the Merger, either (a) the President has not
taken any action after fifteen days from the earlier of the date the President having received such report from CFIUS or the end of the
investigation period, or (b) the President of the United States has announced a decision not to take any action to suspend or prohibit
the Merger;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.13</TD><TD STYLE="text-align: justify">the receipt of any required foreign investment approvals, on terms satisfactory to Bidco, by the competent
authorities (or confirmation, on terms satisfactory to Bidco, that the Merger does not fall within the scope thereof) in:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212721"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.13.1</TD><TD STYLE="text-align: justify">Germany, pursuant to the Foreign Trade and Payments Act (<I>Au&szlig;enwirtschaftsgesetz</I>);</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212721"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.13.2</TD><TD STYLE="text-align: justify">the Czech Republic, pursuant to articles 14 or 15 of Czech Act No. 34/2021 Coll., on Screening of Foreign
Investments or receipt of a decision pursuant to article 10(4) of the Act that there are no grounds to initiate a foreign investment review
procedure or a confirmation in writing that the Merger does not fall within the scope of the Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt"><FONT STYLE="color: #212721">3.13.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #212721">Romania, pursuant to (a) the provisions of National Defence Council (<I>Consiliul
Suprem de Ap&abreve;rare a &#538;&abreve;rii &ndash; CSAT</I>) Decision no. 73/2012; or (b) the provisions of any new foreign investment
or national security laws, rules or regulations which become effective in Romania prior to </FONT>the Effective Date <FONT STYLE="color: #212721">and
require a mandatory notification to be submitted in relation to the Merger;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 92; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt"><FONT STYLE="color: #212721">3.13.4</FONT></TD><TD STYLE="text-align: justify">the Netherlands, to the extent that any new or amended public interest, foreign investment or national
security laws, rules or regulations (including the Security Screening Act for Investments, Mergers and Acquisitions (<I>Wet veiligheidstoets
investeringen, fusies en overnames</I>)) becomes effective in the Netherlands, and pursuant to such laws, rules or regulations a mandatory
notification is required to be submitted in relation to the Merger; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.13.5</TD><TD STYLE="text-align: justify"><FONT STYLE="color: #212721">the United Kingdom, to the extent that any new or amended public interest,
foreign investment or national security laws</FONT>, rules or regulations (including the National Security and Investment Act 2021) become
effective in the United Kingdom prior to the Effective Date and require a mandatory notification to be submitted in relation to the Merger;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Other authorisations, regulatory clearances
and third party clearances</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.14</TD><TD STYLE="text-align: justify">the waiver (or non-exercise within any applicable time limits) by any relevant government or governmental,
quasi-governmental, supranational, statutory, regulatory, environmental or investigative body, court, trade agency, association, institution,
any entity owned or controlled by any relevant government or state, or any other body or person whatsoever in any jurisdiction (each a
 &ldquo;<B>Third Party</B>&rdquo;) of any termination right, right of pre-emption, first refusal or similar right (which is material in
the context of the Wider Avast Group taken as a whole) arising as a result of or in connection with the Merger including its implementation
and financing or the proposed direct or indirect acquisition of any shares or other securities in, or control or management of, Avast
by Bidco or any member of the Bidco Group;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.15</TD><TD STYLE="text-align: justify">all necessary filings or applications having been made in connection with the Merger and all statutory
or regulatory obligations in any jurisdiction having been complied with in connection with the Merger or the offer by any member of the
Wider Bidco Group for any shares or other securities in, or control of, Avast and all authorisations, orders, grants, recognitions, determinations,
confirmations, consents, licences, clearances, permissions, exemptions and approvals reasonably deemed necessary or appropriate by Bidco
or any member of the Wider Bidco Group for or in respect of the Merger including its implementation and financing or the proposed direct
or indirect acquisition of any shares or other securities in, or control of, Avast or any member of the Wider Avast Group by any member
of the Wider Bidco Group having been obtained in terms and in a form satisfactory to Bidco from all appropriate Third Parties or persons
with whom any member of the Wider Avast Group has entered into contractual arrangements and all such material authorisations, orders,
grants, recognitions, determinations, confirmations, consents, licences, clearances, permissions, exemptions and approvals necessary or
appropriate to carry on the business of any member of the Wider Avast Group which is material in the context of the Bidco Group or the
Avast Group as a whole or of the financing of the Merger remaining in full force and effect and all filings necessary for such purpose
having been made and there being no notice or intimation of any intention to revoke or not to renew any of the same at the time at which
the Merger becomes Effective and all necessary statutory or regulatory obligations in any jurisdiction having been complied with;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.16</TD><TD STYLE="text-align: justify">no Third Party having given notice of a decision to take, institute, implement or threaten any action,
proceeding, suit, investigation, enquiry or reference (and, in each case, not having withdrawn the same), or having enacted, made or proposed
any statute, regulation, decision or order, or change to published practice or having taken any other steps, and there not continuing
to be outstanding any statute, regulation, decision or order, which in each case would or might reasonably be expected to:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.16.1</TD><TD STYLE="text-align: justify">require, prevent or delay the divestiture, or materially alter the terms envisaged for any proposed divestiture
by any member of the Wider Bidco Group or any member of the Wider Avast Group of all or any portion of their respective businesses, assets
or property or impose any limitation on the ability of any of them to conduct their respective businesses (or any of them) or to own any
of their respective assets or properties or any part thereof which, in any such case, is material in the context of the Wider Bidco Group
or the Wider Avast Group in either case taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 93; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.16.2</TD><TD STYLE="text-align: justify">require, prevent or delay the divestiture by any member of the Wider Bidco Group of any shares or other
securities in Avast;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.16.3</TD><TD STYLE="text-align: justify">impose any material limitation on, or result in a delay in, the ability of any member of the Wider Bidco
Group directly or indirectly to acquire or to hold or to exercise effectively any rights of ownership in respect of shares or loans or
securities convertible into shares or any other securities (or the equivalent) in any member of the Wider Avast Group or the Wider Bidco
Group or to exercise voting or management control over any such member;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.16.4</TD><TD STYLE="text-align: justify">otherwise adversely affect the business, assets, profits or prospects of any member of the Wider Bidco
Group or of any member of the Wider Avast Group to an extent which is material in the context of the Wider Bidco Group or the Wider Avast
Group in either case taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.16.5</TD><TD STYLE="text-align: justify">make the Merger or its implementation or an offer or proposed offer by Bidco or any member of the Wider
Bidco Group for any shares or other securities in, or control of Avast void, illegal, and/or unenforceable under the laws of any jurisdiction,
or otherwise, directly or indirectly, restrain, restrict, prohibit, delay or otherwise interfere with the same, or impose additional conditions
or obligations with respect thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.16.6</TD><TD STYLE="text-align: justify">require any member of the Wider Bidco Group or the Wider Avast Group to offer to acquire any shares or
other securities (or the equivalent) or interest in any member of the Wider Avast Group or the Wider Bidco Group owned by any third party;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.16.7</TD><TD STYLE="text-align: justify">impose any limitation on the ability of any member of the Wider Avast Group to co-ordinate its business,
or any part of it, with the businesses of any other members which is adverse to and material in the context of the Wider Avast Group taken
as a whole or in the context of the Merger; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.16.8</TD><TD STYLE="text-align: justify">result in any member of the Wider Avast Group ceasing to be able to carry on business under any name under
which it presently does so, and all applicable waiting and other time periods (including any extensions thereof) during which any such
Third Party could institute, implement or threaten any action, proceeding, suit, investigation, enquiry or reference or any other step
under the laws of any jurisdiction in respect of the Merger or an offer or proposed offer for any Avast Shares having expired, lapsed
or been terminated;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Certain matters arising as a result of any arrangement,
agreement etc.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.17</TD><TD STYLE="text-align: justify">save as Disclosed, there being no provision of any agreement, arrangement, licence, permit or other instrument
to which any member of the Wider Avast Group is a party or by or to which any such member or any of its assets may be bound, entitled
or subject, or any circumstance which in consequence of the Merger or an offer or proposed offer for any shares or other securities (or
equivalent) in Avast or because of a change in the control or management of Avast or otherwise, could or might result in any of the following
to an extent which is material and adverse in the context of the Wider Avast Group, or the Wider Bidco Group, in either case taken as
a whole, or in the context of the Merger:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.17.1</TD><TD STYLE="text-align: justify">any moneys borrowed by or any other indebtedness or liabilities (actual or contingent) of, or grant available
to any such member, being or becoming repayable or capable of being declared repayable immediately or earlier than their or its stated
maturity date or repayment date or the ability of any such member to borrow moneys or incur any indebtedness being withdrawn or inhibited
or being capable of becoming or being withdrawn or inhibited;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.17.2</TD><TD STYLE="text-align: justify">any such agreement, arrangement, licence, permit or instrument or the rights, liabilities, obligations
or interests of any such member thereunder being terminated or adversely modified or affected or any obligation or liability arising or
any action being taken or arising thereunder;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 94; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.17.3</TD><TD STYLE="text-align: justify">any asset or interest of any such member being or failing to be disposed of or charged or ceasing to be
available to any such member or any right arising under which any such asset or interest could be required to be disposed of or charged
or could cease to be available to any such member otherwise than in the ordinary course of business;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.17.4</TD><TD STYLE="text-align: justify">the creation or enforcement of any mortgage, charge or other security interest over the whole or any part
of the business, property, assets or interest of any such member;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.17.5</TD><TD STYLE="text-align: justify">the rights, liabilities, obligations or interests of any such member, or the business of any such member
with, any person, firm, company or body (or any arrangement or arrangements relating to any such interest or business) being terminated,
adversely modified or affected;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.17.6</TD><TD STYLE="text-align: justify">the value of any such member or its financial or trading position or prospects being prejudiced or adversely
affected;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.17.7</TD><TD STYLE="text-align: justify">any such member ceasing to be able to carry on business under any name under which it presently does so;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.17.8</TD><TD STYLE="text-align: justify">the creation or acceleration of any liability, actual or contingent, by any such member (including any
material tax liability or any obligation to obtain or acquire any material authorisation, notice, waiver, concession, agreement or exemption
from any Third Party or any person) other than trade creditors or other liabilities incurred in the ordinary course of business or in
connection with the Merger,</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">and no event having occurred which, under
any provision of any agreement, arrangement, licence, permit or other instrument to which any member of the Wider Avast Group is a party
or by or to which any such member or any of its assets may be bound, entitled or subject, would or might reasonably be expected to result
in any of the events or circumstances as are referred to in sub-paragraphs 3.17.1 to 3.17.8 of this Condition;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Certain events occurring since Last Accounts
Date</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.18</TD><TD STYLE="text-align: justify">save as Disclosed, no member of the Wider Avast Group having, since the Last Accounts Date:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.1</TD><TD STYLE="text-align: justify">save as between Avast and wholly-owned subsidiaries of Avast or for Avast Shares issued under or pursuant
to the exercise of options and vesting of awards granted under the Avast Share Schemes, issued or agreed to issue, authorised or proposed
the issue of additional shares of any class;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.2</TD><TD STYLE="text-align: justify">save as between Avast and wholly-owned subsidiaries of Avast or for the grant of options and awards and
other rights under the Avast Share Schemes, issued or agreed to issue, authorised or proposed the issue of securities convertible into
shares of any class or rights, warrants or options to subscribe for, or acquire, any such shares or convertible securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.3</TD><TD STYLE="text-align: justify">other than to another member of the Avast Group, prior to completion of the Merger, recommended, declared,
paid or made any dividend or other distribution payable in cash or otherwise or made any bonus issue, other than Agreed Avast Dividends;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.4</TD><TD STYLE="text-align: justify">save for intra-Avast Group transactions, merged or demerged with any body corporate or acquired or disposed
of or transferred, mortgaged or charged or created any security interest over any assets or any right, title or interest in any asset
(including shares and trade investments) or authorised or proposed or announced any intention to propose any merger, demerger, disposal,
transfer, mortgage, charge or security interest, in each case, other than in the ordinary course of business and, in each case, to the
extent which is material in the context of the Wider Avast Group taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 95; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.5</TD><TD STYLE="text-align: justify">save for intra-Avast Group transactions, made or authorised or proposed or announced an intention to propose
any change in its loan capital in each case, to the extent which is material in the context of the Wider Avast Group taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.6</TD><TD STYLE="text-align: justify">issued, authorised or proposed the issue of, or made any change in or to, any debentures or (save for
intra-Avast Group transactions), save in the ordinary course of business, incurred or increased any indebtedness or become subject to
any contingent liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.7</TD><TD STYLE="text-align: justify">purchased, redeemed or repaid or announced any proposal to purchase, redeem or repay any of its own shares
or other securities or reduced or, save in respect to the matters mentioned in sub-paragraphs 3.18.1 or 3.18.2 above, made any other change
to any part of its share capital, in each case, to the extent which is material in the context of the Wider Avast Group taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.8</TD><TD STYLE="text-align: justify">save for intra-Avast Group transactions, implemented, or authorised, proposed or announced its intention
to implement, any reconstruction, merger, demerger, amalgamation, scheme, commitment or other transaction or arrangement otherwise than
in the ordinary course of business;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.9</TD><TD STYLE="text-align: justify">entered into or varied or authorised, proposed or announced its intention to enter into or vary any contract,
transaction or commitment (whether in respect of capital expenditure or otherwise) which is of a long term, onerous or unusual nature
or magnitude or which involves or could involve an obligation of such a nature or magnitude other than in the ordinary course of business,
in each case, to the extent which is material in the context of the Wider Avast Group taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.10</TD><TD STYLE="text-align: justify">(other than in respect of a member which is dormant and was solvent at the relevant time) taken any corporate
action or steps or had any legal proceedings started or threatened against it in relation to the suspension of payments, a moratorium
of any indebtedness, its winding-up, dissolution or reorganisation or for the appointment of a receiver, administrative receiver, administrator,
manager, trustee or similar officer of all or any part of its assets or revenues or any analogous proceedings in any jurisdiction or appointed
any analogous person in any jurisdiction or had any such person appointed, in each case, to the extent which is material in the context
of the Wider Avast Group taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.11</TD><TD STYLE="text-align: justify">entered into any contract, transaction or arrangement which would be restrictive on the business of any
member of the Wider Avast Group or the Wider Bidco Group other than of a nature and extent which is normal in the context of the business
concerned;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.12</TD><TD STYLE="text-align: justify">waived or compromised any claim otherwise than in the ordinary course of business which is material in
the context of the Wider Avast Group taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.13</TD><TD STYLE="text-align: justify">made any material alteration to its memorandum or articles of association or other incorporation documents;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.14</TD><TD STYLE="text-align: justify">been unable, or admitted in writing that it is unable, to pay its debts or commenced negotiations with
one or more of its creditors with a view to rescheduling or restructuring any of its indebtedness, or having stopped or suspended (or
threatened to stop or suspend) payment of its debts generally or ceased or threatened to cease carrying on all or a substantial part of
its business;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.15</TD><TD STYLE="text-align: justify">entered into any contract, commitment, arrangement or agreement otherwise than in the ordinary course
of business or passed any resolution or made any offer (which remains open for acceptance) with respect to or announced any intention
to, or proposed to, effect any of the transactions, matters or events referred to in this Condition 3.18;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 96; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.16</TD><TD STYLE="text-align: justify">made or agreed or consented to any change to:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.18.16.1</TD><TD STYLE="text-align: justify">the terms of the trust deeds constituting the pension scheme(s) established by any member of the Wider
Avast Group for its directors, employees or their dependents, including the Avast pension schemes;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.18.16.2</TD><TD STYLE="text-align: justify">the contributions payable to any such scheme(s) or to the benefits which accrue or to the pensions which
are payable thereunder;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.18.16.3</TD><TD STYLE="text-align: justify">the basis on which qualification for, or accrual or entitlement to, such benefits or pensions are calculated
or determined; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.18.16.4</TD><TD STYLE="text-align: justify">the basis upon which the liabilities (including pensions) of such pension schemes are funded, valued or
made,</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify">in each case, to the extent which is
material in the context of the Wider Avast Group taken as a whole;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.17</TD><TD STYLE="text-align: justify">proposed, agreed to provide or modified the terms of any of the Avast Share Schemes or other benefit constituting
a material change relating to the employment or termination of employment of a material category of persons employed by the Wider Avast
Group or which constitutes a material change to the terms or conditions of employment of any senior employee of the Wider Avast Group,
save as agreed by the Panel (if required) and by Bidco, or entered into or changed the terms of any contract with any director or senior
executive;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.18</TD><TD STYLE="text-align: justify">taken (or agreed or proposed to take) any action which requires, or would require, the consent of the
Panel or the approval of Avast Shareholders in general meeting in accordance with, or as contemplated by, Rule 21.1 of the Code;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.19</TD><TD STYLE="text-align: justify">entered into or varied in a material way the terms of, any contract, agreement or arrangement with any
of the directors or senior executives of any members of the Wider Avast Group; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.18.20</TD><TD STYLE="text-align: justify">waived or compromised any claim which is material in the context of the Wider Avast Group taken as a whole,
otherwise than in the ordinary course;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>No adverse change, litigation or regulatory
enquiry</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.19</TD><TD STYLE="text-align: justify">save as Disclosed, since the Last Accounts Date:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.19.1</TD><TD STYLE="text-align: justify">no adverse change or deterioration having occurred in the business, assets, financial or trading position
or profits or prospects or operational performance of any member of the Wider Avast Group which, in any such case, is material in the
context of the Wider Avast Group taken as a whole and no circumstances having arisen which would or might reasonably be expected to result
in such adverse change or deterioration;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.19.2</TD><TD STYLE="text-align: justify">no litigation, arbitration proceedings, prosecution or other legal proceedings to which any member of
the Wider Avast Group is or may become a party (whether as a plaintiff, defendant or otherwise) and no enquiry, review or investigation
by, or complaint or reference to, any Third Party or other investigative body against or in respect of any member of the Wider Avast Group
having been instituted, announced, implemented or threatened by or against or remaining outstanding in respect of any member of the Wider
Avast Group which in any such case has had or might reasonably be expected to have an adverse effect on the Wider Avast Group taken as
a whole or in the context of the Merger;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 97; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.19.3</TD><TD STYLE="text-align: justify">no contingent or other liability of any member of the Wider Avast Group having arisen or become apparent
to Bidco or increased which has had or might reasonably be expected to have an adverse effect on the Wider Avast Group taken as a whole
or in the context of the Merger;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.19.4</TD><TD STYLE="text-align: justify">no enquiry or investigation by, or complaint or reference to, any Third Party having been threatened,
announced, implemented, instituted by or remaining outstanding against or in respect of any member of the Wider Avast Group which in any
case is material in the context of the Wider Avast Group taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.19.5</TD><TD STYLE="text-align: justify">no member of the Wider Avast Group having conducted its business in breach of any applicable laws and
regulations and which is material in the context of the Wider Avast Group as a whole or material in the context of the Merger; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.19.6</TD><TD STYLE="text-align: justify">no steps having been taken which are likely to result in the withdrawal, cancellation, termination or
modification of any licence or permit held by any member of the Wider Avast Group which is necessary for the proper carrying on of its
business and the withdrawal, cancellation, termination or modification of which has had, or would reasonably be expected to have, an adverse
effect on the Wider Avast Group taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.05in 0pt 0; text-align: justify"><B>No discovery of certain matters</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.20</TD><TD STYLE="text-align: justify">save as Disclosed, Bidco not having discovered:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.20.1</TD><TD STYLE="text-align: justify">that any financial, business or other information concerning the Wider Avast Group as contained in the
information publicly disclosed at any time by or on behalf of any member of the Wider Avast Group is materially misleading, contains a
material misrepresentation of fact or omits to state a fact necessary to make that information not misleading and which was not subsequently
corrected before the date of this Announcement by disclosure either publicly or otherwise to Bidco or its professional advisers, in each
case, to the extent which is material in the context of the Wider Avast Group taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.20.2</TD><TD STYLE="text-align: justify">that any member of the Wider Avast Group or partnership, company or other entity in which any member of
the Wider Avast Group has a significant economic interest and which is not a subsidiary undertaking of Avast, is subject to any liability
(contingent or otherwise) which is not disclosed in the Annual Report and Accounts for Avast for the year ended 31 December 2020, in each
case, to the extent which is material in the context of the Wider Avast Group taken as a whole; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.20.3</TD><TD STYLE="text-align: justify">any information which affects the import of any information disclosed at any time by or on behalf of any
member of the Wider Avast Group and which is material in the context of the Wider Avast Group taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.21</TD><TD STYLE="text-align: justify">save as Disclosed, Bidco not having discovered that:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.21.1</TD><TD STYLE="text-align: justify">any past or present member of the Wider Avast Group has failed to comply with any and/or all applicable
legislation or regulation, of any jurisdiction with regard to the use, treatment, handling, storage, carriage, disposal, spillage, release,
discharge, leak or emission of any waste or hazardous substance or any substance likely to impair the environment or harm human health
or animal health or otherwise relating to environmental matters or the health and safety of humans, or that there has otherwise been any
such use, treatment, handling, storage, carriage, disposal, spillage, release, discharge, leak or emission (whether or not the same constituted
a non-compliance by any person with any such legislation or regulations, and wherever the same may have taken place) any of which storage,
carriage, disposal, spillage, release, discharge, leak or emission would be likely to give rise to any liability (actual or contingent)
or cost on the part of any member of the Wider Avast Group and which is material in the context of the Wider Avast Group taken as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 98; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.21.2</TD><TD STYLE="text-align: justify">there is, or is likely to be, for any reason whatsoever, any liability (actual or contingent) of any past
or present member of the Wider Avast Group to make good, remediate, repair, reinstate or clean up any property or any controlled waters
now or previously owned, occupied, operated or made use of or controlled by any such past or present member of the Wider Avast Group (or
on its behalf) or by any person for which a member of the Wider Avast Group is or has been responsible, or in which any such member may
have or previously have had or be deemed to have had an interest, under any environmental legislation, regulation, notice, circular or
order of any Third Party and which is material in the context of the Wider Avast Group taken as a whole or the Merger;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.21.3</TD><TD STYLE="text-align: justify">circumstances exist (whether as a result of the Merger or otherwise) which would be reasonably likely
to lead to any Third Party instituting, or whereby any member of the Wider Bidco Group or any present or past member of the Wider Avast
Group would be likely to be required to institute, an environmental audit or take any other steps which would in any such case be reasonably
likely to result in any liability (whether actual or contingent) to improve, modify existing or install new plant, machinery or equipment
or carry out changes in the processes currently carried out or make good, remediate, repair, re-instate or clean up any land or other
asset currently or previously owned, occupied or made use of by any past or present member of the Wider Avast Group (or on its behalf)
or by any person for which a member of the Wider Avast Group is or has been responsible, or in which any such member may have or previously
have had or be deemed to have had an interest which is material in the context of the Wider Avast Group taken as a whole or the Merger;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.21.4</TD><TD STYLE="text-align: justify">circumstances exist whereby a person or class of persons would be likely to have any claim or claims in
respect of any product or process of manufacture or materials used therein currently or previously manufactured, sold or carried out by
any past or present member of the Wider Avast Group which claim or claims would be likely, materially and adversely, to affect any member
of the Wider Avast Group and which is material in the context of the Wider Avast Group taken as a whole or the Merger; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Anti-corruption, economic sanctions, criminal
property and money laundering</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.4in">3.22</TD><TD STYLE="text-align: justify">save as Disclosed, Bidco not having discovered that:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.22.1</TD><TD STYLE="text-align: justify">(A) any past or present member, director, officer or employee of the Wider Avast Group is or has at any
time engaged in any activity, practice or conduct which would constitute an offence under the Bribery Act 2010, the US Foreign Corrupt
Practices Act of 1977 or any other applicable anti-corruption or anti-bribery law, rule or regulation or any other applicable law, rule,
or regulation concerning improper payments or kickbacks or (B) any person that performs or has performed services for or on behalf of
the Wider Avast Group is or has at any time engaged in any activity, practice or conduct in connection with the performance of such services
which would constitute an offence under the Bribery Act 2010, the US Foreign Corrupt Practices Act of 1977 or any other applicable anti-corruption
or anti-bribery law, rule or regulation or any other applicable law, rule, or regulation concerning improper payments or kickbacks; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.22.2</TD><TD STYLE="text-align: justify">any asset of any member of the Wider Avast Group constitutes criminal property as defined by section 340(3)
of the Proceeds of Crime Act 2002 (but disregarding paragraph (b) of that definition) or proceeds of crime under any other applicable
law, rule, or regulation concerning money laundering or proceeds of crime or any member of the Wider Avast Group is found to have engaged
in activities constituting money laundering under any applicable law, rule, or regulation concerning money laundering; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 99; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Split-Segment; Name: 6 -->
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 49.5pt">3.22.3</TD><TD STYLE="text-align: justify">any past or present member, director, officer or employee of the Wider Avast Group, or any other person
for whom any such person may be liable or responsible, is or has engaged in any conduct which would violate applicable economic sanctions
or dealt with, made any investments in, made any funds or assets available to or received any funds or assets from:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.22.3.1</TD><TD STYLE="text-align: justify">any government, entity or individual in respect of which U.S., U.K. or European Union persons, or persons
operating in those territories, are prohibited from engaging in activities or doing business, or from receiving or making available funds
or economic resources, by U.S., U.K. or European Union laws or regulations, including the economic sanctions administered by the United
States Office of Foreign Assets Control, or HMRC; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.22.3.2</TD><TD STYLE="text-align: justify">any government, entity or individual targeted by any of the economic sanctions of the United Nations,
the United States, the United Kingdom, the European Union or any of its member states, save that this shall not apply if and to the extent
that it is or would be unenforceable by reason of breach of any applicable blocking law; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.22.4</TD><TD STYLE="text-align: justify">any past or present member, director, officer or employee of the Wider Avast Group, or any other person
for whom any such person may be liable or responsible:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.22.4.1</TD><TD STYLE="text-align: justify">has engaged in conduct which would violate any relevant anti-terrorism laws, rules, or regulations, including
the U.S. Anti-Terrorism Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.22.4.2</TD><TD STYLE="text-align: justify">has engaged in conduct which would violate any relevant anti-boycott law, rule, or regulation or any applicable
export controls, including the Export Administration Regulations administered and enforced by the U.S. Department of Commerce or the International
Traffic in Arms Regulations administered and enforced by the U.S. Department of State;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.22.4.3</TD><TD STYLE="text-align: justify">has engaged in conduct which would violate any relevant laws, rules, or regulations concerning human rights,
including any law, rule, or regulation concerning false imprisonment, torture or other cruel and unusual punishment, or child labour;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.5pt"></TD><TD STYLE="width: 63pt">3.22.4.4</TD><TD STYLE="text-align: justify">is debarred or otherwise rendered ineligible to bid for or to perform contracts for or with any government,
governmental instrumentality, or international organisation or found to have violated any applicable law, rule, or regulation concerning
government contracting or public procurement; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.22.5</TD><TD STYLE="text-align: justify">any member of the Wider Avast Group is or has been engaged in any transaction which would cause Bidco
to be in breach of any law or regulation upon the Merger, including the economic sanctions of the United States Office of Foreign Assets
Control, or HMRC, or any other relevant government authority.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: center"></P>

<!-- Field: Page; Sequence: 100; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Part B</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Waiver and Invocation of the Conditions</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Merger will be subject to the Conditions in
Part A above, and to certain further terms set out in Part D below, and to the full terms and conditions which will be set out in the
Scheme Document.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Scheme will not become Effective unless the
Conditions (other than Condition 2.6 of Part A of this Appendix 1) have been fulfilled or (if capable of waiver) waived or, where appropriate,
have been determined by Bidco to be or remain satisfied by no later than 11.59 p.m. on the date before the Court Hearing.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Subject to the requirements of the Panel and in
accordance with the Code, Bidco reserves the right to waive:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 40.5pt">(a)</TD><TD STYLE="text-align: justify">any of Conditions 2.2, 2.4 and 2.5 of Part A of this Appendix 1 related to the timing of the Court Meeting,
the General Meeting and the Court Hearing. If any such deadline is not met, Bidco will make an announcement by 8.00 a.m. on the Business
Day following such deadline confirming whether it has invoked or waived the relevant Condition or agreed with Avast to extend the deadline
in relation to the relevant Condition; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 40.5pt">(b)</TD><TD STYLE="text-align: justify">in whole or in part all or any of the above Conditions 3.14 to 3.22 (inclusive) of Part A of this Appendix
1.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">If Bidco is required by the Panel to make an offer
or offers for any Avast Shares under the provisions of Rule 9 of the Code, Bidco may make such alterations to the Conditions as are necessary
to comply with the provisions of that Rule.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Each of the Conditions will be regarded as a separate
Condition and will not be limited by reference to any other Condition.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Under Rule 13.5(a) of the Code, Bidco may not invoke
a Condition so as to cause the Scheme not to proceed, to lapse or to be withdrawn unless the circumstances which give rise to the right
to invoke the condition are of material significance to Bidco in the context of the offer.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Bidco may only invoke a Condition that is subject
to Rule 13.5(a) of the Code with the consent of the Panel and any Condition that is subject to Rule 13.5(a) of the Code may be waived
by Bidco.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Conditions 1, 2, 3.1, 3.2, 3.3 and 3.4 in Part
A of this Appendix 1 are not subject to Rule 13.5(a) of the Code.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Bidco shall not be under any obligation to waive
(if capable of waiver), to determine to be or remain satisfied or to treat, as fulfilled any of Conditions 1 to 3.22 (inclusive) of Part
A of this Appendix 1 (to the extent capable of waiver) by a date earlier than the latest date for the fulfilment of that Condition, notwithstanding
that the other Conditions may at such earlier date have been waived or fulfilled and that there are at such earlier date no circumstances
indicating that any of such Conditions may not be capable of fulfilment.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Part C</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Implementation by way of Takeover Offer</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Subject to obtaining the consent of the Panel,
Bidco reserves the right to elect to implement the Merger by way of a Takeover Offer as an alternative to the Scheme.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Any such Takeover Offer will be implemented on
substantially the same terms and conditions, so far as applicable, as those which would apply to the Scheme subject to appropriate amendments
to reflect the change in method of effecting the Merger. Further, if sufficient acceptances of the Takeover Offer are received and/or
sufficient Avast Shares are otherwise acquired, it is the intention of Bidco to apply the provisions of the Companies Act to compulsorily
acquire any outstanding Avast Shares to which such Takeover Offer relates.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 101; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Part D</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Certain further terms of the Merger</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The availability of the Merger to persons not resident
in the United Kingdom may be affected by the laws of the relevant jurisdictions. Persons who are not resident in the United Kingdom should
inform themselves about, and observe, any applicable requirements. Avast Shareholders who are in any doubt about such matters should consult
an appropriate independent professional adviser in the relevant jurisdiction without delay and observe any applicable requirements.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Merger will be governed by English law and
be subject to the jurisdiction of the English courts and to the conditions to be set out in the formal Scheme Document, and such further
terms as may be required to comply with the Listing Rules and the provisions of the Code and any requirement of the Panel, the London
Stock Exchange, the FCA and the Registrar.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Each of the Conditions shall be regarded as a separate
Condition and shall not be limited by reference to any other Condition.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Fractions of New NortonLifeLock Shares will not
be allotted to Avast Shareholders. Instead, Avast Shareholders shall receive, in lieu of such fractional entitlements, cash in an amount
in USD (rounded down to the nearest cent) (unless an Avast Shareholder has elected to receive cash consideration in Pounds Sterling rather
than USD, in which case such Avast Shareholder shall receive, in lieu of fractional entitlements, cash in an amount in Pounds Sterling
(rounded down to the nearest penny)) equal to such fractional amount multiplied by the last reported sale price of NortonLifeLock Shares
on NASDAQ (as reported in The Wall Street Journal or, if not reported therein, in another authoritative source selected by Bidco) on the
last Business Day prior to the Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Avast Shares will be acquired by Bidco (and/or
its nominee) with full title guarantee, fully paid and free from all liens, equitable interests, charges, encumbrances, rights of pre-emption
and any other third party rights or interests whatsoever and together with all rights existing at the date of this Announcement or thereafter
attaching thereto, including the right to receive and retain, in full, all dividends and other distributions (if any) declared, made or
paid or any other return of capital (whether by way of reduction of share capital or share premium account or otherwise) made on or after
the date of this Announcement in respect of the Avast Shares, other than the Agreed Avast Dividends.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">If, on or after the date of this Announcement and
before the Effective Date, any Return of Value is authorised, declared, made or paid or becomes payable in respect of the Avast Shares,
other than the Agreed Avast Dividends, or in excess of the Agreed Avast Dividends, Bidco reserves the right (without prejudice to any
right of Bidco, with the consent of the Panel, to invoke Condition 3.18.3 in Part A of this Appendix 1), to reduce the aggregate consideration
payable under the terms of the Merger for the Avast Shares by an amount up to the amount of such Return of Value, or by the excess above
the Agreed Avast Dividends, in which case any reference in this Announcement or in the Scheme Document to the consideration payable under
the terms of the Merger will be deemed to be a reference to the consideration as so reduced. To the extent that any such Return of Value
is authorised, declared, made or paid or is payable before the Scheme becomes Effective in accordance with its terms, other than the Agreed
Avast Dividends, or in excess of the Agreed Avast Dividends, and it is: (i) transferred pursuant to the Merger on a basis which entitles
Bidco (and/or its nominee) to receive the Return of Value and to retain it; or (ii) cancelled, the consideration payable under the terms
of the Merger will not be subject to change in accordance with this paragraph. Any exercise by Bidco of its rights referred to in this
paragraph will be the subject of an announcement and will not be regarded as constituting any revision to or variation of the Merger.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The New NortonLifeLock Shares will be fully paid
and non-assessable and will rank pari passu in all respects with the existing NortonLifeLock Shares, save that they will not participate
in any dividend payable by NortonLifeLock with reference to a record date prior to the Effective Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The availability of the Merger and the Majority
Stock Option to persons not resident in the United Kingdom may be affected by the laws of the relevant jurisdiction. Any persons who are
subject to the laws of any jurisdiction other than the United Kingdom should inform themselves about and observe any applicable requirements.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Merger (including the Majority Stock Option)
is not being made, directly or indirectly, in, into or from, or by use of the mails of, or by any means of instrumentality (including,
but not limited to, facsimile, e-mail or other electronic transmission, telex or telephone) of interstate or foreign commerce of, or of
any facility of a national, state or other securities exchange of, any jurisdiction where to do so would violate the laws of that jurisdiction
and will not be capable of acceptance by any such use, means, instrumentality or facility or from within any such jurisdiction.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Bidco reserves the right to implement the Merger
directly or with or through any direct or indirect subsidiary undertaking of NortonLifeLock or Bidco, from time to time.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 102; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>APPENDIX 2</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>SOURCES OF INFORMATION AND BASES OF CALCULATION</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In this Announcement:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Unless otherwise stated, financial information concerning Avast has been extracted from the Annual Report
and Accounts of Avast for the year ended 31 December 2020.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Unless otherwise stated, financial information concerning NortonLifeLock has been extracted from the NortonLifeLock
form 10-K for the year ended 2 April 2021, the NortonLifeLock fiscal 2021 Q4 earnings presentation and the NortonLifeLock fiscal 2022
Q1 earnings press release. NortonLifeLock&rsquo;s stranded costs for the year ended 2 April 2021 have been extracted from the NortonLifeLock
fiscal 2021 Q1 earnings presentation and from the NortonLifeLock fiscal 2021 Q2 earnings presentation.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">The value of Avast&rsquo;s entire issued and to be issued ordinary share capital implied by the terms
of the Merger is based upon:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 45pt">(a)</TD><TD STYLE="text-align: justify">the fully diluted ordinary share capital of Avast comprising (x) 1,031,794,134 Avast Shares in issue on
the Latest Practicable Date and (y) 28,101,508 Avast Shares expected to be issued on or after the date of this Announcement to satisfy
the vesting of awards and the exercise of options granted under the Avast Share Schemes;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 45pt">(b)</TD><TD STYLE="text-align: justify">NortonLifeLock&rsquo;s closing share price of USD 27.20 on 13 July 2021 (being the last Business Day on
which NortonLifeLock Shares traded on NASDAQ before the commencement of the Offer Period in relation to the Merger); and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 45pt">(c)</TD><TD STYLE="text-align: justify">the Announcement Exchange Rate (being USD 1.38595:&pound;1 derived from Bloomberg FX Fixings Spot Exchange
Rate as at 4.30 p.m. on the Latest Practicable Date).</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">The enterprise value of Avast implied by the terms of the Merger is based on the value of Avast&rsquo;s
entire issued and to be issued ordinary share capital set out in paragraph (iii) above, plus Avast&rsquo;s net debt (calculated as the
principal balance of the USD term loan plus the principal balance of the Euro term loan plus lease liabilities less cash and cash equivalents)
of USD 527.0 million as at 30 June 2021 (&pound;380.5 million based on an exchange rate of USD 1.3851:&pound;1 as at 30 June 2021).</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">As at the Latest Practicable Date, NortonLifeLock had 581,276,172 NortonLifeLock Shares issued and outstanding.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">The percentage ownership of the Combined Company which would be held by Avast Shareholders and NortonLifeLock
Shareholders respectively if the Merger completes are based on:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 45pt">(a)</TD><TD STYLE="text-align: justify">the fully diluted ordinary share capital of Avast set out in paragraph (iii)(a) above; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 45pt">(b)</TD><TD STYLE="text-align: justify">the number of NortonLifeLock Shares issued and outstanding is set out in paragraph (v) above.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">Unless otherwise stated, all prices for Avast Shares are the Closing Price derived from Bloomberg for
the relevant date.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">Unless otherwise stated, all prices for NortonLifeLock Shares are the closing price derived from Bloomberg
for the relevant date.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 103; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>APPENDIX 3</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>IRREVOCABLE UNDERTAKINGS</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Avast Directors&rsquo; (and the Vl&ccaron;ek
Family Foundation&rsquo;s) irrevocable commitments, further details of which are set out in Part A and Part B below, are in respect of,
in aggregate, 381,057,227 Avast Shares, representing approximately 36.93% of the existing issued ordinary share capital of Avast on the
Latest Practicable Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Part A &ndash; Avast Directors</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">NortonLifeLock and Bidco have received irrevocable
commitments from the Avast Directors listed below in respect of their own legal and/or beneficial holdings of Avast Shares, representing
in aggregate approximately 35.96% of the existing issued ordinary share capital of Avast on the Latest Practicable Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">These irrevocable commitments have been given by
all of the Avast Directors who hold Avast Shares, being all of the Avast Directors apart from John Schwarz, Maggie Chan Jones, Tamara
Minick-Scokalo and Belinda Richards.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The irrevocable commitments require each Avast
Director who holds a legal and/or beneficial interest in Avast Shares (or whose family member or other connected person holds such an
interest) to: (i) vote or procure that the registered holder votes in favour of the resolutions relating to the Scheme at the Meetings
(or, if the Merger is implemented by means of a Takeover Offer, to accept, or procure acceptance of, the Takeover Offer); and (ii) elect
for the Majority Stock Option, and not to revoke any such election once made.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">Name</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Avast Shares</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Percentage of Avast issued ordinary share capital (rounded to two decimal places)</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: justify; padding-bottom: 1pt">Ondrej Vlcek</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">13,715,184</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.33</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Philip Marshall</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">325,966</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.03</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Pavel Baudi&scaron;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">257,182,165</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24.93</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Eduard Ku&ccaron;era</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">99,793,912</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9.67</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Warren Finegold</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">40,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.00</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">TOTAL</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">371,057,227</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">35.96</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">These irrevocable commitments will continue to
be binding in the event that a higher competing offer is made for Avast.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">These irrevocable commitments will only cease to
be binding if:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Scheme becomes Effective in accordance with its terms, or a Takeover Offer (if applicable) is declared
unconditional in accordance with the requirements of the Code;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Bidco announces, with the consent of the Panel, that it does not intend to proceed with the Merger, and
no new, revised or replacement offer or scheme is announced in accordance with Rule 2.7 of the Code, either at the same time as or within
two Business Days of such announcement;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Scheme lapses or is withdrawn unless Bidco announces, within five business days of such lapse or withdrawal
and with the consent of the Panel, a firm intention to switch to a Takeover Offer;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 104; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Scheme does not become Effective, or, if Bidco elects to implement the Merger by way of a Takeover
Offer, the Takeover Offer does not become unconditional in accordance with the requirements of the Code (as the case may be), by the Long
Stop Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock and/or Bidco announces an amendment to the terms of the Scheme (or Takeover Offer, if applicable)
the effect of which would be to remove the ability for Avast Shareholders to elect for the Majority Stock Option (or any extended, increased
or otherwise improved version of the Majority Stock Option); or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any competing offer is made for Avast and such competing offer is declared unconditional in accordance
with the requirements of the Code (if implemented by way of a takeover offer) or otherwise becomes effective (if implemented by way of
a scheme of arrangement).</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The irrevocable commitments of Pavel Baudi&scaron;
and Eduard Ku&ccaron;era are also terminable upon written notice from them in circumstances where Bidco announces that it intends to increase
the consideration payable in respect of the Majority Cash Option, but does not announce a proportionate increase in the consideration
payable in respect of the Majority Stock Option (with agreed metrics for determining proportionate increases and non-proportionate increases).
The irrevocable commitments of Ondrej Vlcek, Philip Marshall and Warren Finegold are not terminable in such circumstances, though they
may (on written notice) revoke any prior election for the Majority Stock Option, and their obligation to elect for the Majority Stock
Option shall cease to apply.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In addition, if Bidco announces that it intends
to implement the Merger by way of a Takeover Offer rather than by way of the Scheme, and either in the announcement of such intention
or in a subsequent announcement sets the acceptance condition for such Takeover Offer at less than 75%, the obligation of the Avast Directors
(and their obligations with respect to their connected persons and/or related trusts) to elect for, and not to revoke any prior election
for, the Majority Stock Option, shall cease to apply. Accordingly, in those circumstances, the Avast Directors (and their relevant connected
persons and/or related trusts) would be entitled to revoke any previous election for the Majority Stock Option, and to receive the Majority
Cash Option.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Part B &ndash; Vl&ccaron;ek Family Foundation</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In addition, NortonLifeLock and Bidco have received
an irrevocable commitment from the Vl&ccaron;ek Family Foundation in respect of its entire legal and/or beneficial holding of 10,000,000
Avast Shares, representing approximately 0.97% of the existing issued ordinary share capital of Avast on the Latest Practicable Date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This irrevocable commitment requires the Vl&ccaron;ek
Family Foundation to vote, or procure that the registered holder of the relevant Avast Shares votes, in favour of the resolutions relating
to the Scheme at the Meetings (or, if the Merger is implemented by means of a Takeover Offer, to accept, or procure acceptance of, the
Takeover Offer). The Vl&ccaron;ek Family Foundation is not required to elect for the Majority Stock Option.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This irrevocable commitment will continue to be
binding in the same circumstances as the irrevocable commitments given by the Avast Directors, set out in Part A of this Appendix 3.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 105; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 7 -->
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>APPENDIX 4</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>QUANTIFIED FINANCIAL BENEFITS STATEMENT</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Part A</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Paragraph 3 (<I>Background to and reasons for the
Merger</I>) of this Announcement contains statements of estimated cost savings and synergies arising from the Merger (together, the &ldquo;<B>Quantified
Financial Benefits Statement</B>&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">A copy of the Quantified Financial Benefits Statement
is set out below:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&ldquo;<I>Given the complementary nature
of both NortonLifeLock and Avast, the NortonLifeLock Directors believe that the Merger will generate synergies that could not be achieved
independently of the Merger and will lead to significant long-term value creation for all shareholders.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>Significant recurring cost synergies
opportunity</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>NortonLifeLock anticipates that the
Merger will result in recurring annual pre-tax gross cost synergies for the Combined Company to reach a run-rate of approximately USD
280 million, representing between approximately 15% and 20% of combined adjusted cost of sales and operating spend, based on the latest
full year reported results for each of NortonLifeLock and Avast. The synergies are expected to be fully realised by the end of the second
year following completion of the Merger.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>NortonLifeLock intends to approach
integration with the aim of retaining and motivating the best talent and structure across the Combined Company to create a best-in-class
organisation. The expected sources of the identified cost synergies are as follows:</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Organisation: approximately 50% of the total annual run-rate pre-tax gross cost synergies are expected
to be generated through the adoption of shared best practice across existing functions and the reduction of duplicate roles across all
geographies, and from a broad range of job categories, including management, shared services, product and commercial functions;</I></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Systems &amp; Infrastructure operating costs: approximately 25% of the total annual run-rate pre-tax
gross cost synergies are expected to be realised through migration onto a common data and security platform, integration of systems, and
shared technology and analytics infrastructure; and</I></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Contracts &amp; Shared Services: approximately 25% of the total annual run-rate pre-tax gross cost
synergies are expected to be generated primarily from site rationalisation, procurement and vendor consolidation, and spend de-duplication.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>NortonLifeLock expects to realise
approximately 60% of the run-rate cost savings by the end of the first full year following completion of the Merger and 100% by the end
of the second full year following completion of the Merger, excluding any potential synergy reinvestment and associated benefits. On a
reported basis, the synergies assume the Combined Company expects to benefit from approximately USD 75 million of cost savings in the
first full year following completion of the Merger, approximately USD 245 million of cost savings in the second full year following completion
of the Merger, and the full USD 280 million of the cost savings in the third full year following completion of the Merger, excluding any
potential synergy reinvestment and associated benefits. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>One-off costs </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>In order to realise these synergies,
NortonLifeLock is expected to incur one-off restructuring and integration costs of approximately one year&rsquo;s run-rate pre-tax cost
savings, or USD 280 million, with approximately USD 180 million estimated to be incurred in the first full year following completion of
the Merger and approximately USD 100 million estimated to be incurred in the second full year following completion of the Merger. Aside
from integration costs, no material dis-benefits are expected to arise in connection with the Merger. The expected synergies will accrue
as a direct result of the Merger and would not be achieved on a standalone basis.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"></P>

<!-- Field: Page; Sequence: 106; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>The paragraphs above relating to expected
cost synergies constitute a &ldquo;Quantified Financial Benefits Statement&rdquo; for the purposes of Rule 28 of the Code.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>Given the strong strategic, cultural
and operational fit of the two companies, NortonLifeLock believes that the quantified cost synergies are readily achievable.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>NortonLifeLock expects to achieve
the quantified cost synergies while maintaining appropriate investment levels in sales and technology to meet the Combined Company&rsquo;s
growth targets and other objectives.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><I>The estimated cost synergies referred
to above reflect both the beneficial elements and the relevant costs</I>.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Further information on the bases of belief supporting
the Quantified Financial Benefits Statement, including the principal assumptions and sources of information, is set out below.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Bases of belief and principal assumptions</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In preparing the Quantified Financial Benefits
Statement, a synergy working group comprising senior strategy, operations, technical, sales and financial personnel from NortonLifeLock
(the &ldquo;<B>Working Group</B>&rdquo;) was established to identify, challenge and quantify the potential synergies available from the
integration of the NortonLifeLock and Avast businesses, and to undertake an initial planning exercise.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In preparing the detailed synergy plan, both NortonLifeLock
and Avast have shared certain operating and financial information to support the evaluation of the potential synergies available from
the Merger and have conducted a series of virtual meetings with the key management personnel of both NortonLifeLock and Avast. This has
included input from both the NortonLifeLock and Avast executive leadership teams.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Based on the information shared and interactions
with Avast, the Working Group has performed a bottom-up analysis of costs included in the NortonLifeLock and Avast financial information
and has sought to include in the synergy analysis those costs which the Working Group believe will be either optimized or reduced as a
result of the Merger. In circumstances where the information provided by Avast has been limited for commercial or other reasons, the Working
Group has made estimates and assumptions to aid its development of individual synergy initiatives. The assessment and quantification of
the potential synergies have in turn been informed by NortonLifeLock management&rsquo;s industry experience as well as their experience
of executing and integrating acquisitions in the past.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The baseline used as the basis for the Quantified
Financial Benefits Statement is NortonLifeLock&rsquo;s adjusted cost base for the financial year ended 2 April 2021, supported where relevant
by certain information from NortonLifeLock&rsquo;s budgeted cost base for the financial year ending 1 April 2022, and Avast&rsquo;s adjusted
cost base for the financial year ended 31 December 2020, supported where relevant by certain information from Avast&rsquo;s budgeted cost
base for the financial year ending 31 December 2021.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The quantified synergies are incremental to NortonLifeLock&rsquo;s
and, to the best of NortonLifeLock&rsquo;s knowledge, Avast&rsquo;s existing plans.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In general, the synergy assumptions have in turn
been risk adjusted, exercising a degree of prudence in the calculation of the estimated synergy benefit set out above.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In arriving at the estimate of synergies set out
in the Quantified Financial Benefits Statement, the NortonLifeLock management has made the following assumptions:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regarding organisational savings:</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">savings will be possible by removing duplicate resource through the roll-out of the revised operating
model;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 107; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Combined Company will be able to standardise and roll-out best practice systems and procedures, to
generate efficiency and enable headcount reductions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">no restrictions or delays will arise as a result of industrial relations or employment agreements that
significantly affect the realisation of savings by removing duplicate resource;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">there will be no material impact on the underlying operations of either company or their ability to continue
to conduct their businesses, including as a result of, or in connection with, the integration of the Avast Group and the NortonLifeLock
Group;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Combined Company&rsquo;s product offering generates at least the same level of total revenues as the
Avast Group&rsquo;s and NortonLifeLock Group&rsquo;s offerings currently generate;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">procurement savings can be realised through rationalising suppliers and renegotiating supplier terms;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">there will be no material change to macroeconomic, political, regulatory, legal or tax conditions in the
markets or regions in which NortonLifeLock and Avast operate that will materially impact the implementation of, or costs to achieve, the
expected cost savings;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">there will be no material divestments from the existing businesses of either NortonLifeLock or Avast;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">there will be no material change in current foreign exchange rates; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">there will be no business disruptions that materially affect either company, including natural disasters,
acts of terrorism, cyber-attacks and/or technological issues or supply chain disruptions.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>Reports</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As required by Rule 28.1(a) of the Code, Deloitte,
as reporting accountants to NortonLifeLock, and Evercore, as financial adviser to NortonLifeLock, have provided the reports required under
that Rule.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Copies of these reports are included in Part B
and Part C of this Appendix 4. Each of Deloitte and Evercore has given and not withdrawn its consent to the publication of its report
in this Announcement in the form and context in which it is included.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>Notes</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Quantified Financial Benefits Statement relates to future actions and circumstances which, by their
nature, involve risks, uncertainties and contingencies. In addition, due to the scale of the Combined Company, there may be additional
changes to the Combined Company&rsquo;s operations. As a result, the estimated synergies referred to may not be achieved, or may be achieved
later or sooner than estimated, or those achieved could be materially different from those estimated.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The Quantified Financial Benefits Statement should not be construed as a profit forecast or interpreted
to mean that NortonLifeLock&rsquo;s earnings in the first full year following the Effective Date, or in any subsequent period, will necessarily
match or be greater than or be less than those of NortonLifeLock or Avast for the relevant preceding financial period or any other period.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">For the purposes of Rule 28 of the Code, the Quantified Financial Benefits Statement is the responsibility
of NortonLifeLock and the NortonLifeLock Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B></B></P>

<!-- Field: Page; Sequence: 108; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Part B</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>REPORT FROM DELOITTE LLP</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">NortonLifeLock Inc.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">60 E. Rio Salado Parkway</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Suite 1000, Tempe, AZ 85281</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">USA</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Evercore Partners International LLP</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">15 Stanhope Gate</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">London</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">W1K 1LN</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">UK</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">10 August 2021</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Dear Sirs/Mesdames</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>RECOMMENDED MERGER OF AVAST PLC (the &ldquo;Target&rdquo;)
WITH NORTONLIFELOCK INC. (the &ldquo;Offeror&rdquo;)</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We report on the quantified financial benefits
statement made by the directors of the Offeror (the &ldquo;<B>Directors</B>&rdquo;) set out in Part A of Appendix 4 to the announcement
(the &ldquo;<B>Announcement</B>&rdquo;) issued by the Offeror (the &ldquo;<B>Quantified Financial Benefits Statement</B>&rdquo; or the
 &ldquo;<B>Statement</B>&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Opinion</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In our opinion, the Quantified Financial Benefits
Statement has been properly compiled on the basis stated.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Statement has been made in the context of the
disclosures within Part A of Appendix 4 to the Announcement setting out, inter alia, the basis of the Directors&rsquo; belief (identifying
the principal assumptions and sources of information) supporting the Statement and their analysis, explanation and quantification of the
constituent elements.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Responsibilities</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">It is the responsibility of the Directors to prepare
the Statement in accordance with Rule 28 of the City Code on Takeovers and Mergers (the &ldquo;<B>Takeover Code</B>&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">It is our responsibility to form our opinion, as
required by Rule 28.1(a) of the Takeover Code, as to whether the Statement has been properly compiled on the basis stated and to report
that opinion to you.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This report is given solely for the purposes of
complying with Rule 28.1(a)(i) of the Takeover Code and for no other purpose.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Therefore, to the fullest extent permitted by law,
we do not assume any other responsibility to any person for any loss suffered by any such person as a result of, arising out of, or in
connection with, this report or our statement, required by and given solely for the purposes of complying with Rule 23.2 of the Takeover
Code, consenting to its inclusion in the Announcement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Basis of preparation of the Statement </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Statement has been prepared on the basis stated
in Part A of Appendix 4 to the Announcement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 109; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Basis of opinion</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We conducted our work in accordance with the Standards
for Investment Reporting issued by the Financial Reporting Council in the United Kingdom (&ldquo;<B>FRC</B>&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 1.2pt 0pt 0; text-align: justify">We are independent of the Offeror in
accordance with the FRC&rsquo;s Ethical Standard as applied to Investment Circular Reporting Engagements, and we have fulfilled our other
ethical responsibilities in accordance with these requirements.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 1.2pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 1.2pt 0pt 0; text-align: justify">We have discussed the Statement, together
with the underlying plans (relevant bases of belief/including sources of information and assumptions), with the Directors and Evercore
Partners International LLP. Our work did not involve any independent examination of any of the financial or other information underlying
the Statement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 1.2pt 0pt 0; text-align: justify"><BR>
We planned and performed our work so as to obtain the information and explanations we considered necessary in order to provide us with
reasonable assurance that the Statement has been properly compiled on the basis stated.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.15in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our work has not been carried out in accordance
with auditing or other standards and practices generally accepted in jurisdictions outside the United Kingdom, including the United States
of America, and accordingly should not be relied upon as if it had been carried out in accordance with those standards and practices.
We have not consented to the inclusion of this report and our opinion in any registration statement filed with the SEC under the US Securities
Act of 1933 (either directly or by incorporation by reference) or in any offering document enabling an offering of securities in the United
States (whether under Rule 144A or otherwise).&nbsp;We therefore accept no responsibility to, and deny any liability to, any person using
this report and opinion in connection with any offering of securities inside the United States of America or who makes a claim on the
basis they had acted in reliance on the protections afforded by United States of America law and regulation.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We do not express any opinion as to the achievability
of the benefits identified by the Directors in the Statement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.1in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.1in 0pt 0; text-align: justify">Since the Statement and the assumptions
on which it is based relate to the future and may therefore be affected by unforeseen events, we express no opinion as to whether the
actual benefits achieved will correspond to those anticipated in the Statement and the differences may be material.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.1in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Yours faithfully</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Deloitte LLP</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>Deloitte LLP is a limited liability partnership
registered in England and Wales with registered number OC303675 and its registered office at 1 New Street Square, London EC4A 3HQ, United
Kingdom. Deloitte LLP is the United Kingdom affiliate of Deloitte NSE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private
company limited by guarantee (&ldquo;DTTL&rdquo;). DTTL and each of its member firms are legally separate and independent entities. DTTL
and Deloitte NSE LLP do not provide services to clients. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 110; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Part C</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>REPORT FROM EVERCORE PARTNERS INTERNATIONAL LLP</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">The Directors</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">NortonLifeLock Inc.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">60 E. Rio Salado Parkway</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Suite 1000, Tempe, AZ 85281</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">United States of America</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">10 August 2021</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Dear Ladies and Gentlemen</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Recommended merger of Avast plc (&ldquo;Avast&rdquo;)
with NortonLifeLock Inc. (&ldquo;NortonLifeLock&rdquo;) &ndash; Report on Quantified Financial Benefits Statement of NortonLifeLock </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We refer to the Quantified Financial Benefits Statement,
the bases of belief thereof and the notes thereto (together, the &ldquo;<B>Statement</B>&rdquo;) made by NortonLifeLock, as set out in
Part A of Appendix 4 to the announcement dated 10 August 2021 of which this report forms part (the &ldquo;<B>Announcement</B>&rdquo;),
for which the directors of NortonLifeLock (the &ldquo;<B>Directors&rdquo;</B>) are solely responsible under Rule 28.3 of the City Code
on Takeovers and Mergers (the &ldquo;<B>Code</B>&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have discussed the Statement (including the
bases of belief, assumptions and sources of information referred to therein) with the Directors and those officers and employees of NortonLifeLock
who developed the underlying plans, as well as with Deloitte LLP. The Statement is subject to uncertainty as described in the Announcement
and our work did not involve an independent examination or verification of any of the financial or other information underlying the Statement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have relied upon the accuracy and completeness
of all the financial and other information provided to us by or on behalf of NortonLifeLock, or otherwise discussed with or reviewed by
us, and we have assumed such accuracy and completeness for the purposes of providing this report.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have also reviewed the work carried out by Deloitte
LLP and have discussed with them their opinion set out in Part B of Appendix 4 to the Announcement addressed to you and us on this matter
and the accounting policies and bases of calculation for the Statement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We do not express any view or opinion as to the
achievability of the quantified financial benefits, whether on the basis identified by the Directors in the Statement or otherwise.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This report is provided to you solely in connection
with Rule 28.1(a)(ii) of the Code and for no other purpose. We accept no responsibility to NortonLifeLock or its shareholders or any person
(including, without limitation, the board of directors and shareholders of Avast) other than the Directors in respect of the contents
of this report. We are acting exclusively as financial adviser to NortonLifeLock and Nitro Bidco Limited (&ldquo;<B>Bidco</B>&rdquo;)
and no one else in connection with the merger of Avast with NortonLifeLock referred to in the Announcement and it is for the purpose of
complying with Rule 28.1(a)(ii) of the Code that NortonLifeLock has requested Evercore Partners International LLP to prepare this report
relating to the Statement. No person other than the Directors can rely on the contents of this report, or on the work undertaken in connection
with this report, and, to the fullest extent permitted by law, we expressly exclude all liability (whether in contract, tort or otherwise)
to any other person, in respect of this report, its contents, its results, or the work undertaken in connection with this report or any
of the results or conclusions that may be derived from this report or any written or oral information provided in connection with this
report, and any such liability is expressly disclaimed except to the extent that such liability cannot be excluded by law.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On the basis of the foregoing, we consider that
the Statement, for which you as the Directors are solely responsible, for the purposes of the Code, has been prepared with due care and
consideration.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Yours faithfully,</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Evercore Partners International LLP</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 111; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Split-Segment; Name: 8 -->
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>APPENDIX 5</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>NORTONLIFELOCK PROFIT FORECAST</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On 27 July 2021, NortonLifeLock released its results
for its first fiscal quarter ended 2 July 2021 which, in the earnings presentation slides (the &ldquo;<B>Q1 Results Slides</B>&rdquo;)
and in the press release covering the results (the &ldquo;<B>Q1 Release</B>&rdquo;), were supplemented by the following statements relating
to NortonLifeLock&rsquo;s anticipated EPS:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><U>In the Q1 Results Slides</U>:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&ldquo;<I>Q2 FY22 Non-GAAP Guidance &ndash; EPS $0.41
- $0.43</I>&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&ldquo;<I>Reaffirm FY22 Non-GAAP Guidance &ndash;
EPS $1.65-1.75&rdquo;</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><U>In the Q1 Release</U>:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&ldquo;<I>Fiscal 2022 Q2 Guidance &ndash; Non-GAAP
EPS is expected to be in the range of $0.41 to $0.43</I>&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><I>&ldquo;Reiterating Full Year Fiscal 2022 Guidance
 &ndash; Non-GAAP EPS is expected to be in the range of $1.65 to $1.75&rdquo;</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Each of the above statements (together, the &ldquo;<B>NortonLifeLock
Profit Forecast</B>&rdquo;) constitutes an ordinary course profit forecast for the purposes of Rule 28.1(a) and Note 2(b) on Rule 28.1
of the Code.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Notes</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Q1 Release contains the statements set out
below, and the Q1 Results Slides (which refer to the equivalent Q1 Release wording) contain similar statements. References to &ldquo;GAAP&rdquo;
in the NortonLifeLock Profit Forecast are to U.S. GAAP, being the accounting policies applied in the preparation of the NortonLifeLock
Group&rsquo;s annual results for the year ended 2 April 2021.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&ldquo;<I>[NortonLifeLock uses] non-GAAP measures
of operating margin, net income and earnings per share, which are adjusted from results based on GAAP and exclude certain expenses, gains
and losses. We also provide the non-GAAP metrics of Consumer revenues, constant currency revenues and Consumer reported billings, which
exclude revenues from our divested ID Analytics solutions, and free cash flow, which is defined as cash flows from operating activities
less purchases of property and equipment. These non-GAAP financial measures are provided to enhance the user&rsquo;s understanding of
our past financial performance and our prospects for the future. Our management team uses these non-GAAP financial measures in assessing
NortonLifeLock&rsquo;s performance, as well as in planning and forecasting future periods. These non-GAAP financial measures are not computed
according to GAAP and the methods we use to compute them may differ from the methods used by other companies. Non-GAAP financial measures
are supplemental, should not be considered a substitute for financial information presented in accordance with GAAP and should be read
only in conjunction with our consolidated financial statements prepared in accordance with GAAP</I>.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Basis of preparation</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The NortonLifeLock Profit Forecast has been prepared
on a basis consistent with the NortonLifeLock Group&rsquo;s accounting policies, as set out in the notes above.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The NortonLifeLock Profit Forecast excludes any
transaction costs applicable to the Merger or any other associated accounting impacts as a direct result of the Merger.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Assumptions</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The NortonLifeLock Profit Forecast is based on
the assumptions listed below.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 112; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Factors outside the influence or control
of the NortonLifeLock Directors</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material changes to existing prevailing macroeconomic or political conditions in the
markets and regions in which the NortonLifeLock Group operates.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material changes to the conditions of the markets and regions in which the NortonLifeLock
Group operates or in relation to customer demand or the behaviour of competitors in those markets and regions.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The interest, inflation and tax rates in the markets and regions in which the NortonLifeLock Group operates
will remain materially unchanged from the prevailing rates.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material adverse events that will have a significant impact on the NortonLifeLock Group&rsquo;s
financial performance.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material adverse events that will have a significant impact on the timing and market
acceptance of new product releases and upgrades by the NortonLifeLock Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no business disruptions that materially affect the NortonLifeLock Group or its key customers,
including natural disasters, acts of terrorism, cyber-attack and/or technological issues or supply chain disruptions.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material changes to the foreign exchange rates that will have a significant impact on
the NortonLifeLock Group&rsquo;s revenue or cost base.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material changes in legislation or regulatory requirements impacting on the NortonLifeLock
Group&rsquo;s operations or on its accounting policies.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material litigation in relation to any of the NortonLifeLock Group&rsquo;s operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Merger will not result in any material changes to the NortonLifeLock Group&rsquo;s obligations to
customers.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Merger will not have any material impact on the NortonLifeLock Group&rsquo;s ability to negotiate
new business.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Factors within the influence and control
of the NortonLifeLock Directors</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material change to the present executive management of the NortonLifeLock Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material change in the operational strategy of the NortonLifeLock Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material adverse change in the NortonLifeLock Group&rsquo;s ability to maintain customer
and partner relationships.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material acquisitions or disposals.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material strategic investments over and above those currently planned.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material change in the dividend or capital policies of the NortonLifeLock Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no unexpected technical or network issues with products or processes.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>NortonLifeLock Directors&rsquo; confirmation</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">With the consent of Avast, the Panel has granted
a dispensation from the Code requirement for NortonLifeLock&rsquo;s reporting accountants and financial advisers to prepare reports in
respect of the NortonLifeLock Profit Forecast.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The NortonLifeLock Directors have considered the
NortonLifeLock Profit Forecast and confirm that it remains valid as at the date of this Announcement, and has been properly compiled on
the basis of the assumptions set out in this Appendix 5 and that the basis of the accounting used is consistent with NortonLifeLock&rsquo;s
accounting policies.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 113; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>APPENDIX 6</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>AVAST PROFIT FORECAST</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The following statement included in paragraph 9
(<I>Avast current trading</I>) of this Announcement constitutes an ordinary course profit forecast for the purposes of Rule 28.1(a) and
Note 2(b) on Rule 28.1 of the Code (together, the &ldquo;<B>Avast Profit Forecast</B>&rdquo;):</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Set out below is the basis of preparation in respect
of the Avast Profit Forecast, together with the assumptions on which it is based.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&ldquo;<I>Avast&rsquo;s organic group revenue guidance
for the full 2021 financial year is maintained at the upper end of 6% to 8% growth</I>.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&hellip;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>The Avast Group&rsquo;s Adjusted EBITDA margin
percentage for the 2021 financial year is expected to remain broadly flat versus the financial year ended 31 December 2020, in line with
previous guidance and reflecting increased user and customer acquisition costs as well as materially higher marketing spend around the
flagship Avast One product, which remains on track for launch later this year</I>.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Basis of preparation</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Avast Profit Forecast has been prepared on
a basis consistent with the Avast Group&rsquo;s accounting policies which are in accordance with IFRS. These policies are consistent with
those applied in the preparation of the Avast Group&rsquo;s annual results for the year ended 31 December 2020.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Avast Profit Forecast excludes any transaction
costs applicable to the Merger or any other associated accounting impacts as a direct result of the Merger.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Assumptions</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Avast Profit Forecast is based on the assumptions
listed below.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Factors outside the influence or control
of the Avast Directors</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material changes to existing prevailing macroeconomic or political conditions in the
markets and regions in which the Avast Group operates.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material changes to the conditions of the markets and regions in which the Avast Group
operates or in relation to customer demand or the behaviour of competitors in those markets and regions.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The interest, inflation and tax rates in the markets and regions in which the Avast Group operates will
remain materially unchanged from the prevailing rates.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material adverse events that will have a significant impact on the Avast Group&rsquo;s
financial performance.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material adverse events that will have a significant impact on the timing and market
acceptance of new product releases and upgrades by the Avast Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no business disruptions that materially affect the Avast Group or its key customers, including
natural disasters, acts of terrorism, cyberattack and/or technological issues or supply chain disruptions.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material changes to the foreign exchange rates that will have a significant impact on
the Avast Group&rsquo;s revenue or cost base.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material changes in legislation or regulatory requirements impacting on the Avast Group&rsquo;s
operations or on its accounting policies.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 114; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material litigation in relation to any of the Avast Group&rsquo;s operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Merger will not result in any material changes to the Avast Group&rsquo;s obligations to customers.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Merger will not have any material impact on the Avast Group&rsquo;s ability to negotiate new business.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Factors within the influence and control
of the Avast Directors</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material change to the present management of the Avast Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material change in the operational strategy of the Avast Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material adverse change in the Avast Group&rsquo;s ability to maintain customer and partner
relationships.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material acquisitions or disposals.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material strategic investments over and above those currently planned.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no material change in the dividend or capital policies of the Avast Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There will be no unexpected technical or network issues with products or processes.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Avast Directors&rsquo; confirmation</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">With the consent of NortonLifeLock, the Panel has
granted a dispensation from the Code requirement for Avast&rsquo;s reporting accountants and financial advisers to prepare reports in
respect of the Avast Profit Forecast.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Avast Directors have considered the Avast Profit
Forecast and confirm that it remains valid as at the date of this Announcement, and has been properly compiled on the basis of the assumptions
set out in this Appendix 6 and that the basis of the accounting used is consistent with Avast&rsquo;s accounting policies.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 115; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>APPENDIX 7</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>ACCC</B></TD>
    <TD STYLE="width: 51%; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Australian Competition and Consumer Commission;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>ADR</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">American Depositary Receipt;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Adjusted EBITDA</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Avast Group&rsquo;s operating profit/loss before depreciation, amortisation of non-acquisition intangible assets, share-based payments including related employer&rsquo;s costs, exceptional items and amortisation of acquisition intangible assets;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Agreed Avast Dividends </B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in paragraph 2 of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Agreed NortonLifeLock Dividends</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in paragraph 2 of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>AI</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">artificial intelligence; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Announcement</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">this announcement made pursuant to Rule 2.7 of the Code;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Announcement Exchange Rate</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the exchange rate of USD 1.38595:&pound;1 derived from Bloomberg FX Fixings Spot Exchange Rate as at 4.30 p.m. on 9 August 2021 (being the Latest Practicable Date);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Articles</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the articles of association of Avast from time to time;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>associated undertaking</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given by paragraph 19 of Schedule 6 to the Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008 other than paragraph 19(1)(b) of Schedule 6 to those Regulations which shall be excluded for this purpose;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Avast</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Avast plc, a public company incorporated in England and Wales with registered number 07118170;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Avast Board</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the board of directors of Avast from time to time;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Avast Directors</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the directors of Avast as at the date of this Announcement or, where the context so requires or admits, the directors of Avast from time to time;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Avast Group</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Avast and its subsidiary undertakings from time to time and, where the context so requires or admits, each of them;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Avast Profit Forecast</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Avast profit forecast set out in Appendix 6 to this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Avast Share Schemes</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Avast 2018 Long Term Incentive Plan, the Avast 2018 Share Matching Plan, the Existing Employee Share Plan (formerly known as the Avast Holding 2014 Share Option Plan) and any other plan or arrangement under which outstanding options, awards or share-based rights have been granted;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 116; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><B>Avast Shareholders</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%">the holders of Avast Shares from time to time;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Avast Shares</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the ordinary shares of nominal value &pound;0.10 each in the capital of Avast; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>B2B2C</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">business-to-business-to-consumer;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Bidco</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Nitro Bidco Limited, a private limited company incorporated in England and Wales with registered number 13514724;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Bidco Group</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Bidco and its subsidiary undertakings from time to time and, where the context so requires or admits, each of them;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Business Day</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">a day (other than a Saturday, Sunday, public or bank holiday) on which banks are generally open for business in London and New York;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>CAGR</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">compound annual growth rate;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>CFIUS</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Committee on Foreign Investment in the United States;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Clean Team and Joint Defence Agreement</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the clean team and joint defence agreement entered into between Avast, NortonLifeLock, White &amp; Case LLP and Kirkland &amp; Ellis International LLP dated 24 June 2021;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Closing Price</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the closing middle market quotation of a share derived from the Daily Official List of the London Stock Exchange;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>CMA</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Competition and Markets Authority in the United Kingdom;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>CNMC</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the National Commission of Markets and Competition in Spain;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Code</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the City Code on Takeovers and Mergers;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Combined Company</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the enlarged group following the Merger, comprising the NortonLifeLock Group and the Avast Group;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Companies Act</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Companies Act 2006;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Conditions</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the conditions to the Merger set out in Part A of Appendix 1 to this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Confidentiality Agreement</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the confidentiality agreement entered into between Avast and NortonLifeLock, dated 23 June 2021;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 117; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><B>Co-operation Agreement</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%">the agreement entered into on the date of this Announcement between NortonLifeLock, Bidco and Avast and relating, amongst other things, to the implementation of the Merger;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Court</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the High Court of Justice in England and Wales;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Court Hearing</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Court hearing at which Avast will seek an order sanctioning the Scheme pursuant to Part 26 of the Companies Act;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Court Meeting</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the meeting or meetings of the Avast Shareholders to be convened by order of the Court pursuant to Part 26 of the Companies Act for the purpose of considering and, if thought fit, approving the Scheme (with or without amendment approved or imposed by the Court and agreed to by Bidco and Avast) including any adjournment, postponement or reconvention of any such meeting, notice of which shall be contained in the Scheme Document;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Court Order</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the order of the Court sanctioning the Scheme under section 899 of the Companies Act;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>CREST</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the relevant system (as defined in the Uncertificated Securities Regulations 2001 (SI 2001/3755) in respect of which Euroclear UK &amp; Ireland Limited is the Operator (as defined in the Regulations);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Deloitte</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Deloitte LLP, the United Kingdom affiliate of Deloitte NSE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (&ldquo;DTTL&rdquo;). DTTL and each of its member firms are legally separate and independent entities;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>direct customers</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">includes NortonLifeLock direct customers and/or Avast paying customers&nbsp;(excluding consumer indirect)&nbsp;(as applicable), including desktop subscription and mobile subscription;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Disclosed</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the information disclosed by, or on behalf of, Avast: (i) in the annual report and accounts of the Avast Group for the 12 month period to 31 December 2020; (ii) in this Announcement; (iii) in any other public announcement to a Regulatory Information Service by, or on behalf of, Avast prior to the date of this Announcement; (iv) prior to the date of this Announcement by or on behalf of Avast to NortonLifeLock or Bidco (or their respective officers, employees, agents or advisers in their capacity as such), including via the virtual data room operated on behalf of Avast in respect of the Merger or via email, in each case to the extent that such information was fairly disclosed in writing; or (v) during any management presentation in connection with the Merger (including presentations on legal, financial and human resources) which was attended by Avast and either of Bidco or NortonLifeLock (or their respective officers, employees, agents or advisers in their capacity as such), in each case to the extent that such information was fairly disclosed;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 118; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><B>DPA</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%">the United States Defense Production Act of 1950;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>EBITDA</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">earnings before interest, taxes, depreciation and amortisation; </TD></TR>
</TABLE>

<P STYLE="margin: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Effective</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">means:</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt; text-align: left; width: 49%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt; width: 4%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 47%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">if
    the Merger is implemented by way of the Scheme, the Scheme having become effective pursuant to its terms; or</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(b)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">if
    the Merger is implemented by way of a Takeover Offer, the Takeover Offer having been declared or become unconditional in accordance
    with the requirements of the Code;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><B>Effective Date</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%">the date on which the Merger becomes Effective;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>EPS</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">earnings per share;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>EU Merger Regulation</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Council Regulation (EC) 139/2004;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>European Commission</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the European Commission of the European Union;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>ESG</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">environmental, social and governance;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>ET time</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the eastern time zone;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Evercore</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Evercore Partners International LLP;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Excess NortonLifeLock Dividend</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in paragraph 2 of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>FCA</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Financial Conduct Authority;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>FCO</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Federal Cartel Office of Germany;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Form of Election</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the form by which Scheme Shareholders (other than Scheme Shareholders resident in a Restricted Jurisdiction) may elect to receive the Majority Stock Option;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Forms of Proxy</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the forms of proxy in connection with each of the Court Meeting and the General Meeting, which shall accompany the Scheme Document;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>freemium</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">a business model whereby services are provided free of charge; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>FSMA</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Financial Services and Markets Act 2000;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 119; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><B>GAAP</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%">generally accepted accounting principles; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>General Meeting</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the general meeting of the Avast Shareholders (including any adjournment thereof) to be convened for the purpose of considering, and if thought fit, approving the Special Resolution, notice of which shall be contained in the Scheme Document;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>HMRC</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Her Majesty&rsquo;s Revenue and Customs in the United Kingdom;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>IFRS</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">international financial reporting standards;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Interim Avast Dividend</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in paragraph 2 of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="color: #16202C"><B>Interim Facilities Agreement</B></FONT></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the $9.35 billion interim facilities agreement between, amongst others, NortonLifeLock (as borrower), the Interim Lenders and Bank of America, N.A. (as interim facility agent and interim security agent) and dated on or before the date of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="color: #16202C"><B>Interim Lenders</B></FONT></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Bank of America, N.A. and Wells Fargo Bank, N.A.;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>J.P. Morgan Cazenove</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">J.P. Morgan Securities plc, which conducts its UK investment banking business as J.P. Morgan Cazenove;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Last Accounts Date</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">31 December 2020;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Latest Practicable Date</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">close of business on 9 August 2021, being the latest practicable date prior to the date of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Listing Rules</B></TD>
    <TD STYLE="padding-left: 5.4pt">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">the listing rules made by the FCA under Part 6 of
    FSMA;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>London Stock Exchange</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">London Stock Exchange plc;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Long Stop Date</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">11.59&nbsp;p.m. on 31 December 2022, or such later date (if any) as Bidco and Avast may agree, either as required by the Panel or with its consent, and the Court (if required) may allow;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Majority Cash Option</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in the Summary section of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Majority Stock Option</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in the Summary section of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Meetings</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Court Meeting and the General Meeting;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Merger</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the proposed acquisition by Bidco (and/or its nominee(s)) of the entire issued and to be issued ordinary share capital of Avast, to be implemented by means of the Scheme as described in this Announcement (or, should Bidco so elect, by a Takeover Offer under certain circumstances described in this Announcement);</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 120; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><B>MTF</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%">multilateral trading facility, as defined by Article 4(1)(22) of Directive 2014/54/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments (MIFID II);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NASDAQ</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the National Association of Securities Dealers Automated Quotations in the U.S.;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>New NortonLifeLock Shares</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the new NortonLifeLock shares of common stock with a par value of USD 0.01 per share in the capital of NortonLifeLock proposed to be issued to Avast Shareholders in connection with the Merger;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NortonLifeLock</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">NortonLifeLock Inc., a corporation incorporated in the state of Delaware;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NortonLifeLock Board</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the board of directors of NortonLifeLock from time to time;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NortonLifeLock Board Recommendation Change Event</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in the <I>Co-operation Agreement </I>part of paragraph 16 (<I>Merger-related arrangements</I>) of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NortonLifeLock Directors</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the directors of NortonLifeLock at the date of this Announcement or, where the context so requires or admits, the directors of NortonLifeLock from time to time;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NortonLifeLock Group</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">NortonLifeLock and its subsidiary undertakings from time to time (and, where the context so requires or admits, each of them) which shall, for the avoidance of doubt, include the Avast Group following completion of the Merger;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NortonLifeLock Profit Forecast</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the NortonLifeLock profit forecast set out in Appendix 5 to this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NortonLifeLock Proxy Statement</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the proxy statement which is anticipated to be mailed to NortonLifeLock Shareholders by NortonLifeLock in connection with their approval of the issuance of the New NortonLifeLock Shares;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NortonLifeLock Shareholders</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">holders of NortonLifeLock Shares from time to time;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NortonLifeLock Shareholder Approval Failure Event</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in the <I>Co-operation Agreement </I>part of paragraph 16 (<I>Merger-related arrangements</I>) of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NortonLifeLock Shareholders&rsquo; Meeting</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the meeting of NortonLifeLock Shareholders convened for the purpose of considering and approving the issuance of the New NortonLifeLock Shares;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 121; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><B>NortonLifeLock Shares</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%">NortonLifeLock shares of common stock with a par value of USD 0.01 per share in the capital of NortonLifeLock;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NortonLifeLock Prospectus</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the FCA-approved prospectus to be produced by NortonLifeLock and made publicly available to Avast Shareholders (other than persons resident in a Restricted Jurisdiction) at the same time as the Scheme Document in respect of the New NortonLifeLock Shares to be issued to Avast Shareholders in connection with the Merger;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>NZCC</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the New Zealand Commerce Commission;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>OEM</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">original equipment manufacturer;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Offer Period</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the period commencing at 10.23 p.m. on 14 July 2021 and ending on (i) the earlier of the date on which the Scheme becomes Effective and/or the date on which the Scheme lapses or is withdrawn (or such other date as the Panel may decide) or (ii) the earlier of the date on which the Takeover Offer has become or has been declared unconditional and/or the date on which the Takeover Offer lapses or is withdrawn (or such other date as the Panel may decide), other than, in the case of (i), where such lapsing or withdrawal is a result of Bidco exercising its right to implement the Merger by way of a Takeover Offer;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Official List</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the official list maintained by the FCA pursuant to Part 6 of the Financial Services and Markets Act 2000;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Opening Position Disclosure</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">an announcement containing details of interests or short positions in, or rights to subscribe for, any relevant securities of a party to the offer if the person concerned has such a position, as defined in Rule 8 of the Code;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Panel</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the U.K. Panel on Takeovers and Mergers;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Phase 2 CMA reference</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in paragraph 3.6 of Part A of Appendix 1 to this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Post-Merger Buyback</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in the Summary section of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>PRA</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Prudential Regulation Authority;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>PSE</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Prague Stock Exchange (<I>Burza cenn&yacute;ch pap&iacute;r&uring; Praha, a.s.</I>);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>PT time</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the pacific time zone;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Q1 Release</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in Appendix 5 to this Announcement;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 122; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><B>Q1 Results Slides</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%">has the meaning given to it in Appendix 5 to this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Q3</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the third quarter of the relevant calendar year;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Q4</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the fourth quarter of the relevant calendar year;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Quantified Financial Benefits Statement</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in Part A of Appendix 4 to this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>R&amp;D</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">research and development;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Registrar</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the Registrar of Companies in England and Wales; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Regulatory Condition Satisfaction Failure Event</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in the <I>Co-operation Agreement </I>part of paragraph 16 (<I>Merger-related arrangements</I>) of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Regulatory Conditions</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Conditions 3.5, 3.6, 3.7, 3.8, 3.9, 3.10, 3.11, 3.12, 3.13.1, 3.13.2, 3.13.3, 3.13.4 and 3.13.5 (inclusive) of &nbsp;Part A of Appendix 1 to this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Regulatory Information Service </B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">a primary information provider approved by the FCA under section 89P of FSMA;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Restricted Jurisdiction</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">any jurisdiction where local laws or regulations may result in a significant risk of civil, regulatory or criminal exposure if information concerning the Merger were made available in that jurisdiction, or if the Merger (including details regarding any election that may be made for the Majority Stock Option) is or were extended or made available in that jurisdiction, or where to do so would result in a requirement to comply with any governmental or other consent or any registration, filing or other formality which Bidco or Avast regards as unduly onerous;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Return of Value</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in the Summary section of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>RMS</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">RM-SYST&Eacute;M Czech Stock Exchange (<I>RM-SYST&Eacute;M, &ccaron;esk&aacute; burza cenn&yacute;ch pap&iacute;r&uring; a.s.</I>);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Scheme</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the proposed scheme of arrangement under Part 26 of the Companies Act between Avast and the Scheme Shareholders to implement the Merger to be set out in the Scheme Document, with or subject to any modification, addition or condition approved or imposed by the Court and agreed to by Bidco and Avast;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Scheme Document</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the document to be dispatched to Avast Shareholders including the particulars required by section 897 of the Companies Act;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Scheme Record Time</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the time and date specified as such in the Scheme Document, expected to be 6.00 p.m. on the Business Day immediately preceding the Effective Date, or such other time as Bidco and Avast may agree;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 123; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><B>Scheme Shareholders</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%">holders of Scheme Shares;</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt; width: 49%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Scheme Shares</B></FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt; width: 4%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(a)</FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; padding-left: 5.4pt; width: 47%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">the Avast Shares in issue at the date
  of the Scheme Document and which remain in issue at the Scheme Record Time;</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(b)</FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">any Avast Shares issued after the date of the Scheme Document
  and prior to the Voting Record Time which remain in issue at the Scheme Record Time; and</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(c)</FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">any Avast Shares issued at or after the Voting Record
  Time and prior to the Scheme Record Time in respect of which the original or any subsequent holder thereof is bound by the Scheme,
  or shall by such time have agreed in writing to be bound by the Scheme, and, in each case, which remain in issue at the Scheme Record
  Time,</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">excluding, in any case, (i) any Avast Shares
  held in treasury and (ii) any Avast Shares held by or on behalf of Bidco or the Bidco Group, in each case as at the Scheme Record Time;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><B>SEC</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%">the U.S. Securities and Exchange Commission;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Second Avast Dividend</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in paragraph 2 of this Announcement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>significant interest</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">a direct or indirect interest in 20% or more of the total voting rights conferred by the equity share capital (as defined in section 548 of the Companies Act);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>SOHO</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">small office/home office;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Special Resolution</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">the special resolution to be proposed by Avast at the General Meeting in connection with, among other things, the approval of the Scheme and the alteration of the Articles and such other matters as may be necessary or desirable to implement the Scheme and the delisting of the Avast Shares;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>subsidiary undertaking</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in section 1162 of the Companies Act;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Takeover Offer</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">if the Merger is implemented by way of a takeover offer (as that term is defined in section 974 of the Companies Act), the offer to be made by or on behalf of Bidco, or a subsidiary undertaking of NortonLifeLock or Bidco, to acquire the entire issued and to be issued ordinary share capital of Avast including, where the context so requires or admits, any subsequent revision, variation, extension or renewal of such offer;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 124; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>TAM</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">total
    addressable market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Third
    Avast Dividend</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">has
    the meaning given to it in paragraph 2 of this Announcement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Third
    Party</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">has
    the meaning given to it in paragraph 3.14 of Appendix 1 to this Announcement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>UBS</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">UBS
    AG London Branch;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>U.K.</B>,
    <B>UK </B>or <B>United Kingdom</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">the
    United Kingdom of Great Britain and Northern Ireland;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>UK
    Prospectus Regulation Rules</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">the
    rules and guidance published by the FCA in connection with Regulation 2017/1129/EU (as incorporated into domestic law by virtue of
    the European Union (Withdrawal) Act 2018) and contained in the FCA&rsquo;s publication of the same name;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Unaffected
    Date</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">has
    the meaning given to it in the Summary section of this Announcement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>users</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">unique
    devices (which includes PCs, Macs and mobile devices), which have at least one of the Avast Group&rsquo;s, NortonLifeLock Group&rsquo;s
    or the Combined Company&rsquo;s (as applicable) free or paid software products installed and which have connected to the Avast Group&rsquo;s,
    NortonLifeLock Group&rsquo;s or Combined Company&rsquo;s (as applicable) servers at least once in the previous 30 days;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>U.S.</B>,
    <B>US </B>or <B>United States </B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">the
    United States of America, its territories and possessions, any state of the United States of America and the District of Columbia;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>U.S.
    Antitrust Laws</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">the
    Sherman Act, 15 U.S.C. &sect;&sect; 1-7; the Clayton Act, 15 U.S.C. &sect;&sect; 12-27, 29 U.S.C. &sect;&sect; 52-53; the U.S. HSR
    Act; the Federal Trade Commission Act, 15 U.S.C. &sect;&sect; 41-58; and all other United States federal and state statutes, rules,
    regulations, decrees, administrative and judicial doctrines, and other laws that are designed or intended to prohibit, restrict or
    regulate actions having the purpose or effect of monopolisation or restraint of trade;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>U.S.
    Exchange Act</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">the
    U.S. Securities Exchange Act 1934;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>U.S.
    GAAP</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">generally
    accepted accounting principles in the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>U.S.
    HSR Act</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">the
    U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>U.S.
    Securities Act</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">the
    U.S. Securities Act 1933;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Vl&ccaron;ek
    Family Foundation</B></FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">a
    Czech foundation associated with Ondrej Vlcek;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 125; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left; width: 49%"><B>Voting Record Time</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify; width: 51%">the time and date specified in the Scheme Document by reference to which entitlement to vote at the Court Meeting will be determined, expected to be 6.00 p.m. on the day two Business Days prior to the Court Meeting or any adjournment thereof (as the case may be);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>VSB</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">very small business; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Wider Avast Group</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Avast and its subsidiary undertakings, associated undertakings and any other undertaking in which Avast and/or such undertakings (aggregating their interests) have a significant interest (in each case, from time to time) but excluding the Wider Bidco Group; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Wider Bidco Group</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">Bidco and its parent undertakings and its and such parent undertakings&rsquo; subsidiary undertakings, NortonLifeLock and their respective associated undertakings, and any other undertaking in which Bidco, NortonLifeLock and/or such undertakings (aggregating their interests) have a significant interest (in each case, from time to time) but excluding the Wider Avast Group; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: left"><B>Working Group</B></TD>
    <TD STYLE="padding-bottom: 11pt; padding-left: 5.4pt; text-align: justify">has the meaning given to it in Part A of Appendix 4 to this Announcement.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">All references in this Announcement to GBP, &pound;,
pence and Pounds Sterling are to the lawful currency of the United Kingdom. All references in this Announcement to USD, $, U.S. and United
States dollars and cents are to the lawful currency of the U.S.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">All references to statutory provision or law or
to any order or regulation shall be construed as a reference to that provision, law, order or regulation as extended, modified, amended,
replaced or re-enacted from time to time and all statutory instruments, regulations and orders from time to time made thereunder or deriving
validity therefrom.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">References in this Announcement to &ldquo;parent
undertaking&rdquo;, &ldquo;subsidiary&rdquo;, &ldquo;subsidiary undertaking&rdquo;, &ldquo;undertaking&rdquo; and &ldquo;associated bodies
corporate&rdquo; have the meanings given to such terms by the Companies Act.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">References in this Announcement to a &ldquo;Part&rdquo;
of an Appendix to this Announcement are to the applicable part of such Appendix.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">A reference in this Announcement to &ldquo;includes&rdquo;
shall mean &ldquo;includes without limitation&rdquo;, and references to &ldquo;including&rdquo; and any other similar term shall be interpreted
accordingly.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Words in this Announcement importing the singular
shall include the plural and vice versa, unless the context otherwise requires or admits.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">All the times referred to in this Announcement
are London times unless otherwise stated.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 126; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 13pt"><B>Schedule&nbsp;2</B></FONT><B><FONT STYLE="font-size: 7pt"></FONT></B></P>

<P STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>




<P STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Avast Share Plans</P>

<P STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Avast and NortonLifeLock agree that the following
arrangements will, where appropriate and subject to the Transaction becoming effective in all respects, be implemented with respect to
the Avast Share&nbsp;Plans.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">In
the event that the Transaction is effected by way of a takeover offer, references to (i) &#8220;<B>Court Order</B>&#8221; in this </FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt">&#8206;</FONT>Schedule&nbsp;2
shall be read as if they refer to date on which the takeover offer becomes or is declared by NortonLifeLock to be unconditional in all
respects; and (ii) &#8220;<B>Scheme Record Time</B>&#8221; shall be read as if they refer to the Business Day prior to the date on which
the takeover offer becomes or is declared by NortonLifeLock to be unconditional in all respects.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify">Definitions and Interpretation</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">1.1</FONT></TD><TD STYLE="text-align: justify">In this <I>&#8206;</I>Schedule&nbsp;2, the terms and expressions listed in this paragraph&nbsp;<I>&#8206;</I>1
shall have the meanings set out in this paragraph&nbsp;<I>&#8206;</I>1.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Amended and
Restated Co-operation Agreement</B>&#8221; means this amended and restated co-operation agreement entered into on 15 July 2022;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Award</B>&#8221;
means an option or other right to acquire Avast Shares granted pursuant to one of the Avast Share Plans;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Bad Leaver</B>&#8221;
means a holder of a Rolled-Over LTIP Award who has ceased to be an employee or director of any member of the NortonLifeLock Group by reason
of dismissal for gross misconduct or voluntary resignation;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Cashless
Exercise Facility</B>&#8221; means an arrangement to enable the Exercise Price and any Employment Taxes relating to any Award to be withheld
from the cash consideration due to the applicable Participant on the transfer of his or her Avast Shares to NortonLifeLock under the Scheme,
with the direction that such withheld amounts are paid to Avast in satisfaction of the Exercise Price and, if applicable, to allow Avast
to account to the relevant tax authority for the Employment Taxes;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>CMA</B>&#8221;
means the Competition and Markets Authority in the United Kingdom;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Employment
Taxes</B>&#8221; means income tax and/or employee&#8217;s national insurance contribution (or any equivalent tax or contribution arising
in any jurisdiction outside the United Kingdom) arising in connection with any Award and for which, under the terms of the Award or the
applicable Avast Share Plan, the Participant is liable;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Exercise
Price</B>&#8221; means, in relation to any Award, the amount payable by the Participant in connection with the exercise of the Award;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>HMRC</B>&#8221;
means HM Revenue &amp; Customs;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>ITEPA</B>&#8221;
means the Income Tax (Earnings and Pensions) Act 2003;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Merger</B>&#8221;
means the recommended offer by Nitro Bidco Limited, a wholly-owned subsidiary of NortonLifeLock, for the entire issued and to be issued
ordinary share capital of the Company;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>New Award</B>&#8221;
means an Award which is not an Old Award;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 127; Options: NewSection; Value: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Old Award</B>&#8221;
means an Award which either: (a) has a date of grant before 12 August 2021; or (b) was granted or approved in principle at meetings of
the Remuneration Committee (or sub&#45;committee thereof) of the Company on 9 August or 12 August 2021;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Participant</B>&#8221;
means a holder of a subsisting Award or Awards and, in the case of Awards to be granted in accordance with paragraph&nbsp;&#8206;3.2 of
this &#8206;Schedule&nbsp;2, holders of such Awards;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Provisional
Findings Date</B>&#8221; means the date on which the CMA publishes its provisional findings (or if earlier, a summary thereof), in relation
to its investigation of the Merger;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Rule 15 Letter</B>&#8221;
means the communications to be prepared and sent by Avast and NortonLifeLock to each of the Participants in satisfaction of NortonLifeLock&#8217;s
obligations under Rule 15 of the Takeover Code;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Scheme Record
Time</B>&#8221; means the time and date to be specified as such in the Scheme Document, expected to be 6.00&nbsp;p.m. UK time on the Business
Day immediately prior to the date upon which the Scheme becomes effective in accordance with its terms, or such other time and date as
the parties may agree and set out in the Scheme Document;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>SecureKey
Technology Inc. Founders</B>&#8221;; means Jaime Shapiro and Gregory Wolfond; and</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Value</B>&#8221;
means, in relation to an Award, the aggregate market value of the Avast Shares subject to the Award as at the date of grant of the Award,
expressed in USD, determined by reference to the closing price of an Avast Share on the dealing day immediately prior to the date of grant
and converted from GBP at the spot rate at that time. In this &#8206;Schedule&nbsp;2, the references to a &#8220;<B>paragraph</B>&#8221;
shall refer to those of this &#8206;Schedule&nbsp;2 unless stated otherwise.</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>2.</B></FONT></TD><TD STYLE="text-align: justify">General</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">2.1</FONT></TD><TD STYLE="text-align: justify">Subject to confidentiality and regulatory requirements, Avast and NortonLifeLock will (and will procure
that their respective advisers will):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">co-operate and each use its endeavours to provide such details in relation to the Avast Share Plans as
are reasonably required by the other Party in order to facilitate the implementation of the arrangements set out in this &#8206;Schedule&nbsp;2;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">ensure that, so far as is reasonably possible, the proposals to be put to the Participants are formulated
with a view to maintaining any reliefs available in respect of Employment Taxes and/or corporation taxes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">2.2</FONT></TD><TD STYLE="text-align: justify">Avast will, or will procure that its advisors will:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">prepare, in a form to be agreed between Avast and NortonLifeLock, Rule 15 Letters to each of the Participants
in the Avast Share Plans to enable NortonLifeLock to satisfy its obligations under Rule 15 of the Takeover Code; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">send, or arrange for the sending of, such Rule 15 Letters to the Participants as soon as reasonably practicable
after the Scheme Document has been posted (or at such later time as Avast and NortonLifeLock agree).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">2.3</FONT></TD><TD STYLE="text-align: justify">At the Avast General Meeting, Avast will propose an amendment to the articles of association of Avast
by the adoption and inclusion of a new article pursuant to which, subject to the Scheme becoming effective, any Avast Shares issued following
the Scheme Record Time will be automatically sold and transferred to NortonLifeLock for consideration that is equivalent to the consideration
offered for Avast Shares acquired under the Scheme (save that if there is any reorganisation of, or material alteration to, the Avast
Share capital after the Scheme Record Time, the value of any such consideration may be adjusted in an appropriate manner to reflect such
reorganisation or alteration).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 128; Value: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>3.</B></FONT></TD><TD STYLE="text-align: justify">Operation of the Avast Share Plans by Avast prior to the Effective Date</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.1</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock acknowledges and agrees that at any time prior to the Effective Date, the Avast Board (and,
where appropriate, the Avast Remuneration Committee) may determine the treatment for Awards held by leavers as they consider reasonable
and appropriate in accordance with the rules of the Avast Share Plans and Avast&#8217;s normal practice modified as the Avast Remuneration
Committee considers reasonable and appropriate to take account of the Transaction or any change in regulation and subject to Rule 21.1
of the Takeover Code and shall take all actions as they consider necessary to implement the proposals in relation to the Avast Share Plans
as outlined in this <I>&#8206;</I>Schedule&nbsp;2. Notwithstanding the above, the Avast Board confirms that it does not consider that
it will be reasonable in such circumstances for the Avast Board (or, where appropriate, the Avast Remuneration Committee) to exercise
its discretion to accelerate (i) the vesting of any New Awards where the relevant participant is made redundant or otherwise leaves as
a result of or in connection with the Transaction in which case such Awards shall lapse on termination of employment in accordance with
the rules of the LTIP, and (ii) other than with respect to Awards covered by the foregoing sub paragraph&nbsp;(i), which shall be subject
to such sub paragraph&nbsp;(i), the vesting (other than in the ordinary course of business consistent with past practice) of any Awards
of any person who is made redundant or otherwise leaves in each case other than in connection with the synergies with respect to the Transaction;
any such Awards will therefore be treated in accordance with the rules of the LTIP and Avast&#8217;s normal and past practice for such
leavers.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">3.2</FONT></TD><TD STYLE="text-align: justify">NortonLifeLock acknowledges that after the date of this Amended and Restated Co-operation Agreement, subject
to any applicable dealing restrictions or other regulatory requirements, the Avast Remuneration Committee intends to:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">grant Awards under the LTIP in accordance with its established practice, the rules of the LTIP and the
remuneration policy of Avast, which shall be on terms that are consistent with the terms for the LTIP awards granted in 2021, and that,
in aggregate, the value of any New Awards shall not exceed the limits set out in paragraph&nbsp;&#8206;4.1 below; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">continue to offer eligible employees the opportunity to participate in the SMP in accordance with its
established practice and the rules of the SMP.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 13pt"><B>4.</B></FONT></TD><TD STYLE="text-align: justify">Share Plan Proposals</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 13pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>LTIP</I></B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.1</FONT></TD><TD STYLE="text-align: justify">Avast hereby confirms that:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">as at the date of this Amended and Restated Co-operation Agreement, the number of Avast Shares subject
to outstanding Awards under the LTIP is 11,803,635, of which 1,389,463 shares are subject to performance stock units (&#8220;<B>PSUs</B>&#8221;)
and 10,414,172 shares are subject to restricted stock units (&#8220;<B>RSUs</B>&#8221;);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">prior to the Provisional Findings Date (or as soon as practicable thereafter where a grant of awards is
prevented by dealing restrictions), the aggregate value of New Awards that may be granted, under the LTIP during 2022 shall not exceed
the following limits:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">USD 3,030,000 for New Awards granted in the form of RSUs to employees who joined Avast between 1 October
2021 and 17 May 2022 inclusive, and the SecureKey Technologies Inc. Founders;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">USD 670,000 for New Awards granted in the form of RSUs to employees who joined (or will join) Avast between
18 May 2022 and 31 July 2022 inclusive;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 129; Value: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify">USD 7,380,000 for New Awards granted in the form of RSUs to eligible Avast employees who joined the Group
on completion of the acquisition by Avast of SecureKey Technologies Inc. (excluding the SecureKey Technologies Inc.&nbsp;Founders);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(iv)</FONT></TD><TD STYLE="text-align: justify">USD 4,230,000 for New Awards granted in the form of RSUs to senior management of Avast; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(v)</FONT></TD><TD STYLE="text-align: justify">USD 3,500,000 for New Awards granted in the form of PSUs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">all other subsisting Awards granted pursuant to the LTIP as at the date of this Amended and Restated Agreement
have been granted in the form of RSUs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(d)</FONT></TD><TD STYLE="text-align: justify">after the Provisional Findings Date, the aggregate value of New Awards that may be granted under the LTIP
during 2022 shall not exceed USD 25,000,000 for New Awards granted in the form of RSUs to all eligible Avast employees (excluding any
member of the executive management team or any Avast employee who joined the Group on completion of the Acquisition of SecureKey Technologies
Inc.) by reference to their salary on a basis consistent with the grant of RSUs to all eligible Avast employees of RSUs on 12 August 2021;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(e)</FONT></TD><TD STYLE="text-align: justify">the Avast Remuneration Committee shall exercise its discretion pursuant to the LTIP such that a portion
of Awards that are outstanding but have not vested on the date of the Court Order shall vest and be settled pursuant to the LTIP prior
to the Scheme Record Time, provided that the relevant Participant remains in employment and is not under notice of termination at 11:59
p.m. on the date of the Court Order. For the RSUs, that portion shall be determined by applying the fraction <I>x</I> / 365 to the number
of Avast Shares in respect of which the relevant Award would ordinarily vest on the next annual vesting date, where <I>x</I> is the number
of complete days that have elapsed between the relevant date of grant or the most recent vesting date (if later) and the date of the Court
Order. For the PSUs, that portion shall be determined by, first, applying the applicable performance conditions on such basis as the Avast
Remuneration Committee considers appropriate and, second, applying to the resulting number of Avast Shares the fraction <I>x</I> / <I>y</I>,
where <I>x</I> is the number of complete days that have elapsed between the date of grant of the relevant Award and the date of the Court
Order and <I>y</I> is the number of complete days between the date of grant and the normal vesting date of the relevant Award under the
LTIP;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(f)</FONT></TD><TD STYLE="text-align: justify">if and to the extent that any outstanding Award held by a Participant who remains in employment and is
not under notice of termination at 11:59 p.m. on the date of the Court Order has not vested prior to the date of the Court Order and does
not vest in accordance with the exercise of the Avast Remuneration Committee&#8217;s discretion described in paragraph&nbsp;&#8206;4.1&#8206;(e)
above, the relevant unvested portion of such Award will be rolled-over (on a mandatory basis) into an equivalent award over NortonLifeLock
Shares (a &#8220;<B>Rolled-Over LTIP Award</B>&#8221;), assuming for the purposes of calculating the rollover ratio that: (1) the Avast
Shares subject to the Award are valued on the basis of the per-Avast Share value of the Majority Cash Option as at the Scheme Record Time
divided by (2) the price of a NortonLifeLock Share based on the 10-day average closing price prior to the Scheme Record Time. In relation
to each Rolled-Over LTIP Award:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(i)</FONT></TD><TD STYLE="text-align: justify">the same vesting schedule as applied to the original Award shall continue to&nbsp;apply;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(ii)</FONT></TD><TD STYLE="text-align: justify">no performance conditions shall apply; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(iii)</FONT></TD><TD STYLE="text-align: justify">amended leaver terms shall apply, pursuant to which, in the event that the relevant Participant becomes
a Bad Leaver, the Rolled-Over LTIP Award shall</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 130; Value: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">lapse. In the event that the employment
of the relevant Participant terminates in connection with the synergies relating to the Transaction, the Rolled-Over LTIP Award shall
immediately vest in full. If the Participant leaves for any reason other than in connection with the synergies relating to the Transaction,
then the Rolled-Over LTIP Award shall be treated in accordance with the terms of the NortonLifeLock award plans governing such Rolled-Over
LTIP&nbsp;Awards;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(g)</FONT></TD><TD STYLE="text-align: justify">notwithstanding paragraph&nbsp;&#8206;4.1&#8206;(f), Rolled-Over LTIP Awards in respect of New Awards
shall be treated in accordance with the terms of the NortonLifeLock award plans governing such Rolled-Over LTIP Awards; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(h)</FONT></TD><TD STYLE="text-align: justify">the Avast Remuneration Committee has amended the terms of the LTIP so as to enable the grant of the Rolled-Over
LTIP Awards as set out above.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.2</FONT></TD><TD STYLE="text-align: justify">Avast and NortonLifeLock note that, in the Rule 15 Letters sent to Participants in the LTIP, the proposal
was made to Participants that the Participants&#8217; Awards shall (to the extent they remain unvested following any exercise of discretion
referred to in paragraph&nbsp;<I>&#8206;</I>4.1(e) be automatically replaced by the Rolled-Over LTIP Awards (consistent with the approach
outlined in paragraph&nbsp;<I>&#8206;</I>4.1) on or shortly after the Effective Date and agree that the same proposal shall be made in
Rule 15 Letters to be sent in due course to new participants in the LTIP who have not yet received Rule 15 Letters.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.3</FONT></TD><TD STYLE="text-align: justify">In the event that completion of the Merger does not occur before 19 September 2022, Avast and NortonLifeLock
shall consider and may agree to increase the limits on the value of any New Awards and the number of Avast Shares that may be issued as
 &#8220;matched shares&#8221; under the SMP that may be granted after the Provisional Findings Date to such an extent as Avast and NortonLifeLock
agree is reasonably necessary to facilitate the retention of Avast employees. Provided that, if it becomes reasonably apparent to the
parties that completion of the merger shall occur during the month of October 2022, the provisions of this paragraph&nbsp;<I>&#8206;</I>4.3
shall not&nbsp;apply.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>SMP</I></B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.4</FONT></TD><TD STYLE="text-align: justify">Avast hereby confirms that:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">the maximum number of Avast Shares that may be issued as &#8220;matched shares&#8221; (as defined in the
SMP) pursuant to the SMP after the date of this Amended and Restated Co-operation Agreement (as described in paragraph&nbsp;&#8206;3.2
above) shall not exceed 300,000;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">as at the date of this Amended and Restated Co-operation Agreement, Participants in the SMP hold, in aggregate,
367,303 purchased Avast Shares which are subject to the holding period requirements in the rules of the SMP, but such purchased Avast
Shares shall be released to the relevant Participants pursuant to rule 11.1(e)(i) of the SMP as soon as reasonably practicable following
the date of the Court Order; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">the Avast Remuneration Committee will exercise its discretion under the SMP such that each Participant
receives all of the matched shares that the Participant would have received had he/she remained in service and held their purchased Avast
Shares for the full holding period. Such matched shares shall be issued to each Participant prior to the Scheme Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Share Option Plan</I></B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.5</FONT></TD><TD STYLE="text-align: justify">Avast hereby confirms that:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 131; Value: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">as at the date of this Amended and Restated Co-operation Agreement, all options granted under the Share
Option plan have vested and the number of Avast Shares subject to outstanding Awards under the Share Option Plan is 75,826 and no further
Awards will be granted under the Share Option Plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">the Avast Remuneration Committee has, in respect of Awards granted pursuant to the Share Option Plan that
are outstanding and vested on the date of the Court Order, determined that such Awards may be exercised from the relevant date of vesting
up to and including the date of the Court Order and until 90 days after the Effective Date (or such earlier date as applicable to the
relevant Awards pursuant to its terms) in accordance with the rules of the Share Option Plan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">4.6</FONT></TD><TD STYLE="text-align: justify">Avast and NortonLifeLock hereby note that, in the Rule 15 Letters sent to Participants in the Share Option
Plan, the following proposals were made:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(a)</FONT></TD><TD STYLE="text-align: justify">the Participants&#8217; Awards under the Share Option Plan outstanding and vested on the date of the Court
Order may be exercised with effect from the date of the Court&nbsp;Order;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(b)</FONT></TD><TD STYLE="text-align: justify">should the Participants agree to the proposal in paragraph&nbsp;&#8206;4.5&#8206;(b) then a Cashless Exercise
Facility will be made available to them in respect of their outstanding and vested Awards; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt">(c)</FONT></TD><TD STYLE="text-align: justify">if the Participants in the Share Option Plan do not accept the proposal outlined in paragraphs&nbsp;&#8206;4.5&#8206;(a)
and &#8206;4.5&#8206;(b) above, outstanding and vested Awards under the Share Option Plan will lapse if they are not exercised by the
date falling 90 days after the Effective Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 132; Value: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>Signed
    </B></FONT>by Stuart Simpson</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">as authorised signatory for and on behalf of<BR>
 Avast plc</P></TD>
    <TD STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 11pt">&nbsp;<IMG SRC="tm2221114d1_ex2-01img02.jpg" ALT=""></TD>
    <TD STYLE="width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">/s/ Stuart Simpson</P></TD></TR>
  </TABLE>
<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>Signed
    </B></FONT>by Vincent Pilette</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">as authorised signatory for an on behalf of<BR>
 NortonLifeLock Inc.</P></TD>
    <TD STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 11pt">&nbsp;<IMG SRC="tm2221114d1_ex2-01img02.jpg" ALT=""></TD>
    <TD STYLE="width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">/s/ Vincent Pilette</P></TD></TR>
  </TABLE>
<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>Signed
    </B></FONT>by Bryan Ko</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">as authorised signatory for an on behalf of <BR>
Nitro Bidco Limited</P></TD>
    <TD STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 11pt">&nbsp;<IMG SRC="tm2221114d1_ex2-01img02.jpg" ALT=""></TD>
    <TD STYLE="width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">/s/ Bryan Ko</P></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 133; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nlok-20220715.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaCGybOdzZR+OYkxtmB5bUn6ny0rdhBMNCyJM/bmYZMC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:nlok="http://symantec.com/20220715" elementFormDefault="qualified" targetNamespace="http://symantec.com/20220715">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://symantec.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="nlok-20220715_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="nlok-20220715_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nlok-20220715_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nlok-20220715_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://symantec.com/role/Cover" xlink:href="nlok-20220715.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://symantec.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2221114d1_ex2-01img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2221114d1_ex2-01img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  > .T# 2(  A$! Q$!_\0
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M$'C73KVR.UM7@^RM@XW.I"\_4,@_"OH*B@#S7XH>'4B^%$<-I\KZ*(98&'!
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MO&/[+O?BU\4M5NK6\:UM+'"Q3@<HJG"8'J2&;\Z^C** /G3X@?#/5?#>ACQ
M^O3:@]I*@)DR&C4G (.?[Q7\Z]H\">(O^$H\&:=JC',S1[)^/^6B\-^9&?QK
MHZ* /&V^,^G6]Y=Z?XDT!X[F"9T8* W / (/?&,\US<%O;_$OXAZ?>^&=(33
MK+3WCDNY^%+8?.<#O@8%?1%% 'G/QP_Y)K<?]?$/_H5<IH_QOT+3M$L+*31I
MWDM[:.%F!7DJH!/3VKW&B@#S?PK\8=+\4^([31+;3KB&6XW[7=A@;49OY+7I
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2221114d1_ex2-01img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2221114d1_ex2-01img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !C !4# 2(  A$! Q$!_\0
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=#]U:Q9SY<>?PS]/J2 =U1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139667794493952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 15,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-17781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NortonLifeLock Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000849399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0181864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">60
E. Rio Salado Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tempe<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AZ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">85281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">527-8000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NLOK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>tm2221114d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nlok-20220715.xsd" xlink:type="simple"/>
    <context id="From2022-07-15to2022-07-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849399</identifier>
        </entity>
        <period>
            <startDate>2022-07-15</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-07-15to2022-07-15">0000849399</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-07-15to2022-07-15">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-07-15to2022-07-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-07-15to2022-07-15">2022-07-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-07-15to2022-07-15">NortonLifeLock Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-07-15to2022-07-15">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-07-15to2022-07-15">000-17781</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-07-15to2022-07-15">77-0181864</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-07-15to2022-07-15">60 E. Rio Salado Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-07-15to2022-07-15">Suite 1000</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-07-15to2022-07-15">Tempe</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-07-15to2022-07-15">AZ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-07-15to2022-07-15">85281</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-07-15to2022-07-15">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-07-15to2022-07-15">527-8000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-07-15to2022-07-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-07-15to2022-07-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-07-15to2022-07-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-07-15to2022-07-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-07-15to2022-07-15">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-07-15to2022-07-15">NLOK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-07-15to2022-07-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-07-15to2022-07-15">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( $(Q\E2JQ"(6,P$  "("   /
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $(Q\E0D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( $(Q\E1ED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2221114d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://symantec.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2221114d1_8k.htm">tm2221114d1_8k.htm</File>
    <File>nlok-20220715.xsd</File>
    <File>nlok-20220715_lab.xml</File>
    <File>nlok-20220715_pre.xml</File>
    <File>tm2221114d1_ex2-01.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2221114d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2221114d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nlok-20220715_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nlok-20220715_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nlok-20220715.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nlok",
   "nsuri": "http://symantec.com/20220715",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2221114d1_8k.htm",
      "contextRef": "From2022-07-15to2022-07-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://symantec.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2221114d1_8k.htm",
      "contextRef": "From2022-07-15to2022-07-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://symantec.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-22-080312-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-080312-xbrl.zip
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M\P/PCN(H_W_8-Y#UI=%P,DV]_ M02P,$%     @ 0C'R5&V'L-W_"@  ;(<
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M.K=< #;;8&BB@,BP.P/0J,2H4",A]P;''4\VF.\72=33;9A"MWA 1MM\Z*J
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M:!Z R="'B!1DLA>L,M W7PL2;45_N9\>KY9)GMI./$V)L_X),%?W3EIZ$'P
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M#&9L?H3P+8CB))D]RFY2^%J5 Q5'L<AG5(K=O/6(!6H@J9 &A+4J=1P,I,'
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ML]1<0B<<\I >LR@[! K(P0SV,XNNAG=&*%2U0<ZW$N9E8CTEAG\!OX<;X'#
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M"8[.>QJT@HX'*R!PCH-./%NXC;G[M@940XZHPE(QCSX+6PHX="4"%I8ZYS?
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M'5=B6_)"/FG*+Q?$P:;V>]N4J(L:*SZ>G^I89U1B$'G3SB1.<1A")2& ^-1
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MJ9R1C;@:NB7YKHC_5U<0\).A="IN,92'\WRY0LAO(5H=D>?2OH YU);&-;1
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MC'0+$NI];#' C0H0#2W6S72Q?Q*XW01BF)@%%6H='E+'[-%VF%V5@S^] ^C
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M9VF\EAI"V!K57TAR,]3U0YGKR$0MT*$!HER<;3VN[J@VJMUIRO:MP0!2[.&
M+V/_P:U7R#/V*H?-I=4:T46^W4,+WVCQV80TR4S-,PW^>PJT6@"-%YY;@LR
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M>C&9,KH[#6;- @4'H$8S4W8Y3#(L)[E[N.'=MR&GF,Z'.'V5PJ@-)$NL^%R
M*SF='YZ>RT1>"]]Y&Y9#LHI;.H3!/==$VT.GO8,F:K"W]?A)EC)#"84S:2BH
M2)PV1*ETNYCR;>YP9=IR&>8EEKSG@:\H./PTJ+?8G8^MABT"T$S3(*&W@I+V
MK@:>VXD[*6E[O7>G*%*<&7I-I8D&I]R.=L5S<2C%(=K!3&MQVTZZGM"'1XTD
M31QQZ*N+>'>"?TO0LL/L43:5()4\C3KDY;"&&]O.-\AO\V9^$^S5$8T;@R5G
MPTQEB9VH? O:IA[%2-EQS]KIN'B0$>R=9M\?&*E[LA76?>_;"[Q$O<:J,IY
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M"U*]AX\L>*?YYX=!%2_MA. ]$X)="4C+_RKYQ=)M,C7%(,319E3V'*-I8;4
M=$ ,T?I#(>D=]=&\ANW 8D9M 2;C*+_)?(@<#9;AD(+O6B!@-"IBP5G_U1?Q
MC=;(R=B-P"F818 \ Q&D@] 84U&R*'2W1=O*\+>PI)&,B](W(=&\WT.M.-EF
ML\*SKEEAI6:%%UVSP@]O5G#/"4U<^/F88?WX>,Y/3OD-O]?[5=O<&0'?L3(,
M+>Y*!QLO0P/@U'T-G1YI*.4+QT;_F!42Z_I_I'YX0'1RKYML&D49NL&Q00QO
MR7]-(^[)/*I#M+CND2K GG+#52WMNL^/^[#&WN$!4EUD[XR1LAA_/RBY7@2L
M+\JT *&J4E03W&J)]]NH-@Q$65QE.9E9$;K?.273X.9![?F'!\P8$\S]\S?5
M8LB"$^J*QL;9UVTV1K>;M?/N+WF1&/ZCK-FB+1*X0X/L&M8M*0"Z;*\8W0WC
M"V T<$%)E5!MP,FIC()Y;LJUUL^+_CEV^Q98<TA.P$=YL^#EJ T*?OPU>/7^
M]53D,6RL4N6KG]^_KA#GLK96*GN#^AXBN$X\C*?";#LEU\R;PR'I ^#M<C>A
MDT\[(I_\&H3 *M%=^5D^%FFLB#)$$D2Z&( <1P&; 0Y6[B39N=*U*C85$6P(
M<*T!6P1*XNB_T\\&4@"!'U%&1*7DJDR:DC!'O12S:4@F)@F'ESJ2W!&2]"NR
M!/]+ZNS08O$/XC7*ICCZ;9H(BGH8J<KJ!S8"B#*)P1F/K%4&\@QNWHFS7:(=
MOV$P2F+U92(I2);$X*WC7PJ4&6 4D*JG*J P4#=B6K<W$(N9L48I8.[B28.!
MD<18TL\5-8<'*# KT:>4+&K K<J&W%#]FT@T@I@6)L04Y]4-X%$JCF+0[U(U
ML%F=N1(%O!MB^ G*&D[AO&8],JMP40.A8N7&M"E#2_&X2F!2:@ +#L XTB8-
M6)%@T3#F'MXJ&(#T#T8$A)I/;'%6(M,Q7$]/T8G6YKT/#S3C#F1Q@]6]G,I<
M9$I2>O*ESLO:C:K\)3X\BMKE.1X9*:/07)HAO*W(,8M;YORK@:Z@>$EFS%%\
MW:-#4]HVA#NU+:$5DX?*5$WY%)Z9!L7%U9@$<>>Q[8H(\1M&@RW'JF@C66U3
M$X[TQ_/+M^?_P^'=C@IV@0K\IIH0FX=F7%9(H[+B@KU-KO$@N5#KOXLRM^(2
M(Z?C#$7&$4)13:<)%SSVJ-.!Y+0M>P$W;D92"V[L?G;<$=<.E&UY%8N_G\O/
M64 VRLYC@"2D^ G5-G%$Q0VE-*,3P1$8-6PMA*24\2=Q,0OK$:"YG[7/09Z+
M\/0<FX+L(E# &#!1B@RE%8):AP='>K)&2%8'%DA'Y=04H8=DJ=3B$*X94Z&"
M+;@_Q\S0BJ!TY@28LV@/NAX>_*<$0T?FB;,M[NL$_=/C)Y3B45B5W2K_T08,
MT&@X/7GYZ@T5S\%O%ZP-BU+IVO[+WB\=+^^&HO KB6HM\AMC3(/#'UCOER")
M$#6/\ M3ZAN\%3.E[4]=0VE13BQP"1N@X'&XFH;#J\%RXL,RPY4I%9D=GNP2
MK&E@UFNB-\-UH+"1NNXS0X\IJKB.L0GMYR;#3Q'3$3;Y4<!TZ4IT5V['*[O
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MU47 #=@--89]FJ5$P&4^QT NY>PXJ:>@YRC24]@5+B8TOXN+ED47<[KS-GG
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M9G.P,03N4 )&!VF9%3@\]E3_IH*,^_!U.]5.Q/Q(BM[60!BJG?Q,9@9%K:D
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M7?@#3-X\PND(A'4(6N. ZDW,,WK(/I3TK<+0EN/>)[\V_X(+,BSA(RT1>\*
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MWH)Q5&@0'\U3IH)2;@;W@=;!'5W/.RZJ4.FZ"H6OM?G==6;'F$#P)B#-9WG
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MZA@N>R^?][;G<&6#5'*%^%8C&.!5[I5C>7:W4V-ZK8JV9BK:/G5/"V)@<DE
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MS;6?"I(4Z!08>=G_%2V$$(CL+8D75XF WUW] :3"$HJ#40(^!-D757CGB.5
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M?L5-\80-VF3!5HL+.$%3S"&8?]9J!P?>5G+PMJ B'$IYJ*2L<PH&/@3HA9D
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M25NU]W^OBA/@/?96,1YL+>Y(7[)2N74*F!6_MK6G_='!'(,:;9<X0 ;RYSE
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M #)GEGWR?$F=HF\53?W2$#$-LP62J12T *7W^O25"1+,8%);=+%79.;KN-(
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MBFQ1UEB6/<:$@[W@)!X+#A%*CW',3'##JIXTVW62TP6,J!GNXTFJQ%*N) O
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MG50QQCGBM.\-=S_4#E"GK[2Y*X^&NW>__ X&V9__\8X38E]LV-VW/#)D;^7
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MPX=_@]Z/'<I-,MYWG:KK#ZHP+0JSE&[!&4]ESMYLROSZK!'01E['7N[6I#P
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M$$Z_!RS690R4Y8P4L@JMSBG@\,D%$G_FHP"5QLN\X&\Z[/LZFL .CE1E8%4
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M GQ@-B;Q%0=9,)(_BH>D6$MJDN2!H":3A!(]@9^/TMC-7!?RT\[9#J*TQ0W
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MM^L9,W?@AR@:,+^A]#1#OA*A3S=,Y=O:RTF:DB$%OO"P1S*SWL0VS!_\&OL
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M?SO% AQHQ/!TL/]<M>,AW=)D?GM+?BLI67&X3*)SQB<IIWXD>EEHL!0<3"]
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MZG8NJ <Y@VJ&<(X4&!4$R2^9=Q<.(C9#.9=)5H4C3&X"5\7*NQ;W#W57\$>
MM,VT(@3Y*JJIC 9^8:71;@29:E C2+N7E"R^F-"]5%)I*4D)*.9#U4AT.@Q
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MCRJ&%*((!A<5:$XP4+$O0H7ADVF4<+QW!$O(E BXHB S&#W!HVI&%HIR(:,
M4PL:_#:#8[1?4*@BE/(CXL4MXB?Q1#C>]-A3.![2E"-R86Y^4-B;.]T9Y'2_
M8! ,UYG@5N,?&4INB7PO[R+*(75P#T<S8L.>S8BN^X(_G>5U-+^)V:G^P''
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MP(XTK+Z,UK2;'NI=WKCC6I'2PTVEDU-.[6$>R,KM:84WM3RU91))!13'(EG
MPBG>B'4OU6S8>@T%5RRC0CY<'(-BM89?("*=7*7A_#4U?U]!P(7V,#45[T<!
M]E'7_%J<R6\V<E.#$5EX6"D:[Z:F=O,F0L@>#- K6 S%QXI'M"TC%F*PDCC@
MB%7/0 BIJC%,$TDNYQK6$=@A8D+@6*LOA/FXQ\6<CUZ5VV3X:1PY;WVO%^D$
MA W<I%_8MB6K%%ST4#DJ2%05D@''7?8"JUP]V_:J,%HDH^/X8Q?/[-J>DK14
M$,81^@AQC8JZ0\]!Z6%5U]D[@9FKP-5E($7%">_4@)")>XZ]*F+<MB@L['@)
MO-,2 \#</V1<I> @A)6GI_!5NZ_PK((?*U,>C%BN\+R!W9(G[@RTAM^<(C()
M7Q 7%=@V4?85N.H2/#%E,;=&*HRS*2?M.9^'A4&),$;.F+Q3GKL<9H/-D*=Q
M&P6-DS(<VI26AR?[F.\7QLGRHYR'&->+3.,(:;0KS;8)HT)A,5N2%T+E*^LG
MUN)3";/KHV4&^X J3?90]HY&77I #UUE J#)UNF-W8C;Y-R^6+43 L?V+F+U
MG*,V'>Z:5H+PYKX]64U)V<NK]-5;E8:O5BZMBG(@VF^D=.VY#%?APFL<U^:
MI,HXC]8F3 HNO;G8G38C:#A?*KM3I[(EE;U;I[*?1D*MY&P%KL/>NR'<>O#
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MK5_J)/[ 1TJ$_+UM^+ IN(*'B;RCGA!IEH9E8_TR2O)/04%XP*?V5=O!K[=
MJ6@3N#*Q*JP-N0%=IDFJ;')O6;5AQNP,M#CZ#%'W&NT#' UCGQ1B9R..1GYC
M_C^ES<A :_R_3J@U_ "V'QD]23M((RM8>WY'RPE52G7& R7U+]HCPG+Q/A7]
ML(Q16-;#]^M OUYN+CN$O:+W,2\ IT $;D/72PC#:CEW*._L+2')&9;*_"5X
M 5T0P^ Y,_HT]GND!8]!D68#HE#CCO;,)X8-%*63:V]D=;L//?L;F$% ]\D/
ML# ZD4EA!V@>J?D>S0QA/]P[&+YS]LXY0L[0%,>11$%&""D^E;>QPHAUTG=N
MZ:1*-29BBVZIDYB;Y+_6#S=[@(G(>RD'I\9'H/1[?3>'B< G4P:5X*$><H+L
MFOA%S KE>4N]T[15=M98A7U75Y2"=,3FW%!.B$KFN8(:9 1F/J1[R&ZA1-D:
M?(+&1,'3*1F5GS6N,V4.#?BL<*N [+H#DDBA19DV;*QG1Y'@.O )#JPUF@(4
M#+Y,A!9<]NZ9"Y7:07$-+/=]2N9=028*& PS*G SK 6XH$;0.6^;]N&QF$F!
MB5(9%W^+H2N8(N-*UKP%M?Y*EK!+S[D^KENC\K&/D\<&0RD$!5"/C+<($Q8.
MEYIRL?E!6Y4_KYB#4\*'4$&L8"8K;R&B!M=#M*6!(?R=A5;:#B4$!X$Q:HHT
MY&^U;CF3^IGP3K0OVTLUUI\%$> FV38SS(*QK!\A=EW)39+8)I2E-9B(T@-+
MM_ZX)5%"2%M ;#+N-^+FGV.AY59+.(^?@A^7<'=.6.0D%7NK1ZP[8C1^$/")
MW2</E''4\YDM-U]J'Y04*GZB(&7L3LY$:CUK(]8:TPDY*OH[.JI^;M8Q(L &
MAP<^&4;DG6S&-L^5U.W625U)ZN[52=VG5T08''6EKL;BX@([+N#E9X!6&D>!
MB01-ZFO)L;NZT_8"74^G-#S=I7:HI^<?K^WQOKQU!WXP@G,U&MQ$ :S&P/>\
M*(7UP(^./6XR^SCSZ-R@*6,8<!RK=[7ZXK.C W;5O>L'[-_WXDB!/$0#OX>B
M@282395(3WW6Y+ZP7<$J?59IHHFI]._RFJXJ0TP\6?7H75)G;%\M54\B58*L
MU:(B&F5!29%(G1$5X:WC5#6W6NC!J"*,TGAJ0/&%6"C!^NZ]3]Q[3#0/^Y(7
M ""DN6(HM22NGR1RMR"54-^@VR!G%TW=+PX+C7ARWZ:E$.4=8)!X@"%)+?$!
M4I^QU'MY@,92I+6&6U.YFJ#A7 ^K@Y6PW#$@G#['E6M. @^BXDTL'R5?5]<0
M3 M&-!N5 =-:;FJY<5)_H*/2K,$HFJR&*?.(WCJA>L"(.C+1:]@8*[EL>!>[
M&,<1V%>5!-8BMNXB=H/,MYC^\?PDSB3&(N4UYI)BKLXIMQS#(#^KD3&HDA;F
M:W7-?^BF&=;>P$M<)/O#6&E/:J94'$>QGPQ:3F]TH^*7;IJZ7.[V(UICJM</
MHR"Z(^^!FAR0'4<YB!&:C'"?6F.O)7+=)7*2.X"1&_@JQI?I%V*>S:<+.8XX
M-:(O65B.9"3<$*"6IHV3)E 7 5*.!H8P0\BPHWA4:)PAPD/)Z2H;K(P#D=0Z
MN:M4^LELQ&-IHEJF-D:F,*AUQW)4BBM8I"M3E4XN-+58K)]8Z,PER08"("07
M*<T1)MUDTR7B)A"9PL\W&\:@J@5D P2$;11;-N9W\YV\=P5X;7=1ZA/C-#IP
MVHI?K8P\1?9)6H,7DT_,?%1GGS;M^$PUY;0V%?P8^ 6JEZ7^O;(A@%/NX%J?
M;II B%XP-A5!_M!+O)MJC-6"L#&"H..D18&8]U+%W Q!QK7-Q5AQ:7MA['OL
M?U%;8QLD-#UP^A/?N.Z>GPRCQ WJ/=Z</99[P.\AB:IT9H7-OD>D*3([4?4=
M9_:YG ,;X4F3REH,-D8,BO>"YV.5"J,^>N[03S%_JLO":H-A@P4B"_.B8TPP
M47()Z2E5RGVX.<]$I0"2'*6K ?Z.G657'<1=8L%KM=,LUA(ZV4B L%&U(W_I
M>@]IS&I(,+GP^L(-54#5(W?4Q0O+L<A$4&$B!+P:N$/<E58*@8J>)I22Q:89
MN*0(W%# 16-<H(G-9,G?2XB!O\0].AU5OQ%8^8KB@9P-D&)K5OT9@4MG%0MS
MY(A8/2B3Z*<"TDJ<>W@[]W7GU+<G7>.(8])F/FT)?_24+M&F;4/.@V@7-12J
MAO#IFD]Z7RK]9 C%!^2Y):KEJRACJA8^+B@<3TNMK7P(+<5<A12[=2&%%%+L
MUX446G)6PQ'W:KW)T^PI_7ET=;VAU'#7U91GTG>>2XBQGA;,@V'?.6PVMGX^
M^X59M,65=,#Y1!@4IAZV*V^091"UX-U7Q=128-J>R#+#$YC"+;/.[&UYLVNY
M=ZF:4'>,O:DHE+8XL$V&J7*)D%:;5S0O)+9O^JJNV>M\]59P@DC7,)W/CN]<
M\*_ >D:DH 99W1E:J)S#(6"&%,L )@X5ZH_!@5DL!F9#*!L.F6(1]^G5/]!"
M?OT/?,=#VJ?:_8U8TKX* G_YKWFB%M/7YLP4(_!'FMCEY.W9];LC>5RS 3N,
MBA[O?BTD$^3#9A"3$HN;.'(]L,&QI@-;(B49'^[2EYF@9[?CO%,][K@,K]@A
MCLX Y(W.,(P$V\E$\ 0MME(%<ALH!HC!71 S/RA2G+!7H2N+K/"RKH#/F4,L
MD&W?OT.MP2AMNFK0!W!<6*M0G!F8S!UF'V09ST.EHQ.:_47[+@@GB-$BQ94+
M7*PR@?^DQ+,."X9SKRDNUFIZUY-NG H^>_0WIS%;5)W"*FJLG'RI@B;E[/3R
M2M/9Y&1:L2J_$5U?C*O/YMFJ'-9,=JWRX=T(U3]YMVUZ#<=BU\"6!36]1DVO
M,5%P+%:-LE7:;&P>J\;7<1;PTM5@L;7/\*R(JL"ZPFJ&@HT6IJ]D*+ $!)1.
M34Q0"^#2B0FJ=!))-V80:SZ"[T*<'KVNO,)7JVD(:G%9/@V!)7BU9*V[9"W*
M/E"XRJI(!QS#.=!L+$ Z4',.?-]RN$3.@:J@9DTU\%T(T3=0#52:5^O!,+"D
MM\R'[MJKT5V"[GKU?:&[:G6W,G4W%PM&U358DU^LLS1\)?E%I2 4."^<FO)B
MD\1B%N5%9=:_@NG"J8DN*HDNZI3EVIZ5A?@MQEDMZE#8!N_^'&06]?YOXOY7
M<UC,N"7'J"L<B[D"\WPU=<5&RDI-7;'Q>UQ35]1B\%74%;5YL$%R4#-63(!P
M%[W?[XVHHEC@7V*L:#:$LL)9B+&B6+^W!***2GSZ1J#.K\?C,56T%(45:#:>
MG(VB@DO"+@:8R$;QZMO8*(J"M6$<% OV\]RO$Y62J#SXOA*5,V^T53!1'*PW
M5X,UI7<GIV<?SZ[/SC]>/?F<<CO7MFO+=N^BXQ!S$^UB<]Q[41"XPP0D7__M
M!Q+8V18N"?68+;MW",\>NAX"Y_+CTL$SI'^*3"D_.?OM/?QA)87*T?'Q,:\Y
M&)J3WK3?^?HWF5-"5VB&CG'@NR%8,5P'H2'RQW#O9!@#@U\,P#"&G[_)K=^O
M6J=O7IMWEY.7YEN7XPCFBM@SYQW87 GX@O'(N50]Y0_3E<^[6-N_O#68@3&@
MHB^TMGX,H@0M([PW'$^!M8IEL" A8#8-T-!-3$ER&(4O[>)]C+"&=SY6UH*Y
MI-*DY21],'5?<EGET!T)F,NTO:*P*_Q*#89!-%*Q&165ZK805JB&$MSW4S5@
MN[H\CJEC6/D&W\4*9JB-7HY*),[R-AH-6RI[46Z(:WSGWRL"F_AID8FG6VD=
M/Y/U&B.QDX6KUVW2NITM;VE<F,"M3YXL5ET%\&LV75<]9VO]EZDY?:)9R,FH
M!JY'U%))AGAF$!'FCFH?V-11*Q<(>\0G&I]]"?IVN9=, 0J."_+IZIW3:>^^
MWC_<_^G%$,E:WG3@9HGA?$D1W=L@BI">XLXY_5]P)K[ RQ+G:AB5QBW._5Y[
M=\<9M@=M=-0/P<ZY@]<S\\W6C<*CB\-XCT!T#"$@;ICI'M[!C[97OBWXDD M
M49%1L$'>0M>C4%G(;<DW$4>X_ &C*."_JUX7BW #) 1>Z7XF1KBG5?<W(TO1
M=PYQO:YZ?>7A^7ZE 2?OP?%AJ-$'Y?G9X&7B_T=Y9&7#LZ0LBZRLQ-DZXB@.
M__"28W[;\!?"N5-:LKNS\UI81U(0]L( MCK;1$\W/@Q,9]E/X7)6L+<X(BXL
M*)X0PH &$RJ\5>\SB=\237V2[F'0 W,5IGP3^#T*["&^#NS."-8@)B&#*_TD
MO O(GH3__>4&.CN -<)8#@4?"C-BS=DYZ'1>=PYVGL7:.6\C-_:6JSYN\!4H
M=9Z)TCY?S3&&[UOFRE0LR!PA9R>*D8 ,4U:2G\ 7.$FD<PN4BG*]@8]>SX3W
M/-.%)T6W[ .-1Q2+>9+L)O$]'QUXZY9(QM<&O[' DBL7E"<;;X/GL:P5S*++
M#@R4252M-(>5X:#;Y[DY/S3^*PPVT$4Y6+9]Q2_L[G1>.^\CL!ZN53QPSD*,
M>V*#M0NX5UI.Z8,\O ]NVNNCP9%_YD33[IQP&$3)1_$3SA;2!%!^ZG,8/82.
MF"W\W-^B@.(H\/P]^=(YQ4OHN]L<+3&<9HAY(:&/8[2I23'1*1+C 4F@4O@*
ME=EQK@MNT0>X"KBZUXKEQ/Y=/Y74'671))%:$(3J-+H)&T\.>5L?F2]9]*I.
M%DFRZ/6:)XLF2\<:)@^^0:V9D>T=_J.LXOIPZM7R#!WSZOW./UC;R0MS4X2&
M47'K/J-[8,D7@"$@3W@I*!P^\#%0?8^:R)%(QTZ[L\/6A0#3-!A-K^7*@VAO
MNV^[4])2W[I8NB )%,E+^^\]R4&M6F3>^EXO6M[T/_II'#GT$N>]#\:F\L@S
MC?U[=!8"_M&WNZB=W?W.WD%W[UDLY[)] G[)]^03O-4\,._<T1+C_.#!CIPM
M*Q;EPF699C'\&*Y-6%W\KT158*5NW/ S7@X^_'P[9^[''S/3\9T*54P<-1'X
M#Q2+,HPV(-U@.GN2DOZH'IQ_1?'G52_T\=&O2TQ$XS$GMG)A;68^?HJ4KWSB
MIV>?KI9[9Q+:($W!OX%-/Q7FF#.#V=<WY*>05.(5-A)9>?KV.%!P#*Z5.R Q
M_3WR8:#OU"U9U92K7';R"?04C2'58_B;QN#)&%P]!H><"[HV0-_=J/0!_3)I
MU%:&P?[5AS5V7KB#X1OG&#PZ!ZQH>O@??OR9;AS^W4D0@*M_AD\.=94=?M2C
M"ZJ[Y_R>A=QU8/4;%27D5L=^;\D9KIZ\"F'K@>:7=/Z=16D.26"[L)CFPN^^
M<WW0AN>WDDY]#]>X3AJ*-KQ*,>&M$U\K7]8/2\:DE+%)'X2M\RA+^U&,U7M%
MM? '/-J+5GXA'W_\L$2C&>?[49^W'*2%DO+!8C.UUPY6Z6KH^BL'<F'J>\D2
M@T)!P'R8]K7[66&I5R+Y.*166/VE$0UNJ!D/IP27:+%1PCT,,"'I20>AO!57
MWH^@10Y&["?ZQU5=>P6[7H")/8.5E)SJ46_)MVSA59B4?;7ZR6OV["7?9SE+
M=[$CAI4 N'#CU#FBJ(5.!72>92K@&,M#/(S#NU3[_50V6NFU\YAE[/B4+#.Q
MK'8G6%9/%U,_J&/J$E,_K&/JFQE3/XY>&OJ0Y2N*\;CZ!"4A]6>3T01:BY1U
M1QX7R_4+,UN$=P3?#N_0W9#P#@;)6EKC^X-A0 \O-)SB>V#U*CV+EZR^?_/O
M^@Z]!Z?^._ZJIRH#L,]B,>#DN?%2X7%L$>&K^OPJQ+AP>(]EBTJO$Z4^2SM6
M-!?<D#IM:2.3,_$%H"R9$=U7.4[6LKF>Q\I^4-1<<+DK.^"78 Q5_EHB);#S
M? [9#6AAW"MT*FY&LMYF$7'<\ZYRN34N]TGAXEN?&>A;CH]?C+*[/GS<QX+9
MX3".[DO[ND6IB(C[N**9"!=GZ)&"XL\K8E\ S1(E/.Q\M'2D&.F/LQN55=>V
M522">1'7^QN^%W+Y+CPO'4:A1E:!BN.U,<$7^$*2@:3*VK:09L]G&OT23!)3
M -PW5:(,,K=W42]['M8LKM8Y;O?2\YEEB9IPG!DQDBCZG?/Z\/!Y'N;+$]U@
M>UE+AET8[O'$):,D50-GRTTP*FM+TR>XL;EV@JSZ*]7+8O"T8(E* .".LW5U
M1G_Y<?=@?W_;:J><2^U)%D<8"XZ=3W](?/8,KW<X-)):U!V:S\FJ@:-1,2;K
MS2L'P[]30809@>5ME'X#1JU;%7%$;)[@![Z86N;3'Z].^!LN*!%*L!+G@/V1
MZPA4#/ZG/W#3)+.SN[ ].L&K$[LZT0NJ[BYS"2P%&E1Z0K^[OGZOVX:W'?P7
M:4*=@,0DIS4*3JT%ZHX2:PEW"64\N@]G$[US,2E)U%:]Q](FTW#6+F^OI>%\
M4HYNE4>@VU@(ZM$=H88SOV47:8L!]/0;72T+JTM/VI:/N'8ST6VKM08<N>0S
MK":EIGNQ/S31[4%TXP>J\/-5[\\[/\&$AEHRI-P/J=\1K82G7PG'H254_=BX
M+;@%<6_QOOSD;/G;6F>9)K=8/L'&@RZK&.=R,A9.IPOK'2+?#Y@V$5D:Y5ZX
M;^ M^C7E0!;^BG]G02@Y]UVH!D,>;ZU5L7'!F353\(COT?*8/$_4%#C>:+K/
MAZ.YWY[SPVPB%MXF+X-OE@X'?(YMKRU>-3_6%P\"62-,5%%G&"G150@)O6.&
MM3CGM>%]\HEKR^U1 "PA&ZQP+.Y]EP9^[\<I[B=,P'7B"+2PM%WSJL9<O JM
M\"0, )^(_"\!=20GA=G#=*:L$ @C[1 2LI!%:$OA PSQUO416IL+)#:&PRLZ
MO'N#S]^"-?>R6)NA%L6LL,X:6G?0$J'81*:-M(QS*U\!^UO4A)S4>,NF"D)N
MF@Q>A),&.ZRGDFVY_Q^HTB#EKLZPQ;F3KWR23E@>WDL8>6F;E[B[C[#L*PIQ
MOJY#G!SB[.S4(<[-#'&^NUA:_GX\GEE [C!*!I3"!;/M48R5=7CG<'_EM73+
MYML -RVDN(Y0:>3M2E/W"^I9FUMCC-:BB J>H1'?.$2KB%6H++Q5I(OV;_41
M$;K%9W)2%A:!N<<PKU24%VV.A[,L40,^N%%9G'(6RWS(Q^>XJA__YX?NXDM8
M,?RO'2Q6.R<_%8@V1<3RQ9][7*O8I9*"^ZI%*(E_U>G_MD'K(3Z+$>K!'#SB
M:-9,:)[#-CSB(=YRMQ]G3-4,>U\U)O^6AV&Y/7Z29Q7987EP36L&#B:W[, R
M-FX'%^E&]2+XE](ZM9#9P% 8W*.#!+VS6B*?BT0^WK!J';49$K%UL_V8(UN1
MIG(-OA0AVXBCQ&\5?Y;K+16"4=\+W)@3GZ+(LM#@ZX@_BT*7L8=]O7D@)EQ4
MZ'A:9)(:%^OOPB58L?-L['JBCGHZ/YH#N[J<RA)4%JG$,0-;N1=]L<2:(>-"
M#Y6P#ZQ\NI_T3N19U.7-_Q@#^GY@O<O9.CG>=CJ[AS]V=W967NN)^>BA8GY9
MJ5!8;@ZIXH5:3YI??0J?04[MY.K7)1Z+\-Z/(\+"H)(EVC3.&]SAK82)A-4?
ME&NJN%URX8.+-= AU_;^)PI7/VMX#=SM2YRV?@-!O$+,S8S5YJU\$;Y@/Y5)
M!*XU?^N$93L]7G*AW:E),6)=2=9+\Q*[U<_]?,ES5Q[6H3O'<&I4P.67E#K_
M5<4#-US] D0,+CH).(6\W-7 7"PY.61>2O2E@#BU*0"J?A^KA(I=R)T!^R1)
M8Y]:+_V>Q7[B^32);6< 7I3"*>$QC)%P_9Z9%SZX?W-M)Q>[GC\+( QN OE=
M%W'T9<DU>[?Z74-\5Q5^P&*?< K(9%.F]RN3*^B?MPK85G0R&7GV#%&MMUCV
MX&>#93)9&)Z) 7C0 ;-^W"!<C@ YC*$C4#.1I,:*@=!]K*1<.27/Z=6RJZ[S
MR^#*+(A=?,T5D#LKPF4<UK@,P65T:ES&9H:6?CTZNGB:@%+.P0-W@AI2MSNK
MLUCL@QX88F'3JK5>Z3Y;K@*45<DK<296WVQ-K$3!;\0JNMTN5^A,+['A_G,S
M2FR&BK0SF%91D''[E;4M8OGMP^42N3)^ T,5[$FP04>F?<RE@HW(&!-_3,#N
MQ'F6-")GIY=+#*#ZA=A CC'-6U82WRL2O*Y\(7"H_J#4)Z>.%LQ,%,*=%L4_
M.?_5>=7=Z1X7UO+4[?D!EQN5BINGI.0>0[G^]V%[=]^Y\8- 6C+1<&[SX>2%
MSU+*7*I.3LJ,553(!/=Y'#VH>)O3<'J:[Q$0+00P;Y&1#I'CW/$+'M,^:M.7
M2Z,8,<Y9JF;X5PF79\FOF#W9TZAT2N@1DF\Z3G\=!$-6;.FR4+T;5$JM@B !
M 8WO(MHS_M6JE=#O[8NV\R&*[S#%X/Y'A=']$F.Y]MNLRD#J7<$W?(\#=0G!
M7C[]8?6W)XY%RCIK-Q=$O&KXJU[2]ZC.30^49:91?_AEK+AGY7.O;$&T1'K)
M0*Q-(Q7E#DDM)^^0%/#PAM;P2*W-69"TZL45SGQLO35'36$!TB*?>M26ISPP
M6E<968PCXUYA4OM^>GPDY=-4H8\%^CP4#/B(:[RLD=DN_&HWKHKF<'EGHO)U
MJ&17+L#8-^(*JT27JQ0ZG?;^(>^^;II64I1=JDVD0BW4"3$?^BV?F!2V\68I
M$\M@8)]LN)8N/7,3#5\R3 \7;J@"S0]!5Q@ZP:8!>Q[8QC?I+W/2P$4*NU5O
MD$E2'+M)7W(4*W-(R*W/!@.BG)<\P7-4RY69G7K59JV:D, \!9_/C#32ZI<"
M\57+78AA'#$GC=TYV)#0; D] &HLZNF@U%:RO:U#A,BK@/5<29(IYH7BZ)_\
MH-@88JS=0TM_NH@WI;J<(C;>(>H.I FXT9&]<IGW%K852_I1%G@R]B3BA&L+
M'UI&KXKM@90D+F8<_;B7#3 "A.F?Z:_:7DTF" OTZTP098*Z=29H,S-!'ZY/
MGR81-,B"U"<##_11&KN4TM#AL)9C,04AMP WD'7VL -IMTO:CULL(H8#^XW]
MN+_WX\FG,?PE>#:![PYT;"U',!"4%8M_]YT/8.)1RS)0NP-).8/6R0/4?IBD
M<<9 ^*T/9Z=G[YRSLY6S%7T\NGIW],\G8OT^*G;MM0)$[Y0;8+SS*(.W4'CR
MGYIZ/L]RM*]6'DW#EAZE*.Y3=&8*QU^;]VCJ18,!+&A"QBGY)2[&^J5GDS2K
MWFGO='+,>47CIM+CC3E1, 3@'Q79Q*E,(2O?L<*\EM@4J;A^9V&OC;19NO41
M)PV*C9!PD9(TI^G"MH0K#VZ6YK&RQKRE<3R[MFQ5Z^1<8BT+,D;RAA]S8.;D
M?JE4W7/XBS^?3> %=G[^\>R7H<L4L5:3[E?.%GR'3_!+HMM%OR#OL9G@][:?
MI=\Y!M)^^A[*I2$LN9/RFIV4)?=1*Z_]P@W5MKZ^H]JVC6)I&<B,>Q_Y5!M)
M2B[*;E)-(*8J>-YTIPO$N@;J^3%7EQ;X27LZCQLI,YL[[S_+C@[CB_AEQ!Q#
MRV_KP/#L1+],9-9'L ',W!^2KF>S#UGH^!]51J^V_\"U*OVZVB+T8T&$L<5)
M#(H)TB#TE/[W1/OZF6W84_2LA9L][U%;N2C/7M=;RX0GDK?^%(0JBVNSZ+GL
M3"(0PR>FB:^6:2WR<^).F62L #/].I7R=.'?3AW^E?#O;AW^W<SP[Y-&R(H!
MX2>-DCTSG0Y6)-'@9DOV=4^/CUZ:;AA#\U*Q&8=$C<D1]PIGC+!#3#F-Y1OW
M8 P03*LZM&@7;<*^)!@.GK-04[SNQ$7KR.?<8T4A0045\\0;8_V#H?]WO.P.
MG[!V_Z?<0%IY#E3<4Q:UQ:H7X/SDP_+F'\4^W >@*#!,,"3A&KAA=NO"Z8A7
MO_F<+[\@WO@E>YC,3<^QT)[/C98Z.^WNKJ/A6AULLQR,",#)=-\AY>Z0#\;?
M9E "9MWR!B[C!$)RDL<(A'0OA*G?HKN2(CE@J.,Q]6+W(21.<4*-L>*AKXOB
M8.P70KD\U0,-M$UDZOZ\HQUCV$HTFU:D_V63;14IMJ;.J/3D1YA9R\GU;BN_
M!MG\AOW1\3'!UPVI!ZN@XO!MF.Y,0#F#SLR"-.=P5U] 'W#'5@S*P7GI,P6B
M1HX4B*$F4I8]@Y.4M[I><@\C_2I$X&(\1I?%6?#;L399IDO6UY1$KV(]AXI<
M](M(<$O2OR-;)NV,&Q9;7DC%H4^M3N!O 9F-FN*:SE/2QU8=0QDEWO6$,B4Q
M)N- >J#<$!E"BVHK\XY*>;:;1!K#"R,-28_HY/J\:VSHX(!Z*L:][DMK OR6
MO+R ;8 #BI!QYW6)86^EFTI*9;F'XU/[C[:&Y#[3MMD7?=2:7>?XPQ&( FPR
MNKC/H 1PMTU*8FU:((-J2%_*Q? V&]VXR\SE;P@"]^)RR8P;%W$F[:%M/K]G
M0\%T<76R[/F[=YDJUV%@B/AM%O_'Q1A:^&+D]K)4O0'M/72'+WS^5_R"&O"\
MP4?T75#F[:1-L>.5K]E3D-QAPQTP:YX/R=T_.R# @0)5O3*ELDC"\NF"U=TZ
M6"W!ZKTZ6+V9P6HZ^^BF)LX5R.)3!:H?41VL0F'N+O>&@ G'GO/O#,S3/*9B
M7"F8'F+L8F>DW)4' _ZYMVQ:O2Q.^VNR%AB&@*L=?-(\]/!6A>"GXO%:/KYE
MQJFJ<'?VGN7YNJ16R.^6MU#8L]&-,:2 A"#J7@71\%E,7-WY21J[2ZZ6,Z]!
M6<B;?(.(G(1WE+P@1@_W.7"(66U8CW5(&*[:U$\PLX#_J!$USV5?EIAYS=_A
M[+;W6QC!P3\.\(_7^,<A_M'9H3\[]&>7_H3_E__J?^_*?_=(RNFO^\()E\">
MTG*SD;@V\:$9O8J7R<HZC'T*!=D-886%50,>B_%Z+EG5D:/7AQ>XOD*7L>)%
MK,RE+S,&/X)_Y&^2M%(0]3#CX3Y0U#TVH:6$<E225*+L?P+/PU "6D+P&&)F
MZOGWV#LYSB4"'M*#3>+<[)<A)18PV&[OF$3;-8I,0HT/.!R"+.1(!5)U;EH8
M..4!_$(GYRV[=3KG$V!(;NSYPKJHA!B;GX8SNY%W:<Q;)?' -J;6(AF:^B*M
MD^$'\PY3H.V1XU%M]0.56MN+:O7LP8\1$'TDF!D8-W=DX%8-U)*;4H7"@T'0
M>$I[\ 7+;[WU \D0\H=IV8FQC+.8IL,S RIXG8C_"<X*IHFC4,51MO)H_J5*
MLYB"O105J2/0L];KPQ*9("\_O+SZU]7UBQ,.J7YPCO^CD/M]/!I;_F3+>='K
MN7$4OE')YQ<N_]2YF3=F^VR"M0QE>")>B81Q$YB[S,TSF_JI^RI//VJ#&C/,
M0H=HM7:W8!@%[-0D) ##KJSJC@H<5XL5%($<;OX6?G[J;Q]Y=$-(UM03 SHB
ME27_,+<T:O$!SU<N;"88(8\ ;5FNC!B5V8.>AR28Q5ARK9N&SO&^>'XR=%,8
MP&1(G+X(.?B/"P)7<URD5\KMH8-*.7HF2XPEGK'G7"\]2<*81:'K=!"@R($5
MC068= S P%&]O(3G57MGQZ"N\ MO-8_>.[ X_,% >3Z\ .Y8;-VMS#85^\3E
M;%H"#!) Y402K17E*W;K?(7D*_;K?,5FYBLJ+LXGRECDU6CV&!:LH_FVEIWV
M#I<E0(OPI+T;ZQ]:V'3<M>G[6G4OL#2\6UC:*G?@V[O E\2CD@WYT8?[U:.M
MZ/G]-8.K%-RI(_[ZMO%YN;94!, M3.4 =I$_3J1(>V:*#?"F9)<7_&LD+"M_
M?]S*6&(#Z"5+]-<N<G63Y7I03]\AO!:0A;J#/Z4V^]IAHDM<U&!"^GB;*KO
MH%)_X:10A17HM/^,F+0Z5UD+JSA\:"W%]:!J-??L]V*KM]YJCC,41MD5E!=.
MYEJ'70HZ;EQGE>I&\VHL4P4HF1"L"2'O.W6$"2/E%EN8Q[F)LM"$&ODE+3(?
M8]T*:\1A%PJX]%TL;N,P)+S^ <M),%Q#@9ZJ1SG$900?)98B+.!J+:";]7*T
MZI-7#ZI6S?/MQ?$Y!B4^_L\/W<5C4,M6BNJ+!.)))Z!R8I6 %;=EA8GSZ:N
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M03KV:DB'0#I>U9".Y^-H+1QU^':/[&LA ==''V:V15[V="K]OJ_,P:/)SA.
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MF/ 0&F@RK8OM!#3%"N7PDS3.F%W7+5J/E&@Q3V[A<UN53X.O:CK^EK!.X]_
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MFJS"8:SH*L14$_52"48;L3E@('H3A!P[$L3:=H:U"5']QWI/9!\X>1]D&H=
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M'VH$ J9Z_3 *HKL1!CG:S.HB-,$B=%KJ?G=Q'Z[ZX"['7%/\:ZSNL%KLKRB
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MP]CA559#Z[)_;Y]G[8-Q;&QZ$3Y;H7FXQ2K GZT!F@V[W87VOVZS(( IC/&
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M$2-JIMFP&V-45BN//:QV;]=$^!=S;^?)ZK=*,),9+ SC<LA-C<K%L"B3<]7
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M     &YL;VLM,C R,C W,34N>'-D4$L! A0#%     @ 0C'R5&V'L-W_"@
M;(<  !4              ( !:P,  &YL;VLM,C R,C W,35?;&%B+GAM;%!+
M 0(4 Q0    ( $(Q\E2BA6NQ5 <  ,%8   5              "  9T.  !N
M;&]K+3(P,C(P-S$U7W!R92YX;6Q02P$"% ,4    " !",?)4$0S.R8H7  "
M>0  $@              @ $D%@  =&TR,C(Q,3$T9#%?.&LN:'1M4$L! A0#
M%     @ 0C'R5(N]6B.H10( /Y,1 !8              ( !WBT  '1M,C(R
G,3$Q-&0Q7V5X,BTP,2YH=&U02P4&      4 !0!) 0  NG,"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
